The right ventricular response to lung resection by McCall, Philip James
 
 
 
 
 
 
 
 
 
McCall, Philip James (2018) The right ventricular response to lung 
resection. MD thesis. 
 
 
https://theses.gla.ac.uk/30940/  
 
 
 
Copyright and moral rights for this work are retained by the author  
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge  
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author  
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author  
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses  
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
 
   
 
1
 
 
The Right Ventricular 
Response to Lung 
Resection 
 
 
Dr Philip James McCall 
MBChB, FRCA 
 
 
 
 
 
 
 
Submitted in the fulfilment of the requirements for 
the Degree of Doctor of Medicine 
 
 
 
 
 
School of Medicine, Veterinary and Life Sciences 
University of Glasgow 
 
 
October 2018 
 
  2 
 
2
 
 
 
 
Dedication 
Dedication: 
 
To Sophia, Hamish and Euan 
 
This is all for you. Thank-you for your endless patience and continuous 
encouragement. 
  
 
To my Parents 
This is only possible because of you. Thank-you for everything. 
  
Abstract  3 
 
3
 
Abstract 
Lung cancer is the most common cause of cancer death in the UK and although 
the best opportunity for cure is provided by lung resection, surgery is associated 
with high rates of cardiorespiratory complications and long-term morbidity. Existing 
studies indicate right ventricular dysfunction occurs following lung resection and 
may be implicated in any post-op deterioration. Evaluation of right ventricular 
function is challenging, with its complex shape, marked load dependence and 
retrosternal position meaning there is no reliable, non-invasive method of 
assessment. The majority of previous work examining right ventricular function in 
the lung resection population has been performed using the volumetric pulmonary 
artery catheter, the reliability of which has been challenged.  
The first section of this thesis reviews the right ventricle in terms of anatomy, 
physiology and assessment, providing context for future investigations (Chapter 
1). A review of the literature examining the right ventricular / pulmonary vascular 
response to lung resection is then presented, along with the rationale for further 
investigations (Chapter 2). 
As there is a high frequency of complications in this population, often requiring 
critical care support, the first investigation (Chapter 3) of this thesis characterises 
those patients admitted to intensive care following surgery. It also examines the 
incidence of right ventricular dysfunction in this population.  
Given the methodological concerns regarding the techniques previously used to 
assess right ventricular function following lung resection, cardiovascular magnetic 
resonance imaging was used to sequentially assess the right ventricular response 
to surgery (Chapter 5). Cardiovascular magnetic resonance is a reference method 
for assessment of right ventricular function and has not previously been used 
sequentially in this population. This investigation demonstrates right ventricular 
function (measured by right ventricular ejection fraction) deteriorates following lung 
resection with impairment still evident two months following surgery. There were 
no changes in left ventricular function over the same period. 
With the difficulties associated with cardiovascular magnetic resonance imaging in 
this population and its limited use outside of research settings, an alternative 
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method for assessment of right ventricular function would have utility in this 
population. Trans-thoracic echocardiography is the most commonly used non-
invasive method for assessment of right ventricular function with widespread 
availability and low cost. Chapters 6 and 7 attempt to validate conventional and 
novel echocardiographic methods for assessment of right ventricular function in 
this population. The main finding is that established echocardiographic methods; 
fractional area change, tricuspid annular plane systolic excursion and S' wave 
velocity at the tricuspid annulus, are not suitable for assessment of right ventricular 
function in this population. Speckle tracked strain echocardiography is a novel 
method of assessing right ventricular function that has shown promising results in 
other patient groups. Chapter 7 demonstrates that right ventricular global strain is 
not useful, but that right ventricular free-wall strain may have value in this 
population. 
Biomarkers of myocardial dysfunction (B-type natriuretic peptide and high 
sensitivity troponin-t) were measured contemporaneously with the imaging studies 
(Chapter 8). This investigation demonstrates that both biomarkers increase 
following lung resection and that their plasma concentration two days following 
surgery are associated with right ventricular function. There was no association 
with parameters of left ventricular function suggesting the biomarkers are released 
in response to changes affecting the right ventricle. On an exploratory basis the 
association between the peri-operative biomarkers and functional capacity 
following surgery is also assessed. 
Finally, potential mechanisms of right ventricular dysfunction following lung 
resection are explored (Chapter 9). This demonstrates that as pulmonary artery 
acceleration time (a surrogate measure of right ventricular afterload) increases, 
right ventricular ejection fraction deteriorates. Using a cardiovascular magnetic 
resonance surrogate, a deterioration in the matching of right ventricular function 
with right ventricular afterload (coupling) is also demonstrated. 
In combination these studies provide a robust answer to the question "what 
happens to right ventricular function following lung resection?" It provides validated 
methods for future work in this population and suggests an association between 
post-operative right ventricular function and right ventricular afterload.   
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Chapter 1 Introduction 
1.1  General introduction 
1.1.1 Lung cancer 
Lung cancer is the most commonly diagnosed cancer worldwide, accounting for 
1,825,000 cases in 2012 (about 13% of total cancer cases). It represents the 
leading cause of cancer in men, and the third most common in females1. Lung 
cancer is also the most common cause of death from cancer internationally, 
accounting for 19% of cancer deaths in 20122. This pattern is similar in Scotland 
where lung cancer is the second most common cause of cancer (behind non-
melanoma skin cancers) and the most common cause of cancer death. Over the 
last ten years (since 2004) there has been an overall decrease in the incidence of 
lung cancer with rates down by 5.2%. This reduction is mainly due to the decrease 
in the number of cases in men (also down 5.2%). In the same time period, there 
has been a 14.2% increase in the number of cases in females3. Lung cancer 
survival is poor with one, five and ten years survival figures of 32.1%, 9.5% and 
4.9% respectively4. 
A link between smoking and lung cancer was observed in 1950 and smoking 
prevalence largely dictates lung cancer trends, with observed variation in 
incidence reflecting differences in the stage of the tobacco epidemic. This is true in 
the UK, and as smoking rates have fallen, lung cancer rates have fallen in the later 
years (Figure 1, pg 21). Advancing age is also a significant risk factor associated 
with diagnosis (89% of cases in Scotland in 2012 were in patients over the age of 
60) and despite a fall in the incidence of lung cancer, absolute numbers are 
expected to increase (Figure 2, pg 21) 3, 5-7. Projections suggest that absolute 
numbers in the UK will increase by 35.4% (compared to 2014 figures) by 20358.  
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Figure 1. Lung cancer incidence and smoking trends, Great Britain, by sex, 1948-2013 
From Cancer Research UK9. 
 
 
Figure 2. Lung cancer incidence projection to 2024, age standardised (European) rate and 
number of new cases, all person, Great Britain (Based on 1975 to 2004 data) 
From Cancer Research UK6. 
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1.1.2 Lung cancer management and surgery 
Following diagnosis, management of lung cancer is multimodal and ranges from 
smoking cessation to the use of chemotherapeutic agents and radiotherapy. 
Despite advances in the non-surgical management of lung cancer, in suitable 
cases the mainstay of curative treatment is lung resection.10 This offers the best 
opportunity for prolonged survival, with five year survival figures of 54-80% in 
patients with stage Ia (the earliest stage) lung cancer. Surgery has progressed 
since the first successful pneumonectomy (removal of an entire lung) was 
performed in 1933 and procedures now include lung sparing options such as 
lobectomy, segmentectomy and wedge resection11. In the UK, the number of 
resections for primary lung cancer have increased significantly over recent years 
and approximately 8500 lung resections take place in the UK each year (2011)12. 
In Scotland, the total percentage of lung cancer cases having surgery has 
increased from 10.6% in 2008 to 15.7% in 201413. This has been driven by a 
number of factors including efforts to increase resection rates in the UK, which are 
low compared to other countries with equivalent healthcare systems14. In addition, 
guidelines by the National Institute of Clinical Excellence (NICE, UK, 2011) and 
Scottish Intercollegiate Guidance Network (SIGN, Scotland, 2014) have 
recommended increasing the availability of surgery to older patients with more 
comorbidities (and conventionally thought of at increased risk for post-op 
complications and long-term morbidity, including dyspnoea) if they are prepare to 
accept these higher risks15. 
"Offer patients with predicted post-operative FEV1 or TLCO below 
the recommended limit of 30% the option of undergoing surgery if 
they accept the risk of dyspnoea and associated complications." 
NICE (2011)15 
1.1.3 Lung cancer surgery morbidity and mortality 
The majority of patients undergoing lung resection represent a high risk surgical 
population, they are generally over 60 years old, have a significant smoking history 
and are at high risk of heart disease. For that reason, lung resection is associated 
with significant morbidity in addition to the effects of the underlying disease16. 
Post-operatively this includes high rates of cardiorespiratory complications such 
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as; pneumonia, lobar collapse requiring bronchoscopy, adult respiratory distress 
syndrome (ARDS), pulmonary oedema, pulmonary embolus, myocardial 
ischaemia, cardiac failure, arrhythmias (both atrial and ventricular), stroke and 
renal failure17-19. All of these may need interventions and support that will 
contribute to a significant peri-operative patient burden and increased hospital 
resource requirement. In-hospital mortality following lung resection (for all 
procedures) is 1.7%20. 
Although improved survival is the goal of surgical treatment, health related quality 
of life is an important long-term outcome and lung resection is associated with 
significant long-term morbidity. Many survivors will have a decline in their 
underlying functional health status. Quality of life following surgery has been 
assessed using multiple scores, with patients having a decline in numerous 
indicators including; physical function, ability to undertake usual activities, pain, 
persistent cough, mental function, fatigue, sleeping, vitality, sexual activity, 
dyspnoea and overall quality of life. This decline is present immediately post-
operatively and although there does seem to be an improvement with time, many 
patients continue to report functional limitations and symptoms two years after 
their surgery 16, 21-23. Sarna et al.24 followed survivors up at five years and found 
disabling respiratory symptoms contributed to diminished quality of life. Up to two-
thirds of patients reported at least one symptom of cough, phlegm, wheezing or 
dyspnoea and 11% of patients described themselves as being so breathless that 
they couldn't leave the house. 
1.1.4 Predictors of morbidity and mortality 
As may be expected, both the extent of the surgical procedure and the underlying 
health status of the patient contribute to how a patient will progress peri-
operatively. Predictors for mortality (in hospital or within 30 days) and post-op 
morbidity include: pneumonectomy, bilobectomy, higher American Society of 
Anesthesiologists (ASA) rating, Zubrod performance status, renal dysfunction, 
induction chemoradiation therapy, steroid use, advancing age, urgent procedures, 
male gender and low body mass index (BMI)25, 26.  
The use of pre-op pulmonary function tests: Forced Expiratory Volume in 1 second 
as a percentage of predicted (FEV1%) and the Transfer factor for Carbon 
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Monoxide as a percentage of predicted (TLCO%) are key tests in the evaluation of 
patients for lung resection, with lower values indicating higher risk15, 27-29. These 
are often corrected to the predicted post-op lung function values by calculating the 
amount of functional lung that will remain following resection (Equation 1)30.  
          
                  
 
    
Equation 1. Predicted post-operative (PPO) values 
T = total number of functioning segments prior to resection, R = number of functional segments 
remaining following resection. 
 
It would seem logical that those patients with larger lung resections and poorer 
respiratory function would be more likely to suffer from peri-operative morbidity, 
and decreased long-term quality of life. Although FEV1%
25, 26, 31, ppoFEV1%
32-34, 
TLCO%31, 35 and ppoTLCO%32-34, 36 have all been shown to be predictive of post-
op morbidity and mortality following lung resection, there is a significant body of 
work demonstrating they are non-predictive, or their value is limited to particular 
sub-groups15, 33, 35-38. Whilst less work examines long-term outcomes, there is a 
similar picture, with some studies showing a link between poor pre-op PFT's and 
reduced quality of life24, 39 and others showing no association23, 40. It would seem 
that normal lung function is a predictor of good outcome, but there is no reliable 
lower limit for those who will suffer peri-operative complications or long-term 
disability37. 
It would appear that pulmonary function is not the only factor contributing to post-
op outcomes. The 2013 American College of Chest Physicians guidelines for the 
physiological assessment of the patient with lung cancer being considered for 
resection surgery explains;  
"Ultimately though, the factors that contribute to long-term 
pulmonary disability, either individually or in concert, remain 
largely unknown. This makes predicting who exactly will suffer 
long-term pulmonary disability following lobectomy or 
pneumonectomy largely speculative." 
Brunelli et al. (2013)27 
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It is when examining what other factors could be working in concert with 
respiratory function to contribute to post-op morbidity and mortality, that the 
potential role of cardiac function, particularly that of the right ventricle (RV) is 
considered. Due to common aetiological factors, cardiopulmonary dysfunction 
often coexists with primary lung cancer41. It had been noted by the author and his 
colleagues during the course of their clinical work (in the cardiothoracic intensive 
care unit at the Golden Jubilee National Hospital) that a number of patients 
following lung resection were developing acute RV failure. Requirement for critical 
care following lung resection and the incidence of RV failure in this population is 
investigated in Chapter 3. 
The importance of the RV in health is increasingly recognised and its major role in 
disease states is increasingly appreciated42. As the RV and pulmonary vasculature 
are coupled together as a unit it would seem intuitive that resection of large 
amounts of lung tissue would have an impact on RV function. The literature 
investigating RV function following lung resection is and its relationship to early 
and late post-op complications is explored in Chapter 241, 43-45.  
1.2  The right ventricle 
1.2.1 General introduction 
The primary function of the RV is to receive systemic venous blood from the right 
atrium and pump it to the pulmonary circulation where gas exchange with the 
environment occurs. In 1628, the English physician Sir William Harvey published 
his work describing the human circulation, Exercitatio anatomica de motu cordis et 
sanguinis in animalibus (concerning the motion of the heart and blood). In this 
work, the RV and pulmonary circulation were described, but its importance was 
perhaps not appreciated 46-48. 
"...again I ask, when the lungs are so near, the blood vessel to 
them of such size, and themselves in continual motion, what is the 
object of the beat of the right ventricle? And why did nature have 
to add this other ventricle to the heart for the sake of nourishing 
the lungs?" 
William Harvey (1628)47 
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For many years and well in to the 20th century, an emphasis in cardiology was 
placed on the left ventricle (LV), overshadowing the study of the RV. The RV was 
long considered a passive chamber for blood flow between the systemic and 
pulmonary circulations. The focus on the LV echoes William Harvey's comment 
from 1628 when he describes the RV as a servant to the left 47, 49-51. 
 
"...the right ventricle is a sort of servant to the left, it doesn't reach 
to the apex, its walls are three fold thinner and it is somehow 
joined on to the left..." 
William Harvey (1628)47 
The importance of the RV and its function has been increasingly recognised52 and 
it has been identified as an important prognostic factor in many disease states; 
heart failure53, 54, pulmonary hypertension55, myocardial infarction56, valvular heart 
disease57 (particularly mitral valve), pulmonary embolism58, 59 and obstructive 
sleep apnoea60. 
1.2.2 Normal right ventricle structure 
1.2.2.1  Macroscopic anatomy 
The term "right" ventricle is probably incorrect; as in the normally connected in vivo 
human heart, the RV is anteriorly situated, in front of the LV and immediately 
behind the sternum46, 61. It could perhaps be more accurately termed the anterior, 
or pulmonary ventricle. The RV does not contribute to the cardiac silhouette on 
chest x-ray62.  
The RV is delineated by the annuli of the tricuspid (or atrioventricular) and 
pulmonary valves46. The shape of the RV is complex; the thin RV free wall wraps 
around the LV giving it a crescent shaped appearance. When viewed in long axis 
the RV appears triangular and under normal conditions the septum is concave 
towards the LV throughout systole and diastole. Although traditionally divided into 
two components (the sinus and conus), it is functionally better viewed as three 
main regions:62 
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1. The sinus (inflow / inlet) which consists of the tricuspid valve 
apparatus, chordae tendinae and papillary muscles (red region 
Figure 3). 
2. The anteroapical region which is characterised by a complex 
meshwork of muscle bundles with coarse trabeculations that make 
up the trabeculated myocardium. It is this component that allows 
distinction between morphologically right, left or indeterminate 
ventricles, irrespective of the chambers location (orange region, 
Figure 3)63. 
3. The conus or infundibulum (outflow), this is the smooth RV 
outflow tract (green region, Figure 3). 
 
Figure 3. Macroscopic anatomy of right ventricle  
Adapted from Haddad et al.46. TV = tricuspid valve, PV = pulmonary valve. Red (Sinus) = inflow 
region. Orange (Apex) = trabeculated apical region. Green (infundibulum) = outflow region. 
 
Along the outflow tract, an arch of muscle separates the tricuspid and pulmonary 
valves. This arch consists of: the parietal band, the septo-marginal band and the 
moderator band. The parietal band and the infundibulum make up the crista 
supraventricularis (supraventricular crest) which separate the sinus and conus 
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regions. The moderator band crosses the RV septum from the base of the anterior 
papillary muscle to the ventricular septum. The entire heart is enveloped within the 
fibrous pericardium, this serves to hold the heart in a fixed position and protect it 
from other thoracic structures. The pericardium is resistant to acute distension, 
meaning acute alterations in pressure or volume of either chamber can affect 
performance of the other ventricle, so called ventricular interdependence64, 65. 
1.2.2.2  Blood supply to the right ventricle 
The main blood supply of the RV is from the right coronary artery (RCA) which 
arises from the right coronary sinus61. The lateral wall is supplied by the marginal 
branches of RCA while the posterior wall and infero-septal region are supplied by 
the posterior descending artery (PDA). In the majority of cases (80%) who have a 
right dominant system the RCA supplies the PDA, but in the other 20% with a left 
dominant system, the left coronary artery supplies the PDA. The RV also receives 
blood from the left coronary artery with the anterior wall of the RV and the antero-
septal region receiving blood from the left anterior descending artery (LAD). The 
infundibulum derives its supply from the conal artery which has a separate ostial 
origin in 30% of cases46. Venous drainage is accomplished through a complex 
network of Thebesian veins, which drain directly in to the ventricular chamber and 
from anterior cardiac veins66. 
1.2.2.3  Muscle fibre architecture 
The overall muscle mass of the RV is only about one sixth that of the LV but the 
volume is larger64, 66. The ventricles are not composed of single muscle layers but 
of a complex three dimensional network of myocytes in a matrix of fibrous tissue. 
These were described in detail by Ho and Nihoyannopoulos63. In the muscular wall 
of the RV, which is 3-5mm thick and composed of two layers with superficial (sub-
epicardial) and inner (deep) muscle layers, circumferential and longitudinal 
orientations predominate. The superficial myofibres are arranged circumferentially 
in a direction that is parallel to the atrioventricular groove. On the sterno-costal 
aspect the superficial fibres turn obliquely towards the apex, to cross the 
interventricular groove and continue into the superficial fibres of the LV. At the RV 
apex, the superficial myofibres invaginate in a spiral fashion to form the deep or 
sub-endocardial fibres that line the cavity. The deep fibres of the RV are 
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longitudinally aligned base to apex. The arrangement of fibres contribute to RV 
function with longitudinal shortening a major contributor to overall RV 
contraction51. In contrast the LV has three layers with obliquely orientated 
myofibres superficially, longitudinally orientated fibres in the sub-endocardium and 
predominantly circular fibres in between, this contributes to a more complex 
movement which include torsion, translation, rotation and thickening46. 
1.2.3 Normal right ventricular physiology 
Functionally the cardiac ventricles can be viewed as two hydraulic pumps in 
series, therefore they are obligated to eject, on average, the same stroke 
volume65, 66. The RV functions as a low-pressure, high volume pump, in contrast to 
the LV, which may be identified as a high pressure, high volume pump. The RV is 
attached to the high-compliance, low impedance pulmonary vasculature and the 
LV connected to the less compliant systemic vasculature64. This means, despite its 
thinner wall, the RV can pump the same blood volume as the LV. The RV's unique 
physiology is dependent on the low hydraulic impedance characteristics of the 
pulmonary vasculature50. Despite the structural and functional differences between 
the RV and LV, performance of both chambers is largely a function of the same 
factors: preload, contractility and afterload, the specific features of each vary 
between the chambers67. Performance is also influenced by heart rhythm, 
synchrony of ventricular contraction, RV force-interval relationship and ventricular 
interdependence. 
1.2.3.1  Preload 
RV preload represents the sarcomere length at the end of diastole, just prior to 
contraction67. Within physiological limits an increase in preload increases 
myocardial contraction based on the Frank-Starling mechanism46. Just as the LV 
has a point where increased sarcomere length results in reduced contractility, so 
does the RV. This means that excessive and prolonged RV sarcomere stretch 
reduces RV contractility51. Chamber volume is often considered an index of 
preload however, the relationship between volume and sarcomere length is also 
influenced by pressure67. This means that RV preload is influenced not only by 
intravascular volume status but also by the diastolic compliance of the ventricle. In 
the thin walled RV, diastolic compliance is significantly influenced by the pressure 
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exerted by the pericardium, intra-thoracic pressure and left ventricular pressure. 
Heart rate and atrial characteristics also contribute.  
Compared with LV filling, RV filling is longer, normally starting before and finishing 
after the LV. RV isovolumetric relaxation time is shorter and RV filling velocities 
lower. The respiratory variations in RV filling velocities are more pronounced when 
compared with the LV. Filling period is an important determinant of ventricular 
preload and function and the RV follows a force-interval relationship in which 
stroke volume increases above baseline after longer filling periods, as seen in post 
extra-systolic beats46. 
The geometric configuration of the RV is more suited to ejecting large volumes of 
blood with minimal myocardial shortening. The RV is considered to be tolerant of 
preload, meaning it can cope with considerable changes in systemic venous 
return, without large changes in filling pressures because of the greater ratio of 
volume to surface area in the right compared with left ventricle68. 
1.2.3.2  Contractility 
Contractility is the basic property of the myocardium that reflects its active state 
and is distinct from its loading conditions (preload and afterload)69. The RV 
contracts sequentially in a peristaltic pattern that proceeds from the sinus, via the 
trabeculated myocardium to the infundibulum46, 50. Approximately 50 milliseconds 
separates contraction of the sinus and the infundibulum66.  
Ejection of blood from the RV chamber emanates from an interaction of 3 
difference sources: free wall, interventricular septum and conus66. Due to the 
higher surface to volume ratio of the RV, a smaller inward motion is required to 
eject the same stroke volume46. The RV contracts by 3 separate mechanisms: 
1. Inward movement of the free wall which produces a bellows 
effect 
2. Contraction of the longitudinal fibres which shortens the long 
axis and draws the tricuspid annulus towards the apex 
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3. Traction on the free wall at the points of attachment secondary 
to LV contraction. 
1.2.3.3  Afterload 
RV afterload represents the load that the RV has to overcome when emptying and 
is the opposition to sarcomere shortening and chamber ejection67. The efficiency 
of the RV to pump blood comes from its 'coupling' to the low impedance 
pulmonary vasculature. This means that compared to the LV, the less muscular 
RV is intolerant of afterload. This is demonstrated in Figure 4 with a large drop of 
RV stroke volume in response to experimental increases in RV afterload. This is in 
contrast to smaller decreases of LV stroke volume in response to increases in LV 
afterload. This response is particularly relevant in situations where afterload 
increases acutely, such as following pulmonary embolism. 
 
Figure 4. The stroke volume response of the right ventricle and left ventricle to 
experimental changes in afterload.  
Image from Haddad et al.46, adapted from MacNee et al.68 P represents mean pulmonary artery 
pressure (right ventricle) and aortic pressure (left ventricle). 
 
In clinical practice, pulmonary vascular resistance (PVR) is the most commonly 
used index of afterload (Equation 2, pg 32). 
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Equation 2. Pulmonary vascular resistance (PVR) 
mPAP = mean pulmonary artery pressure; PCWP = pulmonary arterial wedge pressure; CO = 
cardiac output. 
 
Although most commonly used in clinical practice, PVR is a measure of opposition 
to mean flow, meaning it represents the static element of afterload and does not 
include the dynamic or pulsatile component70. The pulsatile resistance to flow 
(incorporating resistance, capacitance, inertia and pulse wave reflection) is 
particularly important in the RV where up to 30% of the work performed by the 
ventricle goes to overcoming the elastic and reflective forces of the pulmonary 
vasculature67. Pulmonary vascular impedance is a more comprehensive model 
and represents the true opposition to ventricular ejection66, 70. Impedance has the 
same units as resistance (dyn·s·cm-5) but in addition, it has a term that describes 
the opposition to and energy costs of pulsations in the pulmonary vascular bed. 
Impedance is frequency related and is modulated by heart rate, vessel stiffness 
and wave reflections.  
Acute increases in afterload lead to a major decline in RV performance but with a 
slowly progressive rise, the RV is able to adapt and there is progressive change 
towards an "LV" pattern of pressure-volume loop50, 71. Adaptation is initially with 
increased contractility followed by RV hypertrophy and remodelling72.  
1.2.3.4  Pressure volume loops 
The complex interaction of preload, contractility and afterload can be better 
understood using the pressure-volume (PV) relationship. This can be determined 
for both the RV and LV by simultaneous measurement of pressure and volume73.  
1.2.3.4.1  Left ventricle pressure volume loop 
PV loops are commonly used to describe the function of the LV, the shape and 
features of which are described here to allow comparison with the RV. Figure 5 
(pg 33) demonstrates a single cardiac cycle as it moves (anti-clockwise) from 1 
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(end-diastole) through to 3 (end-systole) and back to 1, with the cardiac cycle 
commencing again. 
 
Figure 5 Left Ventricular Pressure Volume Relationship. 
Image adapted from Chantler et al.74 1 = end diastole (MV closes), 1 to 2 = isovolumetric 
contraction, 2 = start of ejection (AV opens), 2 to 3 = ventricular ejection, 3 = end-systole (AV 
closes), 3 to 4 = isovolumetric relaxation, 4 = start of ventricular filling (MV opens), 4 to 1 = 
ventricular Filling. Stroke volume can be calculated by (EDV - ESV). Area shaded by grey 
represents ventricular stroke work. LV = left ventricle, MV = mitral valve, AV = aortic Valve, EDV 
= end diastolic Volume, ESV = end Systolic Volume. 
 
The LV PV relationship is typically rectangular with well defined periods of 
isovolumetric contraction and relaxation. It was first shown by Suga et al.75 in the 
isolated canine LV that the end-systolic pressure volume relationship (ESPVR, 
Figure 6, pg 34) can be approximated by a linear relationship. This slope is 
ventricular elastance (change in pressure per unit change in volume) and due to 
its load independence is considered a reliable index of LV contractility. The 
ESPVR can be derived by experimentally altering LV loading conditions (preload 
by modifying end diastolic volume, or afterload by altering resistance to ejection). 
The end-diastolic pressure volume relationship (EDPVR) is at a tangent to the PV 
loop at the end-diastolic point and is a measure of ventricular compliance.  
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Figure 6 End Systolic and End Diastolic Pressure Volume Relationships 
Image adapted from Chantler et al.74 Two Pressure volume loops under different loading 
conditions (continuous and dashed lines) demonstrating linearity of ESPVR. ESPVR = end systolic 
pressure volume relationship, EDPVR = end diastolic pressure volume relationship. 
 
1.2.3.4.2  Right ventricle pressure volume loop 
The RV PV loop is a different shape to that of the left and reflects the difference in 
the work it has to perform and the circulation it is coupled with. As can be seen 
from Figure 7, in contrast to the well defined square waveform of the LV, the RV 
PV relationship has a triangular shape, with ill defined periods of isovolumetric 
contraction and relaxation50, 76. It can also be seen that RV ejection occurs over a 
much lower pressure range than LV ejection.  
 
 
Figure 7. Right and left ventricular pressure volume relationships in sheep 
From Redington et al. (1988)77 Note pressure difference between left and right ventricles. 
Right ventricle Left ventricle 
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It can be seen from Figure 7, RV ejection continues as RV pressure declines, this 
phenomenon is as a result of the highly compliant pulmonary vasculature, with this 
"hangout" period shortening as RV afterload increases50, 76. Similarly to as 
described in section 1.2.3.4.1 for the LV, the ESPVR and EDPVR reflect 
contractility and compliance in the RV (Figure 8). Compared to the square shape 
of the LV, it is difficult to identify the precise end systolic point in the RV PV loop 
giving uncertainty in the estimation of the ESPVR. Maximal elastance (Emax) as 
opposed to end-systolic elastance is often described as the best measure of RV 
contractility50. 
 
Figure 8. Right ventricle pressure volume loops  
From McCabe et al.76. Contractility (Emax) is derived from the end systolic pressure volume 
relations ship (ESPVR). The dashed line is the ratio of end systolic pressure to stroke volume and 
is the arterial elastance (Ea). 
 
Effective arterial elastance (Ea) of the pulmonary artery is a parameter that offers 
an assessment of afterload, incorporating resistance, compliance and backward 
reflective waves76. Pressure volume loops allow Ea to be obtained from the ratio of 
end systolic pressure (ESP) and stroke volume (dashed line, Figure 8)71.  
1.2.3.5  Perfusion and cellular biology of the right ventricle 
The mitochondrial density and the mitochondrial to myofibril ratio of the LV and the 
interventricular septum are similar to each other, but much greater than in the RV. 
This ratio is a marker for myocardial oxygen consumption (MVO2) and workload, 
indicating comparatively lower values in the RV64, 66.  
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Unlike the LV where perfusion of the left coronary artery occurs predominantly in 
diastole, in the absence of severe hypertrophy or pressure overload, epicardial 
coronary artery flow to the RV occurs throughout the cardiac cycle. Beyond the RV 
marginal branches however, flow is predominantly diastolic. Under baseline 
conditions coronary blood flow is lower in the right coronary artery (RCA) 
compared with the left anterior descending coronary artery (LADCA)61, 66. Putting 
both ventricles under stress results in increased blood flow in the LADCA with no 
increase in LV MVO2 whereas there is an increase in both RV MVO2 and blood 
flow in the RCA66, 78.  
The decreased oxygen demand of the RV myocardium at baseline, along with a 
lower blood flow rate results in an oxygen consumption that is approximately half 
that of the LV. These properties, along with higher coronary vasomotor tone at 
baseline (allowing an increase in blood flow with increased oxygen demand), 
provide the RV with a more favourable supply/demand profile compared to the LV 
and explain its ability to increase O2 extraction in response to ischaemia
66.  
1.2.3.6  Biventricular function / ventricular interdependence 
The concept that the ventricles can be viewed as independent entities is flawed, 
they are constrained by the same visceral cavity (the pericardium), have a 
common interventricular septum, share coronary blood flow and have common 
myofibres (particularly superficially). So although anatomically independent 
cavities, there is continuous interplay and they are functionally inter-dependent 
meaning the size, shape and compliance of one ventricle may affect the function 
of the other through direct mechanical interactions50, 64, 66. The two chambers are 
also connected in series, meaning a decrease in RV output results in decreased 
LV preload, thus reducing LV output49. 
In the normal heart, contraction of the LV is a significant contributor to ejection of 
blood from the RV, this is mediated through the interventricular septum51 64. 
Damiano and colleagues demonstrated in a canine model that LV contraction in 
the presence of an electrically isolated and inert RV, with an open pericardium, led 
to pronounced pulmonary artery pressure generation (Figure 9, pg 37). The 
authors estimated that 30-35% of the measured RV pressure and volume output 
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were generated by the LV and septum. The converse was not true with RV 
contraction contributing little to LV pressure development79. 
 
Figure 9 Pressure recordings from the electrically isolated canine right and left ventricles. 
Image from Sheehan et al.50 adapted from Damiano et al.79 Note the difference in pressure scale 
between the left (A and C) and Right (B and D) ventricles. A = pressure generated in the LV 
during LV contraction, B = pressure generated in the RV during LV contraction, C = no pressure 
generated in LV during RV contraction, D = pressure generated in the RV during RV contraction. 
 
Diastolic ventricular interdependence is mediated mainly through the pericardium 
and occurs when pressure or volume overload of the RV shifts the interventricular 
septum towards the LV, altering LV geometry and reducing LV distensibility51. 
Brookes et al. demonstrated in a swine model with PV loop analysis of both 
ventricles, that changes in RV geometry directly affected LV contractile 
performance. This indicated that impairment of LV function during RV dilatation 
was not only as a result of reduced LV preload but also as a direct result of 
changes in RV geometry. This effect was attenuated by pericardotomy80. 
The LV is a significant contributor to RV ejection and although RV function does 
not contribute to LV ejection, RV dysfunction can have both a negative series and 
parallel effect on LV function. LV pressure generation can be reduced as a result 
of reduced preload (series effect) but also as a result of changes in RV geometry 
directly affecting LV performance (parallel effect). 
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1.2.3.7  Right ventricular-pulmonary vascular unit (ventriculo-arterial 
coupling) 
Efficient RV function relies on effective interaction between the RV and the low 
resistance, high compliance pulmonary circulation. This matching of contractility 
and afterload is known as coupling and its preservation is important for ventricular 
efficiency81. Contractility and afterload can both be altered by pathology but 
coupling and efficiency is maintained if, as afterload increases, there is a matched 
increase in contractility82. As a disease process progresses, with further increases 
in afterload, the RV starts to fail as a pump and contractility falls, leading to 
inadequate coupling and reduced efficiency83. Effective right ventriculo-pulmonary 
artery (RV-PA) coupling ("coupling") maintains cardiac output while maximising the 
efficiency of the RV. 
Coupling is the ratio of contractility (Emax, section 1.2.3.4.2, pg 34) and afterload 
(Ea, section 1.2.3.4.2, pg 34) and gives an index of the matching between the RV 
and pulmonary circulation71, 76, 81, 84. Theoretical optimal coupling occurs when the 
ratio of Emax/Ea is equal to 1 and the RV is able to generate maximal flow with 
minimal energy loss83, 84. Stroke work is the work performed by the ventricle to 
eject stroke volume into the pulmonary circulation. There is a broad range of 
Emax/Ea of 0.5 to 2.0 where stroke work is close (<5% decrease) to optimal 
85, 86. 
Myocardial efficiency is the ratio of stroke work to myocardial oxygen consumption 
and this is optimal at Emax/Ea=2. Myocardial efficiency is maintained close to 
optimal over a broad range of Emax/Ea values from 1.0 to 3.0
85. As mentioned 
above, coupling is maintained if as afterload increases, there is a matched 
increase in contractility however, this is often at the expense of myocardial 
efficiency which would increase oxygen consumption with maintained coupling83. 
There are no reference values for coupling and results may be dependent on the 
methods used in its calculation, however values are generally larger than one in 
healthy groups and closer to, or lower than one in disease states 81.  
1.2.3.8  Right ventricle and pulmonary interaction 
It would seem intuitive that given their close proximity and interaction with the 
pulmonary circulation that pulmonary function would interact with RV function. The 
mechanical work of breathing has a major impact on beat-by-beat and breath-by-
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breath right heart haemodynamics. During spontaneous breathing, the 2-5cmH2O 
decrease in intra-pleural pressure with inspiration leads to an increase in preload 
and therefore RV cardiac output, accounting for the waxing and waning of RV 
stroke volume during the respiratory cycle50. Conversely, during mechanical 
ventilation, RV stroke volume falls as mean airway pressure increases, preload is 
reduced and afterload is increased. Although not usually important in health, the 
small changes may be amplified in any situation where RV function is already 
compromised50. 
1.2.3.9  Regulation of right ventricular function 
The main mechanisms that regulate RV function are heart rate, the Frank-Starling 
mechanism and the autonomic nervous system. The autonomic nervous system 
has a differential effect on the inflow and outflow regions of the RV 46. 
Two methods act to preserve cardiac function when afterload or preload are 
altered. The first is heterometric autoregulation (changes in contractility are 
dependent on myocyte length), this is based on the Frank-Starling mechanism 
with increased preload increasing contractility. This occurs on a beat to beat 
basis71, 81. The second mechanism is homeometric autoregulation (changes in 
contractility are independent of changes in myocyte length). This response is 
based on the Anrep effect, or slow force response, and reflects an increase in 
contractility associated with increased afterload. This occurs over a longer time 
period (minutes) and is initiated by stretched myocardium leading to increased 
contractility81. This is an autocrine and paracrine controlled chain of events which 
begins with Angiotensin II release and culminates in increased cardiac myocyte 
intracellular Ca2+ concentration and a progressive decline in RVEDP (elevated as 
a result of increased afterload).87 These responses are unlikely to happen 
completely in isolation, for example, in response to increased afterload the RV is 
likely to dilate and trigger the Frank-Starling mechanism first and then the slower 
homeometric autoregulation response develops85.  
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1.2.3.10  Right ventricle vs left ventricle 
Characteristics Right Ventricle Left Ventricle 
Structure 
3 component parts63: 
1) Inlet (inflow region) 
2) Trabeculated 
myocardium 
3) Outlet (infundibulum) 
Inflow region, myocardium, 
no infundibulum 
Coupled circulation82 
Short vessels repeatedly 
dividing into daughter 
vessels. Vasoconstricts in 
response to hypoxia 
A large main artery (aorta) 
with multiple side branches 
Vasodilates in response to 
hypoxia 
Location 
Most anterior cardiac 
structure, Immediately 
behind the sternum61 
Posterior to RV 
Shape 
Crescenteric in cross 
section triangular when 
viewed from the side46 
Elliptical / conical46, 63 
Blood supply (depends 
on dominance of the 
coronary system) 
Majority of cases from right 
coronary artery. Perfusion 
throughout entire cardiac 
cycle 
From left coronary artery 
Perfusion predominantly 
during diastole 
Muscle fibre orientation 
Superficial circumferential 
deep longitudinal myofibres 
predominate (no middle 
layer)63 
Superficial obliquely 
orientated with 
longitudinally orientated 
fibres in the sub-
endocardium circular fibres 
in between63 
Contraction Longitudinal shortening51 
Twisting, rotational 
movements51 
End diastolic volume 
(mm3) 
Larger 
75 ± 13 [49 - 101]46 
Smaller 
66 ± 12 [44 - 89]46 
Mass (g/m2 BSA) 
Smaller 
26 ± 5 [17 - 34]46 
Larger 
87 ± 12 [64 - 109]46 
Thickness of ventricular 
wall (mm) 
2-546 7-1146 
Ventricular pressures 25/4 ([15-30] / [1-7]) 130/8 ([90-140] / [5 - 12]) 
EF (%) 61 ± 7 [47-76] 67 ± 5 [57-78] 
Ventricular elastance 
(Emax), mmHg/ml 
1.30 ± 0.84 5.48 ± 1.23 
End diastolic compliance High Low 
Filling profiles 
Longer. Starts earlier 
finishes later with lower 
filling velocities 
Shorter. Starts later, 
finishes earlier, higher 
filling velocities 
Afterload (dyn·s·cm-5) PVR. 70 [20-130] SVR. 1100 [700-1600] 
Resistance to ischaemia High Low 
Adaption to disease state 
Tolerant of volume 
overload 
Tolerant of pressure 
overload 
Table 1. Comparison of normal RV and LV structure and function 
Values presented as mean ± SD [range]. Adapted from Haddad et al.46. RV = right ventricle, PVR 
= pulmonary vascular resistance, SVR = systemic vascular resistance.  
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1.3  Assessment of the right ventricle 
Determination of RV function is important for management of many clinical 
conditions. The RV can be assessed using a number of imaging and functional 
modalities, with each providing its own strengths and limitations. The assessment 
of RV structure and function is challenging with a number of factors contributing to 
this difficulty46, 88: 
1. The complex geometry of the RV; It is triangular when viewed from the front 
and crescenteric when viewed in transverse section. This means that 
measures using geometric assumption for volume quantification have 
limited application88. 
2. The heavily trabeculated myocardium; When using imaging techniques this 
limits accurate endocardial visualisation and delineation. This is in contrast 
to the smoother LV endocardial border. 
3. The retrosternal position; This applies mainly to echocardiographic 
assessment and means the RV, particularly the free wall, is hidden behind 
the sternum (which acts as an acoustic barrier) limiting its visualisation61.  
4. Marked load dependence; RV function is sensitive to changes in both 
preload and afterload. The ideal measure of function would be independent 
of loading conditions but due to the difficulties in obtaining load independent 
measures of contractility, many of the most commonly used parameters for 
assessing RV function are load dependent46, 88. 
Due to the fundamental difference between the pulmonary and systemic 
circulations, the parameters that have been historically used to assess LV function 
cannot readily be applied to the RV. Pressure-volume loop (PV loop) analysis (as 
described in section 1.2.3.4.2 pg 34) is the gold-standard method for load-
independent assessment of RV function but is technically challenging to perform.  
Methods of RV assessment can be broadly divided into invasive and non-invasive. 
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1.3.1 Invasive assessment 
1.3.1.1  Conductance catheter 
This technique has been widely used in assessment of LV function and involves 
placement of a catheter in to the RV and allows continuous and instantaneous 
measurement of ventricular volume. The conductance catheter (CC) consists of a 
number of equidistant electrodes and utilises the principle of the time-varying 
conductance of blood within the ventricle, with conductance linearly related to 
ventricular volume. Blood is a good conductor of electricity and the ventricular wall 
relatively poor, meaning when the ventricle is full (end diastole), the conductance 
is higher than end systole76, 89. These catheters also contain a high fidelity sensor 
which simultaneously measures pressure, allowing the construction of pressure-
volume loops. A family of pressure-volume loops can be obtained by altering 
preload (e.g. balloon occlusion of the inferior vena cava) or afterload (e.g. 
occlusion of the pulmonary artery). From this family of curves, maximal systolic 
elastance (Emax), effective arterial elastance (Ea) and RV-PA coupling (ratio of 
Emax/Ea) can be obtained (section 1.2.3.7, pg 38).  
In addition to Emax and Ea, pressure-volume loop analysis allows calculation of 
other parameters describing RV function including; Stroke work (the area enclosed 
by the P-V loop and a measure of kinetic energy within the RV), dP/dtmax 
(maximum rate of pressure change in the RV, a measure of systolic performance), 
preload recruitable stroke work (PRSW, a relationship of stroke work and end 
diastolic volume that represents ventricular contractility), dP/dtmin (maximum rate of 
pressure decline which gives an idea of ventricular compliance) and End Diastolic 
Pressure Volume Relationship (EDPVR, ventricular compliance)76, 90. 
Conductance catheterisation is considered the gold standard for assessment of 
RV function, however the requirement for specialised equipment, along with its 
complex measurement and technical difficulty means its use is limited to a small 
number of specialist research centres46, 73, 85, 91. In addition, this is an invasive 
technique requiring placement of an intra-cardiac catheter with incorporated risk.  
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1.3.1.2  Pulmonary artery catheter 
The pulmonary artery catheter (PAC) also known as the right heart catheter 
(RHC), has been used in medical practice since 1970 and allows direct 
measurement of right sided haemodynamics with calculation of cardiac output and 
resistances92. Although its use has diminished in recent years, especially in critical 
care, it is still the reference standard for diagnosis and assessment in a number of 
clinical settings, particularly pulmonary hypertension93-95. Parameters that can be 
measured from the PAC include; right heart pressures (right atrial pressure [RAP] 
and RV pressure [RVP]), pulmonary artery pressures, pulmonary arterial wedge 
pressure (PAWP), trans-pulmonary pressure gradient (TPG) and diastolic 
pressure gradient (DPG). By calculation of flow (cardiac output) other parameters 
can be derived; pulmonary vascular resistance (see Equation 2, pg 32) and 
systemic vascular resistance (SVR)96.  
Some novel PACs allow measurement of additional parameters97. A 
spectrophotometry sensor at the tip of the catheter can allow continuous mixed 
venous oxygen saturation measurement which can provide information on global 
oxygen delivery and consumption98. Continuous cardiac output (CCO) can be 
measured using thermodilution techniques. RV end diastolic volume (RVEDV) can 
purportedly be determined by fast response thermodilution systems and allows 
calculation of RV ejection fraction (RVEF) and RV End Systolic Volume 
(RVESV)99, 100. A more in depth discussion of these 'volumetric' PACs is provided 
in section 2.3.2, pg 77. 
Measurements of pressure and PVR are an important diagnostic tool, giving some 
insight into the RV, but their measurement alone allows only an indirect description 
of RV function72, 81. RAP could be considered a surrogate of RVEDV or preload, 
with PAP or PVR as an estimate of afterload and stroke volume as an 
approximation of contractility. Volumetric measures provide much more 
information on RV function and can be used to compliment the information 
provided by PAC measurements72. 
Although rates are low, complications of PAC occur and can be related to the 
introduction of the catheter (arterial puncture, pneumothorax, haemothorax, 
thoracic duct lesions, infection), or from the PAC itself (valve lesion, catheter 
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knotting, PA rupture, RV perforation and cardiac arrhythmias)96, 101-104. The 
complications associated with PAC insertion would also be expected to apply to 
the introduction of the conductance catheter discussed in section 1.3.1.1, pg 42. 
1.3.2 Non-invasive assessment 
1.3.2.1  Cardiovascular magnetic resonance imaging 
Cardiovascular magnetic resonance (CMR) imaging utilises the interaction 
between a static magnetic field generated by a magnetic resonance imaging (MRI) 
scanner and the tiny magnetic fields that arise from the individual atomic nuclei of 
hydrogen atoms within free water or lipid molecules105-107. CMR is ideally suited to 
assessment of the RV as it allows measurement of ventricular parameters 
overcoming most of the limitations to RV assessment that are described in section 
1.3, pg 41. There is no reliance on acoustic windows, meaning no matter the 
position or orientation of the heart within the thorax, it is possible to obtain high 
resolution, time resolved images free from geometric assumptions which limit 
other modalities108. There is no exposure to ionising radiation, no risk associated 
with intra-cardiac catheter placement (in contrast to the PAC and CC) and non-
contrast imaging can even be completed without the need for intra-venous access 
making it genuinely non-invasive. 
Volume measurements of all cardiac chambers are obtained from cine imaging; 
these consist of anatomical images acquired at consecutive frames throughout the 
cardiac cycle that when played back show a movie of heart motion109. These cine 
images 'slice' the heart from base to apex and are performed during breath holds. 
A 'stack' of these images can be subsequently analysed offline and the 
endocardium contoured at both end systole and end diastole (manually or 
automatically depending on software) to provide an accurate measure of volumes 
using the summation of discs method (illustrated in Methods, section 4.3.2.3, pg 
143). These volumes (end systolic and end diastolic) permit calculation of ejection 
fraction and a volumetric estimation of RV-PA coupling. Although it is load 
dependent, RV ejection fraction is the most commonly used measure of RV 
contractility and is widely accepted46. RVEF is load dependent as it does not 
measure intrinsic contractility and situations may arise where contractility is 
reduced but as a result of loading conditions (decreased afterload or increased 
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preload) ejection fraction remains unchanged. Interventricular septum geometry 
can be determined from cine imaging allowing calculation of the eccentricity index, 
which quantifies the septal bowing that occurs during RV pressure and volume 
overload states110.  
In addition to providing detailed information on the structure, volume and mass of 
the RV from cine imaging, CMR can provide further insights into RV and 
pulmonary vascular function. Velocity encoded imaging can provide information on 
blood flow velocity and blood flow rate within the heart and vasculature. This can 
provide information on valve function and blood flow patterns within the pulmonary 
vessels. T2-weighted imaging can be used to assess myocardial oedema. First 
pass myocardial perfusion imaging allows assessment of perfusion of the 
myocardium in real time111.  
T1 weighted perfusion and late enhancement imaging following administration of 
gadolinium contrast allows characterisation of RV tissues, showing oedema, 
fibrosis, inflammation and scarring112. Interpretation can be difficult in the thin-
walled RV however. Additional information can be provided by simultaneous use 
of pressure catheters to provide pressure-volume loops and give a more in depth 
assessment of RV function, this technique has only been utilised in a research 
setting88, 113. 
Consensus guidelines from the Society of Cardiovascular Magnetic Resonance 
(SCMR) for standard post-processing and interpretation of CMR imaging were 
published in 2013 and help ensure consistent quality and reproducibility114. CMR 
assessment of RV volumes is reproducible with low inter-observer and intra-
observer variability108. Mooij et al. examined 60 patients (20 'normal' and 40 with 
RV dilatation) using CMR and showed low inter and intra-observer variability115. 
This was signified by high intraclass correlation coefficients (ICC) for inter-
observer (ICC 0.94-0.99) and intra-observer (ICC 0.97-0.99) variation for 
comparison of RV volumes (RVEDV, RVESV and RVSV). ICC for RVEF was 
lower with ICC's for inter-observer and intra-observer variability of 0.81 and 0.87 
respectively. There is also some data (published in abstract form) to suggest that 
following a training period, with a standardised protocol, there is little difference 
between novice and experienced CMR readers116.  
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CMR is considered a reference method for non-invasive evaluation of RV function 
and is an important tool for assessment in many clinical conditions, such as heart 
failure, congenital heart disease, pulmonary hypertension and ischaemic heart 
disease108, 117-119. It is also commonly used as the reference method for validation 
of echocardiographic methods120-122.  
CMR does have a number of limitations, it is expensive, especially when 
compared to other imaging modalities (echo or CT)88, 108, 123. Lower availability 
means that not every hospital will have access to CMR imaging. Lack of portability 
means its use is limited in the sickest of patients who would be unsuitable for safe 
transfer to the scanner. Claustrophobia in combination with long scan duration 
means that some patients will decline imaging. The need for breath holds during 
cine imaging, used to reduce respiratory motion artefact, may hinder its use in the 
very sickest patients and provides a unique challenge in the lung resection 
cohort76. Contraindications as a result of implantable devices that are MRI 
incompatible are less frequent with modern materials, but still mean some patients 
will be permanently unsuitable for scanning. When contrast is required, there is 
risk of renal injury or allergy from gadolinium based agents124. Manual 
segmentation is time consuming although automated software has been 
developed125. Expertise is required for imaging to be performed and for robust 
assessment of findings, meaning CMR imaging is often limited to specialist 
centres51. 
1.3.2.2  Echocardiography 
Trans thoracic and transoesophageal echocardiography (TTE and TOE 
respectively) can both be used to assess RV function. TOE is usually reserved for 
the intra-operative assessment of cardiac function and assessment of complex 
valvular disease. For this review, discussion will focus on TTE imaging. TTE 
assessment of the RV is challenging, it's retrosternal position meaning 
visualisation of the anterior RV free wall is difficult. As described in section 1.3, pg 
41, the RV has complex geometry meaning summation disc type volume 
calculations (in contrast to Simpsons bi-plane measurement of the LV) are not 
easy to perform and ultimately inaccurate126. In addition, many of the commonly 
used indices of RV performance are markedly load dependent88. TTE can provide 
information on RV dimensions, RV function and right sided pressures.  
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Despite the difficulties associated with TTE, it is by far the most commonly used 
modality in clinical practice; it is portable, widely available, inexpensive, non-
invasive with no exposure to ionising radiation. The British Society of 
Echocardiography have published a minimum dataset for standard TTE 
assessment which incorporates all aspects required for comprehensive evaluation 
of the RV127. Consensus guidelines have also been produced by the American 
Society of Echocardiography (ASE) for assessment of the right heart in adults and 
these have been endorsed by the European Association of Echocardiography and 
the Canadian Society of Echocardiography128. This guideline recommends that 
any report on right heart function should represent an assessment based on both 
qualitative and quantitative measures.  
Given the difficulties in assessing RV volumes using TTE, there had been a 
previous reliance on qualitative assessment with it still recommended for 
estimation of RV size. The RV should appear smaller (and usually no more than 
2/3 the size) than the LV when viewed in the standard apical 4-chamber view. If it 
appears larger in this view, it is likely to be significantly enlarged. RV assessment 
in this view is very sensitive to angular change and should be interpreted with 
caution. A subjective assessment can also be made of global function and septal 
bowing (which can additionally be quantified with the eccentricity index)129. 
Patterns of RV wall motion abnormality can be useful, such as in acute pulmonary 
embolism and McConnell's sign, which is signified by akinesia of the mid-free wall 
with normal motion at the apex130. Any qualitative assessment of RV function 
should be complemented with objective, quantitative, standardised measures. As 
there are difficulties in obtaining reliable views of the whole RV, quantitative 
assessment of systolic function often relies on surrogate parameters, or 
extrapolating regional assessment to reflect the entire ventricle61.  
As per ASE guidance for the assessment of the right heart in adults, the 
parameters to be obtained should include a measure of right heart size, a measure 
of RV systolic function (at least one of fractional area change [FAC], tricuspid 
annular plane systolic excursion [TAPSE], S' wave velocity at the lateral tricuspid 
annulus [S' Wave] or the RV myocardial performance index [RV-MPI]) and an 
estimate of right sided pressures. 
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1.3.2.2.1  Right heart size 
In addition to qualitative assessment, RV linear dimensions should be obtained 
from the apical 2-dimensional 4-chamber (A4C) view. Caution should be exercised 
here as the view is very dependent on probe position/rotation meaning RV width 
can be underestimated. RV basal, mid-cavity and longitudinal dimensions should 
be recorded.  
1.3.2.2.2  Fractional area change (FAC) 
FAC is a measure of the change in RV area and can be obtained from 2-D 
imaging in the A4C view. FAC is calculated as described in Equation 3 
(Determination of FAC is illustrated in Methods, section 4.4.2.2.1 pg 150). 
     
       
   
     
Equation 3. Fractional area change (FAC) 
EDA = end diastolic area, ESA = end systolic area. 
 
EDA and ESA are obtained by tracing the RV endocardium from the annulus, 
along the free wall to the apex and then back along the interventricular septum to 
the annulus again. In a mixed population of 63 patientsA Focardi et al. 
demonstrated strong association of FAC with RVEFCMR (r=0.77) and that it had an 
area under the receiver operating characteristic curve (AUROCC) of 0.78 for 
predicting an RVEFCMR of <45%
121. This finding is supported by other studies, 
albeit with a lower correlation coefficient (r=0.47) but similar AUROCC for ability to 
predict poor RVEFCMR (0.88-0.89)
122, 131. Other work however, including that by 
Kjaergaard et al. in 34 participantsB, has shown that FAC does not associate with 
RVEFCMR (r=0.34, non-significant [exact p-value not provided in paper])
120, 132.  
The limited range of RVEF assessed by Kjaergaard et al. meant that they were 
unable to evaluate FAC in those with very large or very small RVEF. The range 
                                            
A Referred for clinical assessment, 8 with suspected myocarditis, 8 with idiopathic dilated 
cardiomyopathy, 10 with hypertrophic cardiomyopathy, 10 with arrhythmogenic right ventricular 
dysplasia, 5 with infiltrative cardiomyopathy, and 9 for other reasons. 
 
B 17 with prior ST-elevation myocardial infarction, 7 with a history of pulmonary embolism and 
10 normal subjects. 
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assessed by Focardi et al. was much broader and could have contributed to the 
conflicting results of the two studies. The difficulties of RV visualisation and 
endocardial border contouring described above could also contribute to the 
inconsistency of FAC112. 
1.3.2.2.3  Tricuspid annular plane systolic excursion (TAPSE) 
Given the predominantly longitudinal movement of the RV on contraction, the 
systolic movement of the base of the RV wall at the tricuspid annulus provides one 
of the most visibly obvious movements on echocardiography. TAPSE quantifies 
this movement towards the apex and is obtained by placing an M-mode cursor 
through the tricuspid annulus in the A4C view and measuring the amount of 
longitudinal motion at peak systole. It assumes that the greater the displacement 
of the base during systole, the better the systolic function. It also assumes that 
displacement of the base reflects function of the entire ventricle. TAPSE is 
sensitive to Doppler cursor alignment, loading conditions and heart rate112, 131. 
TAPSE is the most commonly used measure in clinical practice, has been 
extensively studied and has well defined normal ranges51, 133. Global cardiac 
movement can contribute to the movement of the tricuspid annulus during systole 
meaning TAPSE may not truly represent solely RV function. Giusca et al. 
attempted to correct for global cardiac movement by adding the change in position 
of the LV apex to TAPSE values, resulting in improved association with peak 
systolic strain (an alternative echocardiographic method of assessing RV function, 
see section 1.3.2.3.4, pg 53)134.  
TAPSE has been shown to be associated with RVEFCMR (r=0.45-0.48) and has 
shown variable predictive ability for RVEF <45% signified by an AUROCC 0.66-
0.85121, 122, 131, 132. Measurement of TAPSE is illustrated in Methods, section 
4.4.2.2.2, page 151. 
1.3.2.2.4  S' Wave velocity at the tricuspid annulus (S'Wave) 
This method, similar to TAPSE, utilises the longitudinal excursion of the ventricle 
at the basal free wall. S' wave velocity is the highest systolic velocity and is 
obtained from an A4C view of the heart with a tissue Doppler 'region of interest' 
highlighting the RV free wall. As with all tissue Doppler techniques, care must be 
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taken to ensure optimal image orientation to avoid underestimation of velocities. 
Similar to TAPSE, this method assumes that function of a single region represents 
the function of the entire ventricle and is influenced by global cardiac movement. 
Moderate association with RVEFCMR has been shown in a heterogeneous group of 
patients (r=0.48-0.52) with a good ability to predict poor RV function with an 
AUROCC of 0.80121, 122. Other work however, has shown that S'Wave does not 
relate to RVEFCMR
131. Colour coded tissue Doppler can be analysed offline and is 
a novel method that can also be utilised to determine tissue velocities and 
calculate S'Wave. Measurement of S'Wave is illustrated in Methods, section 
4.4.2.2.3, pg 152. 
1.3.2.3  Summary of TTE measures of systolic function 
The measures of systolic function described (FAC, TAPSE, S'Wave) are all 
recommended for assessment of systolic RV function, however their ability to 
determine RV function from a reference method is inconsistent. There is 
association between RVEFCMR and the parameters in some studies, but not in 
others121, 122, 131, 132.  
Part of this inconsistency results from the range of RV function assessed. 
Correlation coefficients are often used to describe the relationship of two variables 
with higher coefficients often resulting from wider ranges of variables (a complete 
description of the use of correlation for validation of measurement is provided in 
the literature review, section 2.3.2, pg 77). In a study of 223 patientsC Pavlicek et 
al. demonstrated better predictive power in those with severely impaired RV 
function (RVEFCMR<30%) in comparison to those with moderately impaired RV 
function (RVEFCMR<50%) (Figure 10, pg 51)
122. 
                                            
C Heterogeneous group with a mixture of Ischaemic heart disease, cardiomyopathy, valvular 
heart disease, congenital heart disease and pulmonary hypertension. Subdivided in to three 
groups based on RVEF 1)RVEF ≥50%, n = 129, 2)RVEF 30-49%, n = 67, 3) RVEF ≤30%, n = 27.  
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Figure 10. Receiver operating characteristic analysis for seven Doppler echocardiographic 
parameters from Pavlicek et al. 
Adapted from Pavlicek et al.122. RVEF = right ventricular ejection fraction, FAC = fractional area 
change, FLC = fractional long axis change, IVA = isovolumic contraction acceleration, MPI = 
myocardial performance index, S RV lat = S'wave velocity at tricuspid annulus, S' = free wall peak 
systolic strain, TAPSE = tricuspid annular systolic excursion. 
 
As can be seen from Figure 10 there is inconsistency between the 
echocardiographic methods. For RVEFCMR <50%, AUROCC ranged from 0.67 to 
0.78 but for RVEFCMR <30%, they ranged from 0.66 to 0.95. For RVEFCMR <50% 
the AUROCC for FAC, TAPSE and S'Wave were 0.73, 0.71 and 0.78 respectively. 
For RVEFCMR <30% for FAC, TAPSE and S'Wave the AUROCC were 0.88, 0.79 
and 0.80. This demonstrates that the parameters perform better for lower 
RVEFCMR but that there is also disagreement amongst them. 
In 413 patientsD presenting for cardiac surgery Peyrou et al. demonstrated 
discrepancy in results for FAC and S'Wave135. For 90.6% of participants there was 
concordance of results with both demonstrating normal or abnormal RV function 
(FAC>35% and S'Wave >10cm/s or FAC <35% and S'Wave <10cm/s). However, 
for the remaining 9.4% of participants there was disagreement between the two 
parameters with either FAC or S'Wave being 'normal' but the other 'abnormal'. 
                                            
D Patients awaiting cardiac surgery. Consisted of 63% awaiting valve surgery, 49% coronary artery 
bypass grafting and 3% other cardiac surgery. 
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1.3.2.3.1  Inferior vena cava (IVC) diameter 
IVC diameter and the presence of inspiratory collapse is commonly used to 
estimate right atrial pressure. As RAP increases, pressure is transmitted to the 
IVC which collapses less with inspiration. This method estimates well when RAP is 
low or high, but less well when intermediate136. IVC diameter of ≤2.1 cm that 
collapses >50% with a sniff suggests a normal RAP of 3mmHg. An IVC diameter 
>2.1cm that collapses <50% with a sniff suggests a high RAP of 15mmHg. In 
indeterminate cases that do not fit these groups, an intermediate value of 8mmHg 
is used128. Assessment of IVC diameter is illustrated in Methods, section 4.4.2.2.4, 
pg 153. 
1.3.2.3.2  Pulmonary artery systolic pressure (PASP) 
Pulmonary artery systolic pressure can be estimated using continuous wave 
Doppler analysis across the tricuspid valve137. The pressure gradient across the 
valve can be determined from the tricuspid regurgitant jet (TRJ) velocity and the 
simplified Bernoulli equation (Equation 4). This gradient combined with an 
estimate of RAP (from IVC diameter, above) is used to reliably determine RV 
systolic pressure. In the absence of a gradient across the pulmonary valve or RV 
outflow tract obstruction, PASP is equal to RVSP. In cases where RVSP is 
elevated, RV outflow obstruction should be excluded. It is recommended to gather 
TR signals from multiple windows and utilise the window with the highest velocity. 
                                        
Equation 4. Simplified Bernoulli equation 
V = peak tricuspid regurgitant jet velocity from continuous wave Doppler 
 
PASP by continuous wave Doppler echocardiography has shown strong 
association with invasively measured PASP (r=0.68±0.19 on pooled meta-
analysis, p=0.003). This association is reduced in those patients with 
predominantly right sided heart disease or with normal PASP (in contrast to 
elevated PASP)138. TRJs are not visible in all patients; in those with PASP 
(measured invasively) >35mmHg, only 80% will have visible jets. This increases to 
more than 95% in those patients with PASP >50mmHg137. PASP by TTE tends to 
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overestimate PASP by PA catheter70. Measurement of PASP by TTE is Illustrated 
in Methods, section 4.4.2.2.5, page154. 
1.3.2.3.3  Pulmonary artery acceleration time (PAAT) 
Mean pulmonary artery pressure (mPAP) can be estimated from the acceleration 
time of the pulsed Doppler signal of the pulmonary artery during systole (PAAT is 
the time from onset of the Q wave on ECG to peak pulmonary flow velocity). 
Decreased PAAT is associated with increased wave reflection in the pulmonary 
artery which suggests increased pulsatile afterload70. A shorter PAAT is 
associated with higher pulmonary artery pressures and increased PVR in 
pulmonary hypertension 70, 139, 140. Measurement of PAAT is Illustrated in Methods, 
section 4.4.2.2.6, page 155. 
1.3.2.3.4  Strain 
Strain and strain rate are parameters of deformation. It is important to make a 
distinction between myocardial displacement and myocardial wall deformation. 
Over time the myocardium may change its position (displacement) but may not 
undergo deformation if all parts move with the same velocity. Wall motion 
measurements (velocity and displacement such as S'Wave and TAPSE) cannot 
differentiate between active and passive movement of a myocardial segment, 
whereas deformation analyses (strain and strain rate) allow discrimination 
between active and passive myocardial tissue movement69. For example, as the 
apical parts of the ventricle contract they pull down the ventricular base, the wall 
motion velocity and displacement parameters of the basal segments will increase, 
even if these segments are completely passive (not contracting). Their velocity 
and displacement is tethered to apical contraction. Deformation parameters can 
overcome this problem by measuring the magnitude of regional myocardial fibre 
contraction and relaxation141. Lagrangian strain (Equation 5, pg 54) is deformation 
relative to the initial length and is mathematically defined as the change of 
(myocardial) fibre length during stress at end systole (L) compared to its length in 
a relaxed state at end diastole (L0). 
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Equation 5. Strain Calculation 
ε = Strain; L0 = baseline length; L = length at time of measurement. 
 
The amount of deformation (positive or negative strain) is usually expressed in 
percent with positive values indicating myocardial thickening and negative values 
describing shortening in comparison to its original length76.  
Current methods allow strain to be calculated from echocardiography and CMR142. 
CMR tagged strain is considered the non-invasive reference method for strain 
measurement but due to its complexity and lengthy image acquisition and analysis 
times, its use is currently limited. Echocardiographic methods allow one-
dimensional (1D) measurements of strain using tissue Doppler and two-
dimensional measurements using speckle tracked imaging. The use of three-
dimensional speckle tracked echocardiographic imaging is also developing143. 
Deformation parameters can be calculated for individual segments and specific 
directions. A good approximation of active cardiac motion can be made with the 
use of three components of contraction; longitudinal, radial and circumferential 
strains (Figure 11, pg 55). This still represents a simplification from true three 
dimensional strain, where shear strains would be used, in addition to these three 
'normal' strains141.  
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Figure 11. The heart coordinate system for interpretation of strain measurements 
From D'hooge et al.144 For each point to be interrogated in any myocardial wall, three 
perpendicular axes can be defined; Radial Axis (R) = perpendicular to the epicardium, away 
from the cavity; Longitudinal axis (L0) = perpendicular to the radial axis, tangent to the 
epicardium and pointing towards the base of the ventricle, away from the apex; Circumferential 
axis (C) = perpendicular to both the radial and longitudinal axis. 
 
Tissue Doppler imaging (TDI) is used for assessment of velocity and displacement 
and due to a relationship between velocity and strain rate (SR), it also allows the 
construction of strain curves69, 145. Assessment of strain by TDI is subject to 
multiple technical limitations. Firstly, an optimised 2D image with rapid frame rates 
(>150 Hz) to resolve regional velocities and calculate SR is required. Also, 
alignment of the Doppler beam with the region of interest is vital as results are 
very angle dependent. If the angle of incidence is >20o, calculations become 
inaccurate69, 141, 145. Assessment of deformation parameters by TDI is only feasible 
if the echo beam can be aligned to the vector of contraction in the respective 
myocardial segment. Therefore, only longitudinal strain in the apical views, and 
radial strain in the parasternal views, can be calculated146. TDI requires 
considerable experience for correct interpretation and due to the analysis requiring 
operator dependent functions, including the positioning of sample volumes, TDI 
strain is semiobjective141, 145. Due to these multiple limitations, other methods to 
calculate myocardial deformation parameters have been developed. 
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1.3.2.3.5  Speckle tracked echocardiography 
Speckle tracked echocardiography (STE) is performed as an offline analysis from 
cine loops of greyscale images. Semi-automated software uses speckle artefacts 
in the echo image which are generated at random due to reflections, refraction and 
scattering of echo beams. This interference pattern results in bright and dark 
pixels which remain relatively constant for any small region of the myocardium and 
can be tracked through the cardiac cycle. These speckles can be used as acoustic 
markers for tagging myocardial motion (Figure 12)69, 128, 141. 
 
Figure 12. Displacement of acoustic markers from frame to frame 
Image from Blessberger et al.147 Green dots represent the initial position and red, the final 
position of the speckles. This displacement is represented as change in position on both the X 
and Y axis, from which strain can be calculated. 
 
Post-processing software defines a 'cluster of speckles' (called a 'kernel') and 
follows it frame to frame trying to recognise the most similar speckle pattern from 
one frame to another. Detection of this 'fingerprint' during the cardiac cycle allows 
calculation of lagrangian strain parameters. Tissue velocity and strain rate 
analyses can also be performed69, 141. Before strain analysis can be performed the 
endocardial and epicardial borders need to be tracked to correctly define the 
region of interest (ROI). Post-processing software automatically divides the 
myocardium into segments. Depending on the software type, and 
echocardiographic view, varying degrees of user interaction is required141, 148. 
Results are displayed as strain curves, graphical colour encoded displays or raw 
figures. Values can be displayed for individual segments and algorithms allow 
them to be averaged over groups of segments (for example the RV free wall) or for 
the entire chamber.  
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By tracking in two dimensions, along the direction of the wall and not only along 
the ultrasound beam, this technique is angle independent. It does not require as 
high frame rates (50 to 90 Hz in contrast to >150Hz required for TDI) and also 
allows measurement of radial and circumferential strain, in addition to longitudinal 
strain145.  
STE is not without limitations. Different filtering algorithms are used by different 
software providers meaning there may be variation across platforms141. STE is still 
dependent on the quality of echocardiographic images, exact detection of borders 
is difficult and even though speckle tracking itself seems to enhance the 
capabilities of endocardial delineation, it is still necessary to correct contours 
manually. In addition, assessment of strain and SR also requires definition of 
epicardial borders. Inadequate tracking of speckles may occur due to out of plane 
movement meaning that it may not be possible to track speckles from image to 
image. STE also has operator dependent functions, such as the positioning of the 
region of interest and approval of myocardial tracking meaning that quantification 
of global and regional measures by this technique are still, to an extent, 
semiobjective145, 149. A further limitation that is not unique to STE, is that it is often 
difficult to image the entire myocardium, particularly the apical segments. 
Two dimensional RV strain with STE is rapidly evolving, however use is still in its 
infancy. Due to the thin wall of the RV, only longitudinal parameters can be reliably 
calculated, this and the fact the RV mainly contracts in a longitudinal direction 
means most experience has been gathered using longitudinal strain. STE free-wall 
and global strain (incorporating the inter-ventricular septum) have both been used 
for assessment of RV function. Speckle tracked RV free-wall longitudinal strain 
has been shown to have a strong association with RVEFCMR (r=-0.86, p<0.0001)
121 
with excellent predictive capability for poor RVEFCMR (AUROCC 0.88-0.96,Table 
2)121, 122, 150.  
STE strain may overcome some of the difficulties associated with conventional 
parameters of RV systolic function, such as: angle dependence, reliance on 
function of a single region to represent the whole ventricle and global cardiac 
displacement. When RVEFCMR is used as a reference method, STE strain 
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parameters have been shown to perform better than these conventional methods 
for assessing RV function (Table 2).  
 AUROCC 
 Focardi et al.121. Pavlicek et al.122. Park et al.150. 
RVEF cut-off <45% <30% <50% 
 n=63 n=223 n=57E 
    
FAC 0.77 0.88 0.73 
TAPSE 0.66 0.79 0.74 
S'Wave - 0.80 - 
    
RV-GPLS 0.78 - - 
RV-FWPLS 0.92 0.88 0.96 
Table 2. Predictive capability of conventional parameters and STE strain parameters for poor 
RV function 
STE = speckle tracked echocardiography, AUROCC = area under the receiver operating 
characteristic curve, RVEF = right ventricular ejection fraction, FAC = fractional area change, 
TAPSE = tricuspid annular plane systolic excursion, S'Wave = S' wave velocity at the tricuspid 
annulus, RV-GPLS = RV global peak longitudinal strain, RV-FWPLS = RV free wall peak longitudinal 
strain. 
  
1.3.2.3.6  Echocardiography summary 
TTE offers anatomic and functional assessment of the RV and pulmonary 
circulation. Its non-invasiveness, widespread availability, low cost and portability 
mean it is an important tool for assessment of RV function. Although other 
methods may provide more accurate results, TTE is suited to the serial clinical 
examination of patients with RV disease. 
The level of agreement between TTE variables and RVEFCMR depends on both the 
subjects included and the parameters measured. Each TTE measure of RV 
function has been validated in different conditions, meaning certain measures can 
be used in specific clinical situations but overall, a combined approach integrating 
several measurements is advocated76, 112, 128, 151. Emerging TTE techniques, such 
as speckle tracking are attempting to overcome some of the difficulties associated 
                                            
E All with ischaemic cardiomyopathy 
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with imaging and will potentially offer a validated method for assessment of RV 
function. Further validation is needed before these novel techniques play a role in 
clinical decision making. 
1.3.3 Biomarker assessment of right ventricular function 
In other clinical settings (pulmonary hypertension, ischaemic heart disease and 
cardiac failure), imaging assessment is complemented with the use of biomarkers. 
Two of the most commonly used cardiac biomarkers are B-type natriuretic peptide 
(BNP) and troponin.  
BNP is a 32-amino acid polypeptide hormone released in response to myocardial 
stretch with levels elevated in situations where a cardiac chamber is enlarged. It 
may be thought of a counter-regulatory hormone to the renin-angiotensin system 
promoting natriuresis, diuresis and vasodilatation152. BNP is easily measurable in 
plasma, either in its active form or as its inactive precursor, NT-pro-BNP152. BNP 
has been measured peri-operatively and in a non cardiac surgery setting, pre-op 
levels are predictive of major adverse cardiovascular events and mortality post-
operatively153. A meta-analysis of natriuretic peptides in pulmonary embolism 
demonstrated that BNP is associated with adverse outcomes, including mortality 
and that it is able to detect RV dysfunction with an AUROCC of 0.92 in this 
population154. NT-pro-BNP has been shown to predict RV systolic dysfunction 
(defined as an RVEF <42%) with 100% sensitivity and 94% specificity in a 
population with pulmonary hypertension155.  
Troponins are released from cardiac myocytes following their necrosis and are 
most commonly used for the diagnosis of acute myocardial infarction. Elevations 
have been described for multiple cardiac and non-cardiac reasons. High sensitivity 
assays allow detection of very low levels of troponin156. Elevated troponins are 
commonly reported in pulmonary embolism and have been shown to be 
associated with RV dysfunction and adverse outcomes154, 157.  
BNP and troponin are not specific for RV failure, but their elevation can signal RV 
dysfunction or failure in the absence of left sided heart disease (Figure 13, pg 
60)158-160. RV dysfunction following lung resection may be reflected with elevation 
of either cardiac biomarker. 
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Figure 13. Mechanism of cardiac biomarker level elevation in RV failure 
Redrawn from Piazza et al.161. and Kucher et al.162. RV = right ventricular, BNP = B-type 
natriuretic peptide. 
 
1.4  Conclusion 
A diagnosis of lung cancer is associated with significant mortality and although 
age adjusted incidence is falling, the total number of cases is expected to rise over 
the next 15-20 years. Lung resection offers the best opportunity for cure, but is 
associated with significant short and long-term morbidity. As a result of efforts to 
reduce historical inequalities in lung resection rates in the UK and changes in 
guidelines, increasing numbers of older and sicker patients will be presenting for 
surgery, at higher risk of post-op morbidity. A better understanding of the factors 
contributing to early and late post-op morbidity, not only has clinical importance 
but also resource implications as the costs of health care rise. Pulmonary function 
does not seem to be the only contributing factor, something else is limiting these 
patients. The importance of RV function in disease is increasingly recognised and 
its role in lung resection is not yet fully understood. 
"Moreover, correction of the RV dysfunction after thoracic 
resection may result in reduced patient morbidity including a 
decrease in post-operative complications such as arrhythmias" 
Reed et al. (1996)163 
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Historically, the RV is understudied when compared to the LV. Advances in 
imaging techniques and the recognition that RV function has an important 
prognostic role in many clinical conditions mean this is changing51. Despite a 
thinner myocardial wall and more complex shape, the RV ejects the same stroke 
volume as the neighbouring LV, albeit over a much lower pressure range. RV 
function is dependent on the same factors that govern LV function, namely; 
preload, afterload and contractility. Effective RV function is particularly dependent 
on its coupling to the low impedance (low afterload) pulmonary circulation. In 
contrast to the LV which is relatively resistant to increases in afterload, the RV is 
very sensitive to increases in afterload. 
Assessment of RV function is challenging and no single technique has become the 
established method in clinical practice. Different techniques can be useful in 
specific clinical situations and can provide complementary information in others. 
Conductance catheterisation offers the ability to assess dynamic changes in 
ventricular volume and pressure, allowing pressure volume loop analysis and load 
independent assessment of RV function. Conductance catheterisation is a 
complex, technically challenging technique that is currently only performed in a 
small number of centres and is not used for the routine assessment of RV function 
in clinical practice. PA catheter assessment allows accurate assessment of 
pressures and flow but is unable to provide reliable measures of RV volumes so 
needs to be complemented with additional imaging techniques to provide more 
information. In addition, both these techniques are invasive and have small, but 
real, risks of complication and their regular use is limited. 
CMR offers a validated reproducible method for assessing RV volumes and 
function and newer techniques allow more precise measurement of RV 
parameters. It is firmly established as the non-invasive reference method. Despite 
the limitations with TTE assessment, it is the most commonly used technique in 
clinical practice and the development of novel techniques, such as speckle tracked 
strain echocardiography, will continue to improve its role in assessment of RV 
function. It is ideally suited to the sequential assessment of patients with RV 
pathology.
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Chapter 2 The Right Ventricle Following Lung 
Resection - Review of the Literature 
2.1  Introduction 
As previously described (section 1.1.4, pg 23), during the course of the authors 
clinical work as an intensive care doctor in the cardiothoracic intensive care unit at 
the Golden Jubilee National Hospital, it became apparent that patients admitted for 
critical care following lung resection not only presented with respiratory failure (as 
may be expected following lung surgery) but frequently manifested with features of 
RV dysfunction/failure. The requirement for intensive care following lung resection, 
along with the incidence of RV dysfunction/failure in this population, is discussed 
in chapter 3.  
This chapter reviews the studies that have examined changes in RV function in 
patients undergoing lung resection. 
2.2  Methods 
A database search was performed by the NHS Greater Glasgow and Clyde library 
network on 9th October 2014. The following strategy was utilised using the Ovid 
Medline (R) Database, 1946 to Present with Daily Update; 
 1. exp Ventricular Function, Left/ (28138) 
 2. exp Ventricular Function, Right/ (4247) 
 3. exp Ventricular Function/ (49943) 
 4. exp Ventricular Dysfunction, Left/ (23076) 
 5. exp Ventricular Dysfunction, Right/ (3776) 
 6. exp Ventricular Dysfunction/ (27594) 
 7. cardiac function.mp. (21293) 
 8. heart function.mp. (14797) 
 9. ejection fraction.mp. (41540) 
 10. ('pulmonary artery' adj2 pressure).mp. (9822) 
 11. exp Pneumonectomy/ (21595) 
 12. (lung adj2 resection).mp. (4035) 
 13. (wedge adj2 resection).mp. (2563) 
 14. (lobectomy adj4 lung).mp. (1131) 
 15. lung volume reduction surgery.mp. (876) 
 16.1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 (131135) 
 17. 11 or 12 or 13 or 14 or 15 (25941) 
 18. 16 and 17 (251) 
 19. limit 18 to English language (155) 
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Studies were included if they reported parameters related to RV or pulmonary 
artery function. Only studies examining the impact of lung resection surgery with 
pre-op and post-op measures were included. Articles examining lung volume 
reduction surgery alone were excluded (See below). References of all articles 
were reviewed for further relevant work, with eleven additional studies being 
identified. Of these final 166 articles, 62 were chosen for full text review. The 
search strategy was repeated in March 2017 with two additional studies being 
identified. Unless specified all data are reported as mean±SD. 
2.2.1 Lung volume reduction surgery 
Lung volume reduction surgery (LVRS) is a palliative treatment performed to treat 
severe emphysema. The least functional parts of the lung are identified and 
removed, with the intention of improving lung function, quality of life and exercise 
capacity. Careful patient selection is important for LVRS as benefits are limited 
and in selected groups it is even associated with an increased risk of death164, 165. 
There are very few LVRS procedures being performed in the UK, with 113 LVRS 
procedures performed during 2013-14, in contrast to 6361 lung resections 
performed for primary cancer20, 166, 167. For this reason, to allow application of any 
findings to real clinical practice, the work presented in this thesis has not included 
studies where patients have had LVRS unless they include subgroups having 
anatomical lung resection for non-emphysematous disease. 
2.3  Results 
For discussion, the studies have been divided in to three main groups; those 
utilising the ‘standard’ pulmonary artery catheter (PAC), those utilising the 
‘volumetric’ PAC (section 2.3.2, pg 77) and those using echocardiography (section 
2.3.3, pg 90). 
Studies utilising PAC or vPAC are summarised in Table 3 below, with discussion 
beginning in section 2.3.1, pg 74. 
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Table 3. Studies using pulmonary artery catheters to examine right ventricular function following lung resection 
Study  
(Year) 
(n) 
Population / 
subgroup 
Method of 
assessing RV 
function & time 
points 
Changes in RV 
function 
Clinical outcome 
associated with RV 
function? 
Comment 
Rams et 
al.8 
(1962) 
61 
All Thoracotomy 
61 Pneumonectomy 
 
 
*Only 24 patients 
had post-op PAC. 
Intra-
op 
PAC 
30 Days - 
7 years 
↑mPAP (exercise) 
No association 
between follow-up 
PA pressures and 
clinical outcome. 
 
PA pressures intra-
op were higher in 
those patients who 
died post-op ly and 
highest in those who 
died of 
"cardiorespiratory 
complications." 
Retrospective study of factors 
associated with increased 
cardiorespiratory risk. 
 
PA pressures obtained by 
needle puncture intra-op before 
and after temporary ligation of 
the PA. 
 
Wide variation in follow-up 
time. 
 
The resting PA pressures at 
post-op follow-up were lower 
than those following intra-op 
occlusion of the PA. 
Jezek et 
al.168 
(1970) 
77 
All Thoracotomy 
43 Pneumonectomy 
34 Lobectomy 
 
*Only 30 cases 
examined at 6 
months 
 
PAC 
Pre-op 
6 Months 
Age 60-64 yrs 
↑mPAP 
↑TPR 
 
Age >65yrs 
↑mPAP 
No clinical outcomes 
associated with RV 
function. 
Study of peri-operative 
changes in cardiopulmonary 
variables following lung 
resection. Main focus was 
association with age. Results 
presented in age groups. 
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Study  
(Year) 
(n) 
Population / 
subgroup 
Method of 
assessing RV 
function & time 
points 
Changes in RV 
function 
Clinical outcome 
associated with RV 
function? 
Comment 
Mlczoch 
et al.169 
(1975) 
49 
All Thoracotomy 
14 Pneumonectomy 
25 Lobectomy 
6 Sub-lobar 
2 Decortication 
2 Thoracotomy 
 
* Only 28 cases 
examined at 6 
months 
PAC 
Pre-op 
6 Months 
Haemodynamics 
measured at rest 
and exercise 
 
All patients 
↑mPAP (rest and ex) 
↑PVR (rest and ex) 
No clinical outcomes 
associated with RV 
function. 
Evaluation of pulmonary 
haemodynamics and lung 
function tests peri-operatively. 
 
Examined in relation to extent 
of resection; carcinoma or not. 
 
"The extent of lung resection 
showed no influence on the 
pulmonary circulation." 
Reed et 
al.170 
(1992) 
15 
All Thoracotomy 
13 Lobectomy 
2 Pneumonectomy 
VPAC 
Intra-op 
4-6 Hrs 
POD 1 
POD 2 
↔RVEDV 
↓RVEF 
↓PVR 
"Three patients had 
periods of sustained 
atrial arrhythmias on 
POD 1 or 2 and at 
that time had 
significant increases 
in RVEDV." 
RVEF decreased post-op and 
was lowest on POD 2. All 
despite a reduction in PVR. 
 
Decline in RVEF is 
independent of changes in 
PVR 
Nishimur
a et al.171 
(1993) 
9 
5 Lobectomy 
4 Bilobectomy 
 
*18 patients 
recruited but only 9 
were able to repeat 
follow-up 
examination. 
 
PAC 
Pre-op 
4-6 
months 
↑mPAP with 
exercise 
 
↑PVRI at rest and 
with exercise 
 
No association 
between RV function 
and clinical 
outcomes 
Same patients (+1 patient) as 
Miyazawa et al.172 (1999) but 
followed up for less time. 
 
Conclusion that "there is a 
deterioration in 
cardiopulmonary function after 
lobectomy" and "reduction in 
exercise tolerance appeared to 
be related mainly to the effects 
of pulmonary hypertension." 
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Study  
(Year) 
(n) 
Population / 
subgroup 
Method of 
assessing RV 
function & time 
points 
Changes in RV 
function 
Clinical outcome 
associated with RV 
function? 
Comment 
Reed et 
al.173 
(1993) 
10 
All Thoracotomy 
9 Lobectomy 
1 Biopsy* 
 
*Biopsy patient not 
included in post-op 
analysis 
 
VPAC 
Pre-op 
1 Hr 
4-6 Hrs 
POD 1 
↔PRSW 
↑RVEDVI 
↑sPAP (↔mPAP) 
↑RVESVI 
↑RVSVI 
↔RVEF 
↓PVRI 
No clinical outcomes 
associated with RV 
function. 
Used PRSW relationship 
(RVSWI v RVEDVI) which has 
been described as a 'load 
independent index of RV 
contractility.' 
 
No change in RVEF. No 
difference in PRSW at 4-6 
hours and 24 hrs suggesting 
contractility was unaltered. 
Lewis et 
al. 44 
(1994) 
20 
All Thoracotomy 
20 Pneumonectomy 
VPAC 
Pre-op 
Intubated 
OLV 
PA 
clamped 
Immediate 
post-op 
All Patients 
↓RVEF 
↔mPAP 
↔RVESVI 
↔RVEDVI 
↔PVR 
↑PVR/RVEF 
Association between 
late 
cardiorespiratory 
symptoms (higher 
NYHA classification) 
and lower RVEF at 
PA clamping.  
Investigates the role of peri-
operative RV assessment on 
post pneumonectomy morbidity 
and mortality. 
 
Develops a suggested 
algorithm for evaluation of a 
pneumonectomy patient using 
RVEF. 
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Study  
(Year) 
(n) 
Population / 
subgroup 
Method of 
assessing RV 
function & time 
points 
Changes in RV 
function 
Clinical outcome 
associated with RV 
function? 
Comment 
Okada et 
al.174 
(1994) 
20 
3 Pneumonectomy 
2 Bilobectomy 
15 Lobectomy 
 
*Same cohort of 
patients as Okada et 
al.41 
 
VPAC 
Pre-op 
Post-op 
hour 1 
Post-op 
hour 6 
POD 1 
POD 2 
Week 3 
All Patients 
↑RVEDVI 
↑RVESVI 
↓RVEF 
↔PVRI 
 
With Exercise(n=10) 
↑RVEDVI 
↑RVESVI 
↓RVEF 
↑PVRI 
↑mPAP 
 
No clinical outcomes 
associated with RV 
function. 
RVEF is depressed post-
operatively and has only 
partially recovered by week 3  
 
Elevations in mPAP and PVRI 
occur only during exercise, with 
the authors suggesting 
changes in afterload are the 
main determinant of RV 
performance and that RV 
function at rest compensates 
by increasing RV volume. 
Boldt et 
al.175 
(1996) 
50 
All Thoracotomy 
10 Pneumonectomy 
40 Lobectomy 
VPAC 
Pre-op 
OLV 
Post-op 
2hrs Post 
POD 1 
Pneumonectomy 
↓RVEF 
↑RVEDVI 
↑RVESVI 
↑CVP 
↑PAP 
(all OLV to POD 1) 
 
Lobectomy 
↓RVEF (OLV) 
No clinical outcomes 
associated with RV 
function. 
Designed to assess different 
anaesthetic regimes in 2 
lobectomy groups (n=20 in 
each). 10 pneumonectomy 
patients also included. 
 
In pneumonectomy, RV 
haemodynamics deteriorated 
at OLV and remained 
depressed until POD 1.  
No influence of anaesthetic 
regime on RV function 
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Study  
(Year) 
(n) 
Population / 
subgroup 
Method of 
assessing RV 
function & time 
points 
Changes in RV 
function 
Clinical outcome 
associated with RV 
function? 
Comment 
Okada et 
al.41 
(1996) 
18 
3 Pneumonectomy 
1 Bilobectomy 
14Lobectomy 
 
*Same cohort of 
patients as Okada et 
al.174 (1994). 
 
VPAC 
Pre-op 
Week 3 
Same patients as 
Okada et al.174 
No association 
between pre-op 
RVEF and post-op 
complications or 
length of stay. 
 
A decrease in RVEF 
with exercise was 
associated with a 
higher rate of 
complications and 
prolonged hospital 
stay. 
Patients dichotomised 
according to severity of RV 
dysfunction, and whether 
RVEF increased or decreased 
with exercise. 
 
"Evaluation of RV performance 
is useful in determining which 
patients are at risk for 
complications after lung 
resection. Exercise induced 
change in RVEF may be a 
better indicator of high risk." 
Reed et 
al.163 
(1996) 
45 
All Thoracotomy 
Part one 
35 Lobectomy or 
Pneumonectomy 
(n not given) 
 
Part two 
6 Lobectomy 
VPAC 
Pre-op 
POD 1 
POD 2 
Part one 
↑RVEDVI 
↓RVEF 
↔PRSW 
↔PVRI 
 
Part two 
↑RVEDVI 
↓RVEF 
↓PVRI 
 
No clinical outcomes 
associated with RV 
function. 
Two part study. Part 1 
assessing PRSW pre-op 
(n=35) and on POD 2 (n=6). 
No difference in PRSW with 
the authors concluding there 
was no change in RV 
contractility. 
 
Part 2 assessing reduction of 
afterload by continuous 
infusion of prostaglandin E1. 
This reduced PVRI although 
RV dysfunction remained. 
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Study  
(Year) 
(n) 
Population / 
subgroup 
Method of 
assessing RV 
function & time 
points 
Changes in RV 
function 
Clinical outcome 
associated with RV 
function? 
Comment 
Backlund 
et al.176 
(1998) 
24 
All Thoracotomy 
4 explorative 
15 lobectomy 
3 bilobectomy 
2 pneumonectomy 
TTE 
VPAC 
Pre-op 
Recovery 
POD 1 
POD 2 
POD 3 
Both Groups 
↔RVSWI 
 
Short O2 (S) 
↔RVEDVI 
↓RVEDD 
↑PVRI (POD 1-3) 
↑mPAP (POD 1&2) 
↓RVEF (POD 1&2) 
 
 
Prolonged O2 (P) 
↓RVEDVI (POD 1) 
↔RVEDD 
↔PVRI 
 
 
Patients developing 
AF had greater PVRI 
and a greater sRVP 
in the immediate 
post-op period 
Complicated study designed to 
assess the effect of O2 on post-
op AF and RV function 
 
Patients allocated to FiO2 35% 
until POD 3 (P, prolonged 
group) or POD 1 (S, short) 
 
RVP and PVRI increased in S-
group compared with P-group. 
The authors conclude "this may 
show evidence of RV strain 
without RV dysfunction" in 
patients on short O2 regimen. 
RVP tended to reduce 
following FiO2 0.6 in both 
groups (except in patients who 
developed AF) 
 
Conclusion that prolonged O2 
therapy did not prevent 
occurrence of AF attributed to 
RV strain. 
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Study  
(Year) 
(n) 
Population / 
subgroup 
Method of 
assessing RV 
function & time 
points 
Changes in RV 
function 
Clinical outcome 
associated with RV 
function? 
Comment 
Miyazawa 
et al.172 
(1999) 
8 
5 Lobectomy 
3 Bilobectomy 
PAC 
Pre-op 
4-6 
months 
42-48 
months 
↑mPAP at rest and 
with maximal effort 
exercise 
 
↑PVRI at rest and 
with maximal effort 
exercise 
No clinical outcomes 
associated with RV 
function. 
Evaluation of post-op changes 
in cardiopulmonary function on 
exertion in patients with lung 
cancer surviving for more than 
3 years. 
 
Conclusion that peak blood 
flow per unit of remaining lung 
during exercise becomes lower 
with time following lung 
resection, indicating 
deterioration of the pulmonary 
vascular bed. 
Haniuda 
et al.177 
(2000) 
8 
All Thoracotomy 
8 Lobectomy 
PAC 
Pre-op 
6 Months 
↑PAP (exercise) 
↑PVRI (rest & 
exercise) 
 
No clinical outcomes 
associated with RV 
function. 
*Study was designed to clarify 
the effects of lung volume 
reduction surgery (LVRS) on 
the cardiopulmonary 
circulation. Studied 7 patients 
having LVRS but had 8 
lobectomy patients included as 
a comparison group. Data for 
lobectomy group is shown. 
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Study  
(Year) 
(n) 
Population / 
subgroup 
Method of 
assessing RV 
function & time 
points 
Changes in RV 
function 
Clinical outcome 
associated with RV 
function? 
Comment 
Mikami et 
al.178 
(2001) 
23 
All lobectomy 
13 VATS 
10 Thoracotomy 
VPAC 
Pre-op 
6 Hrs 
post-op 
12 Hrs 
post-op 
POD 1 
POD 2 
VATS 
↑RVEF 
 
No significant 
changes in other RV 
parameters 
No clinical outcomes 
associated with RV 
function. 
Designed to determine whether 
lobectomy by VATS is also 
advantageous with respect to 
the RV performance in patients 
>70 yrs old. 
 
Values were reported as a 
percentage of pre-op values. 
Trends towards higher 
pulmonary resistance in 
thoracotomy group. 
 
There were minor changes in 
RV afterload following VATS 
compared with thoracotomy. 
"Lobectomy using VATS offers 
beneficial effects of the right 
ventricular afterload." 
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Study  
(Year) 
(n) 
Population / 
subgroup 
Method of 
assessing RV 
function & time 
points 
Changes in RV 
function 
Clinical outcome 
associated with RV 
function? 
Comment 
Jorgense
n et al.179 
(2003) 
10 
All Thoracotomy 
10 Lobectomy 
PAC 
TOE 
Pre-op 
Immediate 
post-op 
↔mPAP 
↔PVRI 
 
No clinical outcomes 
associated with RV 
function. 
*Study designed to investigate 
the effect of LVRS on LV 
function, pulmonary 
haemodynamics and systemic 
haemodynamics. Ten 
lobectomy patients as a control 
group 
 
Although TOE imaging was 
performed it only examined LV 
function. 
 
Main focus of study is on LVRS 
group and beneficial effect of 
surgery on LV function. No 
changes in any parameter in 
the lobectomy group. 
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Study  
(Year) 
(n) 
Population / 
subgroup 
Method of 
assessing RV 
function & time 
points 
Changes in RV 
function 
Clinical outcome 
associated with RV 
function? 
Comment 
Mageed 
et al.180 
(2005) 
30 
All Thoracotomy 
All Lobectomy 
VPAC 
Pre-op 
Post-
induction 
2Hrs post-
op 
All patients 
↓RVEF (2Hrs) 
↔RVEDVI 
↔PVRI 
↔mPAP 
↔RVSWI 
No clinical outcomes 
associated with RV 
function. 
Study designed to investigate 
the effect of lobectomy on 
pulmonary haemodynamic and 
gas exchange variables.  
RV = right ventricular, PAC = pulmonary artery catheter, PA = pulmonary artery, mPAP = mean pulmonary artery pressure, TPR = total pulmonary 
resistance, PVR = pulmonary vascular resistance, VPAC = volumetric pulmonary artery catheter, RVEDV = right ventricular end diastolic volume, RVEF = 
right ventricular ejection fraction, POD = post-op day, PRSW = preload recruitable stroke work, sPAP = systolic pulmonary artery pressure, RVESV = right 
ventricular end systolic volume, RVSV = right ventricular stroke volume, OLV = one lung ventilation, RVSP = right ventricular systolic pressure, SVT = 
supraventricular tachycardia, CVP = central venous pressure, AF = atrial fibrillation, sRVP = systolic right ventricular pressure, FiO2 = fraction of inspired 
oxygen, VATS = video assisted thoracoscopy, TOE = trans oesophageal echocardiography, LVRS = lung volume reduction surgery, LV = left ventricular, FVC 
= forced vital capacity, RVSW = right ventricular stroke work. 
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2.3.1 Studies utilising 'standard' pulmonary artery catheters  
The early studies evaluating pulmonary haemodynamics (pre 1990) exclusively 
involved the use of Pulmonary Artery Catheters (PAC)168, 169, 181. These three 
studies are of reasonable size (49-77 patients) and include a mixture of lobectomy 
and pneumonectomy patients. Although not stated explicitly, all appear to be 
retrospective, with the cohorts examined post-operatively all being smaller than 
the total number of patients examined pre-operatively. They are samples of 
convenience with only those undergoing investigations for other reasons included 
for analysis. For example, Rams et al. included 61 patients in his study but only 
performed follow-up PAC measurements on only 24 patients at follow-up (30 days 
to 7 years following surgery). This showed that mPAP was unchanged at rest but 
increased significantly with exercise. 
These studies have significant selection bias as only those patients who survived 
the follow-up period were investigated. There is agreement from the 3 studies that 
mean pulmonary artery pressure (mPAP) and pulmonary vascular resistance 
(PVR) increase when compared to pre-op values. Those studies performing 
measurements on exercise, found a similar pattern with elevation in pressures 
also present on exertion169, 181. There was no association demonstrated between 
the extent of resection and changes in the pulmonary circulation. 
There is limited information on clinical outcomes across these three studies. In 
addition to the longer term follow-up described above, Rams et al.181 examined PA 
pressures intra-operatively (by direct needle puncture) prior to and following 
pulmonary artery ligation. This demonstrated mPAP prior to, and immediately 
following, occlusion of the pulmonary artery was lowest in those patients that 
survived post-operatively and highest in those who went on to have post-op 
cardiopulmonary deaths (Figure 14, pg 75)181.  
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Figure 14. Operative mean pulmonary artery pressures prior to and following occlusion of 
the pulmonary artery 
From Rams et al. (1962)181 
 
Three studies after 1990 used exclusively PAC171, 172, 177 and one used both PAC 
and trans-thoracic echocardiography (TTE)179. These prospective studies were 
smaller than the earlier PAC studies (8-10 patients) and contained exclusively 
lobectomy patients. There is limited information on clinical outcomes for all these 
studies and, where present there is no association with pulmonary circulation 
variables. 
Nisihimura et al.171 initially set out to examine 18 patients but only nine attended 
follow-up examination. The 9 patients were lost to follow-up "because of 
recurrence of carcinoma or poor general condition." The nine patients were 
examined pre-op and at six-months post-op; both at rest and during exercise 
(graded exercise on a bicycle ergometer). There was no change in mPAP at rest 
but an increase with exercise. Pulmonary vascular resistance index (PVRI)F 
increased at rest and on exercise. Miyazawa et al.172 followed eight of these same 
patients up at 42-48 months. No information is given on the single patient lost to 
follow-up. At this stage there was an increase in mPAP at rest as well as with 
                                            
F A number of studies describe variables indexed to body surface area; Pulmonary vascular 
resistance index (PVRI), RV end diastolic volume index (RVEDVI), RV end systolic volume index 
(RVESVI) 
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exercise (Figure 15). Again, PVRI was increased both at rest and with exercise. In 
a very similar study with many of the same authors, (8 patients examined at rest 
and with a graded exercise protocol) Haniuda et al.177 demonstrated almost 
identical results with an increase in PVRI at rest and an increase in both, PVRI 
and mPAP with exercise.  
 
Figure 15. Changes in mPAP over time from Miyazawa et al. 
Drawn from data presented by Miyazawa et al.172. Continuous lines = at rest. Dashed lines = 
exercise (50W bicycle ergometer). Value (error bars) = mean (SD), # = significant difference from 
pre-op values. 
 
Jorgensen et al.179 explored the effect of LVRS on pulmonary and systemic 
haemodynamics. They included ten patients undergoing lobectomy as a control 
group and also included TOE measures of LV function. There were no changes in 
PAC variables in the lobectomy subgroup. 
The studies using standard PAC do not analyse changes in the immediate peri-
operative period but they do suggest that pulmonary artery pressures are 
increased 6 months168, 169, 171, 177 following surgery and that they continue to be 
increased on later follow-up172 (3-4 years). There is an associated increase in 
PVR168, 169, 171, 177 at this time and this is accentuated with exercise169, 171, 177, 181. 
Despite a paucity of clinical associations, there is a suggestion that elevated PA 
pressures at the time of PA clamping are associated with increased mortality.  
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2.3.2 Studies utilising 'volumetric' pulmonary artery catheters  
The development of fast response PACs allowing calculation of RV volumes 
(vPAC) were ideally suited to the investigation of the RV during lung resection with 
the majority of studies utilising this modality. The validity of this method has been 
questioned and is discussed following an initial review of the studies. 
Reed et al.163, 170, 173 performed a series of 3 studies (1992 - 1996) exploring RV 
dysfunction following lung resection and potential causative mechanisms. The first 
study demonstrated that RVEF fell from 452% pre-op to 363% on POD 2170. 
These changes occurred despite a reduction in afterload (from pre-op values) as 
measured by PVR. In the second of these studies they investigated preload 
recruitable stroke work (PRSW). PRSW is the relationship between RV Stroke 
Work Index (RVSWI, Equation 6) and RV End Diastolic Volume Index (RVEDVI) 
had previously been described as a load independent index of RV contractility182.  
      
                         
   
 
Equation 6. Right ventricular stroke work index (RVSWI) 
MPAP = mean pulmonary artery pressure, CVP = central venous pressure, RVSV = right ventricular 
stroke volume, 0.0136 = conversion factor for pressure to work, BSA = body Surface Area. 
 
The PRSW relationship was initially calculated pre-operatively with the rapid 
infusion of crystalloid (250ml, 250ml and 500ml) and the relationship between 
RVSWI and RVEDVI plotted. A comparison was then made with the relationship 
between RVSWI and RVEDVI post-operatively, with no changes detected. Both 
RVEF and RVSWI were unchanged during the first post-op day and the authors 
conclude that “changes in RV performance during the early post-op period were 
not due to inherent changes in the RV contractile state.” RVEDVI was increased in 
the first post-op day with PVR again reduced. The final study by Reed et al.163 was 
a two part experiment; The first examined the PRSW pre-op and on post-op day 
two with the results showing that RVEF was reduced (43±1 % to 37±1%) and that 
contractility was unaltered. The second part assessed the haemodynamic 
response to a post-op reduction in afterload using an infusion of prostaglandin; this 
showed that despite a fall in PVRI, RVEF remained depressed suggesting 
changes in RVEF following lung resection are independent of changes in 
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afterload. The results of this final study would imply that changes in RV function 
following lung resection are not a result of changes in afterload or contractility with 
the authors suggesting "better control of heart rate may enhance RV pump 
function." The authors made no assessment of the matching of contractility and 
afterload (coupling). The changes in RVEF in this series of studies are 
summarised in Figure 16, showing a consistent decrease in RVEF on POD 2. 
 
Figure 16. Changes in RVEF over time from studies by Reed et al.163, 170, 173  
Drawn from data presented by Reed et al. Continuous lines = Reed (1992)170. Grey lines= Reed 
(1993)173, Dashed lines = Reed (1996)163. Value (error bars) = mean (SD), # = significant difference 
from pre-op values, RVEF = right ventricular ejection fraction, POD = post-op day. 
 
Lewis et al.44 used the vPAC to assess changes in RV variables during the peri-
operative period and their impact on post pneumonectomy morbidity and mortality. 
They showed a reduction in RVEF (45±10% to 39±8%) and an increase in the 
ratio of PVR and RVEF (3.2±2.3 to 4.4±3.1) during PA clamping, both of which 
returned to baseline in the post-op period. They highlighted that those patients 
with a RVEF <35% during PA clamping were more likely to develop 
cardiorespiratory symptoms (signified by New York Heart Association class III or 
IV), providing a link between peri-operative RV function and long-term functional 
outcome. In addition to this group who were more likely to develop late symptoms; 
those patients with pre-op RVEF >35%, a normal PVR (<200 dyn·s·cm-5) or a 
PVR/RVEF ratio <5 were less likely to develop late cardiorespiratory morbidity. 
Okada et al. published two studies41, 174 from the same cohort of patients to 
examine the extent and duration of RV dysfunction following major pulmonary 
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resection. They also examined changes in RV haemodynamic variables with 
exercise. The first part of this first study was performed at rest and showed RVEF 
is reduced post-operatively (43±7% pre-op to 34±4% on POD 2), and that this has 
only partially recovered by 3-weeks post-op (to 37±6%). They also demonstrate 
increased RVEDVI, RVESVI and unaltered PVRI. The second part of this first 
study examined participants during exercise (a sub-maximal exercise protocol on 
a bicycle ergometer) pre-operatively and 3 weeks post-operatively. At 3-weeks 
post-op there were marked increases in pulmonary artery pressures and PVRI 
with exercise. The second study was a secondary analysis of the same patients 
and tried to identify associations between pre-op RV function and post-op 
morbidity. When comparing those who had a decreased RVEF with exercise, to 
those with an increased RVEF with exercise, there was a higher incidence of 
complications (not explicitly defined) in the former group (50% vs 0%). Those with 
a decrease in RVEF also had a longer hospital stay (37.5±15.9 vs 19.4±8.0 days). 
Boldt et al. performed a study175 to examine the impact of two different anaesthetic 
regimes on the cardiorespiratory system (Group 1A and 1B) and compared them 
to a pneumonectomy group (Group 2). The first author of this study, Joachim Boldt 
was later found guilty of research misconduct, including failure to acquire ethics 
and fabrication of study data. The majority of studies (nearly 100) he published 
since 1996 have been retracted from the medical literature183. Although this study 
has not been retracted, given the questions over work published by him, its 
findings will bear no impact on the work of thesis. It is presented here for 
completeness of the review. 
Backlund et al.176 conducted a complex prospective randomised study examining 
the effect of oxygen on post-op atrial fibrillation (AF) and its relationship to RV 
function. Patients were randomlyG allocated to 35% oxygen until POD 1 (short) or 
until POD 3 (prolonged). In addition, the effect of 15 minutes of 60% oxygen on RV 
pressure at each post-op time-point (in both groups) was also examined. RVEF 
was unchanged from pre-op values in both groups. Post-operatively RV pressure 
and PVRI were increased in the short group compared with the prolonged group 
and the authors explain that this may show “RV strain without RV dysfunction”. RV 
pressure was reduced following exposure to 60% oxygen in both groups, except in 
                                            
G No details on randomisation provided 
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those developing AF. Risk factors for post-op AF were found to include intra-
operative bleeding and high pre-op PVRI, with the prolonged administration of 
oxygen not preventing its development. 
To determine if video assisted thoracoscopic surgery (VATS) lobectomy in 
comparison to thoracotomy was advantageous in terms of RV performance in 
patients >70 years old, Mikami et al.178 examined a cohort of 23 patients. Absolute 
values of RV and pulmonary haemodynamic variables are not provided and are 
presented relative to baseline. In the VATS group RVEF was higher at 24 hours 
post-op than in the thoracotomy group (118±31% vs 90±31%) but with no change 
from baseline. There were no significant changes in markers of pulmonary 
resistance, although the study reports that "pulmonary arteriolar resistance indexH 
at 24hours post-op tended to be higher in the standard thoracotomy group than 
the VATS group." Mageed et al.180 performed a study to investigate the effects of 
lobectomy on pulmonary haemodynamics and gas exchange variables in 30 
patients undergoing lobectomy. Values were obtained pre-op, intra-op and 2 hours 
post-op. At two-hours post-op, RVEF was reduced from pre-op values (37±6.6% to 
27±12.7%) with no changes in any other measures of RV or pulmonary vascular 
function. 
A summary of the changes with both, standard and volumetric pulmonary artery 
catheters is provided in 
Table 4 (pg 81) and Table 5 (pg 82). The studies analysing the RV response to 
lung resection using vPAC give inconsistent results. Indeed, on POD 1 there are 
studies suggesting RVEF increases, decreases and remains unchanged163, 173, 174, 
178. Although elevated afterload is the primary hypothesis for RV dysfunction 
following lung resection, there is no evidence of raised peri-operative PVR (a 
surrogate for afterload) with most studies showing it is unchanged or reduced44, 163, 
170, 173, 174, 178-180. PA pressures in this same period are also unchanged44, 163, 170, 173, 
174, 179, 180. Changes in the later post-op period (beyond 4 months) and with 
exercise (Table 5) are clearer, with pulmonary artery pressures and PVR more 
consistently elevated168, 169, 171, 172, 177. 
                                            
H Study refers to total pulmonary resistance index (TPRI) and pulmonary arteriolar resistance 
index (PARI) without defining either. Both have units of dyn·s·cm-5·m2 which is the same unit 
as pulmonary vascular resistance index (PVRI). 
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Table 4. Summary of change in pulmonary artery catheter variables following lung resection at rest 
All changes are in comparison to pre-op levels with references. ↓= decreased in comparison to pre-op, ↑ = increased in comparison to pre-op, ↔ = unchanged in 
comparison to pre-op, POD = post-op day, sPAP = systolic pulmonary artery pressure, dPAP = diastolic pulmonary artery pressure, mPAP = mean pulmonary artery 
pressure, PVR = pulmonary vascular resistance, RVEF = RV ejection fraction, RVEDV = RV end diastolic volume, RVESV = RV end systolic volume. 
 Time point 
Variable Post-op 2-6 hours POD 1 POD 2 2-3 Weeks  4-6 Months 42-48 Months 
sPAP 
↔ 44, 175 ↔ 71, 175 ↔ 163, 170, 174 ↔ 163, 170, 174 ↔ 174 ↑ 169   
↑ 173 ↑ 173 ↑ 173         
dPAP     ↔ 170 ↔ 170 ↔ 170 ↑ 169   
mPAP ↔ 44, 173, 174, 
179, 180 
↔ 170, 173, 174 
↔ 163, 170, 173, 
174 
↔ 163, 170, 174 ↔ 174 ↔ 171, 172, 177   
      ↑ 168, 169 ↑ 172 
PVR ↔ 44, 173, 174, 
179, 180 
↔ 174, 178 ↔ 163, 174, 178 
↔ 163, 170, 174, 
178 
↔ 174 
↑ 168, 169, 171, 
172, 177 
↑ 172 
↓ 170, 173 ↓ 170, 173     
RVEF 
↔ 44, 173, 176 ↔ 173, 178 ↔ 163, 173, 176 ↔ 176, 178 ↓ 174     
↓ 174, 180 ↓ 170, 174 ↓ 174 ↓ 163, 170, 174       
    ↑ 178         
RVEDV 
↔ 
44, 174, 176, 
180 
↔ 170, 174 ↔ 170, 174, 176 ↔ 170, 176 ↔ 174     
   ↑ 163 ↑ 163, 174       
RVESV 
↔ 44, 174 ↔ 174 ↑ 173, 174 ↔ 174 ↔ 174     
  ↑ 173           
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Table 5. Summary of change in pulmonary artery catheter variables following lung resection on exercise 
All changes are in comparison to pre-op levels with references. ↓= decreased in comparison to pre-op, ↑ = increased in comparison to pre-op, ↔ = unchanged in 
comparison to pre-op, sPAP = systolic pulmonary artery pressure, dPAP = diastolic pulmonary artery pressure, mPAP = mean pulmonary artery pressure, PVR = 
pulmonary vascular resistance, RVEF = RV ejection fraction, RVEDV = RV end diastolic volume, RVESV = RV end systolic volume.  
 Time point 
Variable 2-3 Weeks  4-6 Months 42-48 Months 
sPAP ↑ 174 ↑ 169   
dPAP   ↑ 169   
mPAP ↑ 174 ↑ 170, 172, 173, 
181 
↑ 173, 181 
PVR ↑ 174 ↑ 170, 172, 173, 
181 
↑ 172 
RVEF ↓ 174     
RVEDV ↑ 174     
RVESV ↑ 174     
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The vPAC investigations in this section utilise fast response thermodilution 
techniques, based on methods described by Holt et al., to calculate RVEDV and 
by incorporation of SV (Cardiac Output/Heart Rate) the RVESV and RVEF100. 
These catheters were the subject of an editorial by Leibowitz in Critical Care 
Medicine in 2009 that questioned their validity, finding they were inaccurate in 
ventricles that were stable or undergoing pathophysiological changes184. They 
have been in use since the 1980's and a number of method comparison studies 
prior to this editorial had attempted to validate them against established methods 
for assessment of RV volumes. Prior to recognition of CMR and conductance 
catheterisation as the reference methods for assessment of RV volumes and 
function (see section 1.3, pg 41), angiography and radionuclide scanning were 
established methods for the in vivo assessment of RV function108. The 
methodology of these comparison studies is questioned in this section. 
A common error in method comparison studies is to use correlation statistics to 
describe the strength of a relationship between two methods of measurement. 
Correlation coefficients are not best used in this setting as they measure 
association and not agreement, they do not determine if two different methods of 
measurement can be used interchangeably. If the two methods are 
interchangeable, with no error, when plotting the measurements on a scatter plot 
they should fall on the line of equality. Some of the difficulty with correlation 
coefficients is illustrated in Figure 17 (pg 84), which describes an artificial set of 
data (created by the author) for four novel methods of measurement compared 
with a gold standard.  
All measurement methods described in this fictitious data set have a Pearson's 
correlation coefficient of 1. Although they all have perfect correlation and are 
associated, only measurement method A may be a useful alternative to the gold 
standard. There is evidence of systematic bias with method C with the new 
method providing a value consistently above that of the gold standard. Methods B 
and D illustrate there is perfect correlation if the measurements lie along any 
straight line but no evidence of agreement. It is clear from Figure 17 that even 
perfect correlation coefficients do not mean a new method of measurement is 
accurate. Correlation coefficients are also dependent on the range of the data 
provided, with coefficients more likely to be high with wider data ranges (Figure 18, 
Chapter 2  84 
   
 
 
 
pg 85). In addition, although two methods of measurement may use different 
methodology, if they are originally designed to measure the same thing, then it 
would be likely that they would be inherently related so quantifying their 
association is irrelevant185, 186. The conclusion of Bland and Altman sums up the 
use of correlation in measurement studies:  
"correlation is inappropriate for the study of agreement between 
methods. Despite this, people do it." 
Bland & Altman (2003)187"  
 
 
Figure 17. Correlation coefficients from artificial data of methods of measurement 
Correlation coefficient (Pearson's) r = 1.00 for all plots. The dashed red line is the line of 
identity. 
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Figure 18. Correlation coefficients of artificial data for methods of measurement 
A) All data with higher correlation coefficient than both B) which contains only lower values of 
same data and C) which contains higher values. The dashed red line is the line of identity. 
 
Bland and Altman went on to offer a now famous analysis (plotting the difference 
against the mean of the two measurements, along with limits of agreement) which 
is considered a better method of assessing the inter-changeability of two 
measurement methods. It is the recognised statistical technique for validating new 
measurement methods against reference techniques186, 188. 
When vPAC was compared with ventriculography, there was evidence of 
association between the two methods. For RVEF, correlation coefficients ranged 
from 0.80 to 0.83 (although one study showed no significant association)99, 189, 190. 
As can be seen in Figure 19 (pg 86) and Figure 20 (pg 86), the two methods 
although associated, are not interchangeable. If the methods were 
interchangeable, values would lie along the line of equality. In Figure 19 and 
Figure 20 there is evidence of bias with the thermodilution method systematically 
providing lower values than angiographic determined RVEF. For assessment of 
RVEDV and RVESV, correlation coefficients were lower (0.71 and 0.64 
respectively) with some studies again showing no significant association99, 189, 190. 
Bland Altman analysis was not performed. 
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Figure 19. Comparison of angiography (Angio) and thermodilution RVEF measurements 
Taken from Urban et al.99 The dotted line is the line of identity. 
 
 
Figure 20. Relationship of RVEF determined by thermodilution (THERMO) and by angiography 
(ANGIO) 
From Voelker et al.189 The solid black line is the regression line. The dashed red line has been 
added and is the line of identity. Note different labelling of axes compared to Figure 19. 
 
Spinale et al. compared RV volumes obtained from vPAC to those from biplane 
ventriculography in a swine model (n=10)191. This study also compared 
measurements in a number of different physiological states; at baseline, during 
infusion of isoproterenol (isoprenaline, a β1 and β2 receptor agonist), during 
hypovolaemia (haemorrhage to 50% baseline MAP) and with further infusion of 
isoproterenol following hypovolaemia. For all physiological parameters combined, 
there was association of RVEF (r=0.74) but with no evidence of agreement, 
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thermodilution tended to underestimate measurements with a mean difference of 
9.6±1.5% on pooled analysis (Figure 21).  
 
Figure 21. Comparison of RVEF measurements by cine-ventriculographic (CINE) and 
thermodilution (TD)measurements 
From Spinale et al.191 The solid black line is the regression line and the dashed black lines 
represent 90% confidence limits. The dashed red line has been added and is the line of identity. 
 
There is no association testing presented for each of the individual physiological 
states but there was significant difference between the mean values of RVEF 
during the hypovolaemic and hypovolaemic with isoproterenol states (Figure 22). 
Although specific values are not given, extrapolating from this figure suggests this 
error is in the region of 10-15%.  
 
Figure 22. RVEF by ventriculography and thermodilution during pathophysiological states 
ISO = During isoproterenol infusion, Hypo = Hypovolaemia, HYPO/ISO = Infusion of isoproterenol 
during hypovolaemia. # = Significant difference from control. * = significant difference from 
thermodilution measurements. 
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This study demonstrates the vPAC does not given reliable results on pooled 
analysis and that there is a deterioration in agreement in pathophysiological 
states. Bland Altman analysis was not performed. 
Morrison et al. (in addition to comparing vPAC with angiography described above) 
compared vPAC obtained RVEF with both; gated first pass (GFP, n=36) and gated 
blood pool (GBP, n=40) radionuclide ventriculography190. Bland Altman analysis 
was not performed and this study only used correlation statistics (r=0.65 for GFP 
and r=0.69 for GBP). Based on this level of association and the lack of Bland 
Altman analysis, it is difficult not to agree with Morrison et als. conclusion that it 
"does not support the use of vPAC determined RVEF". 
In 2001 Perings et al. attempted to validate vPAC RVEF against radionuclide 
RVEF at rest and during exercise192. The study showed significant association 
between the two methods at rest (r=0.73) and during exercise (r=0.74) but Bland 
Altman was not performed. Given the lack of robust assessment of the vPAC in 
this study the author would disagree with the authors conclusion, and believes the 
device is not useful for reliable and repetitive assessment of RVEF measurements 
at rest or during exercise.  
Two studies have compared vPAC to CMR imaging (now established as the 
reference method for volumetric assessment of the RV) in cohorts with dilated 
cardiomyopathy and pulmonary hypertension193, 194. In the first study by Globits et 
al.193 there was evidence of association between the two methods for RVEF 
(r=0.82). Despite this association, there were marked differences in the values 
obtained by each method with mean RVEF by vPAC 194.3% lower than RVEF by 
CMR. Additionally, vPAC overestimated RVEDVI and RVESVI by 5841ml/m2 and 
5547ml/m2 (76% and 59% respectively). The study concluded that although 
vPAC was not suitable for assessment of absolute volume data, it may be more 
appropriate for assessment of serial measurements. Given that the study 
incorporated no repeat measures in different physiological circumstances, there is 
no evidence to support this statement. The second study by Hoeper et al. 194 
demonstrated RVEDV assessed by vPAC was 231±165ml higher, and RVESV 
was 249±177ml higher than the corresponding CMR value. RVEF was measured 
as 12±8% by vPAC compared to 34±10% in the CMR group. As RVEDV and 
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RVESV were overestimated by 220% and 310% respectively, Hoeper et als. 
conclusion that vPAC provided 'invalid' data seems an understatement. 
Two studies in the same patients have compared transoesophageal 
echocardiographic variables with vPAC at three time points (pre-op, intra-op and 
post-op) in patients undergoing elective cardiac surgery. The first compared vPAC 
determined RVEF to fractional area change obtained from TOE195. Bland Altman 
analysis revealed a bias of -3.7% and a precision (±1.96SD) of 30.9%. The 
authors concluded that this was clinically acceptable, but also noted that the bias 
and precision deteriorated with tachycardia, pulmonary hypertension and low 
cardiac output. The second study made comparison with three-dimensional 
transoesophageal echocardiography (3D-TOE) determined RVEF196. This second 
study showed no association between the two measures of RVEDV and Bland-
Altman analysis of RVEF showed an unacceptable bias of 15.6% for 3D-TOE.  
In the article that was the focus of the editorial questioning the validity of vPAC 
measurements, Hein et al. used conductance catheterisation to attempt to validate 
vPAC in a swine model undergoing induced myocardial ischaemia by ligation of 
the right coronary artery (at baseline, during ischaemia and during reperfusion)91, 
184. Bland Altman analysis indicated that vPAC underestimated RVEF, with a bias 
of -9.9% and limits of agreement of -26% to 6.1%. For RVEDV, vPAC 
overestimated with a bias of 31ml and limits of agreement from -25ml to 88ml. 
Area under the receiver operating characteristic curve (AUROCC) analysis was 
used to assess the ability of each method to diagnose ischaemia; The 
conductance catheter had an AUROCC of 0.98 with 100% sensitivity and 86% 
specificity for change in RVEF during ischaemia and an AUROCC of 0.92 (86% 
sensitivity and 100% specificity) for change in RVEDV. In contrast, the AUROCC 
curves for RVEF and RVEDV determined by vPAC failed to reach statistical 
significance (AUROCC for RVEF of 0.76, p=0.06 and AUROCC for RVEDV of 
0.65, p=0.65). 
As described above, Bland Altman analysis is the recommended investigation for 
method comparison studies and only three of the vPAC validation studies have 
utilised it91, 195, 196. Zink et al. (described on the previous page) was the only study 
that found an acceptable bias, but compared RVEF to fractional area change by 
TOE. The Bland Altman comparison of RVEF with FAC is flawed as one is a 
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measure of RVEF and the other is two-dimensional representation of RV function 
(i.e. they are not measuring the same thing). De Simone found an unacceptable 
bias when comparing 3D TOE derived RVEF (again, a method not yet validated 
for assessing RV volumes) to vPAC determined RVEF196, 197. In the only study 
using Bland Altman analysis and a recognised reference method (conductance 
catheter) there was unacceptable bias for RVEF and RVEDV.  
The data examining RVEF by vPAC suggest that measurement using this method 
is unlikely to be accurate or precise. The majority of studies have not used the 
appropriate methods for validation and where they have, vPAC has been found to 
be inadequate. This is particularly true when comparison is made with established 
reference methods for assessment of RV function (CMR and the conduction 
catheter) where there is no evidence of agreement 91, 193, 194. The author concludes 
that the findings of the Leibowitz editorial are valid. vPAC derived RVEF and 
RVEDV are inaccurate in ventricles that are stable and are unable to detect 
changes in ventricles that are undergoing pathophysiological changes184.  
For these reasons, questions remain over the results reported by these studies 
and suggest further work using validated techniques is required. 
2.3.3 Studies utilising echocardiography 
In the late 20th and early 21st century there was a shift towards non-invasive 
methods of assessing cardiovascular function. Echocardiographic assessment of 
the RV was becoming more common and published studies started to reflect this. 
The studies utilising echo for assessment of RV function following lung resection 
are summarised in Table 6 (below), followed by a discussion (pg 97). 
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Table 6. Studies using echocardiography to examine right ventricular function following lung resection 
Study 
(Year) 
(n) 
Population / 
subgroup 
Method of 
assessing RV 
function & Time 
points 
Changes in RV 
function 
Clinical outcome 
associated with RV 
function? 
Comment 
Amar et 
al.198 
(1995) 
100 
All Thoracotomy 
12 Wedge Resection 
2 Pleural Resection 
47 Lobectomy 
39 Pneumonectomy 
 
*Same cohort of 
patients as Amar et 
al.199 (1996) 
 
TTE 
Pre-op 
POD 1 
POD 2-6 
SVT Group 
↑TRJ (POD 2-6) 
Association between 
elevated tricuspid 
regurgitant jet 
velocity (not RVSP) 
on POD 2-6 and 
development of SVT 
Designed to assess clinical and 
echo correlates of SVT. 
 
Patients dichotomised 
according to development of 
SVT or not. 
 
"Suggests increased right heart 
pressure predisposes to 
clinically significant SVT after 
pulmonary resection." 
Amar et 
al.199 
(1996) 
86 
All Thoracotomy 
47 Lobectomy 
39 Pneumonectomy 
 
* Same cohort of 
patients as Amar et 
al.198 (1995) 
 
TTE 
Pre-op 
POD 1 
POD 2-6 
Pneumonectomy 
↑RVSP (POD 2-6) 
 
No changes in 
lobectomy group 
"the incidence of 
right ventricular 
enlargement by 
echocardiography 
was 
low in both groups 
and worsened in 
those patients in 
whom respiratory 
failure developed" 
 
Pneumonectomy associated 
with mild post-op pulmonary 
hypertension without 
associated RV systolic 
dysfunction. 
 
"An early post-op increase in 
right heart pressure was more 
common after pneumonectomy 
than lobectomy but did not 
appear to adversely affect RV 
systolic function." 
 
 
 
  C
h
a
p
te
r 2
 
 
  
9
2
 
Study 
(Year) 
(n) 
Population / 
subgroup 
Method of 
assessing RV 
function & Time 
points 
Changes in RV 
function 
Clinical outcome 
associated with RV 
function? 
Comment 
Amar et 
al.200 
(1997) 
70 
All Thoracotomy 
70 Pneumonectomy 
TTE 
"First 
Follow-up" 
Diltiazem & Digoxin 
groups 
↔RAS 
↔TRJ 
↔RVSP 
No clinical outcomes 
associated with RV 
function. 
Study designed to determine if 
diltiazem or digoxin were 
superior for prophylaxis of 
supraventricular dysrhythmias. 
Assessed by serial Doppler 
echo for left and right heart 
function. 
 
Conclusion that diltiazem is 
safe and effective following 
pneumonectomy 
Kowalew
ski et al.45 
(1999) 
31 
All Thoracotomy 
22 Pneumonectomy 
9 Lobectomy 
TTE 
Pre-op 
POD 2 
Pneumonectomy 
↑RVEDVI 
↑RVESVI 
↓RVEF 
 
No changes in the 
lobectomy group 
In the 
pneumonectomy 
group, those 
patients that 
developed 
supraventricular 
arrhythmia were 
found to have ↓ 
post-op RVEF and ↑ 
post-op RVEDVI 
Designed to investigate the 
effect of pulmonary resection 
on RV performance and it's 
possible contribution to 
mortality and morbidity. 
 
"Pulmonary resection caused a 
significant dilatation and 
dysfunction of the RV in the 
early post-op period." 
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Study 
(Year) 
(n) 
Population / 
subgroup 
Method of 
assessing RV 
function & Time 
points 
Changes in RV 
function 
Clinical outcome 
associated with RV 
function? 
Comment 
Foroulis 
et al.201 
(2004) 
52 
All Thoracotomy 
35 Pneumonectomy 
2 Bilobectomy 
15 Lobectomy 
TTE 
Pre-op 
6 Months 
Pneumonectomy 
↑PASP 
↑RV dimensions (cf 
lobectomy group) 
 
Lobectomy 
↑PASP 
 
In the 
pneumonectomy 
group, patients with 
more debilitating 
dyspnoea at 6 
months had higher 
PASP at this time 
Prospective study using 
Doppler echocardiography 
assessment of RV parameters 
to detect the influence of 
pneumonectomy on right heart 
function. 
 
PASP elevation was higher in 
pneumonectomy group 
compared with lobectomy 
patients. Elevated PASP is 
associated with RV dilatation in 
both groups. 
 
"Significant percent reduction 
of 6-month post-op FVC values 
is associated with increased 
PASP detecting that the 
amount of vascular bed 
resected plays an important 
role." 
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Study 
(Year) 
(n) 
Population / 
subgroup 
Method of 
assessing RV 
function & Time 
points 
Changes in RV 
function 
Clinical outcome 
associated with RV 
function? 
Comment 
Venuta et 
al.202 
(2007) 
51 
36 Lobectomy 
15 Pneumonectomy 
TTE 
Pre-op 
1 Week 
3 Months 
6 Months 
1 Year 
4 Years 
Pneumonectomy 
↑TRJ 
↑PASP 
↑RVDD 
 
 
Lobectomy 
No statistically 
significant 
modification of any 
variable 
No clinical outcomes 
associated with RV 
function. 
Study of RV function with serial 
Doppler echocardiography. 
 
"Right ventricle modifications 
are clearly evident after 
pneumonectomy." 
Colkesen 
et al.203 
(2009) 
19 
All Thoracotomy 
16 Lobectomy 
3 Pneumonectomy 
TTE 
Pre-op 
2-4 weeks 
post-op 
All Patients 
↑Mitral A 
↓Mitral E/A ratio 
↑Tricuspid A 
↓Tricuspid E dec 
↓Mitral E'/A' ratio 
↓Tricuspid E' 
 
No clinical outcomes 
associated with RV 
function. 
Study designed to evaluate the 
influence of lung resection on 
cardiac function by using 
Doppler echocardiography. 
 
Multiple Doppler and tissue 
Doppler measurements. Study 
determined that there were no 
systolic changes in function but 
that diastolic parameters may 
be affected. 
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Study 
(Year) 
(n) 
Population / 
subgroup 
Method of 
assessing RV 
function & Time 
points 
Changes in RV 
function 
Clinical outcome 
associated with RV 
function? 
Comment 
Cumbo-
Nacheli 
et al. 204 
(2013) 
67 
All Thoracotomy 
67 Pneumonectomy 
TTE 
Pre-op 
24 (±29) 
months 
All Patients 
↔TRJ 
↔RVSP 
↑RV Size# 
↓RV Function# 
No clinical outcomes 
associated with RV 
function. 
*Only 40 patients had pre and 
post-op TTE. 67 patients had 
post-op TTE. 
 
Retrospective study assessing 
changes in RV function in 
those patients who had TTE 
performed as part of clinical 
course. 
 
#RV size and function were 
qualitatively described as 
normal, mild, moderate or 
severe. Those patients with 
higher RVSP (≥40mmHg) had 
a higher proportion of patients 
with RV dilatation and 
dysfunction. 
Kumbasa
r et al.205 
(2013) 
20 
All Thoracotomy 
14 Lobectomy 
6 Pneumonectomy 
TTE 
Pre-op 
POD 2 
POD 7 
All Patients 
↓Tricuspid E 
↑Tricuspid A 
↓ Basal S' 
No clinical outcomes 
associated with RV 
function. 
Preliminary study assessing 
effect of lung resection on RV 
function using TDI. No 
comparison to other technique. 
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Study 
(Year) 
(n) 
Population / 
subgroup 
Method of 
assessing RV 
function & Time 
points 
Changes in RV 
function 
Clinical outcome 
associated with RV 
function? 
Comment 
Wang et 
al.206 
30 
Unknown approach 
10 Pneumonectomy 
20 Lobectomy 
TTE 
Pre-op 
POD 7 
Pneumonectomy 
↑PAP 
↓ Longitudinal Strain 
↓Circumferential 
Strain 
↓Radial Strain 
 
Lobectomy 
↓ Longitudinal Strain 
↓Circumferential 
Strain 
↓Radial Strain 
No clinical outcomes 
associated with RV 
function. 
First study using speckle 
tracked echocardiography to 
assess the impact of lung 
resection on biventricular 
function. 
 
RV = right ventricular, POD = post-op day, TTE = trans thoracic echocardiography, RVEF = right ventricular ejection fraction, RVSP = right ventricular 
systolic pressure, SVT = supraventricular tachycardia, RAS = right atrial size, TRJ = tricuspid regurgitant jet, RVEDD = right ventricular end diastolic 
diameter, AF = atrial fibrillation, FiO2 = fraction of inspired oxygen, VATS = video assisted thoracoscopy, TOE = trans oesophageal echocardiography, FVC = 
forced vital capacity, RVDD = right ventricular diastolic diameter, TDI = tissue Doppler imaging. 
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Amar performed a series of studies198-200 examining the incidence, risk factors and 
management of tachyarrhythmias following lung resection. As part of these 
studies, the role of RV function was investigated. His first study198 was performed 
to examine the clinical and echocardiographic associations in those who 
developed supraventricular tachycardia (SVT) (mixed pneumonectomy, 
lobectomy, sub-lobar resections and pleural resections). Adequate 
echocardiographic images for measurement of Tricuspid Regurgitant Jet (TRJ) 
velocity were possible in 88% of participants pre-op, 74% on POD 1 and 82% on 
POD 2-6. There was no change in any values from pre-op to post-op, but in those 
patients who developed SVT, there was a higher TRJ velocity (TRJ; 2.7±0.6m/s vs 
2.3±0.6m/s) on POD 2-6. Despite TRJ being used to calculate RVSP, there was 
no significant difference in RVSP between those patients who developed SVT and 
those who didn't. A logistic regression model demonstrated intra-operative blood 
loss ≥1L and elevated TRJ (≥2.7m/s) were independently associated with post-op 
SVT development. A secondary analysis of the same patients aimed to establish 
the effect of pneumonectomy and lobectomy on right heart echocardiographic 
parameters 199. This demonstrated that by POD 2-6 those patients who had a 
pneumonectomy had a higher TRJ (2.5±0.6m/s vs 2.2±0.5m/s) compared to 
baseline and a larger RVSP (31±15mmHg vs 25±10mmHg) than those patients 
having a lobectomy. The study concluded that despite an early 'modest' post-op 
increase in RV pressure following pneumonectomy, there was no adverse effect 
on RV function.  
Amars third study200 was a prospective randomisedI study to determine whether 
diltiazem is superior to digoxin for the prophylaxis of SVT after pneumonectomy 
and to assess the influence of these drugs on cardiac function. There was no 
change in RV echocardiographic parameters (right atrial size, Tricuspid 
regurgitation and RVSP) following pneumonectomy and no difference between the 
two groups (diltiazem or digoxin) at any time point. There was no significant 
difference in the incidence of SVD in either the diltiazem or digoxin group (14% vs 
31%, p=0.09). In contrast to his first study, there is no comment on 
echocardiographic image availability at any time point. 
 
                                            
I No details on randomisation provided 
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Backlunds 1998 study176 using vPAC to assess RV function (section 2.3.2, pg 77) 
also performed TTE pre-op and on POD 1. RV end diastolic diameter (RVEDD) 
remained at pre-op levels in the group exposed to prolonged oxygen but 
decreased significantly in the group with short oxygen exposure (35±5mm to 
27±4mm, p<0.05). There was a discrepancy between changes in RVEDD 
measured by TTE and RVEDVI measured by vPAC, this was attributed to the 
different measurement techniques and as described above, the accuracy of vPAC 
determined volumes has been questioned. Tricuspid regurgitant jets (TRJ's) were 
only seen in 8 (33.3%) patients pre-operatively and in only 4 (16.7%) on POD 1, 
irrespective of oxygen therapy. TRJ's are used to provided an estimation of RVSP 
(section 4.4.2.2.5, pg 154) but the inability to visualise them may result from 
imaging difficulties in this patient cohort that is exacerbated in the post-op period. 
Kowalewski et al.45 utilised TTE in a combined pneumonectomy and lobectomy 
group (pre-op and POD 2). They utilised the 'subtraction method' to assess RV 
volumes; "RV volumes were calculated by subtracting the entire LV area on echo 
(including the left myocardium) from the entire heart area (including the RV area 
and the entire LV area)." This method has previously been validated against 
volumetric PA catheter determined RVEF in a cohort with ARDS (r=0.74, p<0.01 
for RVEF, no Bland Altman assessment)207. Imaging was available in all patients 
at both time points. In the pneumonectomy cohort there was an increase in the 
RVEDVI (66.2±5.2ml/m2 to 80.0±7.2 ml/m2, p=0.004), an increase in RVESVI 
(34.0±5.7 ml/m2 to 48.5±6.8 ml/m2, p=0.003) and a decrease in RVEF (48±5% to 
39±4%, p=0.017). Those patients who developed post-op supraventricular 
arrhythmias following pneumonectomy (14/22, 63.6%) were found to have a lower 
post-op RVEF (37±3.9% compared with 42±4.5%, p=0.021) and higher RVEDVI 
(82.1±7.4 ml/m2 compared with 76.3±6.4 ml/m2, p=0.031), compared to those who 
didn't. There were no significant changes (RVEF, RVEDVI or RVESVI) in the 
cohort undergoing lobectomy and no association with those who developed post-
op SVT.  
Foroulis et al.201. assessed RV function in a pneumonectomy and lobectomy group 
pre-op and 6-months post-operatively. Tricuspid regurgitation was detectable pre-
op in 9 (24.3%) patients within the pneumonectomy group and in 2 (11.8%) 
patients within the lobectomy group, with mean PASP ≤25mmHg ("normal") in 
both groups. Tricuspid regurgitation was found post-operatively in 31 (88.6%) 
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patients in the pneumonectomy group and 10 (58.8%) patients in the lobectomy 
group. This corresponded to an increase in PASP in both groups (≤25mmHg to 
40.5±12.5mmHg in the pneumonectomy group and ≤25mmHg to 32.9±5.3mmHg 
in the lobectomy group, p=0.012 between groups). There was also the finding of 
higher PASP in those patients who had a right pneumonectomy in comparison to 
those who had a left sided procedure (48.3±10.6mmHg vs 35.3±10.8mmHg, 
p=0.002). There was a higher incidence of RV dilatation (defined as a diameter 
≥25mm) post-operatively in the pneumonectomy group in comparison to the 
lobectomy group (60% vs 23.5%, p=0.03). Post-operatively there was an 
association with elevated PASP and RV dilatation in both groups with those 
patients with the largest RVEDD (>28mm)J having the highest PASP in both 
groups (48.5±11.3mmHg in the pneumonectomy group and 46.5±15.9 in the 
lobectomy group). In the pneumonectomy group those patients with post-op class 
IV dyspnoea (dyspnoea with minimal exertion, or at rest - incapacitating) had 
significantly higher PASP (65.0±7.1mmHg, p=0.016) than those with less severe 
post-op dyspnoea (Class I; 35.4±8.6mmHg, Class II; 39.8±10.4mmHg or Class III; 
41.6±13.9mmHg). In the lobectomy group there was no association between 
PASP and class of dyspnoea. 
Venuta at al.202 and Cumbo-nacheli et al.204 performed longer term 
echocardiographic follow-up (2-4 years) following lung resection. The first study202 
by Venuta et al. prospectively assessed RV function up to 4 years following 
lobectomy or pneumonectomy. Only one patient from each group was lost to 
follow-up as a result of death. In the lobectomy group there was no change in any 
of the measured variables (TVI; Tricuspid valve insufficiency measured by a 
subjective scale of 0 = normal valve and competent to 3 = high grade insufficiency, 
PASP, RVEDDJ and TRJ velocity). In the pneumonectomy group there was an 
increase in the all the measured variables from pre-op values; TVI (0.9±0.7 to 
1.3±0.5, p=0.05), PASP (26.1±2.8mmHg to 34.3±7.6mmHg, p<0.00001), RVEDD 
(26.4±2.3mm to 31.4±3mm, p<0.001) and TRJ velocity (2.3±0.1m/s to 2.6±0.1m/s, 
p<0.0001). There were no clinical changes associated with RV function in either 
group. The second study by Cumbo-nacheli et al. was retrospective with a sample 
of convenience of 67 patients who had TTE performed 2 years following 
pneumonectomy. Only 40 patients had pre-op TTE and comparison is made 
                                            
J Level of measurement of dimension is not provided. This level (basal or mid-cavity) can impact 
on size and is important for reproducibility of measurement. 
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between these groups. There were no changes in post-op TRJ velocity and RVSP. 
RV size was described qualitatively as normal or mild, moderate or severe 
dilatation. Likewise function was described qualitatively as normal or mild, 
moderate or severe dysfunction. Post-operatively there was an increase in the 
proportion of patients with dilatation (0% to 20%) and dysfunction (0% to 17%). 
Those patients with a higher RVSP (≥40mmHg) had a higher proportion of patients 
with RV dilatation (40% vs 8%) and RV dysfunction (40% vs 11%) than those with 
a lower RVSP (<40mmHg). There was no association between RV parameters 
and clinical outcomes. 
Two studies incorporated tissue Doppler (TDI) measurements to examine changes 
following lung resection. The first study by Colkesen et al.203 examined changes 2-
4 weeks following lobectomy (16 patients) and pneumonectomy (3 patients). There 
were no changes in volume parameters, but when examining the tissue Doppler 
velocities of the tricuspid valve, changes were evident. The tricuspid A velocity 
increased (65±19cm/s to 80±30 cm/s, p=0.006) and tricuspid E deceleration time 
decreased (327±68msec to 274±51msec, p=0.01) with an associated decrease in 
tricuspid E' (9±2cm/sec to 8±2cm/sec, p=0.03). This pattern would suggest 
impaired RV relaxation and filling. Caution must be taken when interpreting 
Doppler values as they can be heavily influenced by heart rate which increased 
significantly (78±13bpm to 90±12bpm, p=0.001) during the study128. There were 
no clinical outcomes associated with RV function in this study.  
The second study by Kumbasar et al.205 (14 lobectomy and 6 pneumonectomy) 
examined TDI measurements of the tricuspid valve and RV pre-op, and on POD 2 
& POD 7. There was a decrease in tricuspid E by POD 7 in comparison to POD 2. 
There was an increase in tricuspid A from pre-op to post-op (POD 2 and POD 7). 
The E/A ratio drops from 0.94 pre-operatively to 0.78 on POD 2 and 0.61 on POD 
7. This pattern suggests impaired RV relaxation in the post-op period. In addition, 
there was a decrease in ventricular basal S' on POD 2 which had recovered to 
pre-op levels by POD 7. Those patients who had pneumonectomy had a lower 
ventricular basal S' on POD 2 in comparison to those who had a lobectomy 
(10.7±2.4cm/s vs 14.4±3.3cm/s, p=0.04). This pattern suggests a decrease in 
systolic function that has recovered by POD 7 and that those patients who have a 
pneumonectomy had more systolic dysfunction on POD 2 than those undergoing a 
lobectomy. The authors conclude that there is significant systolic dysfunction 
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(more following pneumonectomy) following lung resection which largely recovers 
by POD 7. Alongside the systolic dysfunction, there is ongoing diastolic 
dysfunction with evidence of impaired RV relaxation one week following surgery. 
Both of these studies are small in numbers and in addition; diastolic function 
following lung resection is still being explored and the role of TDI assessment of 
the RV and tricuspid valve for assessment of diastolic function needs validated128. 
In the most recent study and one that incorporates a novel echocardiographic 
parameter, Wang et al.206 performed a prospective study using speckle tracked 
echocardiography (STE) in patients undergoing pneumonectomy (n=10) or 
lobectomy (n=20). Results show that following pneumonectomy there is an 
increase in PASP and that PASP is higher in the pneumonectomy group 
compared with the lobectomy group. Following both pneumonectomy and 
lobectomy there was a deterioration in all RV strain values (longitudinal, 
circumferential and radial strain) in all RV regions (free wall, septal and global) 
with the effect larger in the group undergoing pneumonectomy (Figure 23). There 
was no association made with clinical parameters. Radial strain of the RV is 
difficult given the thin RV free wall with limited thickening during systole. The main 
component of RV contraction is longitudinal shortening and the majority of values 
reported in the broader literature for strain assessment of the RV are for 
longitudinal strain (free-wall or global). 
 
 
Figure 23. Changes in strain from Wang et al. 
Drawn from data presented by Wang et al.206. A) = Lobectomy, B) = Pneumonectomy. Continuous 
black lines = longitudinal strain. Grey line = circumferential strain, Dashed lines = radial strain. 
Value (error bars) = mean (SD), # = significant difference from pre-op values. Radial strain 
represents myocardial thickening and is a positive value. Longitudinal and circumferential strain 
represent myocardial shortening and are negative values. 
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The majority of studies utilising echocardiography demonstrate an elevation in TRJ 
velocity measured by continuous wave Doppler (used to determined PASP, see 
section 4.4.2.2.5, pg 154)198, 201, 202, 206. This is particularly true in the 
pneumonectomy group199, 201, 206, 208. Only two studies (both following 
pneumonectomy however) showed no change in TRJ/PASP200, 204. Although not 
every study reported availability of imaging, TRJ were not visible in all patients 
with Amar reporting 74-82% availability in the post-op period (up to POD 6). This is 
consistent with previous work in other populations which has shown TRJ are 
visible in 80% of patients with PASP >35mmHg and 95% of patients with PASP 
>50mmHg137.  
Caution must be used when analysing those echo studies with volumetric or area 
changes45, 176, 201, 202, 204, 208. RV dimensions are very difficult to measure and are 
highly probe position dependent128. ASE guidelines for echo analysis of the right 
heart recommend that 2D estimates of RVEF should not be performed given the 
numerous geometric assumptions45. None of these methods have been validated 
in this particular sub-group. 
There was also evidence of dysfunction using less established echocardiographic 
parameters such as tissue Doppler analysis and speckle tracked strain 
measurements203, 205, 206. The two tissue Doppler studies highlight diastolic 
dysfunction and a minimal (or transient) effect on systolic function. Strain 
echocardiography demonstrated post-op RV dysfunction in both pneumonectomy 
and lobectomy patients. 
2.3.4 Additional studies 
A number of additional studies contribute to the picture of what happens to RV 
function following lung resection but do not fit the original search criteria of having 
pre-op and post-op values. Two studies examined changes intra-operatively at the 
time of one lung ventilation (OLV) and pulmonary artery clamping.  
Wink et al.85 performed a study using the conductance catheter in patients 
undergoing lung resection. Measurements were taken during OLV, before and 
after clamping of the (right or left) pulmonary artery, with and without thoracic 
epidural analgesia. The study showed that at clamping, afterload increased (as 
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signified by increased effective arterial elastance [Ea]; 0.49mmHg/ml to 
0.75mmHg/ml, described in section 1.2.3.4.2, pg 34), contractility increased 
(measured by end systolic elastance [Ees]; 0.30mmHg/ml to 0.33mmHg/ml), 
ejection fraction fell (48.3% to 44.3%) and RV-PA coupling deteriorated (Ees/Ea; 
0.64 to 0.48). This was a homeometric response (increased contractility) to 
increased afterload (see section 1.2.3.9, pg 39). Although epidural analgesia 
reduced baseline contractility, it did not impair the homeometric response to 
increased afterload. This study utilised the reference method for assessment of 
RV function and demonstrated an increase in afterload, an increase in contractility 
and a deterioration in coupling (Figure 24) at the time of PA clamping. Clamping of 
the pulmonary artery is an analogous situation to pneumonectomy, where the 
pulmonary artery is ligated at the time of resection. A lobectomy would result in 
ligation of a branch pulmonary artery and may result in less pronounced 
physiological changes. 
 
Figure 24. Change in RV-PA coupling at time of PA clamping 
Drawn from data presented by Wink et al.85. Black lines = Control patients. Grey lines = Patients 
with thoracic epidural. Value (error bars) = mean (95% CI), # = significant difference from 
baseline values. PA = pulmonary artery. 
 
Matyal et al.43 used trans oesophageal echo (TOE) to examine the RV myocardial 
performance index (RV-MPI) in patients undergoing lung resection. RV-MPI was 
measured prior to one lung ventilation (OLV) and 10 mins after being established 
on OLV. There was no change in RV-MPI following OLV however there was a 
complex association between RV-MPI and those patients who developed SVT 
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post-op. Those patients with a normal RV-MPI (<0.4) prior to OLV were more likely 
to develop SVT (42%) than those with an abnormal RV-MPI (≥0.4, 10%). 
Additionally, in those patients who had a normal RV-MPI at baseline, if their RV-
MPI deteriorated on OLV they were more likely to develop SVT (8/14 patients, 
57%) than those patients whose RV-MPI remained unchanged (0/4 patients, 
p=0.045). 
In the only study using CMR to assess cardiac function following lung resection, 
Smulders et al.209 reviewed 15 patients more than 5 years following initial 
pneumonectomy and made comparison with 25 normal controls. They showed that 
pneumonectomy is associated with alterations in cardiac function (higher HR, 
lower stroke volume and lower LVEF). RV ejection fraction was not assessed and 
there were no changes in RV volumes or RV mass. The study demonstrated that 
there are marked intra-thoracic anatomical changes following lung resection; this 
was characterised by rotation following left sided pneumonectomy (at times to 
such an extent it resulted in the cardiac apex being directed posteriorly) and lateral 
movement following right-sided pneumonectomy. The authors feel these 
anatomical changes may explain the deterioration in LV function they observed 
following pneumonectomy. It is hard to see how such dramatic changes in cardiac 
position would not have an effect on cardiac function.  
2.4 Conclusion 
Although there are concerns about the methodology used, the literature in totality 
suggests that lung resection has a significant impact on the right ventricular-
pulmonary vascular unit, with changes evident in the immediate post-op period 
and continuing to be present at long-term follow-up.  
There appears to be a difference in those undergoing pneumonectomy in contrast 
to lobectomy; where studies report outcomes for both groups, there is increased 
frequency45, 199, 201, 202, 206 and magnitude201, 205, 206 of changes in RV parameters in 
those undergoing pneumonectomy.  
Although clinical outcomes were not measured for all studies there does appear to 
be an association between peri-operative changes in RV parameters and both, 
short and long-term morbidity. Those patients with higher PASP at 6 months had 
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more debilitating dyspnoea201. Those patients developing post-op arrhythmias had 
higher RV pressures, increased PVR, RV dilatation and decreased RVEF45, 176. 
Amar et al. showed those patients developing SVT had elevated TRJ velocity198. 
The group with a deterioration in RVEF with exercise, had a higher rate of 
complications (although complication type not specifically described)41. This was 
also true with the two studies that showed complex association between intra-
operative changes in RV parameters and post-op morbidity. The first 
demonstrated that those patients who had a deterioration in the RV-MPI from a 
normal level, were more likely to develop post-op SVT43. In the second, those 
patients who had a lower RVEF at the time of PA clamping were more likely to 
have poor functional status (as signified by NYHA class III or IV) at long-term 
follow-up (10 months)44. These studies suggest that peri-operative events continue 
to have an impact long in to the recovery period. 
The most commonly hypothesised mechanism of RV dysfunction following lung 
resection is elevated afterload, but this has not been consistently demonstrated in 
these studies43, 44, 174. PVR is often measured as a surrogate of afterload but there 
is no consistent change in the post-op period (up to POD 2), with most studies 
showing it unchanged or even reduced44, 163, 170, 173, 174, 178-180. PVR is commonly 
measured in clinical practice but is a measure of opposition to mean flow and 
ignores the pulsatile component of afterload70. True afterload is the RV input 
impedance and is a composite of both static and pulsatile components46, 70. Wink 
et al.85. used the conductance catheter in patients undergoing lung resection and 
were able to demonstrated an elevation in Ea (Effective arterial elastance, a more 
complete measure of afterload, see section 1.2.3.4.2, pg 34) at the time of 
pulmonary artery clamping but no studies have been able to demonstrate a 
consistent increase in the immediate post-op period despite evidence of RV 
dysfunction at this time.  
Given the methodological concerns regarding the techniques used in the majority 
of studies to date, further work using validated methods is required to fully 
understand the RV response to lung resection. As described in chapter 1, CMR is 
considered the reference method for non-invasive evaluation of RV function and 
being free from acoustic windows, it would be ideally suited to the assessment of 
the RV following lung resection. Validation of further non-invasive methods in this 
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population, potentially utilising trans thoracic echocardiography (with its portability 
and widespread availability) would have utility in this population.  
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Chapter 3  Critical Care and Right Ventricular 
Function Following Lung Resection 
3.1  Introduction 
As described in Chapter 1, the best opportunity of cure following a diagnosis of 
lung cancer is with surgery. Although operative mortality is low (1.7%), lung 
resection is associated with significant peri-operative morbidity and high rates of 
complications, including; bleeding, respiratory failure, cardiac arrhythmia, 
myocardial infarction, cerebrovascular accident (CVA) and renal failure20, 210-214. 
Many of these complications will require management and interventions that can 
only be provided in an intensive care unit (ICU). Such treatments include invasive 
ventilation, inotropic support and renal replacement therapy (RRT)215. Prolonged 
ICU admission may also require tracheostomy to aid ventilator weaning212. Data 
regarding morbidity following lung resection is plentiful but usually focused on 
specific individual complications e.g. atrial fibrillation (AF) or acute lung injury 
(ALI). Comparatively little data exists on the need for intensive care; whilst the 
data that is available can be difficult to interpret due to regional variation in patient 
selection and resource availability influencing outcomes and provision of critical 
care214.  
Existing studies indicate that 6.3% to 18.0% of patients undergoing lung resection 
require unplanned intensive care post-operatively, with high in-hospital mortality of 
between 16.6% and 46% in this group212, 215-220. Extrapolating these figures to UK 
resection rates indicate that between 535 and 1530 patients annually may require 
unplanned ICU admission following their surgery. 
As discussed in Chapter 1, lung resection numbers are increasing, with older and 
sicker patients with more comorbidities presenting for surgery with an increased 
risk of ICU admission post-operatively. ICU care has significant patient and 
financial costs and in this context, understanding the factors influencing the need 
for ICU admission not only has clinical importance but also has implications for 
resource consumption as the costs of health care rise213. 
It is known that RV function is affected by conditions that require critical care 
management; acute respiratory distress syndrome (ARDS),221, 222, sepsis223, 
pulmonary embolism58 and pulmonary hypertension. It is also known that 
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interventions provided in ICU, such as positive pressure ventilation, are known to 
negatively affect RV function224. No previous work has specifically examined RV 
function in those patients admitted to ICU following lung resection and as 
described in Chapter 1, it was the authors anecdotal experience that patients 
admitted to ICU following lung resection frequently had evidence of RV 
dysfunction / failure. 
This investigation was performed to provide an estimate of the number of patients 
requiring unplanned intensive care support following lung resection at our 
institution. It also aims to provide information on who is admitted, their resource 
requirement, mortality and to investigate the factors associated with their 
admission, including the incidence of RV dysfunction / failure. 
The work in this investigation was performed by the author as pilot data to be used 
for a competitive proposal for the Association of Cardiothoracic Anaesthetists and 
Critical Care (ACTACC) national collaborative audit 2015225. The proposal was 
titled "Critical Care After Lung Resection (CALoR) and was successfully adopted, 
resulting in a multi-centre retrospective project (CALoR 2), which commenced in 
2015. The original pilot data was published in Anaesthesia in 2015 and is 
expanded on here226. The published manuscript is provided as Appendix 1. The 
original article was written by the author with review by co-authors: Dr Alistair 
Macfie, Professor John Kinsella and Dr Ben Shelley. 
3.2  Methods 
The study was registered with the hospital's clinical governance department and 
approval was obtained from the hospitals Caldicott guardian (personal 
communication, 31st July 2015). Research ethics committee approval was not 
sought as this study was judged to be service evaluation227. A retrospective review 
of consecutive patients undergoing lung resection at the Golden Jubilee National 
Hospital over a 2-year period (1st Jan 2013 to 31st Dec 2014) was performed. 
Individual patient data was collated from a prospectively collated surgical database 
(Cardiac, Cardiology and Thoracic Health Information System; CaTHI, Amor 
Group, Renfrew, Scotland). Lung resections within this database were categorised 
as "pneumonectomy"; "lobectomy/bilobectomy" and "sublobar resection 
(segmentectomy/wedge/biopsy)." Consequently all resections not involving 
anatomic lobectomy, including metastasectomy, wedge resections and wedge 
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biopsies were all included in the same ‘sublobar resection' group. The primary 
anaesthetic technique, namely total intravenous anaesthesia (TIVA) or volatile 
based, was obtained from the Recall AIMS electronic anaesthetic charting system 
(Informatics Clinical Information Systems Limited, Glasgow). For this study, any 
patients exposed to volatile anaesthetic agents (even for short periods e.g. for 
blood pressure control) were allocated to the volatile anaesthetic group. Data for 
ICU patients were obtained from patient notes, the hospitals ICU clinical 
information system (Centricity CIS; GE Healthcare®, Buckinghamshire, UK) and 
from the Scottish ICU audit database (Ward Watcher; Critical Care Audit Ltd, 
Yorkshire, UK). 
To investigate the incidence of RV dysfunction in the cohort admitted to ICU, a 
case note review was performed. Complete clinical notes for each ICU admission 
was provided as Rich Text Format (RTF, Microsoft, Washington, USA) documents. 
To ensure all episodes of RV dysfunction were captured, a search procedure was 
performed in each document (Microsoft Word, Microsoft, Washington, USA) for the 
following terms; right, ventricle, RV, ventricular, TTE, Echo, TOE, nitric oxide, iNO, 
pulmonary hypertension and pulmonary artery pressure. Additionally, the clinical 
portal system (NHS Scotland) was searched for additional information, including 
imaging reports for this group. The echocardiography system (EchoPAC, GE 
Healthcare) within the hospital was searched for any imaging performed. RV 
dysfunction was defined as; a TAPSE <1.6cm, mid RV diameter >3.5cm or a 
verbal description of dysfunction or dilatation without clinical features consistent 
with low cardiac output or hypoperfusion. RV failure was defined as evidence of 
RV dysfunction with signs of reduced cardiac output and/or hypoperfusion 
including; cardiac index <2.2L/min/m2 on cardiac output monitoring, requirement 
for inotropic support, evidence of renal failure, acidaemia, hyperlactaemia, or a 
verbal description of 'failure'.  
The Golden Jubilee National Hospital is a tertiary referral cardiothoracic surgery 
centre and is the one of the largest thoracic surgery units in the UK12. Pre-op 
assessment, broadly in keeping with the British Thoracic Society guidelines, 
occurs at clinic prior to admission228. Admission is typically the day before 
operation and surgery is performed by a team of five consultant thoracic surgeons. 
Unless otherwise indicated all patients are routinely extubated in the operating 
theatre at the completion of surgery and are transferred to the theatre recovery 
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unit. After a period of observation they are then transferred to a high dependency 
unit (HDU, level 2 care as per Intensive Care Society "levels of critical care")229 
where invasive monitoring, vasopressor infusions, high flow nasal oxygen and 
non-invasive ventilation can all be provided. 
For this study, ICU admissions (level 3 care)229 were defined as those patients 
requiring intubation for invasive ventilation and/or requirement for renal 
replacement therapy (RRT). In our institution patients requiring these interventions 
must be transferred to the intensive care unit where care is shared between the 
surgical team and cardiothoracic intensivists. Those patients with immediate post-
op respiratory failure who were unable to be extubated at the end of their 
operation were included as unplanned ICU admissions if ventilated for more than 
12 hours. 
Categorical data are presented as frequency (%) and continuous data are 
presented as mean (SD) or median (IQR) as appropriate to data distribution. 
Categorical variables were compared using the Chi-squared or Fisher's exact tests 
and continuous variables were compared using the Student t or Mann-Whitney U 
tests as appropriate. A p-value <0.05 was considered statistically significant. All 
analyses were performed using SPSS for windows, version 22 (IBM Corp, 
Armonk, NY, USA). Logistic regression was performed to assess the role of 
potential explanatory anaesthetic and surgical variables on the need for ITU 
admission. To allow adjustment for patient co-morbidity and surgical complexity, 
these analyses were adjusted for Thoracoscore230. Thoracoscore was chosen as it 
reflects a composite of patient and surgical risk factors. Logistic regression models 
were created to ascertain the effects of anaesthetic technique (TIVA or Volatile), 
regional anaesthetic choice (epidural or paravertebral block) and surgical 
approach (video assisted thoracoscopy (VATS) or open).  
3.3  Results 
3.3.1 Critical care following lung resection 
One thousand, one hundred and sixty nine patients underwent lung resection 
during the study period. Seventy eight (6.7% of all resections) pneumonectomies 
were performed, 775 (66.3%) lobectomy/bilobectomies and 316 (27.0%) sublobar 
procedures. Thirty patients (2.6% of all resections) required unplanned intensive 
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care following their surgery. One patient (1.3% of all pneumonectomies) following 
pneumonectomy; 27 patients (3.5%) following lobectomy/bilobectomy and 2 
patients (0.6%) following a sublobar resection. Overall hospital mortality was 0.9%. 
In the ICU cohort mortality was 26.7%, in contrast to 0.2% for the group not 
requiring ICU (p<0.001, Fisher's exact test). Those patients admitted to ICU were 
older, had worse baseline lung function and a higher pre-op Thoracoscore (Table 
7, pg 112). Patients surviving following an admission to ICU had a longer length of 
hospital stay (Median 7.0 and 25.5 days, p<0.001, Mann Whitney U-Test).  
Patients admitted to ICU within a week of their surgery had a lower mortality (8.7% 
of 23 patients) than those patients admitted beyond post-op day 7 (85.7% of 7 
patients) (p<0.001, Fisher's exact test, Figure 25). 
 
Figure 25. Intensive care unit mortality for admission time period 
Mortality in those admitted from day 0-7 = 8.7%, Mortality in those admitted beyond day 7 = 
85.7%, Fisher's exact test. 
 
 
 
 
 
Chapter 3  112 
 
 
Characteristic 
No ICU admission 
(n=1139) 
ICU admission 
(n=30) 
p value 
Age (yrs) 67.0 (59.0, 73.0) 71.0 (64.5, 74.3) 0.02* 
Female Sex 624 (55%) 15 (50%) 0.60§ 
FEV1% 
88.2 (21.4) 
n=539 
80.1 (19.3) 
n=30 
0.043† 
TLCO% 
70.9 (18.8) 
n=476 
60.8 (16.1) 
n=30 
0.004† 
APACHE II - 17 (14.8, 23.3) - 
    
Thoracoscore 
0.8 (0.4, 2.0) 
n=941 
2.2 (1.2, 2.7) 
n=30 
<0.001* 
Resection type    
 Pneumonectomy 77 (6.8%) 1 (3.3%) 0.478‡ 
 Lobectomy / Bilobectomy 748 (65.7%) 27 (90.0%) 0.007§ 
 Sublobar Resection 314 (27.6%) 2 (6.7%) 0.011§ 
     
 Right Sided 686 (60.2%) 18 (60.0%) 0.980§ 
     
Approach (c.f. VATS)    
 Open 782 (68.7%) 28 (93.3%) <0.01‡ 
     
In-hospital mortality 2 (0.2%) 8 (26.7%) <0.001‡ 
    
Post-op stay, survivors 
(days) 
7.0 (5.0, 9.0) 
n=1137 
25.5 (13.0, 44.8) 
n=22 
<0.001* 
Duration of ventilation (days) - 5.5 (2.0, 19.5) - 
ICU stay (days) - 8.5 (2.8, 19.5) - 
Table 7. Characteristics of those patients not admitted to ICU and those admitted to ICU 
following lung resection at the Golden Jubilee National Hospital between Jan 2013 and Dec 
2014 
Values are number (%) and median (IQR). Where the dataset was incomplete,(n) represents the 
number of patients with data available. FEV1% = percent predicted forced expiratory volume in 1 
second; TLCO% = percent predicted transfer factor for carbon monoxide; APACHEII = acute 
physiology and chronic health evaluation II; VATS = video assisted thoracoscopy; § = chi-squared 
test, * = Mann Whitney U-Test; † = students t-test; ‡ = Fisher's exact test. 
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Twenty three patients (76.7%) were admitted to ICU with respiratory failure. 
Admission diagnosis was categorised as documented in patient notes, some 
patients had more than one cause of respiratory failure (e.g. lobar collapse with 
ARDS and respiratory infection) (Table 8). Mechanical ventilation was required in 
28 (93.3%) patients and median duration of ventilation was 5.5 days (Table 9). 
Diagnosis 
ICU admission 
(n=30) 
ICU Deaths 
(n=8) 
Respiratory failure 23 (76.7%) 6 (75.0%) 
 - Respiratory infection*  15 (65.2%)  
 - ARDS* 8 (34.8%)  
 - Lobar collapse* 6 (26.1%)  
 - Pulmonary embolism* 1 (4.3%)  
 - Cardiac failure* 4 (17.4%)  
Renal failure 1 (3.3%) 0 (0%) 
Cardiac arrest 3 (10.0%) 1 (12.5%) 
Bleeding 3 (10.0%) 1 (12.5%) 
Table 8. Admission diagnosis in patients admitted to ICU following lung resection.  
Values are number (%). *Reflects the number of patients admitted with each diagnosis, some 
patients had multiple diagnoses. ARDS = acute respiratory distress syndrome. 
 
Intervention 
ICU Admission 
(n=30) 
ICU Deaths 
(n=8) 
IPPV 22 (73.3%) 5 (22.7%) 
CVVH 2 (6.7%) 0 (0%) 
CVVH & IPPV 6 (20.0%) 3 (50.0%) 
Tracheostomy 11 (36.7%) 1 (9.1%) 
Duration of Ventilation (days) 5.5 (2.0, 19.5) - 
ICU Stay (days) 8.5 (2.8, 19.5) - 
Table 9. Interventions, mortality, duration of ventilation and length of stay in patients 
admitted to ICU following lung resection 
Values are number (%) or median (IQR). IPPV = Intermittent positive-pressure ventilation; CVVH = 
continuous veno-venous haemofiltration. 
 
Data were complete for the group admitted to ICU. The databases for the group 
not admitted to ICU were incomplete. Pulmonary function tests, Thoracoscore, 
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primary anaesthetic technique and primary analgesic technique were all missing 
some data points (Table 7, pg 112 and Table 10).  
Anaesthetic and surgical Technique 
No ICU 
admission 
(n=1139) 
ICU 
Admission 
(n=30) 
p value 
Approach 
Open 782 (68.7%) 28 (93.3%) 
<0.01† 
VATS 357 (31.3%) 2 (6.7%) 
Primary 
Anaesthetic 
TIVA 583 (51.9%) 11 (36.7%) 
0.10* 
Volatile 540 (48.1%) 19 (63.3%) 
Primary 
Analgesia 
Epidural 418 (47.6%) 13 (43.3%) 
0.77* 
PVB 461 (52.4%) 16 (56.7%) 
Table 10. The influence of anaesthetic and surgical technique on need for ICU admission 
following lung resection 
Values are number (%); † = Fisher's exact test; * = Chi-squared test; VATS = video assisted 
thoracoscopic surgery; TIVA = total intravenous anaesthesia; PVB = paravertebral blockade. 
 
When assessing the influence of surgical and anaesthetic factors, VATS 
procedures accounted for 30.7% of all lung resections but represented only 6.7% 
of those patients requiring intensive care (p<0.01, Fisher's exact test). Total 
intravenous anaesthesia was the sole primary anaesthetic technique for 51.5% of 
all procedures but only 36.7% of patients admitted to ICU (p=0.10, chi-squared 
test). There was no apparent association between paravertebral or epidural 
anaesthesia and requirement for ICU, with proportions similar in both the ICU 
admission group and the no ICU admission group (Table 10). 
As there were a small number of patients admitted to ICU (n=30), we created three 
separate logistic regression models to assess for any association between the 
surgical and anaesthetic factors listed in Table 10 and the need for ITU admission 
(following adjustment for Thoracoscore). Due to the extreme skewed distribution of 
the data, Thoracoscore was log transformed to normality (Log10 Thoracoscore) 
and inputted along with approach, primary anaesthetic type and primary analgesic 
type. The three logistic regression models were statistically significant (p≤0.001) 
and accounted for between 8% and 10% (Nagelkerke R2) of the variance in ICU 
admission (Table 11, pg 115). 
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 Odds Ratio 95% CI P-value 
Log10 Thoracoscore 4.05 (1.76, 9.33) 0.001 
Surgical Approach 5.25 (1.23, 22.43) 0.025 
Note: Approach is for open procedure compared with VATS 
Log10 Thoracoscore 5.26 (2.31, 11.96) <0.001 
Primary Anaesthetic 2.08 (0.97, 4.47) 0.061 
Note: Primary anaesthetic is for volatile compared with TIVA 
Log10 Thoracoscore 5.17 (2.15, 12.47) <0.001 
Secondary analgesia 1.08 (0.50, 2.30) 0.847 
Note: Secondary analgesia is for PVB compared with epidural 
Table 11. Logistic Regression models predicting ICU admission following lung resection. 
VATS = video Assisted thoracoscopic surgery, TIVA = total intravenous anaesthesia, PVB = 
paravertebral Blockade. 
 
Log10 Thoracoscore was a significant predictor variable in all three models 
(p≤0.001) however the only independently significant predictor was surgical 
approach, with the use of an open procedure associated with 5.25 (p=0.025, 95% 
CI 1.23, 22.4) times higher odds of ICU admission. There was a trend towards 
increased ICU admission in patients undergoing volatile anaesthesia (p=0.061, OR 
2.08, 95% CI 0.97, 4.47). There was no association between ICU admission and 
regional anaesthetic choice (p=0.847).  
3.3.2 Right ventricular function in critical care following lung 
resection 
Of the patients admitted to ICU, nine (30%) had evidence of RV dysfunction/failure 
at some point during their critical care admission. A description of the basic 
demographics and clinical course of these patients is given in Table 13 (pg 119). 
Of these nine patients, two (patient no. 8 and 9) had evidence of alternative 
pathologies that may have significantly contributed to RV dysfunction; one had 
evidence of saddle pulmonary embolism and the other had severe RV impairment 
pre-operatively. As this investigation was to determine the incidence of RV 
dysfunction resulting from lung resection and given the confounding nature of the 
pathologies in these two patients, they have not been included in the analysis. 
Therefore, seven patients (25.0%) had evidence of RV dysfunction in the ICU 
cohort following lung resection (six with evidence of RV failure) and they are 
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compared with the 21 patients admitted to ICU with no evidence of RV 
dysfunction. The characteristics of these two groups are provided in Table 12. 
Given the small numbers and the retrospective nature of the study, no statistical 
comparison has been made and this review is of a descriptive nature only.  
Characteristic RV Dysfunction 
(n=7) 
No RV Dysfunction 
(n=21) 
Age (yrs) 69.0 (63.0, 73.0) 73.0 (63.5, 75.5) 
Female Sex 4 (57.1%) 11 (52.4%) 
FEV1% 71.0 (60.0, 102.0) 82.0 (72.0, 93.5) 
TLCO% 56.0 (43.0, 73.0) 57.0 (46.0, 74.0) 
APACHE II 17.0 (12.0, 24.0) 17.0 (14.5, 23.0) 
   
Thoracoscore 2.7 (1.0, 5.0) 2.0 (1.2, 2.6) 
   
Day of admission 8.0 (2.0, 12.0) 2.0 (1.0, 5.5) 
   
Resection type   
 Pneumonectomy 0 (0%) 1 (4.8%) 
 Lobectomy / Bilobectomy 7 (100%) 19 (90.5%) 
 Sublobar Resection 0 (0%) 1 (4.8%) 
    
 Right Sided Procedure 5 (71.4%) 13 (61.9%) 
    
Approach (c.f. VATS)   
 Open 7 (100%) 20 (95.2%) 
    
In-hospital mortality 5 (71.4%) 3 (14.3%) 
Table 12. Characteristics of patients admitted to ICU with evidence of RV dysfunction and 
those without evidence of RV dysfunction. 
Values are number (%) and median(IQR). FEV1% = percent predicted forced expiratory volume in 1 
second, TLCO% = percent predicted transfer factor for carbon monoxide, APACHEII = acute 
physiology and chronic health evaluation II, VATS = video assisted thoracoscopy. 
 
Of the seven patients, all had evidence of RV dysfunction on echocardiography, 
four with trans thoracic echocardiography (TTE) and three with trans oesophageal 
echocardiography (TOE). Of the 30 patients admitted to ICU, 19 (63.3%) had 
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echocardiography (TTE or TOE) during their admission. As part of their 
assessment, two patients had pulmonary artery catheters (PAC) inserted which 
demonstrated evidence of pulmonary hypertension. All seven patients had 
evidence of RV dilatation on echocardiography. Five patients had evidence of 
dilatation and functional impairment which was described from "moderate" to 
"severe". The other two patients had evidence of ventricular dilatation but function 
was described as "satisfactory" or "coping". Echocardiographic images of a patient 
admitted to ICU with RV failure following lung resection are provided (Figure 26 
and Figure 27, pg 118). 
Five patients (71.4%) with evidence of RV dysfunction died in ICU, in contrast to 
three (14.3%) in the cohort without evidence of RV dysfunction. The two patients 
who survived had evidence of dilatation but function was described on echo as not 
being impaired, whereas the patients that died all had evidence of functional 
impairment. All patients with evidence of RV dysfunction had respiratory failure on 
admission to ICU and all required intermittent positive pressure ventilation (IPPV). 
Six patients (85.7%) had evidence of RV failure with haemodynamic compromise, 
and all of these patients were on multiple vasoactive infusions (including 
adrenaline, nor-adrenaline, dobutamine, vasopressin and milirinone). Five of the 
six patients (83.3%) with haemodynamic compromise received pulmonary 
vasodilator therapy; all five had inhaled nitric oxide (iNO) administered and one 
patient received epoprostenol (Flolan) in addition to iNO. No patients had 
extracorporeal support. Two patients required RRT in the form of continuous veno-
venous haemofiltration, although it is not clear from the review if this was as a 
focused intervention for RV failure or part of management of multi-organ failure. 
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Figure 26. Trans thoracic echocardiography of patient admitted to ICU with RV failure 
following lung resection (Apical 4-chamber view) 
A) Plain image B) Annotated image. Area in white is the right ventricle and is dilated (similar size 
to the left ventricle). RV = right ventricle, LV = left ventricle, RA = right atrium, LA = left 
atrium. 
 
Figure 27. Trans thoracic echocardiography of patient admitted to ICU with RV failure 
following lung resection (Para-sternal short axis view) 
A) Plain image B) Annotated image. Area in white is the left ventricle and is compressed during 
systole ("D-shaped") suggesting RV pressure overload. RV = right ventricle, LV = left ventricle. 
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Table 13. Intensive care unit (ICU) patients with right ventricular dysfunction 
No. 
Age 
sex 
Approach 
resection 
type 
PMHx Clinical course 
RV 
dysfunction/failure 
identified 
ICU 
outcome 
1 
70 
♀ 
Thoracotomy 
RLL & upper 
wedge 
Obesity 
Type 2 DM 
PVD 
Previous PE 
HTN 
COPD 
OA 
Ex-smoker 
Progressive respiratory failure with Increasing FiO2 
requirement from POD 3. Required NIV from POD 7. 
 
Acute deterioration POD 9 requiring ventilation. 
Persistently hypotensive with low cardiac output state 
requiring high doses of vasoactive medications (NA, 
adrenaline, vasopressin and dobutamine) and iNO. 
 
POD 10 TOE 
RV severely dilated 
and impaired 
Died 
POD 10 
2 
75 
♂ 
Thoracotomy 
RLL and RML 
COPD 
IHD 
Kidney Ca with 
previous 
nephrectomy 
Oliguria/anuria post-op 
Admitted to ICU for CVVH POD 2. 
 
Respiratory failure and cardiovascular collapse POD 
3 
TOE-> RV dysfunction. 
 
Managed with iNO, dobutamine, NA, vasopressin 
and CVVH. 
POD 2 TOE 
Dilated dyskinetic 
RV 
"only just coping" 
Discharged 
POD 10 
  
  
1
2
0
 
No. 
Age 
sex 
Approach 
resection 
type 
PMHx Clinical course 
RV 
dysfunction/failure 
identified 
ICU 
outcome 
3 
63 
♀ 
VATS to 
thoracotomy 
LUL 
 
CVA 
ALD 
(oesophageal 
varices) 
COPD 
Hypertension 
Intra-op bleeding requiring transfusion. Extubated 
post-op. 
, 
Admitted from HDU with cardiovascular collapse 
POD 3. Managed with NA, dobutamine, adrenaline, 
vasopresin, milirinone, iNO and Flolan. 
 
TTE and PAC at that time. 
POD 3 TTE 
RV dilated, 
moderate 
impairment of 
systolic function 
 
PAC showed PA 
pressures of 
93/43mmHg 
Died 
POD 3 
4 60♂ 
Thoracotomy 
RUL 
AF - warfarin 
IHD 
Ex-smoker 
For aspergilloma. Intra-op bleeding requiring 
transfusion. Initially managed in HDU. 
 
Admitted ICU POD 8 with respiratory failure and 
sepsis. On POD 9 noted to have RV dysfunction 
which was managed with dobutamine, adrenaline 
and iNO. 
 
Parameters improved but developed MOF and died. 
POD 9 TTE RV 
dilated and 
moderately impaired 
Died 
POD 19 
5 
74 
♀ 
VATS to 
thoracotomy 
RUL 
 
Pulmonary 
fibrosis 
IHD 
Initially good post-op progress, slowly deteriorated 
from respiratory dysfunction. Admitted ICU POD 17 
with respiratory failure requiring ventilation. 
 
Developed cardiovascular collapse and RV 
dysfunction with persistent pulmonary hypertension. 
Required CVVH for renal failure. 
 
Managed with iNO, dobutamine and NA. 
POD 18 TOE 
showed dilated RV 
 
POD 18 PAC PAP 
80/40 
Died 
POD 24 
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No. 
Age 
sex 
Approach 
resection 
type 
PMHx Clinical course 
RV 
dysfunction/failure 
identified 
ICU 
outcome 
6 66♀ 
Thoracotomy 
LUL 
Pulmonary 
fibrosis 
 
Admitted with respiratory failure POD 2, treated as 
post-op ARDS. 
 
No significant haemodynamic compromise evident 
although TTE performed. 
TTE POD 4 
- RV mildly dilated 
with satisfactory 
function 
RVSP moderately 
elevated (57mmHg) 
Discharged 
POD 18 
7 69♂ 
Thoracotomy 
RUL and 
RML 
Ex smoker 
IHD 
AF on warfarin 
Admitted POD 12 with respiratory failure and sepsis, 
initially made good progress and was extubated. 
 
Re-ventilated for respiratory failure on POD 26 with 
significant haemodynamic compromise and RV 
dysfunction on TTE. 
 
Managed with NA and dobutamine. 
TTE poorly 
functioning. Dilated 
RV with septal shift, 
severe TR, 
increased PAP 
Died 
POD 28 
8 72♂ 
Thoracotomy 
LLL 
AF 
COPD 
IHD 
 
Uneventful immediate peri-operative period. 
Developed respiratory failure POD 7. 
 
POD 12 found to have bilateral PE's. TTE at that 
time demonstrated dilatation but preserved function. 
RVSP reduced as clinical picture improved. 
 
Developed respiratory failure (?ARDS), required 
ventilation. No significant haemodynamic instability. 
TTE POD 12 
showed a large 
'serpentine' 
thrombus. Moderate 
dilatation, normal 
systolic function and 
severely elevated 
RVSP (67mmHg) 
Discharged 
POD 50 
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No. 
Age 
sex 
Approach 
resection 
type 
PMHx Clinical course 
RV 
dysfunction/failure 
identified 
ICU 
outcome 
9 51♂ 
Thoracotomy 
L Wedge 
resection 
Ex-smoker 
HTN 
Rheumatic 
valvular 
disease 
AF 
 
Pre-op rheumatic valvular disease with right heart 
dilatation and severe systolic impairment. 
 
Deterioration immediately post-operatively with poor 
respiratory function and hypotension. Requirement 
for ventilation and vasoactive medication for 
management of haemodynamic instability; NA and 
dobutamine. 
TTE immediately 
post-op showed 
torrential tricuspid 
regurgitation, dilated 
RV and RA with 
severely impaired 
function 
Discharged 
POD 5 
PMHx = past medical history, RLL = right lower lobectomy, RML = right middle lobectomy, LUL = left upper lobectomy, RUL = right upper lobectomy, LLL = left lower 
lobectomy, DM = diabetes mellitus, PVD = peripheral vascular disease, PE = pulmonary embolus, HTN = hypertension, COPD = chronic obstructive pulmonary disease, 
OA = osteoarthritis, IHD = ischaemic heart disease, Ca = cancer, CVA = cerebrovascular accident, ALD = alcoholic liver disease, AF = atrial fibrillation, FiO2 = fraction of 
inspired oxygen, NIV = non invasive ventilation, NA = nor-adrenaline, POD = post-op day, iNO = inhaled nitric oxide, CVVH = continuous veno-venous haemofiltration, TTE 
= trans thoracic echocardiogram, TOE = trans oesophageal echocardiogram, HDU = high dependency unit, ARDS = acute respiratory distress syndrome, RVSP = right 
ventricular systolic pressure, PAP = pulmonary artery pressure, RA = right atrium. 
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3.4  Discussion 
The main finding of this study is an unplanned ICU admission rate of 2.6% 
following lung resection. ICU admission was associated with increased mortality, 
prolonged duration of ventilation, requirement for tracheostomy and prolonged 
hospital stay. An incidence of RV dysfunction in ICU following lung resection of at 
least 25% was also discovered. RV dysfunction in this group is associated with 
high mortality (71.4%) and appears to have a large resource burden. Of the eight 
patients who died in the ICU cohort, five (62.5%) had evidence of RV dysfunction. 
Both patient factors and surgical factors are known to influence the need for ICU 
admission following lung resection. Patient factors include; increasing age >65 
years old, poor respiratory function including; Forced Expiratory Volume in 1 
second (FEV1) <45% predicted, Diffusion Limitation of Carbon Monoxide (TLCO) 
<50% predicted and medical co-morbidities213-215. Consistent with previous work, 
patients admitted to ICU for support in this study were older and had worse lung 
function when compared to the patients not requiring ICU.  
In other reported series, respiratory failure was the primary reason for admission in 
50% to 77% of patients212, 215, 218. There were similar findings in this cohort with 23 
patients (76.7%) admitted with a diagnosis of respiratory failure and 28 patients 
(93.3%) requiring ventilatory support. Mean ventilation time was just under two 
weeks and a third of patients further required tracheostomy for prolonged 
ventilator wean. In the 22 patients requiring respiratory support alone (i.e. without 
RRT), mortality was 28.6%. Of the two patients requiring RRT alone, both 
survived. Six patients required both RRT and ventilation, with a survival of 50%, 
this is in contrast to previous work which reported poor outcomes in this patient 
group.  
"The combination of mechanical ventilation and haemofiltration 
was universally fatal in our patients." 
Pilling et al. (2004)212 
The marked difference in mortality between those patients requiring ICU early 
(post-op days 0 to 7) and late (after post-op day 7) is interesting. The author 
theorises that the group of patients admitted late are a different population and 
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have continued to deteriorate despite maximal ward or high dependency unit 
treatment and are 'self selecting' themselves to do poorly. Qualitative review 
indicates that the patients admitted early were more likely to have diagnoses 
amenable to immediate intervention such as lobar collapse or bleeding and those 
admitted later had a higher incidence of consequential secondary pathologies 
such as ARDS or bronchopneumonia. This early and late phenomenon is 
analogous to primary and secondary lung injury as described by Licker et al.231 
(Figure 28).  
 
Figure 28. Time related distribution of acute lung injury following thoracic surgery 
From Licker et al.231. 
 
The choice of a TIVA or volatile anaesthetic for thoracic procedures has been the 
subject of much debate. In this investigation, following adjustment for 
Thoracoscore, there is a trend towards decreased risk of ITU admission in patients 
anaesthetised using a TIVA technique (p=0.061). Though volatile agents have 
been described as having theoretical, physiological and laboratory advantages 
over TIVA for thoracic anaesthesia, there is a lack of data looking at patient 
outcomes232-234. Importantly, in this study we included all patients with any 
exposure to a volatile agent, no matter what the duration. We therefore may be 
over estimating the proportion having a volatile anaesthetic in the group not 
admitted to ICU. In contrast to the potential benefits offered by volatile agents, 
there is a body of evidence demonstrating a theoretically advantageous free 
radical scavenging and antioxidant effect of Propofol235, 236. There is no strong 
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clinical evidence in favour of either volatile or TIVA in lung resection and a 2013 
Cochrane review update concluded; 
 “no evidence indicated that the drug used to maintain anaesthesia 
during one-lung ventilation affected participant outcomes” 
Modolo et al. (2013)232  
Furthermore, it is not yet clear if there is a cumulative effect from use of these 
agents or if any effect (beneficial or detrimental) is as a result of all or nothing 
exposure.  
Pneumonectomy has previously been reported as an important surgical factor in 
determining the need for ICU admission215. In this cohort only one patient was 
admitted following pneumonectomy, the small number means that any in-depth 
analysis of the factors associated with ICU admission in this specific group would 
be underpowered and meaningless. This also needs to be considered in the wider 
context of a decline in the number of pneumonectomies performed over the last 30 
years and a shift in national guidelinesK.  
"avoid pneumonectomy where possible by performing 
bronchoangioplastic resection or non-anatomical resection"  
Lim et al.(2010)228  
There has been no published work looking at the importance of surgical approach 
(open or VATS) on the need for unplanned ICU admission. In this cohort, the 
logistic regression model incorporating surgical approach demonstrated a 
significant effect on the need for ICU care, with the use of an open procedure 
associated with a five times higher odds of ICU admission. There are several 
confounders to this as there will be cases where a VATS procedure will not be 
possible due to relative contraindications such as; pneumonectomy, previous 
thoracic surgery and central tumours. Also, if there is intra-operative difficulty 
during a VATS procedure, the default will be to progress to an open procedure. 
Peri-operative difficulties requiring conversion could influence the need for ICU 
                                            
K Joint guidelines by the British Thoracic Society and Society for Cardiothoracic Surgery in Great 
Britain and Ireland. 
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admission. In our cohort, two of the patients admitted to ICU following an open 
procedure were conversions from a VATS technique. 
Though anecdotally, it appears as if there has been more widespread adoption of 
a paravertebral analgesic technique for patients undergoing lung resection, 
historically UK practice has been significantly in favour of the use of thoracic 
epidural blockade237. Current evidence is conflicting with several large systematic 
reviews and meta-analyses showing no difference in the techniques or favouring 
paravertebral blockade238-240. This investigation demonstrated no difference in the 
need for ITU admission between patients undergoing thoracic epidural versus 
paravertebral analgesia.  
Brunelli et al. developed a scoring tool designed to predict the need for emergency 
ICU admission following lung resection. Increasing score was associated with an 
incremental increase in the need for ICU admission, although this was shown to 
only have moderate discriminative ability (signified by an area under the receiver 
operating characteristic curve (AUROCC) of 0.66) in an external validation 
study215, 219. Thoracoscore is a scoring system incorporating both patient and 
surgical risk factors and is used to evaluate the risk of in-hospital mortality 
following thoracic surgery (Table 14 and Equation 7, pg 127)230. Although not 
previously reported as important in determining the need for ICU care, it would 
seem intuitive that those patients at higher risk of mortality would be at higher risk 
of unplanned ICU admission. This is consistent with mortality scoring tools 
predicting ICU requirements in other surgical groups, for example, following 
cardiac surgery241. In our study, as might be anticipated, patients admitted to ICU 
had a higher Thoracoscore compared to those not requiring ICU admission and 
although not previously validated to predict ICU requirement, Thoracoscore had 
good predictive power with an AUROCC of 0.74 (95% CI 0.68, 0.80, p<0.001) 
(Figure 29, pg 128)242. A Thoracoscore of 0.89 had 93.3% sensitivity and 54.2% 
specificity with a positive predictive value of 6% but with a negative predictive 
value of 99.6%. Thoracoscore could therefore be used to highlight patients at 
lower risk of ICU admission, potentially identifying those suitable for enhanced 
recovery programmes or same day admission. 
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Variable Value β-coefficient 
Age (Yrs) 
<55 - 
55-65 0.7679 
>65 1.0073 
Gender  
Female - 
Male 0.4505 
ASA scale243 
≤2 - 
≥3 0.6057 
MRC dyspnoea scale 
≤2 - 
≥3 0.9075 
WHO Performance 
status  
≤2 - 
≥3 0.689 
Comorbidities  
0 - 
1-2 0.7447 
≥3 0.9065 
Priority of surgery  
Elective - 
Emergency 0.8443 
Procedure class  
Other - 
Pneumonectomy 1.2176 
Diagnosis group  
Benign - 
Malignant 1.2423 
Table 14. Variables used to calculate Thoracoscore 
Adapted from Falcoz et al.230. MRC = Medical Research Council; WHO = World Health 
Organisation. Values for MRC dyspnoea scale and WHO performance status are detailed in 
appendix 3. Comorbidities included: smoking addiction, history of cancer, chronic obstructive 
pulmonary disease, arterial hypertension, heart disease, diabetes mellitus, peripheral vascular 
disease, obesity and alcoholism. 
 
                          
                                 
        
            
 
Equation 7. Logistic regression equation used to calculate Thoracoscore 
-7.3737 is constant from Falcoz et al.230. Beta is calculated from values obtained from Table 14. 
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Figure 29. Receiver operating characteristic curve for prediction of ICU admission following 
lung resection using Thoracoscore 
Dashed line AUROCC = 0.74 (95% CI 0.68-0.80, p<0.001). Solid line AUROCC = 0.5 (line of no 
effect).  
 
Although 'thoracic surgery' is often thought of as 'high risk' for complications when 
compared with other 'non-thoracic procedures', these results demonstrate that not 
all lung-resection procedures are equal. In this cohort, sub-lobar resections were 
less likely to require ICU than lobectomy patients. Likewise, VATS procedures 
were less likely to require ICU than those requiring open resections. This is 
consistent with Thoracoscore where pneumonectomy patients are at higher risk of 
in-hospital death than those undergoing lesser resections. 
The cause of RV failure in all settings can be divided in to three main categories; 
excessive preload, excessive afterload and insufficient contractility. In most cases, 
acute RV failure is multi-factorial and results from a combination of established 
disease, complicated by acute derangements in one or more of these three 
factors158, 244. In the patient undergoing lung resection, the multi factorial elements 
could include both patient and surgical factors. The patient factors may include 
diseases resulting from the common aetiological factor as their lung cancer, 
namely cigarette smoking. Pulmonary hypertension (PH) is common in patients 
with advanced COPD and some patients have 'out of proportion' PH with only mild 
COPD245, 246. Patients presenting for lung resection are also prone to 
atherosclerotic disease with ischaemic heart disease being common27, 247. These 
factors may make this group of patients susceptible to RV dysfunction.  
AUROCC = 0.74 
95% CI (0.68, 0.80) 
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Surgical factors such as one lung ventilation and surgical handling of the lung, 
may result in post-op lung injury248. Post-op sepsis, respiratory failure and 
myocardial ischaemia are also common complications following lung resection17, 
249, 250. All of these may result in disruption of preload, afterload or contractility, and 
contribute to RV dysfunction and failure. In addition the commonly hypothesised 
increase in afterload following lung resection, may significantly contribute. 
Consistent with the idea that patient factors contribute to development of RV 
dysfunction in the ICU, all patients with evidence of RV dysfunction had a history 
of significant cardiovascular and/or respiratory disease. All of the patients with RV 
dysfunction presented with respiratory failure requiring ventilation (which can 
contribute to RV dysfunction in its own right)251 and the majority had 
cardiovascular instability requiring vasoactive medications. None of the patients in 
this cohort were admitted immediately post-operatively with evidence of RV 
dysfunction. This suggests the hypothesised increase in afterload that occurs 
following lung resection was not the only factor associated with the development of 
post-op RV dysfunction.  
3.4.1 Strengths and limitations 
A strength of this study is that it is one of the largest reported data sets looking at 
critical care requirement following lung resection with complete information on the 
patients admitted to ICU. It is also the first time the incidence of RV dysfunction in 
ICU following lung resection has been examined.  
The investigation has limitations, primarily it is retrospective and will demonstrate 
association not causation. There are also confounders; though reflecting data from 
a large number of patients (n=1169), as the incidence of ITU admission was only 
2.6%, there were insufficient ‘positive’ outcomes (ICU admissions) to allow for 
comprehensive multi-variable assessment of predictive variables. Despite the 
dataset for the cohort admitted to ICU being complete, some variables for the 
group not requiring ICU were missing. To account for this missing data, the 
number of analyses performed for any variable less than 80% complete was 
limited. Finally, as data on the presence of cardiac comorbidities was not recorded 
in our database, we were unable to calculate and compare Brunelli score for risk 
of ICU admission. 
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Despite the large denominator (of non-ICU patients and ICU patients without RV 
dysfunction), only seven patients had evidence of RV dysfunction in the ICU 
cohort, meaning detailed statistical analysis would be meaningless. It is also 
difficult to unpick exactly the cause of RV dysfunction. As already described, RV 
dysfunction is common in ICU patients without lung resection. It is therefore 
unknown whether the RV dysfunction observed in this cohort would have 
happened independently of lung resection. 
As the data was reviewed retrospectively, there was a reliance on the fidelity of 
documentation. Many of the echocardiograms in ITU were performed on portable 
machines with imaging not stored and not available for further analysis. In many 
situations no formal report was issued. This means diagnosis of RV dysfunction 
was often based on the written comments of the echocardiographer. This 
introduced a degree of subjectivity to identification of patients with RV dysfunction.  
The investigation will have been subject to selection bias. Although there was a 
high incidence of RV dysfunction in the group who died, these patients are more 
likely to have required investigations as they deteriorated. In addition, only 19 
(63.3%) of all the patients admitted to ICU had echocardiography performed 
meaning RV function of one third of the patients is unknown. Although the 
remaining patients would have had low clinical suspicion, this means the incidence 
of RV dysfunction in ICU patients may be higher than reported here. Although it 
would not have been possible with the methodology employed, we have no data 
on RV function in the cohort not admitted to ICU. There may been patients who 
developed RV dysfunction, not requiring ICU interventions (ventilation and renal 
replacement therapy in this cohort), who were managed in the HDU or ward 
environment. 
3.5  Conclusion 
This review provides single centre data for those patients requiring unplanned ICU 
care following lung resection. It gives an indication of the factors that may be 
important in influencing the need for admission and demonstrates a favourable 
ICU admission and survival rate when compared to existing data. Future work 
should focus on the comprehensive assessment of potentially modifiable risk 
factors associated with unplanned ICU admission.  
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RV dysfunction is common in patients admitted to ICU following lung resection and 
is associated with a high mortality. Patients following lung resection may be at 
increased risk of RV dysfunction (and failure) as a result of their underlying 
medical history and the surgical intervention. Work is required to prospectively 
identify the incidence of RV dysfunction following lung resection and its impact on 
those patients requiring critical care support. 
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Chapter 4  Materials and Methods and Generic 
Results 
4.1  Introduction 
This chapter details the methods common to the imaging and biomarker studies 
presented in this thesis (chapters 5, 6, 7 and 8) as they were carried out on the 
same population.  
Results common to this population, such as demographics and post-op change in 
functional status, are also described in this chapter. 
4.2  Generic methods 
4.2.1 Ethical approval 
The study received ethical approval from the West of Scotland Research Ethics 
Committee (REC Ref: 134/WS/0055, Approval Date 16th April 2013). 
4.2.2 Study setting 
The study was performed at the Golden Jubilee National Hospital / West of 
Scotland heart and Lung Centre, Clydebank. The details of this hospital are 
described in section 3.2, pg 108. 
4.2.3 Patient population 
Patients meeting inclusion criteria were highlighted from the Wednesday elective 
list of the lead surgeon (Mr Alan Kirk, consultant thoracic surgeon) and were 
initially approached on the Friday prior to their admission when they attended the 
pre-op assessment clinic. Those patients not meeting any of the exclusion criteria 
were provided with information about the study and given written details to review 
prior to their admission on the Tuesday morning, the day before their surgery. 
Those participants providing informed consent went on to participate in the study. 
Inclusion criteria were; the provision of informed consent, age >16 years and 
planned elective lobectomy by thoracotomy. Exclusion criteria were; Pregnancy, 
on-going participation in any investigational research which could undermine the 
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scientific basis of the study, contraindications to magnetic resonance imagingL, 
wedge/segmental/sub-lobar lung resection, pneumonectomy, isolated middle 
lobectomy and video assisted thoracoscopic surgery (VATS)/minimal access lung 
resection. 
4.2.3.1  Justification of inclusion/exclusion criteria 
Greater physiological disruption may be expected following pneumonectomy, 
however the numbers of this more invasive procedure are reducing and accounted 
for only 5.3% of the lung resections performed in the UK in 2014-15252. To make 
any findings applicable to practice we have excluded those undergoing 
pneumonectomy. Conversely lesser resections may involve less physiological 
disruption and have less of an impact on the right ventricular-pulmonary vascular 
unit meaning any deterioration may be more subtle. To allow any changes to be 
confirmed within a reasonable sample size, these patients have also been 
excluded. Additionally, these lesser resections (segmentectomy/wedge/sub-
lobar/isolated middle lobectomy) made up only 19.7% of the lung resections 
performed in the UK in 2014-15, meaning lobectomy/bilobectomy accounted for 
the vast majority (73.5%) of lung resections performed252.  
VATS resections have increased significantly in recent years. Although VATS 
accounted for 16.9% of all UK lobectomies in 2011-12, by 2013-14 this had 
increased to 30.5%252. The decision to exclude VATS results from two factors. 
Firstly, at the time of this studies conception, the majority of lung resections were 
performed by thoracotomy and to ensure adequate recruitment, this type of 
approach was preferable. The second reason relates to the inflammatory response 
to lung resection; the inflammatory response is attenuated with VATS resections in 
contrast to thoracotomy253. The inflammatory response may be implicated in post-
op RV dysfunction (further discussed in future work, section 10.3.1, pg 289) and 
although not examined in this thesis, to allow this mechanism to be explored, 
VATS procedures are excluded254. 
                                            
L i) Cardiac pacemaker, artificial heart valve, neurotransmitter, cochlear implant, ii) Aneurysm 
clips, iii) Metal injuries to the eye and iv) Loose metal in any part of the body. 
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4.2.4 Anaesthetic protocol 
The intention of the study was not to alter anaesthetic, surgical or post-op 
management. In an attempt to standardise care as much as possible, a protocol 
based on the practice of the lead anaesthetist (Dr Mark Steven, consultant 
cardiothoracic anaesthetist) and lead surgeon (Mr Alan Kirk) was developed. This 
reflected the practice of the majority of the clinicians working in the Golden Jubilee 
National Hospital. 
This involved intravenous induction and volatile maintenance of anaesthesia. For 
analgesia, a thoracic epidural was sited pre-operatively and maintained post-
operatively with continuous infusion. Where insertion was unsuccessful, 
paravertebral catheters were sited intra-operatively by the operating surgeon and 
augmented with patient controlled analgesia (PCA) with morphine boluses. Lung 
isolation was achieved using a double lumen endo-tracheal tube. Ventilation was 
with a lung protective protocolM; tidal volume <8ml/kg, positive end expiratory 
pressure (PEEP) 0-5cm H2O, Maximum Airway Pressure (Pmax) limited to 30cm 
H2O, Fraction of inspired oxygen (FiO2) was titrated to maintain oxygen saturation 
(SaO2) 92% to 98% along with a generally permissive approach to hypercapnia. 
4.2.5 Data collection 
Data were collected by the author and research nursing staff during the patients 
hospital admission and at 2-month clinic follow-up. Postal questionnaire was 
performed one year following surgery. All anonymised data were collated and 
stored in a password protected database created using proprietary database 
software (Microsoft Access® 2007, Microsoft, Washington, USA) by a research 
nurse (Miss Christine Groundwater) assisting with the study. 
4.2.5.1  Baseline demographic data 
Routine patient demographics were collected prospectively at the time of 
recruitment. Data were extracted from patient records and from face to face 
                                            
M Although the protocol would not be considered 'lung protective' in the conventional sense, it 
was setting protocolised limits for the intra-operative care of the patient and reflected the 
broad practice within our institution. 
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interview. Information was recorded in dedicated case report forms (Appendix 2 
and 3).  
As part of their routine work-up for lung resection, Pulmonary Function Tests 
(PFT's) were performed in all patients prior to attending the Golden Jubilee 
National Hospital for lung resection. Where these had not been performed prior to 
attendance, they were performed at the GJNH by respiratory physiologists 
according to standardised guidelines. These are reported as absolute values and 
as percent predicted, this compares the participant to values obtained from 
population studies of healthy subjects with values matched for age, height, sex 
and ethnicity255. Parameters were collected to allow calculation of 
Thoracoscore230. This score is described in section 3.4, pg 127.  
4.2.5.2  Self report of exercise tolerance and function status 
Self report of functional status was collected by completion of a written 
questionnaire encompassing; New York Heart Association (NYHA) functional 
classification256, World Health Organisation (WHO) performance status 
classification257, Medical Research Council (MRC) Dyspnoea Scale258 and the 
EuroQOL 5 Dimension (EQ-5D) score. Permission was obtained from EuroQOL 
for use of the EQ-5D score (personal communication, September 2012). These 
were all completed pre-operatively (pre-op), at 2-month clinic follow-up and by 
postal questionnaire at 1 year. Three attempts were made at postal follow-up and 
if no response was received then this was abandoned. The individual domains of 
each of these scores is provided in case report form 2 in Appendix 3. 
4.2.5.3  Six minute walk testing 
Six minute walk testing (6 MWT) was completed on a 30 metre flat, straight course 
as per American Thoracic Society (ATS) Guidelines259. Six MWT was completed 
pre-op and where the participant was able to complete the test, at 2-month follow-
up. As per ATS guidelines, pulse oximetry was performed for the duration of the 
study and emergency medical equipment was immediately available. 
Small changes in 6MWT distance can be attributed to the inherent source of 
variation within the test itself, such as participant motivation and a training effect 
from having previously performed the test. To include those patients with 
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significant clinical changes in functional status, we chose to use the minimal 
clinically important distance (MICD) for patients with severe COPD, 26±2m. 
Although normally utilised to measure improvement, the MID is the change in 
6MWT distance where patients sense an actual change in their functional status 
and is essential for determining the effectiveness of interventions in clinical 
trials260. A MID has not been validated for patients following lung resection. 
4.2.5.4  Imaging 
Non-contrast cardiovascular magnetic resonance (CMR) and Trans-thoracic 
Echocardiographic (TTE) imaging were performed contemporaneously. Imaging 
took place pre-operatively (pre-op), on post-op day (POD) 2 and at 2-month clinic 
follow-up. Full details of CMR imaging, including protocol and analysis are 
described in section 4.3. Full details of echocardiographic imaging, including 
protocol and analysis are described in sections 4.4 and 4.5. 
4.2.5.5  Laboratory sampling 
Blood sampling was performed pre-op (prior to induction of anaesthesia), 
immediately post-op (once extubated in recovery area) and then on the mornings 
of POD 1 and 2, and at 2-month follow-up. The analysis of B-Type Natriuretic 
Peptide (BNP) and Highly Sensitive Troponin-T (HS TnT) is described in section 
4.6, pg 160. 
4.2.5.6  Intra-operative clinical data 
Intra-operative data were collected continuously and automatically for the duration 
of the anaesthetic by the 'RECALL Anaesthetic Intra-operative Management 
System' (AIMS) electronic charting system (Informatics Clinical Information 
Systems Limited, Glasgow). Duration of surgery was taken as the duration of the 
end tidal carbon dioxide (ETCO2) trace. The appearance of CO2 represents 
intubation and it's disappearance, represents extubation. Duration of one lung 
ventilation (OLV) was prospectively recorded in the RECALL AIMS electronic 
anaesthetic charting system by the primary anaesthetist or where this did not 
happen, from manual inspection of the airway pressure and tidal volume vs. time 
curves. 
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4.2.5.7  Post-operative clinical data 
Post-op clinical data was collected as described above (exercise tolerance, 
6MWT, CMR imaging, echocardiography and laboratory sampling) along with data 
describing the patients critical care and hospital stay.  
Critical care stay parameters were continuously and automatically recorded (at 
approximately 2 minute intervals) by the ICU clinical information system (Centricity 
CIS; GE Healthcare©, Buckinghamshire, UK). This systems allows accurate 
recording of multiple parameters combined with electronic patient notes. 
Haemodynamic variables included; heart rate, cardiac rhythm (manually inputted 
by nursing staff), blood pressure and central venous pressure. Respiratory 
variables included; continuous oxygen saturations (SaO2), respiratory rate, 
supplemental oxygen administered, ventilator settings and arterial blood gas 
results. Other data collected by this system included; fluid administration (type and 
volume), urine output, cumulative fluid balance and medication prescriptions (dose 
and / or infusion rate). This system automatically calculates fluid balance and 
cumulative totals are reset at 07:59 in the morning, meaning fluid balance is for the 
24 hours prior to this point. Requirement for vasoconstrictor (typically nor-
adrenaline) during critical care stay was documented. Arrhythmia was recorded as 
per patient notes (CIS or paper copy) and where possible, confirmed with a 12 
lead electrocardiogram (ECG). 
Length of high dependency unit (HDU) stay was calculated as the time from the 
first recorded oxygen saturation on CIS to the end of continuous recording of 
oxygen saturations. This was chosen as a pragmatic solution to the problem of 
defining exact discharge time from HDU. Discharge from any critical care 
environment can vary from the time the patient is actually ready to leave. This is 
often for logistical reasons, including the time of day (patients tend not to be 
discharged overnight) and the availability of ward beds. The change of continuous 
to intermittent measurement is believed to reflect the time of stepping down the 
care requirement of the patient (from HDU/level 2 care, to ward/level 1 care229). 
Also for pragmatic reasons, hospital stay for the purpose of this study was 
calculated as post-op hospital stay. Although the majority of patients are admitted 
to the Golden Jubilee National hospital the day before their surgery, some are 
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admitted earlier for logistical reasons e.g. as the hospital is a referral centre for the 
West of Scotland (including rural and island communities), some patients have 
significant distances to travel and are admitted earlier. 
4.2.6 Data synthesis and statistics 
Data are presented as mean (SD) or median (IQR) as appropriate to distribution. 
Normality was assessed with visual inspection of the data and the Shapiro-Wilk 
test (p>0.05). Where possible, transformations were made as appropriate for data 
distribution, where it was not possible to transform to a normal distribution, a non-
parametric test was used. Inter and intra-observer variability (reproducibility and 
repeatability) were assessed with the intraclass correlation coefficient (ICC) for 
both absolute agreement and consistency, and the coefficient of variation (COV). 
Coefficient of variation is a measure of variability and was defined as the ratio of 
the standard deviation to the mean (Equation 8)261.  
                              
                 
    
      
Equation 8. Coefficient of Variation 
 
The ICC and COV were interpreted as described in Table 15. Bland Altman plots 
were created to assess bias and any systematic differences between observers or 
measures186. 
Coefficient of 
Variation 
Intraclass correlation 
coefficient 
Interpretation 
>15% <0.5 "poor" 
10-15% 0.5-0.75 "moderate/acceptable" 
<10% 
0.75-0.90 "good" 
>0.90 "excellent" 
Table 15. Quantitative interpretation of the intraclass correlation coefficient and coefficient 
of variation 
From  Holm et al.262 and Koo et al.263. 
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Changes over time for normally distributed data were assessed using one-way 
repeated measures analysis of variance (ANOVA) with post-hoc comparisons 
using the paired t-test. Changes over time for non-parametric data were assessed 
using Friedman's test with post-hoc pairwise comparisons using the Wilcoxon rank 
sum test. Comparisons of parametrically distributed data between unpaired groups 
was using an independent-samples t-test or one way analysis of variance as 
appropriate. Comparisons of non-parametrically distributed data between unpaired 
groups was using the Mann-Whitney U-test or Kruskal-Wallis test as appropriate. 
Categorical variables were compared using the Chi-squared or Fisher's exact 
tests. The McNemar test was used to determine difference between paired 
dichotomous variables. 
All associations were visually inspected and assessed using Pearson's correlation 
coefficient or Spearman's correlation coefficient as appropriate. The ability of 
continuous variables to predict binary outcomes was assessed using the area 
under the Receiver Operating Characteristic curve (AUROCC). The optimal cut-off 
of a continuous variable was defined by the point at which the sum of sensitivity 
and specificity was maximal (Youden's index). Positive and negative predictive 
values (PPV and NPV respectively) were also calculated as shown in Equation 9 
and Equation 10 . 
    
                        
                                                  
 
Equation 9. Positive predictive value (PPV) 
 
    
                        
                                                  
 
Equation 10. Negative predictive value (NPV) 
 
For assessment of association between variables with repeated measures made 
in the same patients at multiple time points, analysis of covariance (ANCOVA) was 
performed allowing within-subject correlation to be partitioned out264. The strength 
of association between variables obtained from correlation coefficients (Pearson's 
or Spearman's) are interpreted as described in Table 16, pg 140. 
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Correlation coefficient (r) Interpretation 
0-0.19 "very weak" 
0.20-0.39 "weak" 
0.40-0.59 "moderate" 
0.60-0.79 "strong" 
0.80-1 "very strong" 
Table 16. Interpretation of strength of association by correlation coefficients 
From BMJ.com265. 
 
Statistical analyses were performed using SPSS for Windows, version 22 (IBM 
Corp, Armonk, NY, USA). A p-value <0.05 was considered statistically significant 
and absolute p values are reported. When SPSS produced an output of p=0.000, 
the p-values is presented as p<0.0005. No adjustments were made for multiple 
comparisons. 
4.3  Cardiovascular magnetic resonance assessment of 
right ventricular function 
4.3.1 Introduction 
Given the methodological concerns regarding the techniques used to assess RV 
function in previous studies and ongoing uncertainty about mechanism of RV 
dysfunction (section 2.4, pg 104), further work using validated techniques was 
required to understand the RV response to lung resection. As described in chapter 
1, cardiovascular magnetic resonance (CMR) is the non-invasive reference 
method for assessment of RV structure and function and has not yet been used to 
sequentially assess RV function in a lung resection cohort46, 266. The aim of this 
investigation is to provide a comprehensive understanding of the volumetric 
changes in the RV following lung resection. By using a volumetric estimate of RV-
PA coupling (1.2.3.7. pg 38) the matching of ventricular performance and arterial 
load following lung resection was assessed. 
The role of patient and surgical factors on post-op changes in RV function was 
explored and the potential impact of RV dysfunction in terms of short and long 
term (up to one year) morbidity will be investigated. 
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4.3.2 Methods 
CMR imaging was performed pre-op, on POD 2 and at 2-month follow up. Where 
possible, pre-op CMR imaging was performed the day before surgery but in a 
proportion of cases, due to MRI unavailability, imaging was only possible on the 
morning of the operative day. In these situations the case was scheduled as part 
of an afternoon list. Following surgery, CMR imaging took place on the afternoon 
of POD 2 and when the patient returned for 2-month clinic follow-up.  
4.3.2.1  Power analysis 
The primary outcome of the study was to determine a change in RVEF from pre-
op to POD 2 using CMR. POD 2 was chosen as the time for post-op CMR imaging 
as previous work (using alternative methodology) consistently suggested a 
decrease in RVEF on POD 2163, 170, 174. Although the validity of this work has been 
questioned, these studies describe an absolute fall in RVEF of 6-9% by POD 2163, 
176. It was prudent therefore that this study was powered to detect a change of at 
least this magnitude. 
Power calculation was carried out in consultation with the Robertson Centre for 
Biostatistics (University of Glasgow). Based on a 2-sided, paired t-test with a 
significance level of 5%, a study of 19 patients would have 80% power to detect a 
deterioration in RVEF of 6%. Allowing a margin of 30% for withdrawals, 28 
patients were to be recruited. 
4.3.2.2  Image acquisition 
All CMR imaging was performed at the Golden Jubilee National Hospital using a 
1.5 Tesla Siemens Avanto (Siemens, Germany) whole body scanner by band 7 
Health and Care Professionals Council (HCPC) accredited advanced practitioner 
radiographers according to a standardised protocol. All patients completed a short 
safety questionnaire about suitability for CMR imaging prior to study recruitment 
and consent, however before entry in to the CMR scanning room, patients were 
asked to complete and sign a departmental safety questionnaire to ensure there 
were no absolute contraindications to CMR imaging. Patients were dressed in a 
hospital gown or their own pyjamas and were asked to lie on the examination table 
which was remotely removed from the bore of the scanner to an accessible 
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position. Adhesive pads for continuous 3-lead ECG monitoring were placed on the 
patient's chest and a pulse oximeter was positioned on the patient's finger allowing 
continuous oxygen saturation monitoring. The patient was provided with an 
emergency buzzer and protective ear defenders. The scanning table was then 
positioned within the bore of the magnet and staff retreated to the CMR control 
room. Proper functioning of the microphone and headphones, that allow direct 
communication between patient and operator, was verified prior to the 
commencement of image acquisition. There were no deviations from this 
methodology for both the pre-op and two-month post-op scans.  
Imaging on POD 2 followed a similar pattern except for a few differences as a 
result of recent surgery. During the procedure of thoracotomy and lung resection, 
surgical clips and linear stapling devices are required. To ensure that all implanted 
equipment was suitable for immediate MR imaging, a record of all equipment used 
intra-op was collected by the surgical team so that CMR safety could be verified 
with the manufacturer. All equipment confirmed by the manufacturer as being safe 
was 'signed off' by a radiologist with an interest in MR imaging (Dr Des Alcorn, 
consultant radiologist). The majority of cases used similar equipment and a list of 
'confirmed MR safe' equipment was developed. In the event of new equipment 
being used, MR safety was confirmed with the manufacturer, signed-off by Dr 
Alcorn and added to the confirmed MR safe list. As the patients had been safely 
scanned on POD 2, there were no concerns with scanning at 2-months, unless the 
patient had undergone an additional procedure in the interim. 
Chest drainage is required following lung resection to remove any air and liquid 
that may have collected in the thoracic cavity as a result of surgery. At the Golden 
Jubilee National Hospital, chest drainage is usually performed using the Thopaz 
(Mendela, Switzerland) thoracic drainage system. This is an electronic drainage 
system that is not MR safe. In those patients where chest drainage was still 
required at the time of scanning, the drain was changed to an underwater seal 
chest drain shortly before the scan and changed back immediately after. The chest 
drain was secured to the side of the MR examination table while in the scanner. 
Where feasible, all infusions were discontinued for the short duration of CMR 
scanning. This was to minimise the number of patient connections whilst in the 
scanner. If possible, for example in the case of epidural infusions, this was 
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discontinued immediately before scanning and reinstituted immediately after 
scanning. In the specific case of an epidural infusion, this was often with an 
additional 'top up' dose post scan. Where it was not possible to discontinue 
infusions, for example when the patient required inotropes or vasoconstrictors, MR 
safe syringe pumps were available. All patients scanned on post-op day 2 were 
escorted throughout by a member of the research team. This was either the author 
or a research nurse with experience in critical care. All POD 2 imaging was 
completed 'in hours' with immediate availability of a consultant thoracic surgeon for 
management of potential complications.  
ECG-gated fast imaging steady state free precision cines (TrueFISP, Siemens) 
were utilised throughout. Methodological details of particular importance include 
standardised imaging parameters of repetition time, echo time, flip angle, voxel 
size, field of view = 4.3ms, 1.2ms, 60o, 1.4 x 1.4 x 6mm, 340mm respectively; 
6mm imaging slices were used with a 4mm interslice gap. Short axis imaging was 
performed during breath holds and initiated at the atrioventricular valve plane, 
identified from a horizontal long-axis views, and propagated sequentially to the 
cardiac apex to provide complete coverage of both ventricles.  
On completion of each scan, the images were saved to the hard-drive of the 
scanner and backed up to the hospitals clinical imaging network. At completion of 
the study, all images were randomised and anonymised by a member of the 
radiography staff (Miss Vanessa Orchard) according to a random number 
sequence generated using the 'RAND' function of proprietary spreadsheet 
software (Microsoft Excel® 2007, Microsoft, Washington, USA). Images were 
stored on CD's (10 per disc) for batch analysis. Two copies of the protocol to allow 
identification were stored in sealed envelopes, one in the radiography department 
and another in a locked drawer within the anaesthetic research office, both at the 
Golden Jubilee National Hospital. 
4.3.2.3  Image analysis 
To ensure no incidental findings of clinical importance were missed, safety 
reporting of all anonymised CMR imaging was performed by Dr John Payne 
(consultant cardiologist and lead for cardiac imaging at the GJNH), with a report 
generated and placed in the patient record. Post-processing software using 
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manual planimetry was utilised to determine left ventricular and RV volumes. 
Randomised and anonymised images were dual reported by the author and by his 
co-investigator Dr Alex Arthur (a clinical research fellow in cardiothoracic 
anaesthesia). Initial training in assessment was performed by Dr David Corcoran 
(Clinical Research Fellow in CMR imaging, with level 3 European Association of 
Cardiovascular Imaging certification in CMR imaging)N 267 who also assisted with 
ongoing scan analysis and held the deciding vote in any disagreements over RV 
contours. All analyses were performed using proprietary software (Argus, 
Siemens, Erlangen, Germany).  
For assessment of intra-observer variability, ten of the randomised and 
anonymised scans were selected for repeat analysis by Dr Alex Arthur. This was 
performed more than one month after first analysis.  
The images making up the 'short axis stack' from each anonymised patient were 
loaded on to the Argus program from the CD copy of each file. At the time of 
image acquisition, if there are concerns about the image quality or there is 
evidence of artefact, duplicate scans are performed. Any duplicate 'slices' from the 
stack were identified and removed. An example of the analysis screen from the 
software is provided in Figure 30, pg 145. 
                                            
N Level 3 competency is required for individuals wishing to perform, interpret, and report CMR 
studies fully independently, to lead a CMR laboratory and to supervise CMR training 
programmes in an accredited CMR training centre. 
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Figure 30. Screen shot from Argus analysis software 
Each row of images represents a loop of cine images acquired during one cardiac cycle at 
consecutive slice positions. This begins at the base of the heart (top of screen) and moves 
apically to the bottom of the heart (bottom of screen). The first image on each row is the end-
diastolic image (indicated by yellow ED at top of left hand column).  
 
Image acquisition is triggered by R-wave deflection on the ECG, so the end 
diastolic image was determined automatically by the software as the first image 
within each loop of cine images. The full image stack was assessed and the end 
systolic image was determined manually as the point where the LV blood pool was 
smallest. The same images were used for determination of both LV and RV 
volumes at end diastole and end systole.  
The methods for assessment of LV and RV volumes are standard in clinical MR 
practice114. Following identification of the end systolic and end diastolic images, 
the endocardial border of the RV was contoured in both diastole and systole. The 
RV outflow tract up to the pulmonary valve (where it was visible) was included in 
the analysis. As per convention, to improve reader reproducibility, the 
trabeculations of the RV were ignored and a smooth endocardial border drawn 
(Figure 31, pg 146)114. 
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Figure 31. Defining endocardial borders of the right ventricle 
The endocardial surface of the right ventricle at end diastole and end systole. End diastole 
(identified by the yellow 'ED') is on the left with the smooth endocardial border identified by the 
red line. End systole (identified by the blue 'ES') is on the right with the endocardial border 
identified by the red line. 
 
Definition of the basal ventricular slice can prove difficult, with large volumes 
erroneously included or excluded, leading to errors in analysis. To overcome this 
problem, once the basal slice was identified, it was cross-referenced with the 
horizontal long axis view to ensure the slice was not atrial in origin (Figure 32). 
 
 
Figure 32. Cross referencing of right ventricular basal slice 
Comparison of a short axis image (left) with the horizontal long axis image (right) to determine if 
the image is ventricular in origin. In this example the structures are not right ventricular in origin 
and would not be included. RA = right atrium, RV = right ventricle, LV = left ventricle, LA = left 
atrium. 
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A similar process took place for determination of LV volumes with the endocardial 
border of the LV being determined in both systole and diastole. The papillary 
muscles were included as part of the myocardial blood pool (Figure 33); this is 
accepted practice as long as reference values using the same approach are 
used114. The basal slice for the LV was determined as the most basal slice 
surrounded by 50% or more of ventricular myocardium. Where there was any 
difficulty in defining the LV basal slice a similar process as described for the RV 
was used where the slice was cross referenced against the horizontal long axis 
image. 
 
Figure 33. Defining endocardial borders of the left ventricle 
The endocardial surface of the left ventricle at end diastole and end systole. End diastole 
(identified by the yellow 'ED') is on the left with the endocardial border identified by the red 
line. End systole (identified by the blue 'ES') is on the right with the endocardial border 
identified by the red line. 
 
Following tracing of the myocardial borders for each slice, an automated 
calculation was carried out, using the sum of discs method, to obtain; Right and 
left end systolic volume (ESV) and end diastolic volume (EDV). From these, Right 
and left stroke volume (SV) and ejection fraction (EF) are automatically calculated 
(Equation 11 and Equation 12, pg 148).  
                                                                     
Equation 11. Stroke Volume 
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Equation 12. Ejection Fraction 
 
4.4  Echocardiographic assessment of right ventricular 
function following lung resection 
4.4.1 Introduction 
Although the non-invasive reference method for assessment of RV function is 
CMR, the most commonly used tool in clinical practice is trans-thoracic 
echocardiography (section 1.3.2.2, pg 46). This investigation will describe changes 
in commonly used echocardiographic parameters for assessment of RV systolic 
function following lung resection and will also attempt to validate these methods in 
this population by comparing them to contemporaneously obtained CMR results 
In the American Society of Echocardiography guideline for assessment of the right 
heart in adults, Rudski et al.128 recommends using a number of measures for 
assessment of RV systolic function, including; Fractional area change (FAC), 
tricuspid annular plane systolic excursion (TAPSE) and S' wave velocity at the 
tricuspid annulus (S'Wave). This guideline also recommends measurement of 
pulmonary artery systolic pressure (PASP) and an estimation of right atrial 
pressure from inferior vena cava (IVC) size and collapse. Additional measures 
depend on clinical scenario but as pulmonary artery acceleration time (PAAT) can 
be used to estimate mean pulmonary artery pressure (MPAP), it is measured here.  
4.4.2 Methods 
Trans thoracic echocardiography (TTE) was performed contemporaneously to 
CMR imaging (pre-op, POD 2 and at 2-month clinic follow-up). Effort was taken to 
ensure TTE was performed as close in time to CMR as possible. This was often 
on the same transfer from the ward or high dependency unit. e.g. patients went 
from the ward to CMR imaging, then to TTE imaging (or vice versa) and then back 
to the ward. 
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4.4.2.1  Image acquisition 
All TTE imaging was performed at the Golden Jubilee National Hospital on a Vivid 
E9 cardiovascular ultrasound system (GE Healthcare, Chicago, Illinois, USA) 
using a M5Sc-D transducer with a frequency of 1.5 to 4.6 MHz. All studies were 
performed by band 7 British Society of Echocardiography (BSE) accredited 
cardiac physiologists according to a standardised protocol268. Two-dimensional 
recordings were collected with frame rates ranging from 60 to 80 frames per 
second. Four consecutive cardiac cycles were recorded for further analysis. Three 
lead ECG analysis took place simultaneously.  
Where possible, allowing for recent surgery and chest drain placement, imaging 
took place in the lateral decubitus position. Two dimensional images were 
obtained from the standard parasternal and apical 4-chamber (A4C) views. 
Additional focussed RV imaging was obtained from the A4C view. A sub costal 
view was utilised to obtain images of the inferior vena cava. Colour Doppler 
imaging was performed of all valves. Continuous wave Doppler was performed of 
tricuspid valve (TV) regurgitation in all available views. Pulsed wave Doppler 
analysis of the RV outflow tract and TV inflow was performed. Pulsed tissue 
Doppler imaging was performed of the TV annulus and RV free wall. M-mode 
analysis could be obtained offline from 2D scans. The full protocol incorporated all 
aspects required for a comprehensive echocardiogram as recommended by the 
British Society of Echocardiographers269. There were no deviations from this 
methodology for any of the scanning time points. 
4.4.2.2  Image analysis 
At completion of the study, all images were randomised and anonymised by the 
author according to a random number sequence generated using the 'RAND' 
function of proprietary spreadsheet software (Microsoft Excel® 2007, Microsoft, 
Washington, USA). More than one month following randomisation and 
anonymisation, all images were dual reported by the author and by a band 7, BSE 
accredited cardiac physiologist. All image analysis was performed offline using 
proprietary software (EchoPAC, GE Healthcare, Chicago, United States). Where 
appropriate, end diastole was determined as the peak of the R-wave and end-
systole as the end of the T-wave. All analyses were performed as described in 
international consensus guidelines referred to above128. Only analysis of those 
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parameters examined as part of this thesis are described in this chapter. For 
assessment of intra-observer variation, 10 scans were chosen for repeat analysis 
by the author. This happened more than one month following their first analysis. 
4.4.2.2.1  Fractional area change  
Fractional area change (FAC) was calculated from a standard apical 4-chamber 
(A4C) TTE view. The RV endocardium was traced from the annulus, along the free 
wall to the apex, and then along the interventricular septum back to the annulus. 
Care was taken to trace the free wall beneath trabeculations (Equation 13 and 
Figure 34). 
                                  
                                         
                        
  
Equation 13. Fractional area change 
 
 
Figure 34. Right ventricular fractional area change (FAC) 
Contouring of right ventricle during A) End-systolic area (ESA) and B) End-diastolic area (EDA). 
Area in A) = 8.8cm2 Area in B) = 17.2cm2 giving FAC of 48.8%. 
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4.4.2.2.2  Tricuspid annular plane systolic excursion 
Tricuspid annular plane systolic excursion (TAPSE) was obtained from a standard 
A4C TTE view by placing an M-mode cursor across the lateral tricuspid annulus 
and measuring the amount of longitudinal motion of the annulus at peak systole 
(Figure 35). 
 
Figure 35. Tricuspid annular plane systolic excursion (TAPSE) 
A) Apical 4-chamber view B) M-mode cursor placed across lateral tricuspid annulus with TAPSE of 
2.2cm. 
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4.4.2.2.3  S' wave velocity at the tricuspid annulus (S' wave) 
S' wave was obtained by pulsed Doppler analysis of the tricuspid annulus or basal 
segment of the RV free wall from an A4C TTE view (Figure 36A). Velocity profiles 
were produced for the whole cardiac cycle and S' taken as the highest systolic 
velocity (Figure 36B). Care was taken not to over gain the Doppler envelope. 
 
Figure 36. S' wave velocity of the tricuspid annulus (S' wave) 
A)Pulsed tissue Doppler of apical 4-chamber view B) Velocity profile with region of interest 
placed at lateral tricuspid annulus. S' wave of 9cm/s. 
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4.4.2.2.4  Inferior vena cava diameter 
Right atrial pressure was estimated from inferior vena cava (IVC) diameter and 
collapse (Figure 37A). An M-mode cursor was placed across the IVC with 
diameter measured at end expiration and following a 'sniff' (Figure 37B). Care was 
taken to ensure that any change in diameter was not the IVC translating in to 
another plane. An IVC diameter of ≤2.1cm that collapses >50% with a sniff was 
interpreted as reflecting a RAP of 3mmHg. An IVC diameter of ≥2.1cm that 
collapses >50% with a sniff, or an IVC diameter of ≤2.1cm that collapses <50% 
with a sniff, was interpreted as of 8mmHg. An IVC diameter of >2.1cm that 
collapses <50% with a sniff was interpreted as 15mmHg128.  
 
Figure 37. Inferior vena cava (IVC) diameter and collapse 
A) Sub-costal view with IVC B) M-mode cursor placed across IVC with measurement during end 
expiration and during sniff. IVC diameter at end expiration = 1.2cm, IVC diameter during sniff = 
0.4cm (collapse of >50%) giving a right atrial pressure of 3mmHg. 
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4.4.2.2.5  Pulmonary artery systolic pressure (PASP) 
Continuous wave Doppler was used to assess the tricuspid regurgitant jet (TRJ) 
velocity. The TRJ was interrogated from all available views and measurements 
taken from the signal with the highest velocity (Figure 38A & B). Pressure gradient 
across the tricuspid valve was estimated with the simplified Bernoulli equation 
(Equation 14). With the addition of estimated right atrial pressure (as estimated 
from Inferior Vena Cava diameter), RVSP was determined (Equation 14). In the 
absence of RV outflow tract or pulmonary valve obstruction, this is widely 
considered an estimate of pulmonary artery systolic pressure (PASP). 
 
Figure 38. Tricuspid regurgitant jet (TRJ) 
A) RV inflow view (right ventricle at top right of image and right atrium at bottom right of image 
with tricuspid valve in middle) B) Continuous wave Doppler interrogation of tricuspid valve. Peak 
TRJ velocity = 3.27m/s giving a gradient of 42.8mmHg. 
 
                                                                      
Equation 14. Right Ventricular Systolic Pressure/ Pulmonary artery systolic pressure (PASP) 
TRJ = Tricuspid regurgitant jet, RAP = Right Atrial Pressure. 
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4.4.2.2.6  Pulmonary artery acceleration time (PAAT) 
Pulmonary artery acceleration time (PAAT) was obtained from pulsed Doppler 
analysis of the pulmonary artery. PAAT was quantified as the interval between 
onset of flow and peak flow (Figure 39A & B). 
 
Figure 39. Pulmonary artery acceleration time (PAAT) 
A) Parasternal short axis view of right ventricular outflow track, pulmonary valve and pulmonary 
artery B) Velocity profile with PAAT measurement of 100ms. White arrow indicates the gradient 
from onset of flow to peak flow with PAAT measured as the time (x-axis) between the points. 
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4.5  Two dimensional speckle tracked strain assessment of 
right ventricular function 
4.5.1 Introduction 
As described in section 1.3.2.3.5, pg 56, speckled tracked strain echocardiography 
allows for angle independent assessment of RV deformation parameters and has 
been shown to overcome some of the difficulties associated with other 
echocardiographic measures of RV function. RV strain has been advocated as a 
less load-dependent method of assessing RV function and may yield further 
information regarding contractility following lung resection270. This investigation will 
describe the changes in RV global peak longitudinal strain (RV-GPLS, 
incorporating the free wall and the septum) and RV free wall peak longitudinal 
strain (RV-FWPLS) following lung resection.  
Previous work in other populations has shown these two parameters have a strong 
association with RVEFCMR and that they have excellent predictive capability for 
poor RV function. This study will seek association of RV-GPLS and RV-FWPLS 
with RVEFCMR in this population and if evident, assess their predictive capability for 
poor RV function as determined by RVEFCMR. 
4.5.2 Methods 
4.5.2.1  Image acquisition 
As described in section 4.4.2.1, pg 149, apical four-chamber views were obtained 
using conventional two-dimensional grey scale echocardiography at a frame rate 
of 60-80 frames per second. Four consecutive cardiac cycles were recorded and 
care was taken to ensure the best visualisation of the RV, allowing accurate 
delineation of the endocardial border. 
4.5.2.2  Image analysis 
Off-line analysis of speckle tracked strain of the RV was performed on randomised 
and anonymised images using semi-automated, proprietary analysis software 
(EchoPAC, GE Healthcare, Chicago, United States). Analysis of all images was 
performed by the author. For assessment of inter-observer variability, Dr Piotr 
Sonecki (Consultant cardiologist with a special interest in imaging), agreed to the 
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dual reporting of eight randomised and anonymised scans. For assessment of 
intra-observer variability, 19 (one quarter of the total performed) randomised and 
anonymised scans were selected for repeat analysis more than one month 
following their first analysis. Where there was any discrepancy in results of 
imaging (different strain results or inability to obtain global and/or free wall strain 
due to image quality), these scans were reviewed by both the author and Dr 
Sonecki to assess potential causative factors. Where there was an ongoing 
disagreement, Dr Sonecki had the casting vote. 
From A4C echocardiographic video loops, the software automatically stops at end 
systole by automatic identification of the end of the T-wave. The region of interest 
(ROI) of the RV was defined by tracking the endocardial border of the free wall 
and septum (Figure 40A, pg 158). The ROI of the RV consists of six segments and 
the width was adjusted to fit the wall thickness. Appropriate tracking was signified 
by the software (Figure 40B) and segments with insufficient tracking were 
excluded. The endocardial border was re-drawn if there were concerns about 
contouring and it looked as though the segment had been inappropriately 
excluded. The process was then repeated for the RV free wall only (Figure 41A & 
B, pg 159). Following this process and approval of each of the segments, a strain 
output with strain curves was produced by the software (Figure 40C and Figure 
41C). RV-GPLS was obtained by averaging values for six segments and RV-
FWPLS was obtained by averaging values for the three free wall segments. In the 
case of segment exclusion due to inability to achieve adequate tracking, values 
were averages of the remaining segments. 
. 
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Figure 40. Two dimensional right ventricular global peak longitudinal strain (RV-GPLS) 
analysis 
A) Contouring of RV endocardial border B) Region of interest with approval of segment tracking 
C) Strain output with longitudinal strain curves. RV-GPLS value of -21.5%. Curves illustrate strain 
in each segment (coloured lines) and globally (dashed line). 
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Figure 41. Two dimensional right ventricular free wall peak longitudinal strain (RV-FWPLS) 
analysis 
A) Contouring of RV free wall endocardial border B) Region of interest with approval of segment 
tracking C) Strain output with longitudinal strain curves. RV-FWPLS value of -27.3%. Curves 
illustrate strain in each segment (coloured lines) and for entire free wall (dashed line). 
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4.6  Biomarkers of myocardial dysfunction 
4.6.1 Introduction 
B-type natriuretic peptide (BNP) is released in response to myocardial stretch and 
high-sensitivity troponin T (hsTnT) is released in response to cardiac myocyte 
necrosis. Elevation of BNP and hsTnT has been demonstrated in a number of 
clinical conditions with RV dysfunction and failure154, 155, 271-273. Following lung 
resection, peri-operative BNP elevation is associated with the extent of resection 
and post-op complications, including atrial fibrillation (AF)274-278. Furthermore, 
troponin rise is associated with early mortality in the same population279. In an 
non-cardiac surgery setting, peri-operative BNP and troponin are associated with 
post-op complications and long-term mortality152, 275, 280-284. 
BNP and hsTnT reflect myocardial injury although not specific to the RV. The 
author hypothesises that elevation of BNP and hsTnT following lung resection, in 
the absence of LV disease, would signal RV dysfunction. 
4.6.2 Methods 
4.6.2.1  Biomarker sample handling 
Routine care for patients undergoing lung resection involves placement of an 
arterial cannula; this allows continuous assessment of haemodynamic variables 
and sampling without need for further venepuncture. Where possible blood for 
biomarker analysis was sampled from this arterial cannula along with bloods 
required for normal clinical care. When the arterial cannula had been removed as 
part of the patients care, a peripheral venous sample was obtained. Blood 
sampling was performed pre-op (prior to induction of anaesthesia), immediately 
post-op (once extubated in recovery area) and then on the mornings of POD 1 and 
2, and at 2-month follow-up. Twenty millilitres (ml) of blood were collected using 
BD Vacutainer® blood collection tubes with 2x 4ml Lithium Heparin (green top) 
tube, 1x3.5ml Serum Sep Clot Activator (yellow top) tube, 1x4ml EDTA (purple 
top) tube and 1 x 1.8ml Citrate (Blue top) tube. BNP and hsTnT were measured as 
described below, the remaining samples were immediately centrifuged at room 
temperature and stored at -80oC in the research laboratory of the Golden Jubilee 
National Hospital. 
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4.6.2.2  B-type natriuretic peptide measurement 
BNP was measured immediately using the Alere Triage® system (Alere, 
Stockport, UK)285. This is a point of care fluorescence-based immunoassay 
system. The Alere CardioRenal® panel was used which allows rapid 
measurement of BNP and neutrophil gelatinase-associated lipocalin (NGAL). Prior 
to commencing recruitment, training for all members of the research team was 
provided by Ms Janice McIvor (Alere specialist support team). The provided 
transfer pipette was used to place a sample of EDTA plasma in to the test device 
and the manufacturers guidelines were followed throughout. BNP was expressed 
as ng/ml and coefficient of variation was assessed seven times during the study by 
using high and low reference frozen controls for every batch (25) of test devices. 
4.6.2.3  High sensitivity Troponin T measurement 
hsTnT assays were processed with routine clinical samples in the biochemistry 
laboratories at the Golden Jubilee National Hospital under the supervision of Dr 
Frank Findlay (consultant clinical scientist, biochemistry). hsTnT was determined 
by enhanced immunoturbidimetric assay run on a Roche Cobas 6000e analyser 
(Roche, Basel, Switzerland).  
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4.7  Generic results 
The results described here apply to the cohort recruited for the imaging and 
biomarker studies described above. Results for the specific imaging and biomarker 
studies are detailed in chapters 5, 6, 7 and 8. 
4.7.1 Patient demographics and operative characteristics 
From September 2013 to September 2014 28 patients were recruited to the study 
by the author and his co-investigator (Dr Alex Arthur, clinical research fellow) 
(Figure 42).  
 
Figure 42. Study Recruitment consort diagram 
 
One patient (RV19) was excluded from further participation in the study due to the 
unexpected discovery of an embedded piece of ferromagnetic material in their 
chest wall during pre-op scanning, meaning no usable images of the heart could 
be obtained. There were no clinical sequelae, but as they were unable to take any 
part in the main study, this patient was removed from all further analyses. Baseline 
demographic data on the remaining 27 patents are presented in Table 17, pg 164. 
44 Patients Approached 
Following Identification by Lead Surgeon 
 
(Sep 2013 - Sep 2014) 
16 Patients Excluded 
1 Procedure change to pneumonectomy pre-recruitment 
2 Claustrophobia 
1 CMR unavailability 
12 Patient Refusal 
 
28 Patients Recruited 
(RV1-RV28) 
27 Participants 
1 Patient Excluded (RV 19) 
Contraindication to MRI discovered 
post-recruitment, excluded from 
ongoing participation in study  
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Twenty-six patients underwent lobectomy or bilobectomy (incorporating the right 
middle lobe); one patient required unplanned intra-operative conversion to 
pneumonectomy and is included in all analyses. Sensitivity analysis was 
performed without this patient for the primary outcome and is described in section 
5.3.1, pg 180. The majority of participants had a diagnosis of primary lung cancer 
and operative characteristics are detailed in Table 18, pg 165. 
Epidural placement was possible in the majority of patients (24, 85.1%) and this 
was usually continued until POD 3. No patients required intensive care admission 
post-operatively and median high dependency unit stay was two days (47.2 
hours). Median hospital stay was 8 days. One patient had a prolonged air leak 
requiring additional intercostal catheter drainage and spent three weeks in 
hospital. Twenty-five patients attended for 2 month follow-up; one patient was sick 
at another hospital with a broncho-pleural fistula and the other declined to attend. 
Only two patients developed post-op arrhythmia; both of whom developed atrial 
fibrillation (AF), one on POD 1 and the other on POD 7. Both responded to 
medical management (amiodorone and digoxin respectively). Post-op clinical data 
is summarised in Table 19, pg 166. 
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Patient Demographics n Descriptive Statistics 
 Age (years) 27 67.0 (59.0,74.0) 
 Female Sex  27 17 (62.9%) 
 Height (cm) 27 163.3 (9.0) 
 Weight (kg) 27 69.9 (13.4) 
 BMI (kgm-2) 27 26.1 (3.9) 
    
Smoking Status   
 Current Smoker  13 (46.4%) 
 Ex-Smoker  12 (42.9%) 
 Never Smoked  2 (7.1%) 
 Pack Years History 25 38.2 (21.7) 
    
Pre-operative Pulmonary Function   
 SaO2 on Air (%) 27 96.4 (1.7) 
 FEV1 (L) 27 1.9 (1.6, 2.4) 
 FEV1/FVC (%) 27 64.1 (14.8) 
 % Predicted FEV1 (FEV1%) 27 87.5 (25.1) 
 TLCO (ml/kPa/min) 27 5.2 (1.7) 
 % Predicted TLCO (TLCO%) 27 66.6 (15.2) 
    
Co-morbidities   
 History of Cancer 27 7 (25.9%) 
 COPD 27 6 (22.2%) 
 Hypertension 27 9 (33.3%) 
 IHD 27 6 (22.2%) 
 Diabetes Mellitus 27 0 
 PVD 27 5 (18.5%) 
 Obesity 27 2 (7.4%) 
 Alcoholism 27 0 
    
Thoracoscore (%) 27 0.7 (0.5, 0.8) 
    
ASA score 27  
  1  0 
  2  2 (7.4%) 
  3  25 (92.6%) 
  4  0 
  5  0 
Table 17. Baseline demographic data 
Values are number (%), mean (SD) or median (IQR). n represents number of patients available for 
each parameter. BMI = body mass index, SaO2 = oxygen saturation, FEV1 = forced expiratory 
volume in 1 second, FVC = forced vital capacity, TLCO = transfer factor for carbon monoxide, 
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COPD = chronic obstructive pulmonary disease, IHD = ischaemic heart disease, PVD = peripheral 
vascular disease, ASA = American Society of Anesthesiologists. 
Characteristic n Descriptive Statistics 
Resection Type 27  
 Pneumonectomy  1 (3.7%) 
 Lobectomy  22 (81.5%) 
 Bilobectomy  4 (14.8%) 
 Right Sided Procedure  17 (63%) 
 Pulmonary Segments Resected  5 (3, 5) 
 ppoFEV1 % 27 67.66 (20.8) 
 ppoTLCO% 27 51.2 (11.6) 
    
Pathology 27  
 Primary Lung Cancer  24 (88.9%) 
 Other Malignant  1 (3.7%) 
 Benign Disease  2 (7.4%) 
    
Lung Cancer Staging 24  
Stage TNM Subset   
1A 
T1a N0  5 
T1b N0  4 
1B T2a N0  9 
2A T2b N0  2 
2B T2b N1  1 
3A 
T2a N2  1 
T3 N2  1 
T4 N0  1 
    
Volatile Anaesthetic Agent 27  
 Desflurane  1 (3.7%) 
 Isoflurane  3 (11.1%) 
 Sevoflurane  23 (85.2%) 
    
Duration   
 Duration of surgery (mins)  146 (116, 169) 
 Duration of OLV (mins)  56 (48, 84) 
Table 18. Operative data 
Values are number (%), mean (SD) or median (IQR), n represents number of patients available for 
each parameter. ppo = predicted post-op , FEV1 = forced expiratory volume in 1 second, TLCO = 
transfer factor for carbon monoxide, OLV = one lung ventilation. 
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 Characteristic n Descriptive Statistics 
Analgesia 27  
 Epidural  23 (85.1%) 
  Epidural discontinued operative day   1 (4.3%) 
  Epidural discontinued POD 2   2 (8.7%) 
  Epidural discontinued POD 3   18 (78.3%) 
  Epidural discontinued POD 4   2 (8.7%) 
 Paravertebral Infusion and PCA (PV & PCA)  4 (14.8%) 
  PV & PCA discontinued POD 1   1 (25%) 
  PV & PCA discontinued POD 2   1 (25%) 
  PV & PCA discontinued POD 3   2 (50%) 
    
Fluid administration (L)   
 Intra-op 27 0.9 (0.4) 
 Operative day (to 07:59 POD 1) 27 1.7 (1.4, 2.2) 
 to 07:59 POD 2 17 2.3 (2.0, 2.5) 
 to 07:59 POD 3 6 1.9 (1.4, 2.7) 
 Cumulative fluid administration by morning POD 2 17 5.0 (4.3, 5.2) 
    
HDU Fluid Balance (L)   
 Operative day (to 07:59 POD 1) 27 1.0 (0.6, 1.4) 
 To 07:59 POD 2 17 0.1 (-0.5, 0.7) 
 To 07:59 POD 3 6 -0.6 (-1.2, 0.3) 
 Cumulative fluid balance morning POD 2 17 1.1 (0.4, 1.8) 
    
Vasoconstrictor required during HDU admission 27  
 Nor-adrenaline  9 (33.3%) 
    
Arrhythmia   
 Atrial Fibrillation 2 2 (7.4%) 
    
Follow Up   
 Number attending for 2 month follow up 25 25 
 Time from operative day to follow up (Days) 25 57 (14.0) 
    
Length of stay   
 HDU (Hours) 27 47.2 (29.2, 53.5) 
 Hospital (Days) 27 8 (7, 11) 
Table 19. Post-operative clinical data 
Values are number (%), mean (SD) or median (IQR [range]). No patients required Nor-adrenaline 
at the time of MRI scanning on POD 2. cumulative fluid balance and cumulative fluid 
administration on the morning of POD 2 is for those patients still in HDU only. POD = post-op day, 
PCA = Patient controlled analgesia, HDU = high dependency unit. 
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From 1st January 2013 to 31st December 2014, 1169 patients underwent lung 
resection at the Golden Jubilee National hospital. This period encompassed the 
complete study duration. Although the cohort recruited was selected from patients 
presenting for surgery under a single surgeon, Table 20 illustrates no significant 
differences in the age, sex, operative side, pulmonary function and Thoracoscore 
of those participating in the study and those not taking part.  
Characteristic 
Study 
Participants 
n=27 
 
Non Study 
Participants 
n=1142 
 p value 
Age 67.0 (59.0,74.0)  67 (59.0, 73.0)  0.956* 
Female Sex 17 (62.9%)  622 (54.5%)  0.381† 
Right Sided 
Procedure 
17 (62.9%)  688 (60.2%)  0.775† 
FEV1 1.9 (1.6, 2.4)  
2.0 (1.6, 2.6) 
(n=555) 
 0.455* 
FEV1%  86.0 (66.5, 104.5)  
88.0 (73.8, 102.0) 
(n=558) 
 0.816* 
TLCO% 65.0 (55.0, 75.0)  
69.0 (57.0, 83.0) 
(n=494) 
 0.439* 
Thoracoscore 0.7 (0.5, 0.8)  
0.9 (0.4, 2.0) 
(n=944) 
 0.069* 
Table 20. Characteristics of study participants and non study participants undergoing lung 
resection at the Golden Jubilee National Hospital between Jan 2013 and Dec 2014 
Values are number (%) and median(IQR). Where the dataset was incomplete,(n) represents the 
number of patients with data available. *Mann-Whitney U-test, † Chi-squared test. 
 
4.7.2 Functional status, quality of life and six-minute walk test 
distance 
Functional status and quality of life was assessed pre-op, at 2-months and 1 year 
post-op. All patients completed the self-reported questionnaire pre-op. All patients 
presenting for 2-month follow-up (92.6%) completed the questionnaire and 22 
participants (81.5%) returned the postal questionnaire at 1 year. Mean (SD) time 
to 2-month follow-up was 55.9 (13.1) days. 
4.7.2.1  Functional status 
Self reported functional status was assessed in three domains. Using the World 
Health Organisation performance status (WHO-PS), there is a trend towards a 
decrease in the proportion of patients who were WHO-PS zero (fully active) at 2-
months (p=0.09, McNemar's test [MT]). There is no change in the proportion who 
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were WHO-PS zero at 1 year (p=0.180, MT) (Table 21, pg 169 and Figure 43, pg 
170). Medical Research Council dyspnoea scale (MRC-DS), showed a trend 
towards an increase in the proportion of patients who were limited by their 
breathlessness (MRC-DS ≥3) at 2-months (p=0.063, MT). There was an increase 
in the proportion who were limited by breathlessness from 7.4% pre-op to 27.3% 
at 1-year (p=0.031, MT, Table 21 and Figure 44, pg 170). New York Heart 
Association (NYHA) classification showed no change in the proportion of patients 
who were NYHA 1 (no symptoms and no limitations) at 2-months or at 1 year 
(p=0.754 and p=0.625 respectively, both MT) (Table 21 and Figure 45, pg 171). 
There was no association between pre-op %predicted FEV1 (FEV1%), pre-op 
%predicted TLCO (TLCO%), pre-op FEV1/FVC ratio and pre-op WHO-PS, MRC-
DS and NYHA score (p>0.161 for all, Spearman's correlation coefficient). There 
was association between ppoTLCO% and WHO-PS at 2-months (r=-0.441, 
p=0.027, Spearman's correlation coefficient). There was association between 
ppoFEV1% and both, MRC-DS and NYHA class at one year (r=-0.516, p=0.020 
and r=-0.556, p=0.009 respectively, both Spearman's correlation coefficient). 
There was no association between respiratory variables and functional outcome at 
other time points (p>0.075 for all, Spearman's correlation coefficient). 
Six minute walk testing (6MWT) was performed pre-op and at 2-months. Two 
patients did not have a 6MWT performed pre-operatively; this was as a result of 
one patient declining and the other because of unavailability of a safe area for 
testing to take place. There was no change in the median [IQR] distance walked 
from pre-op (412m [360, 486]) to 2-months (420m [362.5, 473.5], p=0.639, 
Wilcoxon rank sum test). Although there was no change in median distance 
walked, there was a decrease in the number of patients who could complete the 
test. Twenty five patients performed testing pre-op. At 2-months, 25 patients 
attended for follow-up but four declined walking due to shortness of breath. Seven 
participants had their 6MWT drop by more than 28m (the MICD for 6MWT in 
COPD, see section 4.2.5.3, pg 135). Four patients had an increase in walking 
distance by more than the MID accounting for the lack of change in median 
distance. 
There was no association between pre-op FEV1%, TLCO%, FEV1/FVC ratio and 
pre-op 6MWT distance (p>0.506, Pearson's correlation coefficient for both). There 
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was no association between ppoFEV1%, ppoTLCO% and 6MWT distance at 2-
months (p>0.935, Pearson's correlation coefficient). There was no difference in the 
ppoFEV1% and ppoTLCO% between those patients who had a significant 
reduction in their 6MWT distance (by >28m or were unable to walk) and those who 
were able to walk the same distance or further (p>0.765, Mann-Whitney U-test).  
Functional Status Descriptive Statistics 
 Time Point 
 Pre-op 2-Months 1 Year 
 n=27 n=25 n=22 
 WHO-PS    p value  p value 
 0 17 (63.0%) 10 (40.0%) 
0.092* 
8 (36.4%) 
0.180* 
 1 7 (25.9%) 10 (40.0%) 13 (59.1%) 
 2 2 (7.4%) 5 (20.0%) 1 (4.5%) 
 3 1 (3.7%) 0 0 
 4 0 0 0 
       
 
MRC dyspnoea 
scale 
     
 1 9 (33.3 %) 6 (24.0%) 
0.063* 
6 (27.3%) 
0.031* 
 2 16 (59.3%) 13 (52.0%) 10 (45.5%) 
 3 1 (3.7%) 4 (16.0%) 5 (22.7%) 
 4 1 (3.7%) 1 (4.0%) 0 
 5 0 1 (4.0%) 1 (4.5%) 
       
 
NYHA 
classification 
     
 I 9 (33.3%) 7 (28.0%) 
0.754* 
5 (22.7%) 
0.625* 
 II 17 (63.0%) 16 (64.0%) 14 (63.6%) 
 III 1 (3.7%) 2 (8.0%) 3 (13.6%) 
 IV 0 0 0 
Table 21. Self reported functional Status 
Values are number (%). WHO-PS = World Health Organisation performance status. MRC = Medical 
Research Council. NYHA = New York Heart Association. * = McNemar's Test compared to pre-op. 
For WHO performance status (PS) comparison is made between proportion PS 0 and proportion PS 
1, 2, 3 or 4, For MRC dyspnoea scale (MRC) comparison is made between proportion MRC 1 & 2 
and proportion MRC 3, 4 or 5, for NYHA classification (NYHA) comparison is made between 
proportion NYHA 1 and proportion NYHA 2, 3 or 4. Definitions of each score as per appendix 3. 
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Figure 43. World Health Organisation (WHO) Performance Status 
Percentage of participants in each performance status category at each time point. Definitions 
as per Appendix 3. 
 
 
 
Figure 44. Medical Research Council (MRC) Dyspnoea Scale 
Percentage of participants in each group at each time point. Definitions as per Appendix 3. 
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Figure 45. New York Heart Association (NYHA) functional classification 
Percentage of study participants reporting any problem in each class at each time point. 
Definitions as per Appendix 3. 
 
4.7.2.2 Quality of life 
Quality of life was assessed using the EuroQOL 5 domain score (EQ5D). This 
score allows creation of a health utility score from the unique responses in each 
domain. There were no changes in the health utility score over the period of the 
study (p=0.228, Friedman's test). When examining the individual domains of the 
EQ5D score (Table 22, pg 173 and Figure 46, page 172) there is a trend towards 
an increase in the proportion of patients reporting problems with their mobility 
(EQ5D>1) at 2-months (p=0.063, MT). There is an increase in the proportion of 
patients describing problems with their mobility and self-care (EQ5D>1) at one 
year (p=0.031 and p=0.016 respectively, both MT). There were no changes in the 
proportions reporting problems (EQ5D>1) in the other domains (usual activities, 
pain/discomfort and anxiety/depression) at either 2-months or at one year 
(p>0.125 for all, MT). 
The global health score is obtained by asking the patient to grade their 'global' 
health from 0-100. This changed over the course of the study (p=0.011, one way 
repeated measures ANOVA) with a significant deterioration at 2-months and one 
year (p=0.044 and 0.012 respectively, both paired samples t-test).  
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There was no association between pre-op FEV1%, pre-op TLCO%, pre-op 
FEV1/FVC ratio and pre-op health utility score or pre-op global health score 
(p>0.076 for all, Pearson's correlation coefficient). There was no association 
between these pre-op pulmonary function results and any of the individual 
domains of EQ5D pre-operatively (p>0.095 for all, Spearman's correlation 
coefficient). 
There was no association between ppoTLCO%, ppoFEV1% and health utility score 
or global health score, both at 2-months and one year (p>0.54 for all, Pearson's 
correlation coefficients). There was no association between the predicted post-op 
pulmonary function results and any of the individual domains of EQ5D at 2-
months. There was negative association between ppoFEV1% and both mobility 
(r=-0.531, p=0.013, Spearman's correlation coefficient) and usual activities (r=-
0.434, p=0.049, Spearman's correlation coefficient) at one year. There was no 
association between ppoFEV1% and the remaining domains (p>0.152 for all, 
Spearman's correlation coefficient). There was no association between 
ppoTLCO% and any of the individual domains of EQ5D at one-year. (p>0.658 for 
all, Spearman's correlation coefficient). 
 
Figure 46. EuroQol 5 domain (EQ5D) responses 
Percentage of study participants reporting any problem in each of the five 'EQ5D' domains at 
each time point. * = significant difference to pre-op (McNemar's test). 
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EQ5D Quality of 
Life domain 
Descriptive Statistics 
 Time Point 
 Pre-op 2-Months 1 Year 
 n=27 n=25 n=22 
Mobility   p value*  p value* 
 1 18 (66.7%) 13 (52.0%) 
0.063# 
9 (40.9%) 
0.031# 
 2 7 (25.9%) 8 (32.0%) 6 (27.3%) 
 3 1 (3.7%) 4 (16.0%) 7 (31.8%) 
 4 1 (3.7%) 0 0 
 5 0 0 0 
Self-Care      
 1 26 (96.3%) 21 (84.0%) 
0.125# 
15 (68.2%) 
0.016# 
 2 1 (3.7%) 4 (16.0%) 7 (31.8%) 
 3 0 0 0 
 4 0 0 0 
 5 0 0 0 
Usual Activities     
 1 15 (55.6%) 9 (36.0%) 
0.125# 
10 (45.5%) 
0.453# 
 2 10 (37.0%) 9 (36.0%) 5 (22.7%) 
 3 2 (7.4%) 6 (24.0%) 7 (31.8%) 
 4 0 0 0 
 5 0 1 (4.0%) 0 
Pain / Discomfort     
 1 12 (44.4%) 9 (36.0%) 
0.453# 
10 (45.5%) 
0.999# 
 2 10 (37.0%) 12 (48.0%) 8 (36.4%) 
 3 2 (7.4%) 4 (16.0%) 4 (18.2%) 
 4 3 (11.1%) 0 0 
 5 0 0 0 
Anxiety / Depression     
 1 18 (66.7%) 19 (76.0%) 
0.453# 
16 (72.7%) 
0.727# 
 2 7 (25.9%) 5 (20.0%) 3 (13.6%) 
 3 2 (7.4%) 1 (4.0%) 3 (13.6%) 
 4 0 0 0 
 5 0 0 0 
       
Health Utility 
Score (0-1) 
0.8 (0.7, 
1.0) 
0.8 (0.7, 
0.9) 
0.072† 
0.8 (0.6, 
1.0) 
0.446† 
Global Health 
Score (0-100) 
79.6 (15.1) 77.2 (12.2) 0.044‡ 74.3 (17.1) 0.012‡ 
Table 22. Self reported quality of life 
Values are number (%), mean (SD) or median (IQR). EQ5D = EuroQOL 5 Dimension. * = comparison 
to pre-op. # = McNemar's Test compared to pre-op (all are comparison of proportion quality of 
life (QOL) score 1 with proportion QOL score 2, 3, 4 or 5). † = Wilcoxon rank sum test compared 
to pre-op, ‡ = paired t-test compared to pre-op. Definitions of each level as per appendix 3. 
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4.7.3 Discussion 
This study recruited 27 patients to examine the RV response to lung resection. 
The study protocol as a whole was well tolerated with 25 patients (92.6%) 
attending for 2-month follow-up and 22 patients (81.5%) returning postal follow-up 
at one year. The cohort recruited to this study were representative of all patients 
undergoing surgery at the Golden Jubilee National Hospital during the study 
period.  
A deterioration in functional capacity following lung resection is demonstrated. This 
was determined subjectively by questionnaire (MRC-DS and EQ-5D) and 
objectively by use of the 6MWT. An MRC dyspnoea scale of three, four or five 
corresponds to severe disability as a result of dyspnoea and this study has 
demonstrated a trend towards an increase in the proportion of patients disabled by 
dyspnoea at 2-months and an increase in the proportion disabled by dyspnoea at 
one year258. Although there was no change in the median 6MWT distance at 2-
months, the proportion who declined to walk as a result of dyspnoea increased. 
The deterioration in functional capacity following lung resection has previously 
been well described in this population, with work documenting an increase in 
subjective dyspnoea scores24, 35. Deterioration in exercise capacity following 
surgery has been demonstrated with cardiopulmonary exercise testing286, 287 and 
shuttle walk testing288. In a mixed pneumonectomy and lobectomy cohortO, Win et 
al. demonstrated a deterioration in shuttle walk test distance at 1-month, 3-months 
and 6-months following lung resection288. The deterioration in distance walked was 
larger in the pneumonectomy group compared to the lobectomy group and there 
was evidence of some recovery in distance walked at 6-months.  
The current investigation demonstrates a decline in quality of life following lung 
resection. A score of one in an EQ5D domain describes "no problems" within that 
domain, with a score of two corresponding to "slight problems" and a score of five 
corresponding to being "unable" to perform that function. This study also 
demonstrates there is a decrease in the proportion of participants who had no 
problems with mobility or self-care at one year. The scores in individual domains 
can be used to calculate a summary score which is based on population 
                                            
O 110 consecutive patients prospectively recruited, 73 lobectomy and 37 pneumonectomy. 
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responses to the same questions. This shows that despite the deterioration in 
mobility and self-care, there is no change in the summary health-utility score. 
There is a small but significant change in global health score by POD 2 and a 
larger change by one year. This score is determined from a visual analogue scale 
with the respondent recording their self-rated health on a vertical scale with the 
endpoints labelled "best imaginable health state" and "worst imaginable health 
state (see appendix 4)." The change by one year (79.6 to 74.3) is smaller than the 
minimally important clinical difference in this measure of seven289. This 
deterioration although statistically significant, is therefore of the magnitude that 
would not be considered clinically relevant290. This decline in health related quality 
of life has been documented before, with previous work showing a deterioration in 
physical functioning, mental health, social functioning and pain22, 23, 35, 39, 291-293. 
Many studies suggest ongoing problems years following lung resection22, 24, 291.  
As described in section 1.1.4, pg 23, the inconsistent association between 
pulmonary function and post-op morbidity (functional capacity and quality of life) 
has been previously described. This study demonstrates negative association 
between ppoTLCO% and WHO-PS at 2-months. Additionally there is negative 
association between ppoFEV1% and both, MRC-DS and NYHA class at one year. 
There is no association between pulmonary function and both, 6MWT distance 
and quality of life.  
The lack of consistent association between pulmonary function and both, 
functional capacity and quality of life suggests that other factors, such as 
cardiovascular function, may influence these changes following lung resection. 
4.7.3.1  Strengths and weaknesses 
The study protocol was well tolerated with only one patient who was able to return 
at 2-months, declining follow-up. Return of postal follow-up questionnaires at one 
year was above 80%. 
The multiple comparisons (21 for comparison of pulmonary function and functional 
status outcomes, 49 for comparison of pulmonary function and quality of life 
outcomes) and small sample size mean the findings described are at high risk of 
type I error. 
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4.8  Conclusion 
This chapter provides generic results for the studies within this thesis examining 
the RV response to lung resection. The study protocol was well tolerated with only 
one patient declining follow-up at 2-months. Twenty-eight patients were recruited 
to the study but as a result of a contraindication to CMR imaging (implanted 
ferromagnetic material), one patient was excluded from ongoing trial participation. 
One patient required intra-operative conversion to pneumonectomy and is 
included in all results. 
The findings regarding declining functional status are confirmatory of previous 
work in this patient group. In this cohort there is a suggestion of deterioration in 
functional status, with an increase in the proportion with disabling dyspnoea and a 
reduction in the number of participants able to complete the 6MWT. There was 
deterioration in the mobility and self-care domains of quality of life scoring at one 
year.
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Chapter 5  Cardiovascular Magnetic Resonance 
Results 
5.1  Introduction 
This chapter describes the results of the cardiovascular magnetic resonance 
(CMR) imaging component of this study. Firstly, reproducibility of CMR 
assessment of RV function is reported. Changes in RV and LV function over time, 
along with changes in ventricular volumes are described next. The association of 
pre-op and intra-op variables with RV function will then be assessed. Finally, on an 
exploratory basis, comparison of RV function with post-op outcomes is made.  
CMR imaging was well tolerated with all patients completing the scan protocol pre-
operatively; twenty-two (81.5%) on post-op day (POD) 2 and 24 (88.9%) at 2-
months. Due to an administration error, one participant did not have short axis 
images obtained pre-operatively so it was not possible to calculate ventricular 
volumes meaning 26 patients are included in the analysis at this time point. Of the 
five patients unable to complete the protocol on POD 2; three declined, one was 
unwell with persistent air-leak requiring additional inter-costal catheter drainage 
and CMR transfer was deemed unsafe. A final patient had an epidural catheter in-
situ that was CMR incompatible resulting in imaging being contraindicated294. Of 
the three patients unable to complete the protocol at 2-months, one declined, one 
was within six weeks of cataract surgery (a contraindication to CMR imaging) and 
the third was unwell in another hospital with broncho-pleural fistula and was 
unable to attend for imaging. This gave 72 scans for dual reported analysis. 
 
5.2  Assessment of reproducibility 
5.2.1 Inter and intra-observer variation of ventricular volume 
measurements 
The measured parameters of RV end diastolic volume (RVEDV) and end systolic 
volume (RVESV) showed good inter-observer variation with intraclass correlation 
coefficients (ICC) for agreement of 0.86 and 0.84 respectively (Figure 47 and 
Table 23, pg 178). There was also good intra-observer variation for RV volumes 
with ICCs > 0.92 (Table 24, pg 179). Left ventricular volumes showed better inter-
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observer and intra-observer variation than RV volumes, with ICCs >0.87 and 
>0.97 respectively. 
 
 
Figure 47. Association between observer1 and observer 2 for RV variables 
Solid line is the line of identity. Reproducibility statistics as per Table 23, pg 178. RV = right 
ventricle, EDV = end diastolic volume, ESV = end systolic volume, SV = stroke volume, EF = 
ejection fraction. 
 
Inter-observer variation (n = 72) 
  CV (%) ICC Agreement (95% CI) 
RV 
EDV (ml) 9.97 0.86 (0.56, 0.94) p<0.001 
ESV (ml) 12.23 0.84 (0.75, 0.90) p<0.001 
SV (ml) 21.75 0.64 (-0.20, 0.86) p<0.001 
EF (%) 15.10 0.53 (-0.15, 0.79) p<0.001 
    
LV 
EDV (ml) 5.9 0.95 (0.91, 0.97) p<0.001 
ESV (ml) 14.3 0.87 (0.74, 0.93) p<0.001 
SV (ml) 12.5 0.82 (0.36, 0.93) p<0.001 
EF (%) 9.6 0.71 (0.29, 0.86) p<0.001 
Table 23. Inter-observer variability for ventricular volumes and ejection fraction 
Coefficient of variation (CV) calculated as per Equation 8, pg 138, intraclass correlation 
coefficient (ICC) calculated as mixed effect, absolute agreement. LV = left ventricle, RV = right 
ventricle, EDV = end diastolic volume, ESV = end systolic volume, SV = stroke volume, EF = 
ejection fraction. 
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Intra-observer variation (n = 10) 
  CV (%) ICC Agreement (95% CI) 
RV 
EDV (ml) 5.0 0.92 (0.67, 0.98) p=0.001 
ESV (ml) 6.6 0.94 (0.77, 0.99) p<0.001 
SV (ml) 11.4 0.89 (0.59, 0.97) p=0.001 
EF (%) 8.8 0.85 (0.44, 0.96) p=0.003 
    
LV 
EDV (ml) 2.7 0.99 (0.94, 1.00) p<0.001 
ESV (ml) 5.4 0.97 (0.89, 0.99) p<0.001 
SV (ml) 5.4 0.96 (0.68, 0.99) p<0.001 
EF (%) 3.6 0.93 (0.68, 0.98) p<0.001 
Table 24. Intra-observer variability for ventricular volumes and ejection fraction 
Coefficient of variation (CV) calculated as per Equation 8, pg 138, intraclass Correlation 
coefficient (ICC) calculated as mixed effect, absolute agreement. LV = left ventricle, RV = right 
ventricle, EDV = end diastolic volume, ESV = end systolic volume, SV = stroke volume, EF = 
ejection fraction. 
 
5.2.2 Impact of surgery on reproducibility 
The influence of surgery on reproducibility was assessed using CV at each time 
point. CV for assessment of the RV appears to deteriorate from pre-op to both 
post-op time points (Table 25). 
 
Inter-observer coefficient of variation (%) 
  Pre-op POD 2 2-Months 
  n=26 n=22 n=24 
RV 
EDV (ml) 9.1 8.3 12.4 
ESV (ml) 12.2 14.9 9.8 
SV (ml) 18.2 21.8 25.6 
EF (%) 12.9 16.8 15.9 
     
LV 
EDV (ml) 5.2 6.1 6.5 
ESV (ml) 14.6 15.8 12.5 
SV (ml) 11.4 14.5 11.7 
EF (%) 9.9 11.6 7.3 
Table 25. Coefficient of variation over time 
POD = post-op day, CV = coefficient of variation, LV = left Ventricle, RV = right Ventricle, EDV = 
end diastolic volume, ESV = end systolic volume, SV = stroke volume, EF = ejection fraction. 
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The influence of side of resection on reproducibility was also assessed (Table 26). 
Post-operatively, when assessing RV function there appears to be an increase in 
CV for those having right sided surgery compared to those having left sided 
surgery. 
 
Inter-observer coefficient of variation (%) 
  Pre-op POD 2 2-Months 
  Left Right Left Right Left Right 
  n=10 n=16 n=9 n=13 n=8 n=16 
RV 
EDV (ml) 10.5 8.2 7.3 9.0 8.8 14.3 
ESV (ml) 9.1 14.2 12.3 16.7 11.2 9.1 
SV (ml) 20.4 16.8 15.8 25.9 17.3 29.7 
EF (%) 13.2 12.8 11.5 20.5 13.8 16.9 
        
LV 
EDV (ml) 5.2 5.2 6.8 5.6 4.2 7.6 
ESV (ml) 13.2 15.4 17.6 14.5 10.0 13.8 
SV (ml) 9.4 12.6 14.7 14.4 10.0 12.6 
EF (%) 8.6 10.7 12.6 11.0 7.1 7.4 
Table 26. Coefficient of variation by side of surgery over time 
CV = Coefficient of variation, LV = left ventricle, RV = right ventricle, EDV = end diastolic 
volume, ESV = end systolic volume, SV = stroke volume, EF = ejection fraction. 
 
5.3  Changes in cardiac function 
Heart rate (HR) and cardiac output (CO) increased from a baseline level on POD 2 
before returning to pre-op levels at 2-months (Table 27, pg 182).  
5.3.1 Right ventricular function over time 
One-way repeated measures analysis of variance (ANOVA) determined there was 
a significant difference in RVEF over the duration of the study (p=0.003). Data 
were normally distributed pre-op and at POD 2. There was one outlier at the 2-
month time point, this result was identified as the lowest RVEF by both observers 
(Figure 47, pg 178) and was included for analysisP. Sensitivity analysis showed 
                                            
P RV 13 is identified on a number of occasions through this study as an outlier. Despite minimal 
changes in cardiac function by POD2, this patient presented at 2-month follow-up with severe 
biventricular dysfunction, with RVEF of 16.9% and LVEF of 24.0%. The participant was 
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there was no difference in the final result when performing the test without the 
outlier (p=0.003). Paired samples t-tests revealed that RVEF decreased 
significantly from 50.45% (6.92) pre-op, to 45.61% (4.45) on POD 2 (p<0.0005) 
and remained decreased at 44.89% (7.74) by 2-months (p=0.002, Figure 48 and 
Table 27, pg 182). 
 
 
Figure 48. Right ventricular ejection fraction (RVEF) over time 
Bar (error bars) represent mean (95% CI). one-way repeated measures ANOVA, p=0.003. Pairwise 
comparisons with paired samples t-test. RVEF = right ventricular ejection fraction, POD = post-op 
day.  
 
The mean reduction in RVEF from pre-op to POD 2 was 4.84%. As can be seen 
from Figure 49 (pg 182) there appears to be a consistent drop in RVEF across the 
majority of participants. The upper quartile (those patients with the largest 
deterioration) had a median (IQR) change in RVEF in excess of 10% over this 
time. 
 
 
                                                                                                                                    
reviewed by cardiology and had been felt to have had a myocardial infarction in the follow-up 
period. They were followed up as an out-patient and by their general practitioner. 
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Figure 49. Change in right ventricular ejection fraction (RVEF) from pre-op to POD 2 
Each coloured line represents an individual patient. n = 27. RVEF = right ventricular ejection 
fraction, POD = post-op day. 
 
 Pre-op POD 2 2 Months p-value 
 n=26 n=22 n=24  
HR (bpm) 64.4 (13.0) 77.0 (11.0) # 69.4 (10.3) ¥ 0.002* 
     
CO 6.6 (1.7) 8.0 (1.6) # 6.5 (1.7) ¥ 0.004* 
     
RVEF (%) 50.45 (6.92) 45.61 (4.45)# 44.89 (7.74)# 0.003* 
     
RVEDV (ml) 119.13 (25.35) 125.93 (22.47) 109.40 (31.59)# ¥ 0.019* 
RVESV (ml) 59.80 (17.14) 68.60 (14.48)# 59.83 (17.63)¥ 0.040* 
RVSV (ml) 59.32 (12.01) 57.33 (10.70) 49.57 (16.47)# 0.002* 
Table 27. Right ventricular ejection fraction and volumes over time 
Values are mean (SD). * = one-way repeated measures ANOVA. # = significant difference from 
pre-op. ¥ = significant difference from POD 2. HR = Heart rate, CO = cardiac output, RVEF = right 
ventricular ejection fraction, RVEDV = right ventricular end diastolic volume, RVESV = right 
ventricular end systolic volume, RVSV = right ventricular stroke volume, POD = post-op day. 
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Changes in RV volume measurements over time are shown in Table 27 above and 
Figure 50, below. RVEDV was lower at 2-months compared to other time points 
(p<0.017, paired t-test). RVESV was higher at POD 2 compared to other time 
points (p<0.004, paired t-test) and the RVSV was lowest at 2 months compared to 
pre-op (p=0.0005, paired t-test).  
 
Figure 50. Right ventricular volumes over time 
Bar (error bars) represent mean (95% CI). One-way repeated measures ANOVA (results as per 
Table 27). Pairwise comparisons with paired samples t-test. RVEDV = right ventricular end 
diastolic volume, RVESV = right ventricular end systolic volume, RVSV = right ventricular stroke 
volume, POD = post-op day. 
 
5.3.2 Left ventricular function over time 
There was no difference in LVEF over the study period (repeated measures 
ANOVA, p=0.621, Figure 51 and Table 28, pg 184). The data were normally 
distributed pre-op and at POD 2. There was one outlier at the 2-month time point 
(participant described on pg 180), this result was identified as the lowest LVEF by 
both observers (figure not shown) and was retained in all analyses. As the 
Chapter 5  184 
 
 
assumption of sphericity was violated a Greenhouse & Geisser adjustment was 
made and a corrected p-value reported.  
 
Figure 51. Left ventricular ejection fraction (LVEF) over time 
Bar (error bars) represent mean (95% CI). One-way repeated measures ANOVA with Greenhouse & 
Geisser adjustment p = 0.621. LVEF = left ventricular ejection fraction, POD = post-op day. 
 
Changes in LV volume measurements over time are shown in Table 28 and Figure 
52 (pg 185). LVEDV, LVESV and LVSV were all lower at 2-months compared to 
pre-op (p<0.017, paired t-test). LVEDV and LVESV were also lower at 2-months 
compared to POD 2 (p<0.033, paired t-test). 
 Pre-op POD 2 2 Months p value 
 n=26 n=22 n=24  
LVEF (%) 58.35 (7.09) 57.44 (7.26) 59.68 (9.30) 0.621* 
     
LVEDV (ml) 109.18 (19.49) 106.31 (19.18) 93.62 (28.21)#¥ 0.001* 
LVESV (ml) 45.96 (13.17) 46.00 (14.17) 37.72 (13.06)#¥ 0.019* 
LVSV (ml) 63.22 (11.73) 60.32 (9.01) 55.90 (17.97)# 0.004* 
Table 28.Left ventricular ejection fraction and volumes over time 
Values are mean (SD). * = one-way repeated measures ANOVA. # = significant difference from 
pre-op. ¥ = significant difference from POD 2. LVEF = left ventricular ejection fraction, LVEDV = 
left ventricular end diastolic volume, LVESV = left ventricular end systolic volume, LVSV = left 
ventricular stroke volume, POD = post-op day. 
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Figure 52. Left ventricular volumes over time 
Bar (error bars) represent mean (95% CI). One-way repeated measures ANOVA (results as per 
Table 28). Pairwise comparisons with paired samples t-test. LVEDV = left ventricular end 
diastolic volume, LVESV = left ventricular end systolic volume, LVSV = left ventricular stroke 
volume, POD = post-op day. 
 
5.4  Changes in RV function compared to pre-op and intra-
op variables 
5.4.1 Relative change in right ventricular ejection fraction 
Examining changes in RVEF (ΔRVEF), relative to baseline allows interpretation in 
the context of pre-op RVEF. For example, an absolute change in RVEF of 5% by 
POD 2 may be less significant if RVEFpreop was 70% (relative change of 7.1%) 
compared to RVEFpreop of 35%, where this would represent a 14.3% relative 
change. Unless otherwise stated when describing ΔRVEF they are relative to pre-
op.  
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5.4.2 Relationship of pre-op right ventricular function and 
changes in right ventricular ejection fraction 
There is strong negative association between RVEFpreop and ΔRVEFPOD2-preop (r=-
0.712, p<0.0005, Figure 53). This shows that those patients with better pre-op RV 
function, were more likely to have a larger drop in RVEF by POD 2.  
 
Figure 53. Relationship of RVEFpreop and relative ΔRVEFpod2-preop. 
Pearson's correlation coefficient. 
 
When making a similar analysis of RVEFpreop and ΔRVEF2months-preop, there is no 
association (Figure 54, pg 187), however on visual inspection of the scatter plot 
there appears to be linear association with a significant outlier (bottom of the plot, 
indicated by arrow). This patient has been previously described as an outlier at 2-
months (footnote P, pg 180). Sensitivity analysis with this patient excluded, 
showed a strong negative association between the two variables (r=-0.691, 
p<0.0005, Pearson's correlation coefficient). 
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Figure 54. Relationship of RVEFpreop and relative ΔRVEFpreop-2months. 
Pearson's correlation coefficient. Black arrow indicates outlier described in section 5.4.2. 
 
5.4.3 Right ventricular function and baseline demographics 
Association was sought between patient demographics and the measures of RV 
function at each time point. The comparisons are all displayed in Table 29, pg 188 
and there was no association between RVEF and age, pre-op SaO2, pre-op 
respiratory function and Thoracoscore (p>0.057 for all). In addition, other than 
TLCO%, there were no associations between changes in RVEF (ΔRVEFPOD2-preop 
and ΔRVEF2months-preop) and any of the pre-op demographics (Table 29, pg 188, all 
p> 0.190). 
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  RVEF  Relative ΔRVEF 
  pre-op POD 2 2-Months  
POD2-
preop 
2months
-preop 
Age 
r -0.161 -0.036 -0.113  0.271 -0.014 
p 0.432 0.872 0.599  0.223 0.949 
Pre-op SaO2 
r 0.345 0.313 0.324  -0.290 -0.024 
p 0.085 0.156 0.122  0.190 0.915 
FEV1% 
r -0.202 -0.219 0.030  0.023 0.186 
p 0.332 0.339 0.893  0.920 0.408 
TLCO% 
r -0.379 0.024 -0.006  0.517 0.260 
p 0.057 0.915 0.980  0.014 0.232 
Log10 
Thoracoscore 
r -0.251 -0.186 -0.214  0.072 -0.053 
p 0.215 0.406 0.316  0.749 0.809 
Table 29. Association between pre-op demographics and RV function 
Associations are all Pearson's correlation coefficient. RVEF = Right ventricular ejection fraction, 
POD = post-op day, SaO2 = oxygen saturation, FEV1% = percent predicted forced expiratory 
volume in 1 second, TLCO% = percent predicted transfer factor for carbon monoxide. Significant 
associations are highlighted in bold. 
 
As is evident from Table 29 the association of RVEFpre-op and TLCO% approached 
significance (r=0.517, p=0.057). Visual inspection of the data (Figure 55, pg 189) 
showed that there was an outlier in the data in the upper left corner of the scatter 
plot skewing the correlation statistic, this patient had no valid reason for exclusion. 
This apparent negative relationship does not fit with previous hypotheses 
regarding lung function and RV function. If this relationship were true, better RV 
function would be associated with poorer lung function. Sensitivity analysis with 
this patient excluded showed no association between TLCO% and RVEFpre-op (r=-
0.196, p=0.348). 
Chapter 5  189 
 
 
 
Figure 55. Relationship of RVEFpreop and TLCO% 
Pearson's correlation coefficient. RVEF = right ventricular ejection fraction, TLCO = transfer 
factor for carbon monoxide. Black arrow indicates outlier described in section P, pg 180. 
 
There was strong positive association between ΔRVEFPOD2-preop and pre-op 
TLCO% (Figure 56). This suggests that poorer pre-op lung function is associated 
with a larger change in RVEF by POD 2. 
 
Figure 56. Relationship of ΔRVEFpreop-POD2 and pre-op TLCO% 
Pearson's correlation coefficient. RVEF = right ventricular ejection fraction, POD = post-op day, 
TLCO = transfer factor for carbon monoxide.  
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5.4.4 Right ventricular function and operative data 
To explore the impact of surgical and anaesthetic factors on post-op RV function, 
association was sought between each of the variables described in Table 30 and 
post-op RV function. The significance for association of these operative factors are 
displayed in Table 30 with other factors further explored below. There were no 
associations between RVEF (or ΔRVEF) at any time point and; number of 
pulmonary segments resected, pathology type and volatile anaesthetic group 
(Table 30, all p>0.234). There was no association between RVEF (or ΔRVEF) at 
any time point and; duration of surgery (p>0.153) or duration of one lung 
ventilation (p>0.121, results not shown). 
  RVEF  Relative ΔRVEF 
  POD 2 
2-
Months 
 
POD2-
preop 
2months-
preop 
Pulmonary segments resected 
r 0.023 -0.093  -0.177 -0.328 
p 0.919 0.665  0.431 0.137 
       
Pathology type p 0.363 0.636  0.895 0.381 
Volatile anaesthetic Group p 0.234 0.509  0.864 0.639 
Table 30. Significance for association of operative variables and RV function 
Number of pulmonary segments was analysed using Spearman's correlation coefficient. Pathology 
type and volatile anaesthetic group were all analysed using the Kruskal-Wallis Test. Variables are 
as defined in Table 18 (Operative data in generic methods section, chapter 4). RVEF = right 
ventricular ejection fraction, POD = post-op day. 
 
5.4.5 Right ventricular function and predicted post-operative 
pulmonary function 
There is a strong positive association between ppoTLCO% and ΔRVEFPOD2-preop 
(r=0.682, p<0.0005, Pearson's correlation coefficient, Figure 57, pg 191). There 
was no association between ppoTLCO% and RVEF, or ΔRVEF2months-preop at other 
time points (p > 0.121 for all). There were no associations between RVEF (or 
ΔRVEF) and ppoFEV1% (p > 0.164 for all). 
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Figure 57. Relationship of relative ΔRVEFpreop-POD2 and ppoTLCO%. 
Pearson's correlation coefficient. RVEF = right ventricular ejection fraction, POD = post-op day, 
PPO = predicted post-op , TLCO = transfer factor for carbon monoxide.  
 
5.4.6 Right ventricular function and analgesia 
The study protocol included epidural placement in all patients. As this was not 
feasible in four patients, a sensitivity analysis of the impact of analgesic technique 
on post-op RV function was performed. There was no relationship between the 
use of epidural or paravertebral analgesia for either absolute RVEF post-
operatively or ΔRVEF (p > 0.273 for all, Figure 58).  
 
 
Figure 58. A) RVEF and B) Relative ΔRVEF for each primary analgesic technique  
All Mann-Whitney U-Test. Light grey = epidural group (n=23), Dark Grey = paravertebral group 
(n=4). RVEF = right ventricular ejection fraction, POD = post-op day. 
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The above analysis includes all patients in each primary analgesic group, this 
does not take account of whether the method was functional or not.  
5.4.7 Right ventricular function, intra-op fluid administration and 
post-operative fluid balance 
Mean intra-op fluid administration was 933.3 ml (402.9) but as fluid tended to be 
administered in 500ml aliquots, 26 of the values of fluid administration were 
multiples of 500. This did not allow fluid administration to be treated as a 
continuous variable. Intra-op fluid administration was therefore categorised in 
ranges of ≤500ml (n=9), 501-1000ml (n=13) and >1000ml (n=5). 
RVEFpre-op did not influence the amount of intra-op fluid given (p=0.971, Kruskal 
Wallis test, Figure 59A). There was no difference in RVEF or ΔRVEF across the 
fluid administration ranges at all post-op time points (p>0.538 for all, Kruskal Wallis 
test, Figure 59A & B). 
 
Figure 59. A) RVEF and B) Relative ΔRVEF for each fluid administration group 
A) No difference in RVEF across groups of fluid administration at each time point, all Kruskal 
Wallis Test; Pre-op (p=0.971), POD 2 (p=0.728), 2-Months (p=0.538). B) No difference in ΔRVEF 
across groups at each time point, all Kruskal Wallis; Pre-op to POD 2 (p=0.934) and Pre-op to 2 
Months (p=0.718). Light grey = ≤500ml, Dark Grey = 501-1000ml, White = >1000ml. 
 
There was no association between RVEDV measurements (absolute and 
ΔRVEDV) at any time point with intra-op fluid administration or HDU fluid balance 
(p>0.059 for all, not shown). There was no association between RVEF (or ΔRVEF) 
with both; cumulative fluid administration and fluid balance on the morning of POD 
2, (p>0.534 for all, not shown).  
Chapter 5  193 
 
 
5.5  Right ventricular function and post-operative 
outcomes 
5.5.1 Right ventricular function and post-operative cardiovascular 
outcomes 
Only two patients developed post-op atrial fibrillation, one on post-op day one and 
the other on post-op day seven. No other arrhythmias developed post-operatively. 
Detailed statistical analysis would be meaningless but pre-operatively and on POD 
2, these two patients were not outliers for RVEF or ΔRVEFPOD2-preop.  
Nine participants required a vasoconstrictor during the post-op period. In this 
group the only vasoconstrictor used was nor-adrenaline (NA)Q. NA was 
discontinued in all patients by the morning of POD 2 (i.e. no patients were on a 
vasoconstrictor during POD 2 CMR imaging). There was no difference in the 
RVEFpre-op of those patients who would go on to require NA post-operatively 
(Figure 60A). Post-operatively there was no difference in the RVEF and ΔRVEF in 
those patients requiring NA and those not requiring a vasoconstrictor (Figure 60A 
& B). 
 
Figure 60. A) RVEF and B) Relative ΔRVEF for each vasoconstrictor group 
All Mann-Whitney U-Test. Light grey = nor-adrenaline group, Dark Grey = No vasoconstrictor. 
 
                                            
Q In our institution, the use of nor-adrenaline for epidural induced hypotension is standard 
practice. 
Chapter 5  194 
 
 
5.5.2 Right ventricular function and duration of high dependency 
unit and hospital stay 
The association of RVEFpre-op and length of High Dependency Unit (HDU) stay 
approached significance (r=-0.372, p=0.061, Spearman's correlation coefficient) 
and there was strong association between RVEFPOD2 and HDU length of stay 
(Figure 61, p=0.001). 
 
Figure 61. RVEF against length of HDU stay 
Spearman's correlation coefficient. HDU = high dependency unit, RVEF = right ventricular 
ejection fraction. 
 
There was no association between ΔRVEFPOD2-preop and duration of HDU stay 
(p=0.505, Spearman's correlation coefficient). There was no association of 
RVEFpre-op, RVEFPOD2 and ΔRVEFPOD2-preop with length of hospital stay (p>0.361). 
 
5.5.3 Right ventricular function and six minute walk test 
performance 
As described in section 4.7.2.1, pg 167 there was no deterioration in median 6 
minute walk test (6MWT) distance from pre-op to 2-months. At 2-months there 
were 4 patients who were unable to walk and seven who had a 6MWT distance 
which had dropped by more than the minimal important distance of 28m. There 
was no association between RVEF and relative ΔRVEF at any time point with pre-
op 6MWT or 2-month 6MWT (p>0.087, Pearson's correlation coefficient).  
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When examining those participants with an unchanged (or increased) 6MWT and 
those with a deterioration in 6MWT (by more than 28m or unable to walk), there 
was a difference in RVEF at 2-months (Figure 62 A, p=0.041). This shows a higher 
RVEF in those participants with a deterioration in 6MWT. This is the opposite to 
what might be expected with poorer RV function being associated with decreased 
exercise capacity. At other time points there was no difference in RVEF or relative 
ΔRVEF between the two groups. 
 
 
Figure 62. A) RVEF and B) Relative ΔRVEF for each 6MWT group 
All Mann-Whitney U-Test. p-values as illustrated. Light grey: Deterioration in 6MWT of >28m or 
unable to walk. Dark Grey: Unchanged 6mWT or deterioration of ≤ 28m. 6MWT: 6 Minute Walk 
Test. Unchanged 6MWT n=14, Deteriorated 6MWT n=11. 
 
5.6  Right ventricular function, functional outcomes and 
quality of life 
Tables displaying all associations examining functional outcomes and quality of life 
are provided in Appendix 4. 
5.6.1 Association between pre-op right ventricular function, pre-
op functional status and pre-op quality of life 
There was no association between RVEFpreop and pre-op functional status 
measures, global health score or any measure of the EQ5D scoring system.  
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5.6.2 Association between post-operative right ventricular 
function, post-operative functional outcomes and post-
operative quality of life 
There was no association between RVEFPOD2, RVEF2months, relative ΔRVEFpod2-
preop, relative ΔRVEF2months-preop and any of the measures of functional status or any 
component of EQ5D at 2-months.  
There was no association between RVEFPOD2, RVEF2months, relative ΔRVEFPOD2-
preop and global health score at 2-months (p>0.093 for all). There was association 
between relative ΔRVEF2months-preop and global health score at 2-months (r=0.438, 
p=0.037, Spearman's correlation coefficient) however, visual inspection of the 
scatter plot (not shown) revealed a significant effect from an outlier (participant 
discussed, footnote P pg 180). Sensitivity analysis with this patient excluded 
meant that significant association was lost (r=0.264, p=0.234, Spearman's 
correlation coefficient).  
There was no association between RVEFPOD2, RVEF2months, relative ΔRVEFPOD2-
preop, relative ΔRVEF2months-preop and; functional status measures, global health 
score or any component of EQ5D at one year. 
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5.7  Discussion 
The main finding of this investigation (the first using CMR to sequentially describe 
changes in RV function following lung resection) is that RV function deteriorates by 
POD 2 (primary outcome) and remains depressed at 2-months. This is evidenced 
by a median relative decrease in RVEF of 10.9% from baseline on POD 2, with 
four patients experiencing a relative decrease of RVEF in excess of 20.0%. The 
observed changes in RV function occur despite preservation of LV function, 
suggesting changes following lung resection primarily affect the right ventricular-
pulmonary vascular unit. 
CMR was feasible and well tolerated post-operatively with more than 80% of 
patients completing the examination protocol. RVEF assessment was reproducible 
with coefficients of variation (CV) between 12.9% and 16.8% over the duration of 
the study. As this was the first study to describe CMR for assessment of 
ventricular function in a lung resection cohort, CVs in this population have not 
previously been described. Work in normal subjects and those with cardiac 
pathology have shown CVs for RVEF between 8.0 and 10.7%115. Pre-op values in 
the current study were similar to this with a CV of 12.9%, which deteriorated to 
16.8% by POD 2 suggesting surgery has an impact on CMR reproducibility. Post-
hoc analyses suggest surgical side is also important to observed variability. Pre-op 
CV's were similar for those having left or right sided resections (12.8% and 13.2% 
respectively) but post-operatively those patients with right sided resections had 
larger CVs (20.5% on POD 2) than those having left sided surgery (11.5%). There 
is no apparent difference at 2-months. Surgery and side did not appear to impact 
on the reproducibility for left ventricular CMR measurements. 
Although the heart sits within the left thoracic cavity and it may be expected that 
surgery on this side would impact on reproducibility, the opposite is true. Previous 
studies using CMR to examine cardiac position following lung resection has shown 
lateral shift of the RV209. In the post-op period this would bring the heart, 
particularly the anteriorly located RV free wall, closer to the surgical site. The 
present of post-op haemothorax and/or pneumothorax, with inter costal drains, 
may play a role in the ability to accurately contour the RV at this stage. Future 
studies using CMR in this population for mechanistic research, may wish to 
prioritise patients undergoing left sided resections. 
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In the setting of acutely increased afterload, the RV responds by attempting to 
increase systolic function in an attempt to maintain RV-PA coupling (homeometric 
auto-regulation as described in section 1.2.3.9, pg 39). This is followed by 
heterometric autoregulation (section 1.2.3.9, pg 39) with dilatation to preserve 
cardiac output55, 159, 160. By POD 2 following lung resection, RVEDV and RVESV 
have increased (by 6.8ml and 8.6ml respectively) from pre-op levels. Although the 
increases are small absolute volumes, this may demonstrate evidence of 
heterometric autoregulation in the acute phase following lung resection. 
At 2-months following surgery biventricular volumes are lower than compared to 
pre-op values, with RVEDV, LVEDV and LVESV all reduced. Due to the proportion 
of changes this resulted in ongoing decreased RVEF and unchanged LVEF. 
With half of the participants having a relative decrease in RVEF over 10% and four 
participants having a decrease in excess of 20%, it could be reasonably 
hypothesised that a reduction of this magnitude would result in clinical sequelae. 
Unfortunately this investigation, with its sample size, does not allow robust 
assessment of the clinical implications of post-op RV dysfunction and any results 
would be under-powered and hypothesis generating only. However, the impact of 
pre-op factors, surgical variables and anaesthetic technique on post-op RV 
function were examined on an exploratory basis, along with the impact of RV 
function on post-op outcomes. The majority of pre-op variables demonstrated no 
association with post-op RV function. Age, sex, smoking status, pre-op SaO2, pre-
op FEV1 and Thoracoscore showed no association. There was association 
between RVEFpreop and ΔRVEFPOD2-preop, with better pre-op RV function present in 
those who would have a bigger drop in RVEF post-operatively (Figure 53, pg 186). 
This could be considered figuratively as a 'bigger you are, the harder you fall' 
association. A similar association has previously been demonstrated by Lewis et 
al.44 in a pneumonectomy cohort. At the time of PA clamping (Figure 63, pg 199); 
those patients with normal RVEF (≥45%) generally showed a significant decline in 
RVEF (p=0.0006), whereas most with subnormal levels (RVEF <45%) showed no 
change44. 
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Figure 63. Change in RVEF at time of PA clamping. 
From Lewis et al.44. RVEF on Y-axis. RVEF = right ventricular ejection fraction. PA = pulmonary 
artery. 
 
Another comparable clinical example is from the study by Matyal et al. which 
examined RV myocardial performance index (RV-MPI) at the time of OLV in a 
cohort undergoing lung resection43. This demonstrated that patients with better 
baseline RV function (as measured by MPI) were more likely to develop SVT than 
those with poorer RV function. They hypothesised;  
"this resulted from these subjects having a degree of 
compensated cardiac dysfunction as a result of a chronically 
elevated pulmonary vascular resistance or afterload, which allows 
them to better tolerate acute changes in ventricular afterload or 
volume."  
Matyal et al.43. (2010) 
The pattern of change in the current study could support this concept of pre-
conditioning. It could be hypothesised those patients with poorer RV function pre-
op, have previously been exposed to increases in afterload resulting from their 
underlying pathology, meaning they are better equipped to cope when they 
undergo surgery. 
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This study demonstrated moderate positive association between pre-op lung 
function (as signified by TLCO%, Figure 56, pg 189) and deterioration in RV 
function by POD 2. This demonstrates poorer pre-op lung function was associated 
with a larger decrease in RVEF by POD 2. In severe COPD an association 
between poor pulmonary function and RV-PA haemodynamics has previously 
been demonstrated, with higher PA pressures present in those with a lower 
TLCO%295. It could be hypothesised that the larger drop in RVEF in those with 
poorer lung function results from these patients being vulnerable to changes in 
pulmonary haemodynamics. There is also a strong positive association between 
predicted post-op lung function (ppoTLCO%) and change in RVEF by POD 2 
(Figure 57, pg 191). This suggests those patients with poorer pulmonary function 
post-operatively, have a larger drop in RVEF by POD 2. This should be interpreted 
with caution as post-op lung function (ppoTLCO%) and pre-op lung function 
(TLCO%) are significantly associated (r=0.895, p<0.0005, Pearson's correlation 
coefficient, not shown). 
This study has demonstrated that patients with better pre-op RV function and 
those with poorer pre-op respiratory function, are likely to have a larger 
deterioration in RV function following lung resection. Although not possible to 
demonstrate with the current investigation, this may be demonstrating two 
independent mechanisms. A group at higher risk of deterioration in RV function, 
would therefore be those presenting with good pre-op RV function and poor 
pulmonary function. In contrast, those with poor pre-op RV function and good 
pulmonary function may be protected when undergoing lung resection. 
Previous work has suggested the extent of lung resection (mainly lobectomy v 
pneumonectomy45, 199, 201, 202, 206) may impact on the degree of post-op RV 
dysfunction. This investigation included only lobectomy patients (with one intra-op 
conversion to pneumonectomy) and the median (IQR) number of resected 
segments was only 5 (3, 5) meaning any association between size of resection 
and post-op RV function would be hard to demonstrate. The one pneumonectomy 
patient was not an outlier for any RV function variable, at any time point and was 
retained in all analyses. There was no association between post-op RV function 
and both; resection side and pathology type.  
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The impact of anaesthetic factors on post-op RV function was explored. Thoracic 
epidural has been shown to negatively affect RV contractility (with preserved 
coupling) at times of increased afterload85, 296. Although small numbers in the 
paravertebral group (n=4), there was no difference in post-op RV function 
depending on analgesic technique. The importance of fluid balance in patients 
following lung resection is well established, with excess fluid administration 
associated with lung injury post-operatively297. Given the potential interplay of RV 
function and acute lung injury (especially the more severe form, ARDS), the 
impact of fluid volume administration on post-op RV function was assessed. In this 
investigation the volume of fluid administered and fluid balance in the peri-
operative period had no influence on post-op RV function and volume (RVEF and 
RVEDV). Our institution practices a fluid restrictive approach in patients following 
lung resection. The low volume of fluid administered, along with low variability 
means any impact on post-op RV function would be difficult to demonstrate. 
Previous work has suggested association between peri-operative changes in RV 
function and both; development of complications43, 45, 176 and poor long-term 
functional status44, 201. This study demonstrates a strong association between 
RVEFPOD2 and post-op HDU stay. The reasons for remaining in critical care are 
multi-factorial and this investigating may be highlighting that post-op RV function is 
one of the factors important in this patient group. There were no other significant 
associations between RV function and post-op outcomes. This study was unable 
to find any association between RV function and; 6MWT results, functional status 
and quality of life. 
This thesis consistently refers to the post-operative changes in RV function as 
'dysfunction.' However, the author acknowledges that the changes may be 
demonstrating an adaptive change in cardiovascular mechanics, with the right 
ventricle compensating for changes occurring following lung resection.  
5.7.1 Strengths and limitations 
The first use of CMR (a non-invasive reference method for assessment of RV 
function) in this patient cohort, with dual analysis of RV parameters by blinded 
clinicians, is a significant strength of this study. 
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This investigation made no assessment of the loading conditions experienced by 
the RV so further work is required to examine the mechanisms of RV dysfunction 
following lung resection. Mechanisms of post-op RV dysfunction are explored in 
chapter 9.  
Although association was sought on an exploratory basis, this size of this study did 
not allow robust clinical correlation and future work should assess the clinical 
implications of RV dysfunction. Additionally, this study made no assessment of RV 
function during exercise; previous work in this patient group has consistently 
demonstrated marked changes in pulmonary haemodynamics and RV function on 
exercise (Table 5, pg 82)172, 174. Although the deterioration in RVEF observed in 
this cohort is modest, the author suggests the changes observed at rest would be 
exacerbated during exercise, potentially limiting functional capacity. 
CMR is a reference method for assessing RV volumes but its widespread use in 
this group is limited, firstly by availability and secondly by suitability in the 
immediate post-op patient. Although withdrawals were well within the number 
allowed by the studies power analysis, a group of participants were unable to 
undergo CMR assessment post-operatively. The requirement for transfer, also 
meant assessment was performed at discrete time points with no continuous 
monitoring possible. A validated bedside alternative, potentially utilising trans-
thoracic echocardiography, biomarkers or a combination would have utility in this 
population. The use of echocardiography and biomarkers to assess RV function 
following lung resection is explored in chapters 6, 7 and 8. 
5.8  Conclusion 
This is the first study showing that RV function is impaired not just in the 
immediate post-op period following lung resection, but remains depressed months 
later, long in to the recovery period. Although this study was unable to 
demonstrate association with clinical outcomes, in other settings RV dysfunction is 
associated with poor prognosis and reduced exercise capacity. The author 
hypothesises that the changes in RVEF are likely to have clinical sequelae and 
may provide a target for clinical interventions allowing amelioration of post-op 
cardiorespiratory morbidity.  
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The challenges of CMR imaging in this population mean the validation of 
alternative methods of assessing RV function would have utility. 
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Chapter 6  Conventional Echocardiographic 
Parameters of Right Ventricular Systolic Function 
This chapter describes conventional echocardiographic parameters of RV systolic 
function; Fractional area change (FAC), Tricuspid annular plane systolic excursion 
(TAPSE) and S' Wave velocity at the tricuspid annulus (S'Wave). It will first 
describe the availability and reproducibility of each imaging modality, it will then 
describe changes in each parameter over time. The final step will be comparison 
with cardiovascular magnetic resonance (CMR) determined RV ejection fraction 
(RVEFCMR) as a reference method of assessing RV function.  
Trans thoracic echocardiography (TTE) was well tolerated with all 27 patients 
(100%) completing the scan protocol pre-operatively, 26 (96.3%) on post-op day 
(POD) 2 and 24 (88.9%) at 2-months. The one patient not scanned on POD 2 
declined echo imaging. Of the patients not imaged at 2-months, two declined and 
one was unwell at another hospital. This gave a total of 77 scans available for 
analysis. 
6.1  Imaging availability and reproducibility  
6.1.1 Imaging availability 
All echocardiographic parameters were dual reported by the author and 
echocardiography technicians (ET's) from blinded images. Ten of the anonymised 
and randomised scans were dual by the author for assessment of intra-observer 
variability. There was disparity in imaging availabilityR for FAC between the author 
and the ET's, particularly on POD 2 where the author obtained results on 12 
patients (46.2%) in contrast to the ET's who managed imaging on 25 patients 
(96.2%). For the other variables (TAPSE and S'Wave) imaging was available in 
the majority of patients (>88.5%) at each time point with no disparity between the 
author and ET's (Table 31, pg 205).  
 
                                            
R Availability in this context refers to the ability to obtain a result from the echocardiographic 
image provided. Availability will have been affected by the quality of the image and by the 
interpretation by the observer. 
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 Pre-op POD 2 2-Months 
 (n=27) (n=26) (n=24) 
 ET Author ET Author ET Author 
FAC 
26 
(96.3%) 
18 
(66.7%) 
25 
(96.2%) 
12 
(46.2%) 
23 
(95.8%) 
20 
(83.3%) 
TAPSE 
27 
(100%) 
26 
(96.3%) 
23 
(88.5%) 
23 
(88.5%) 
24 
(100%) 
23 
(95.8%) 
S' Wave 
27 
(100%) 
27 
(100%) 
23 
(88.5%) 
23 
(88.5%) 
24 
(100%) 
24 
(100%) 
Table 31. Availability of echocardiographic imaging at each time point 
POD = post-op day, ET = echocardiography technician, FAC = fractional area change, TAPSE = 
tricuspid annular plane systolic excursion, S'Wave = S' Wave velocity at the tricuspid annulus. 
 
The impact of operative side on imaging availability was explored. Table 32 
demonstrates it was not possible to determine FAC, for as many patients 
undergoing left sided resections (compared to right sided) pre-operatively and on 
POD 2, with this pattern reversed at 2-months. When determining TAPSE on POD 
2 there is less paired imaging available for those undergoing left sided resections. 
For the other time points and other modalities, there was no impact of side of 
resection on availability of imaging. 
 Pre-op POD 2 2-Months 
Resection side Left Right Left Right Left Right 
 (n=10) (n=17) (n=9) (n=17) (n=8) (n=16) 
FAC 
5 
(50.0%) 
12 
(70.6%) 
3 
(33.3%) 
8 
(47.1%) 
7 
(87.5%) 
12 
(75.0%) 
TAPSE 
9 
(90.0%) 
17 
(100%) 
7 
(77.8%) 
16 
(94.1%) 
8 
(100%) 
15 
(93.8%) 
S' Wave 
10 
(100%) 
17 
(100%) 
8 
(88.9%) 
15 
(88.2%) 
8 
(100%) 
16 
(100%) 
Table 32. Paired image availability (by author and echotechs) for echocardiographic 
parameters by side of resection at each time point 
POD = post-op day, FAC = fractional area change, TAPSE = tricuspid annular plane systolic 
excursion, S'Wave = S' Wave velocity at the tricuspid annulus. 
 
6.1.2 Imaging reproducibility 
A summary of the inter-observer and intra-observer variability of each of the 
echocardiographic parameters is provided in Table 33 (pg 206). There was poor 
reproducibility for FAC, signified by a coefficient of variation (CV) of 15.8% and a 
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non-significant intraclass correlation coefficient. TAPSE and S'Wave demonstrated 
excellent inter, and moderate intra-observer variability. 
Inter-Observer Variability 
 
Paired 
Measures 
CV (%) ICC Agreement (95% CI) 
FAC (%) n=47 15.8% 0.12 (-0.16, 0.38) p=0.207 
TAPSE (mm) n=72 2.6% 0.94 (0.90, 0.97) p<0.0005 
S' Wave (cm/s) n=74 5.5% 0.91 (0.86, 0.94) p<0.0005 
    
Intra-Observer Variability 
 
Paired 
Measures 
CV (%) ICC Agreement (95% CI) 
FAC (%) n=10 12.6% 0.20 (-0.21, 0.65) p=0.192 
TAPSE (mm) n=10 3.9% 0.71 (0.23, 0.92) p=0.006 
S' Wave (cm/s) n=10 9.0% 0.77 (0.15, 0.94) p<0.0005 
Table 33. Inter and intra-observer variability for echocardiographic measures of systolic 
function 
Coefficient of Variation (CV) calculated as per Equation 8, pg 24, intraclass Correlation 
coefficient (ICC) calculated as mixed effect, absolute agreement. FAC = fractional area change, 
TAPSE = tricuspid annular plane systolic excursion, S'Wave = S' Wave velocity at the tricuspid 
annulus. 
 
The impact of surgery on imaging reproducibility was assessed by examining the 
CV's at each time point (Table 34). There is an apparent improvement in CV for 
FAC by POD 2, however this must be taken in the context that paired imaging (by 
both author and ET) was only available for 11 patients (42.3%) at this time point. 
Surgery did not appear to impact on CV's for the other variables. 
Inter-Observer Variation 
 Pre-op POD 2 2-Months 
 CV (%) CV (%) CV (%) 
FAC 18.3 9.5 17.2 
TAPSE 2.5 2.4 2.9 
S'Wave 5.5 5.9 5.1 
Table 34. Coefficient of variation for echocardiographic variables over time 
POD = post-op day, CV = coefficient of variation, FAC = fractional area change, TAPSE = tricuspid 
annular plane systolic excursion, S'Wave = S' Wave velocity at the tricuspid annulus. 
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The impact of side of surgery on reproducibility was also assessed (Table 35). 
There was a suggestion of better reproducibility for FAC with those undergoing left 
sided resections in contrast to those undergoing right sided resections. However, 
as described above, it was not possible to determine FAC for as many patients 
undergoing left sided procedures as for those undergoing right and this may 
impact on these figures. There was no obvious impact of side on the 
reproducibility of TAPSE and S'Wave values. 
Inter-Observer Variation 
 CV (%) 
Resection side Left Right 
FAC 12.4 15.9 
TAPSE 2.9 2.5 
S'Wave 5.1 5.6 
Table 35 Coefficient of variation for echocardiographic variables by side of resection 
CV = coefficient of variation, FAC = fractional area change, TAPSE = tricuspid annular plane 
systolic excursion, S'Wave = S' Wave velocity at the tricuspid annulus. 
 
 
6.1.3 Bland Altman Analysis 
Bland Altman (BA) analysis between the two observers (the author and ET's) for 
FAC, despite minimal bias (-2.9%), showed unacceptable limits of agreement (-
27.1, 21.4%, Figure 64, pg 208). BA analysis for TAPSE showed minimal bias (-
0.5mm) and acceptable limits of agreement (-2.9, 1.9mm) with no evidence of 
systematic variability (Figure 65, pg 208). BA analysis for S'Wave showed minimal 
bias (-0.1cm/s) and acceptable limits of agreement (-2.1, 1.8cm/s) with no 
evidence of systematic variability (Figure 66, pg 209). 
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Figure 64. Bland Altman analysis of fractional area change (FAC) measurements (n = 47) 
Solid line represents mean bias (-2.9%) and dashed lines represent 95% limits of agreement (-
27.1, 21.4%). 
 
 
 
Figure 65. Bland Altman analysis of tricuspid annular plane systolic excursion (TAPSE) 
measurements (n = 72) 
Solid line represents mean bias (-0.5mm) and dashed lines represent 95% limits of agreement (-
2.9, 1.9mm). 
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Figure 66. Bland Altman analysis of S' Wave velocity at the tricuspid annulus (S' Wave) 
measurements (n = 74) 
Solid line represents mean bias (-0.1cm/s) and dashed lines represent 95% limits of agreement (-
2.1, 1.8cm/s). 
 
6.2  Changes over time 
One-way repeated measures analysis of variance (ANOVA) determined there was 
no significant difference in FAC over the duration of the study (p=0.089, Figure 67, 
pg 210 and Table 36, pg 211). Changes in TAPSE over time approached 
significance (p=0.057, Figure 68, pg 210 and Table 36, pg 211) and there was a 
change in S'wave over time with an increase from 10.4cm/s pre-op to 12.1cm/s on 
POD 2 (p=0.009) before returning to baseline levels (Figure 69, pg 211 and Table 
36, pg 211) .  
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Figure 67. Fractional area change (FAC) over time 
Bar (error bars) represent mean (95% CI). One-way repeated measures ANOVA p=0.089. POD = 
post-op day. 
 
 
Figure 68. Tricuspid annular plane systolic excursion (TAPSE) over time 
Bar (error bars) represent mean (95% CI). One-way repeated measures ANOVA p=0.057. Pairwise 
comparisons with paired samples t-test. POD = post-op day. 
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Figure 69. S' Wave velocity at the tricuspid annulus (S'Wave) over time 
Bar (error bars) represent mean (95% CI). One-way repeated measures ANOVA p=0.014. Pairwise 
comparisons with paired samples t-test. S'Wave = S' Wave velocity at the tricuspid annulus, POD 
= post-op day. 
 
 
Pre-op POD 2  2-Months p-value 
FAC (%) 
n=17 n=11 n=19 
0.089* 
46.2 (8.0) 46.4 (7.0) 43.3 (6.0) 
TAPSE (mm) 
n=26 n=23 n=23 
0.057* 
21.3 (3.7) 21.8 (4.5) 20.2 (3.0)† 
S' Wave (cm/s) 
n=27 n=23 n=24 
0.014* 
10.4 (1.7) 12.1 (2.3)# 10.8 (2.4) 
Table 36. Echocardiographic parameters of RV function over time 
Values are mean (SD). * = one-way repeated measures ANOVA. # = significant difference from 
pre-op. † = Significant difference from POD 2. FAC = fractional area change, TAPSE = tricuspid 
annular plane systolic excursion, S'Wave = S' Wave velocity at the tricuspid annulus, POD = post-
op day. 
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6.3  Comparison of echo parameters of systolic function 
with cardiovascular magnetic resonance determined 
measures of right ventricular function 
6.3.1 Pooled analysis 
Pooled analysis of all paired measures across all time points was performed and 
revealed no association between RVEFCMR and FAC (Pearson's correlation 
coefficient, p=0.374, Figure 70). There was weak positive association between 
both TAPSE (r=0.337, p=0.006, Figure 71), S'Wave (r=0.290, p=0.017, Figure 72, 
pg 213) and RVEFCMR. All displayed in Table 37, pg 213. 
 
Figure 70. Relationship between FAC and CMR determined RV ejection fraction (RVEFCMR) 
RVEF = right ventricular ejection fraction, FAC = fractional area change. Pearson's correlation 
coefficient (pooled analysis).  
 
 
Figure 71. Relationship between TAPSE and CMR determined RV ejection fraction (RVEFCMR) 
RVEF = right ventricular ejection fraction, TAPSE = tricuspid annular plane systolic excursion. 
Pearson's correlation coefficient (pooled analysis).  
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Figure 72. Relationship between S'Wave and CMR determined RV ejection fraction (RVEFCMR) 
RVEF = right ventricular ejection fraction, S'Wave = S' Wave velocity at the tricuspid annulus. 
Pearson's correlation coefficient (pooled analysis).  
 
There was weak pooled association between TAPSE, S'Wave and RVEF. 
Following within-subject (ANCOVA) analysis, there was no evidence of association 
between any of the echocardiographic variables and RVEFCMR (Table 37).  
Pooled analysis (Pearson's) 
  FAC TAPSE S' Wave 
RVEFCMR 
r 0.136 0.337 0.290 
p 0.374 0.006 0.017 
     
Within-subject analysis (ANCOVA) 
  FAC TAPSE S' Wave 
RVEFCMR 
r 0.271 0.051 0.120 
p 0.292 0.777 0.493 
Table 37. Association between echocardiographic measures of systolic function and RVEFCMR 
RVEF = right ventricular ejection fraction, FAC = fractional area change, TAPSE = tricuspid 
annular plane systolic excursion, S'Wave = S' Wave velocity at the tricuspid annulus. ANCOVA = 
analysis of covariance. Significant results are highlighted in bold. 
 
The ability of the three pooled echocardiographic methods to detect poor RV 
function, defined by RVEFCMR of ≤45%, was assessed using area under the 
receiver operating characteristic curve analysis (Figure 73 and Table 38, pg 214). 
TAPSE was the only variable to show predictive power (AUROCC 0.65, p=0.039); 
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a value of 21.25mm had 65.8% sensitivity and 71.4% specificity for detecting an 
RVEFCMR of ≤45%.  
 
Figure 73. Receiver operating characteristic curves to identify RVEFCMR ≤45% using 
echocardiographic parameters 
FAC = Fractional area change, TAPSE = Tricuspid annular plane systolic excursion, S'Wave = S' 
Wave velocity at the tricuspid annulus, AUROCC = Area under the receiver operating 
characteristic curve.  
 
  FAC TAPSE S'Wave 
 RVEFCMR ≤45% 
AUROCC (95%CI) 0.61(0.45, 0.78) 0.65 (0.51, 0.79) 0.57 (0.43, 0.71) 
p 0.211 0.039 0.325 
Cut-off valueS - 21.25mm - 
Sensitivity - 65.8% - 
Specificity - 71.4% - 
PPV - 75.7% - 
NPV - 60.6% - 
Table 38. Predictive performance of echo parameters to detect RVEFCMR ≤45% 
AUROCC = Area under the receiver operating characteristic curve, PPV = Positive predictive 
value, NPV = negative predictive value, RVEF = Right ventricular ejection fraction, FAC = 
Fractional area change, TAPSE = Tricuspid annular plane systolic excursion, S'Wave = S' Wave 
velocity at the tricuspid annulus. 
 
                                            
S Defined by Youden's index (Maximum combination of sensitivity and specificity). 
AUROCC = 0.65 
95% CI (0.51, 0.79) 
AUROCC = 0.61 
95% CI (0.45, 0.78) 
AUROCC = 0.57 
95% CI (0.43, 0.71) 
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6.3.2 Trend analysis 
Trend analysis was performed to assess the ability of each of the 
echocardiographic techniques to detect changes in RVEFCMR. Change in each of 
the echo parameters (ΔFAC, ΔTAPSE and ΔS' Wave) was plotted against change 
in RVEFCMR (ΔRVEFCMR). The associations are demonstrated in Figure 74, Figure 
75, and Figure 76, pg 216. 
 
Figure 74. Changes in FAC against corresponding changes in RVEFCMR 
n = 30, Pearson's correlation coefficient. RVEF = right ventricular ejection fraction, FAC = 
fractional area change. 
 
 
Figure 75. Changes in TAPSE against corresponding changes in RVEFCMR 
n = 55, Pearson's correlation coefficient. RVEF = right ventricular ejection fraction, TAPSE = 
tricuspid annular plane systolic excursion. 
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Figure 76. Changes in S'Wave against corresponding changes in RVEFCMR 
n = 58, Pearson's correlation coefficient. RVEF = right ventricular ejection fraction, S'Wave = 
S'Wave velocity at the tricuspid annulus. 
 
None of the echocardiographic parameters showed any association between a 
change in their measurement and a change in RVEFCMR. The predictive ability of 
each of the echo techniques to detect a change in RVEFCMR was further assessed. 
The standard deviation of ΔRVEFCMR, 7.55%, was used as the minimal change 
that would be useful to determine from echocardiography and AUROCC analysis 
was performed. None of the echocardiographic parameters were able to detect a 
change in RVEFCMR of >7.55% (p>0.069, Figure 77 and Table 39, pg 217). 
 
Figure 77. Receiver operating characteristic curves to identify ΔRVEFCMR ≥7.55% using 
Δechocardiographic parameters 
FAC = fractional area change, TAPSE = tricuspid annular plane systolic excursion, S'Wave = S' 
Wave velocity at the tricuspid annulus. 
 
 
AUROCC = 0.53 
95% CI (0.31, 0.75) 
AUROCC = 0.52 
95% CI (0.35, 0.68) 
AUROCC = 0.57 
95% CI (0.43, 0.71) 
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 ΔFAC ΔTAPSE ΔS'Wave 
 ΔRVEF >7.55% 
AUROCC (95%CI) 0.53 (0.31, 0.75) 0.52 (0.35, 0.68) 0.57 (0.43, 0.71) 
p 0.792 0.838 0.069 
Table 39. Receiver operating characteristic analysis to detect ΔRVEF >7.55% 
AUROCC = area under the receiver operating characteristic curve, RVEF = right ventricular 
ejection fraction, FAC = fractional area change, TAPSE = tricuspid annular plane systolic 
excursion, S'Wave = S' Wave velocity at the tricuspid annulus. 
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6.4  Discussion  
This aim of this investigation was to validate conventional measures of RV systolic 
function (FAC, TAPSE and S'Wave) against an established reference method for 
assessment of RV function (RVEFCMR) in a lung resection cohort. Its main finding 
is that none of these established parameters have utility in this population.  
The TTE imaging protocol was well tolerated and acceptable to patients, with all 
participants completing the protocol pre-operatively and the majority completing it 
in the post-op period. Despite the vast majority of patients being able to undergo 
imaging, not all echo parameters were available in all patients. Prior to this 
investigation, the author hypothesised that TTE would be more difficult in those 
patients undergoing left sided resections than those having right sided surgery, 
with a significant impact on image availability, quality and reproducibility. This is 
because the majority of TTE imaging is performed through the left side of the 
thorax (through rib spaces). The presence of drains, pneumothorax and additional 
fluid following left sided surgery may impact on the ability to obtain usable images 
with the impact diminishing by 2-months, when drains were removed and patients 
were well in to the recovery period.  
There was some evidence that side of resection was important on imaging 
availability in the immediate post-op period. On POD 2 dual reported TAPSE was 
available in 77.8% of those who had left sided resections in contrast to 94.1% of 
those who had right sided resections. In those with available imaging, side did not 
impact on reproducibility with CV's similar for both left and right sided surgeries. 
There was no such trend when determining S'Wave as this was equally available 
in left and right sided resections at all time points with no difference in 
reproducibility.  
On POD 2 paired FAC results were available in 33.3% of patients undergoing left 
sided resections and 46.2% of those undergoing right sided resections. This was 
in contrast to the reproducibility figures where CV were much better on POD 2 in 
contrast to other time periods (9.5% vs 18.3 and 17.2%). These figures do not tell 
the whole story; in patients undergoing FAC assessment the echocardiography 
technicians (ET's) obtained a result in 74/77 (96.1%) of patients and the author 
obtained a result in 50/77 (64.9%) of images. This was worse on POD 2 when the 
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ET's obtained a result on 96.2% of images and the author obtained results on 
46.2% of images. In previous work by Kjaergaard et al.132. (in a non-thoracic 
surgery cohort) images were of sufficient quality to determine a FAC result in 82% 
of patients. This is still substantially better than the 64.9% availability by the author 
in this cohort. The hypothesised deterioration in imaging following thoracic surgery 
may account for poor quality images but would not account for why one observer 
was able to obtain values and the other was not. 
On reviewing the images that the author was unable to obtain a FAC result for, it 
would appear a much more punitive approach was utilised, in that if the apex of 
the RV free wall was not available a value would not be calculated. This is in 
contrast to the ET's who calculated values for the RV that was visible. This will 
have falsely improved the CV on POD 2 when only those images with the clearest 
endocardial border having been selected by the author. Sensitivity analysis 
incorporating only those values obtained by the ET's showed no improvement in 
the performance of FAC when compared with RVEFCMR, with a Pearson's 
correlation coefficient of 0.117 (p=0.345) and ANCOVA of 0.06 (p=0.712). 
Fractional area change showed poor inter- and intra-observer variability (CV's of 
15.8% and 12.6% respectively) with intraclass correlation coefficients (ICC's) that 
failed to achieve statistical significance. In addition, on Bland Altman (BA) analysis 
there was no evidence of agreement between two observers. All of these 
characteristics indicate that FAC is not a reproducible and would be unsuitable as 
a measurement technique in this population.  
RV area estimation can be challenging in cases of sub-optimal image quality and 
the above inconsistency highlights how there is still subjectivity with regards to RV 
assessment. Recognising this subjectivity, guidelines from the American Society of 
Echocardiography recommend the integration of quantitative and qualitative 
assessment of RV parameters128, 298.  
In contrast to FAC, TAPSE and S'wave were available in the majority of patients 
and showed good inter- and intra-observer variability (CV's of ≤9.0% for all). BA 
analysis of these variables showed good agreement with minimal bias. This 
suggests that TAPSE and S'Wave are reproducible and may be useful as 
measurement techniques in this population.  
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There were minimal changes in all the echocardiographic parameters over the 
duration of the study and none mirrored the changes in RVEFCMR described in 
Chapter 5. FAC showed no change over time. TAPSE decreased from 21.8mm on 
POD 2 to 20.2mm at 2-months. Although this was a statistically significant change 
(p=0.012), it was a small absolute change (of 1.6mm) and was still at a 
considerable level above the lower reference value for normal TAPSE (16mm)128. 
S'Wave increased on POD 2 from 10.4cm/s to 12.1cm/s. This suggests improved 
RV systolic function on POD 2 following lung resection, returning to baseline by 2-
months. This is in contrast to the results obtained by RVEFCMR which shows that 
RV function deteriorates by POD 2 and remains depressed at 2-months. Again, all 
of the values were above the lower reference value for normal systolic function by 
S'Wave (10cm/s)128. 
Using RVEFCMR as a reference method this investigation attempted to validate the 
use of these echocardiographic parameters in this population. The first step was 
pooled analysis of the echo variables which showed weak association between 
TAPSE, S'Wave and RVEFCMR. When taking account of the within-subjects 
correlation from the repeated measures nature of the data, there was no evidence 
of a relationship between RVEFCMR and any of the echocardiographic variables.  
Analysis so far suggests that FAC, TAPSE and S'Wave are not suitable as a 
continuous measure of RV function. To assess the ability of each of the 
parameters to predict poor RV function (signified by RVEFCMR≤45%, a previously 
described cut-off for poor RV function)121, 299 area under the receiver operating 
characteristic curve (AUROCC) analysis was performed. This demonstrated that 
FAC and S'Wave had no predictive ability for 'poor RV function'. TAPSE showed 
some discriminatory ability with AUROCC of 0.65 (95% CI 0.51, 0.79). Johnson 
has suggested that when it comes to prediction, an AUROCC of "0.75 is good and 
greater than 0.8 is exciting," the AUROCC for TAPSE falls considerably lower than 
this242. Additionally, the 95%CI for this AUROCC are close to 0.5 and the ability of 
TAPSE to determine RVEFCMR ≤45% is not adequate for clinical or research use. 
As well as the ability of the parameters to determine absolute values of RVEFCMR, 
their ability to detect changes of RVEFCMR was assessed. This analysis showed 
that there was no association between a change in RVEFCMR and any change in 
the echocardiographic parameters. The ability of the parameters to detect a 
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change of RVEFCMR of ≥7.55% was assessed using AUROCC analysis. The 
standard deviation of ΔRVEFCMR (7.55%) was used as this represented a clinical 
change in RVEF would be desirable to detect in this population. None of the 
parameters showed any ability to determine a change in RVEF ≥7.55%. 
In summary, despite excellent reproducibility for TAPSE and S'Wave, they have no 
relationship to RVEFCMR and are unable to provide information on absolute values 
of RVEFCMR or changes in RVEFCMR in this population. FAC showed no 
reproducibility and no ability to predict values of RVEFCMR. This finding is in 
contrast to previous work in other populations which has shown that these 
parameters have good association with RVEFCMR
121, 122, 131, 132, 300
 (Table 40, pg 
222).  
As can be seen in Table 40, in other studies FAC has correlation coefficients 
ranging from non-significant to 0.84, and good ability to predict poor RV function 
with an AUROCC of up to 0.89. In this investigation there was no association and 
no predictive ability. Although unlikely based on the available information (poor 
reproducibility and no linear association for RVEFCMR and ΔRVEFCMR), a complete 
set of FAC measurements may be able to provide some information on RV 
function in patients undergoing lung resection. It is unlikely to achieve the levels 
described in previous studies. 
The studies in Table 40 show correlation coefficients for TAPSE ranging from non-
significant to 0.48. It has also shown AUROCC of 0.66 to 0.85. The data in the 
current study has shown pooled association between RVEFCMR and TAPSE of 
0.38 which is lost when taking account of within subjects correlation. An AUROCC 
of 0.65 was obtained, which is similar to the level of 0.66 described by Focardi et 
al.121. In their article they describe surprise at this lower level of agreement 
between TAPSE and RVEFCMR, with the discordance attributed to TAPSE being a 
"qualitative" assessment in contrast to RVEFCMR which is a more "accurate 
quantitative" method. In the two studies in Table 40 examining S'wave, there is 
evidence of moderate association with correlation coefficients of 0.48-0.52. S'wave 
also has good discriminative capability with AUROCC of 0.80 for RVEFCMR≤30%. 
Again, S'Wave showed no association in this cohort and no predictive ability. 
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The reason why these echo parameters may be predictive in other populations, 
but not in the current lung resection cohort is discussed next. 
Study Population Parameter Association Prediction 
   
Correlation 
coefficient 
AUROCC 
Schenk et 
al.301 
(2000) 
n = 32 
patients 
presenting for 
lung 
transplantation 
FAC 0.84 - 
Kjaergaard 
et al.132 
(2006) 
n = 34 
17 prior STEMI 
7 prior PE 
10 normal 
FAC 0.34 (ns) - 
TAPSE 0.48 - 
Anavekar et 
al.300 
(2007) 
n = 36 
mixed 
FAC 0.80 - 
Pavlicek et 
al.122 
(2011) 
n = 223 (mixed) 
38 normal 
36 IHD 
51 CM 
12 VHD 
30 TOF 
19Transposition 
29 other CHD 
8 PH 
FAC 0.47 
RVEF≤50% = 0.73 
RVEF≤30% = 0.88 
TAPSE 0.34 
RVEF≤50% = 0.72 
RVEF≤30% = 0.79 
S'Wave 0.48 
RVEF≤50% = 0.78 
RVEF≤30% = 0.80 
Focardi et 
al.121 
(2015) 
n = 63 (mixed) 
21 ?myocarditis 
8 IDC 
10 HCM 
10 ARVD 
5 Infiltrative CM 
9 other 
FAC 0.77 
RVEF≤45% = 0.78 
 
TAPSE 0.45 RVEF≤45% = 0.66 
S'Wave 0.52 - 
Hamilton 
Craig et 
al.131 
(2016) 
n = 92 
- 46 normal 
- 46 others 
(CHD, ARVD, 
Ebsteins 
anomaly, PH, 
septal defects) 
FAC - RVEF≤45% = 0.89 
TAPSE - RVEF≤45% = 0.85 
Table 40. Summary of literature comparing RVEFCMR with FAC, TAPSE and S'Wave 
Correlation coefficients are all Pearson's, FAC = fractional area change, TAPSE = tricuspid annular 
plane systolic excursion, ns = non significant, S'Wave = S' Wave velocity at the tricuspid annulus, 
AUROCC = area under the receiver operating characteristic curve, STEMI = ST elevation 
myocardial infarction, PE = pulmonary embolus, IHD = ischaemic heart disease, VHD = valvular 
heart disease, TOF = tetralogy of fallot, CHD = congenital heart disease, IDC = idiopathic dilated 
cardiomyopathy, HCM = hypertrophic cardiomyopathy, ARVD = arrhythmogenic right ventricular 
dysplasia, CM = cardiomyopathy, Transposition = transposition of the great arteries. 
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A number of reasons may account for why these variables have shown good 
association in other populations but not in this cohort. First, may be as a result of 
the inherent differences of the patients themselves; as can be seen in Table 40 
(pg 222), the majority of studies had heterogeneous examples of cardiovascular 
disease with likely dysfunction. Of the entire cohort in the current investigation, 
22.2% had IHD and none had active cardiac failure. The mechanism of RV 
dysfunction may be important; with elevated afterload popularly hypothesised in 
the lung resection cohort but multiple other mechanisms present in the previous 
studies. The echocardiographic parameters may be predictive in one population 
but not in another. 
The range of RVEFCMR values in the current cohort is also important. In the study 
by Pavlicek et al. 27 patients (12.1%) had evidence of RVEFCMR ≤30%, this is 
contrast to one patient (1.5%) in the current investigation. This can be seen in 
Figure 78 where mean (95%CI) values of RVEFCMR and TAPSE from the current 
study have been superimposed on results by Pavlicek et al.122. The current study 
has a tighter range of RVEFCMR and TAPSE in comparison to this previous work 
with the majority of values falling outside the range of the current study. 
 
Figure 78. TAPSE and RVEFCMR from Pavlicek et al.
122 with addition of data from current 
investigation 
Red box represents the mean (95% CI) of RVEFCMR and TAPSE from the current investigation. RVEF 
= 47.1% (33.5, 60.8), TAPSE = 21.10mm (13.75, 28.45).  
 
As described in section 2.3.2, (pg 85), extremes of data can contribute to improved 
correlation statistics. Studies comparing echocardiographic measures of RV 
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function may have good correlation coefficients as a result of normal controls and 
study participants with severe RV dysfunction.  
 
Figure 79. S'Wave velocity and RVEFCMR from Pavlicek et al.
122 with addition of data from 
current investigation 
A) Original figure from Pavlicek et al. showing association of S'Wave and RVEFCMR B) Amended 
image with addition of S'Wave and CMR data from current investigation. 
 
As can be seen from Figure 79B, the distribution of S'Wave results from the 
current investigation falls entirely within the distribution of results from the study by 
Pavlicek et al. (n=223). The impact of normal controls (top right of Figure 79B with 
RVEFCMR >50%) and those with severe RV dysfunction (bottom left of Figure 79B 
with RVEFCMR ≤30%) would improve the association and provide better predictive 
power. 
The purpose of this discussion is not to suggest that more patients are required to 
show association but to account for why the variables were not reliable in this 
population. It appears that the population undergoing lung resection has a lower 
RVEFCMR than the normal population and that when RV dysfunction develops in 
the post-op period that it is not as severe as those with primary cardiac pathology. 
This tighter range means that association with other parameters is harder to 
demonstrate. The cohort in this investigation is representative of a typical group of 
patients undergoing lung resection (See Table 20, pg 167) and if the parameters 
are not able to provide reliable information on RV function then they are not 
appropriate for use in this population.  
In validation studies, the adequacy of the reference method must also be 
considered122. RVEFCMR was used in this investigation as it is established as a 
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reference method for validation of RV echocardiographic parameters. Despite its 
widespread use it is not a measure of RV contractility and is highly load 
dependent. In this setting where the most commonly hypothesised mechanism for 
RV dysfunction following lung resection is elevated afterload, this is important. 
Without information on loading conditions, there is a confounder that is not 
accounted for in this investigation and means that we cannot determine if these 
echocardiographic parameters can provide load independent information on 
contractility. 
6.4.1 Strengths and limitations 
A strength of this investigation is that it attempts to validate parameters in a real 
world representative population. This means they are being assessed in the 
population where they will be used and not extrapolated from other clinical 
situations. The robust assessment of RV parameters, with dual analysis of 
anonymised images, assessment of within patient correlation and assessment of 
trends over time mean we can be confident that these results are valid. 
Lack of agreement between the author and echocardiography technicians for 
determination of FAC is a weakness of this study. With paired analyses only 
available for 2/3 of the patients, the results for this parameter are not as robust as 
for TAPSE and S'Wave. Sensitivity analysis using only the values by ET's 
suggested there was no significant difference to the results displayed.  
The deterioration of imaging availability on POD 2 is important as more than 10% 
of patients (even for S'Wave, the most available of the current imaging 
parameters) will not have echocardiographic assessment possible in the 
immediate post-op period. A reliable imaging parameter at this time would have 
utility in this population. 
6.5  Conclusion 
The conventional echo parameters FAC, TAPSE and S'Wave are not valid for the 
assessment of RV function following lung resection. Further work should look at 
alternative, novel, echocardiographic methods for assessment of RV function and 
may incorporate the use of biomarkers to improve the identification of patients with 
poor RV function in the post-op period following lung resection. 
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Chapter 7  Speckle Tracked Strain Assessment of 
RV Function 
This chapter describes the use of speckle tracked strain (strain) for assessment of 
RV function. It will first describe imaging availability and reproducibility, it will then 
describe changes in strain over time and will finally make comparison with 
RVEFCMR as a reference method for assessment of RV function. 
As described in chapter 6, Trans Thoracic Echocardiography (TTE) was well 
tolerated, with 27 patients (100%) undergoing pre-op echo imaging, twenty-six 
(96.3%) on POD 2 and twenty-four at 2-months. Following first analysis, there 
were 17 scans with discrepancy in results between the author and Dr Piotr 
Sonecki (Consultant cardiologist with an interest in cardiac imaging). These scans 
were selected for dual analysis with Dr Sonecki; five yielded no further results, six 
had free wall strain when it wasn't previously available and six had free wall and 
global strain when it wasn't previously available. Global and free-wall strain results 
were available on 27 patients (100%) pre-operatively, 22 patients (84.6%) on POD 
2 and 24 (100%) at 2-months. Of those with imaging unavailable in the immediate 
post-op period, three (75%) had left sided resections and one (25%) had a right 
sided resection. 
7.1  Intra and inter-observer variability 
Strain imaging showed good reproducibility with intraclass correlation coefficients 
above 0.91 for both inter and intra-observer variability (Figure 80, Figure 81 [pg 
227] and Table 41 [pg 228]). 
 
 
 
 
 
Chapter 7  227 
 
 
 
 
Figure 80. Inter-observer variability of RV strain measurements 
n=8. Dashed line is line of identity. RV-GPLS = RV global peak longitudinal strain, PS = Piotr 
Sonecki (imaging cardiologist). 
 
 
Figure 81. Intra-observer variability of RV strain measurements 
n=19. Dashed line is line of identity. RV-GPLS = RV global peak longitudinal strain. 
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Inter-observer variation 
 ICC Agreement (95% CI) 
RV-GPLS  (n=8) 0.913 (0.631, 0.982)  p<0.0005 
  
Intra-observer variation 
  ICC Agreement (95% CI) 
RV-GPLS  (n=19) 0.930 (0.823, 0.973)  p<0.0005 
Table 41. Inter and intra-observer variation for RV-GPLS measurements 
ICC = intraclass correlation coefficient, RV-GPLS = RV global peak longitudinal strain. Intraclass 
correlation coefficient calculated as mixed effect, absolute agreement with single measures. 
 
7.2  Changes in right ventricular strain over time 
As can be seen in Figure 82, Figure 83 and Table 42 (pg 229), there were no 
changes in either RV-global or RV-free wall peak longitudinal strain (RV-GPLS or 
RV-FWPLS) over the duration of the study (p>0.229, Friedman's test)T. 
 
 
Figure 82. Changes in RV-GPLS over time 
Box plots represent median, IQR and range. RV-GPLS = RV free wall peak longitudinal strain, POD 
= post-op day. 
 
                                            
T Longitudinal strain represents myocardial shortening and more negative values represent better 
function and values closer to zero represent poorer function. 
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Figure 83. Changes in RV-FWPLS over time 
Box plots represent median, IQR and range. RV-FWPLS = RV free wall peak longitudinal strain, 
POD = post-op day. 
 
 Pre-op POD 2 2 Months p-value 
 n=27 n=22 n=24  
RV-GPLS -17.7 (-20.1, -13.6) -17.5 (-21.8, -14.1) -17.8 (-18.8, -12.2) 0.387* 
     
RV-FWPLS -22.1 (-27.2, -16.0) -20.4 (-26.5, -13.3) -22.7 (-26.1, -18.6) 0.229* 
Table 42. RV-GPLS and RV-FWPLS values over time 
Values are median (IQR). * = Friedman's test. POD = post-op day, RV-GPLS = RV global peak 
longitudinal strain, RV-FWPLS = RV free wall peak longitudinal strain. 
 
7.3 Association of strain and cardiovascular magnetic 
resonance determined right ventricular function 
Pooled analysis revealed moderate association between RV-GPLS, RV-FWPLS 
and RVEFCMR (Figure 84, Figure 85 [pg 230] and Table 43 [pg 231]). To allow 
adjustment for within-subject correlation, analysis of covariance (ANCOVA) was 
performed allowing within-subject variability to be partitioned out. Following within-
subject analysis there was no association between RV-GPLS and RVEFCMR, and a 
trend towards association between RV-FWPLS and RVEFCMR (p=0.054, Table 43). 
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Figure 84. Relationship of RV-GPLS and RV ejection fraction (RVEF) 
RVEF = right ventricular ejection fraction, RV-GPLS = RV global peak longitudinal strain. Pearson's 
correlation coefficient (pooled analysis).  
 
 
 
Figure 85. Relationship of RV-FWPLS and RV ejection fraction (RVEF) 
RVEF = right ventricular ejection fraction, RV-FWPLS = RV free wall peak longitudinal strain. 
Pearson's correlation coefficient (pooled analysis).  
 
 
Chapter 7  231 
 
 
 
Pooled analysis (Pearson's) 
  RV-GPLS RV-FWPLS 
RVEFCMR 
r -0.412 -0.477 
p 0.001 <0.0005 
    
Within-subject analysis (ANCOVA) 
  RV-GPLS RV-FWPLS 
RVEFCMR 
r 0.120 0.306 
p 0.454 0.054 
Table 43. Association of RV-GPLS and RV-FWPLS with RVEFCMR 
RVEF = right ventricular ejection fraction, ANCOVA = analysis of covariance, RV-GPLS = RV global 
peak longitudinal strain, RV-FWPLS = RV free wall peak longitudinal strain. Significant 
associations are highlighted in bold. 
 
The ability of the pooled values of RV-GPLS and RV-FWPLS to detect poor RV 
function, signified by RVEFCMR of ≤45%, was assessed using area under the 
receiver operating characteristic curve analysis (Figure 86). Both RV-GPLS and 
RV-FWPLS achieved significance (Table 44, pg 232).  
 
 
Figure 86. Receiver operating characteristic curves to identify RVEFCMR ≤45% using RV-GPLS 
and RV-FWPLS 
AUROCC = Area under the receiver operator characteristic curve, RVEF = Right ventricular 
ejection fraction, RV-GPLS = RV global peak longitudinal strain, RV-FWPLS = RV free wall peak 
longitudinal strain. 
 
AUROCC = 0.74 
95% CI (0.61, 0.87) 
AUROCC = 0.76 
95% CI (0.65, 0.88) 
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 RV-GPLS RV-FWPLS 
AUROCC (95%CI) 0.74 (0.61, 0.87) 0.76 (0.65, 0.88) 
p 0.001 <0.0005 
Cut-off valueU -17.7% -20.0% 
Sensitivity 76.0% 62.5% 
Specificity 66.7& 79.5% 
PPV 59.4% 65.2% 
NPV 81.3% 77.5% 
Table 44. Predictive performance of RV-GPLS and RV-FWPLS to detect RVEFCMR ≤45% 
AUROCC = area under the receiver operating characteristic curve, PPV = positive predictive 
value, NPV = negative predictive value, RVEF = right ventricular ejection fraction, RV-GPLS = RV 
global peak longitudinal strain, RV-FWPLS = RV free wall peak longitudinal strain. 
 
To assess the ability of RV-GPLS and RV-FWPLS to perform at each peri-
operative stage, analysis was performed at each individual time point (Figure 87 
and Figure 88 [pg 233]). 
 
Figure 87. Relationship of RV-GPLS and RV ejection fraction (RVEF) at each time point 
RVEF = Right ventricular ejection fraction, RV-GPLS = RV global peak longitudinal strain, POD = 
post-op day. Pearson's correlation coefficient (pooled analysis).  
 
                                            
U Defined by Youden's index (Maximum combination of sensitivity and specificity). 
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Figure 88. Relationship of RV-FWPLS and RV ejection fraction (RVEF) at each time point 
RVEF = right ventricular ejection fraction, RV-GPLS = RV global peak longitudinal strain, POD = 
post-op day. Pearson's correlation coefficient (pooled analysis).  
 
This analysis demonstrated moderate association of both RV-GPLS and RV-
FWPLS with RVEFCMR at each time point. The ability of the two strain parameters 
to predict RV dysfunction (signified as RVEF<45%) at each time point was 
assessed. RV-GPLS showed good predictive ability at each time point (AUROCC 
0.78-0.79, Table 45, pg 234). RV-FWPLS showed similar predictive ability pre-op 
(AUROCC 0.79), no discriminative ability at 2-months (AUROCC 0.68, p=0.147) 
and excellent predictive ability on POD 2 (AUROCC 0.86, Table 45 [pg 234] and 
Figure 89 [pg 235]). 
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  Pre-op POD 2 2 Months 
RV-
GPLS 
AUROCC 
(95%CI) 
0.79 (0.62, 0.96) 0.78 (0.56, 0.99) 0.79 (0.60, 0.98) 
p 0.047 0.047 0.018 
Cut-off valueV -16.5% -14.6% -17.3 
Sensitivity 100% 44.4% 67% 
Specificity 67% 100% 90% 
PPV 42% 100% 89% 
NPV 100% 64.3% 69% 
     
  Pre-op POD 2 2 Months 
RV-
FWPLS 
AUROCC 
(95%CI) 
0.79 (0.62, 0.96) 0.86 (0.69, 1.00) 0.683 
p 0.047 0.009 p = 0.147 
Cut-off valueW -21.8% -18.0%  
Sensitivity 100% 67% - 
Specificity 62% 100% - 
PPV 39% 100% - 
NPV 100% 75% - 
Table 45. Predictive performance of RV-GPLS and RV-FWPLS to detect RVEFCMR ≤45% at each 
peri-operative time point 
AUROCC = area under the receiver operating characteristic curve, PPV = positive predictive 
value, NPV = negative predictive value, RVEF = right ventricular ejection fraction, RV-GPLS = RV 
global peak longitudinal strain, RV-FWPLS = RV free wall peak longitudinal strain, POD = post-op 
day. 
 
                                            
V Defined by Youden's index (Maximum combination of sensitivity and specificity). 
W Defined by Youden's index (Maximum combination of sensitivity and specificity). 
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Figure 89. Receiver operating characteristic curve to identify RVEF ≤45% using RV-FWPLS on 
POD 2 
AUROCC = area under the receiver operator characteristic curve, RVEF = right ventricular 
ejection fraction, RV-FWPLS = RV free wall peak longitudinal strain. 
 
7.4  Trend analysis 
Trend analysis was performed to assess the ability of RV-GPLS and RV-FWPLS 
to detect changes in RVEFCMR between time points. Change in the strain 
parameters (ΔRV-GPLS and ΔRV-FWPLS) was compared with change in 
RVEFCMR (ΔRVEF, Figure 90). 
 
Figure 90. ΔRV-GPLS (n=56) and ΔFWPLS (n=54) against ΔRVEFCMR 
Pearson's correlation coefficient as illustrated. ΔRVEF = change in right ventricular ejection 
fraction, ΔRV-GPLS = change in RV global peak longitudinal strain, ΔRV-FWPLS = change in RV 
free wall peak longitudinal strain. 
AUROCC = 0.86 
95% CI (0.69, 1.00) 
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There was no association between ΔRV-GPLS and ΔRVEFCMR (Figure 90). ΔRV-
FWPLS showed moderate association with ΔRVEFCMR. The predictive ability of 
both strain parameters to detect a change in RVEFCMR was further assessed. The 
standard deviation of ΔRVEFCMR, 7.55%, was used as the minimal change that 
would be useful to determine from strain and AUROCC analysis was performed. 
Neither parameter showed predictive power for ΔRVEF >7.55% (Table 46). 
 
 ΔRV-GPLS ΔRV-FWPLS 
AUROCC (95%CI) 0.62 (0.45, 0.78) 0.58 (0.41, 0.75) 
p 0.171 0.331 
Table 46. Receiver operating characteristic analysis to detect ΔRVEF >7.55% 
AUROCC = Area under the receiver operating characteristic curve, RVEF = Right ventricular 
ejection fraction, RV-GPLS = RV global peak longitudinal strain, RV-FWPLS = RV free wall peak 
longitudinal strain. 
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7.5  Discussion 
This investigation describes changes in longitudinal RV strain following lung 
resection. It also describes validation against a reference method for assessment 
of RV function. It's main finding is that speckle tracked strain, particularly RV-
FWPLS, may have utility to determine RV function in this population. 
Strain results were available in 100% of patients pre-operatively and at 2-months. 
As demonstrated in 0, surgery appeared to have an impact on imaging availability 
with strain results only available in 84.6% of participants on POD 2. Three quarters 
of unavailable scans were on those patients having left sided resections 
suggesting this group had difficulties with imaging availability. Where initial results 
were provided by both authors, strain values were reproducible with good intra 
class correlation coefficients.  
The study has been unable to demonstrate any change in strain over the duration 
of the study. The lack of change observed is in contrast to a 2016 study by Wang 
et al. which measured longitudinal RV strain one week following lung resection in a 
mixed pneumonectomy and lobectomy cohort (n=30). They demonstrated RV-
GPLS and RV-FWPLS (corrected for heart rate) deteriorated following lung 
resection, with the magnitude of change larger in the group undergoing 
pneumonectomy (Figure 91). This study used the same software as utilised in the 
current investigation and they report no problems with image analysis in the post-
op period. Inter and intra-observer variability was similar with ICC's of 0.84 and 
0.87.  
 
Figure 91. RV-GPLS and RV-FWPLS following lung resection redrawn from Wang et al.206 
Significant differences within groups as illustrated. RV-GPLS = RV global peak longitudinal strain, 
RV-FWPLS = RV free wall peak longitudinal strain, Grey = pre-op, White = one week post-op. 
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A number of reasons may account for the difference in results between the current 
investigation and this previous study by Wang et al. The timing of assessment may 
be important as the current investigation examined patients on POD 2 and it is 
uncertain whether RV function continues to deteriorate following this time-point. 
The study population may also impact the results, the population recruited by 
Wang was younger than the cohort in the current study (57.0±11.4 years vs 
65.2±10.8 years) and their protocol excluded patients with hypertension, diabetes 
and coronary artery disease. In contrast, 33.3% of participants in the current 
investigation had hypertension and 22.2% had coronary artery disease. The 
patients being younger and with fewer comorbidities may account for better 
baseline RV function (RV-FWPLS of -29.7±6.2% in Wang et al. vs RV-FWPLS of -
22.2±7.5% in current study). The larger drop in RV function observed by Wang et 
al. may support the hypothesis described in section 5.7, pg 197 that better RV 
function pre-operatively, results in a larger drop in RV function following lung 
resection. This is potentially as a result of prior exposure to elevated RV afterload 
allowing better tolerance of acute changes at the time of surgery. 
As strain parameters have been reported to be influenced by heart rate302, with 
higher heart rate resulting in lower strain (poorer function), Wang et al. "used heart 
rate as a covariate" when analysing changes following surgery. The methods 
within the paper did not describe how this was performed and no response was 
received when the authors were contacted about their methods (personal 
communication x 3, February 2017).  
The impact of heart rate on strain results in this cohort was assessed on an 
exploratory basis. There was no association between the strain parameters (RV-
GPLS or RV-FWPLS) and heart rate on pooled analysis (p>0.115). Two multiple 
linear regression models incorporating the strain parameters, heart rate and the 
patient (to account for within patient association) were created. The models for 
RV-GPLS (p=0.094 r2=0.72) and RV-FWPLS (p=0.51, r2=0.089) were both non-
significant, with heart rate not making a significant contribution (p>0.102 for both) 
to either. In other studies examining speckle tracked RV strain, no attempt has 
been made to correct for heart rate121, 167, 303-305 therefore, no correction has been 
made in this investigation. 
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RV strain has been shown to have clinical utility for assessment of RV function, 
with predictive value in pulmonary hypertension303, 304, heart failure306 and acute 
myocardial infarction307. As longitudinal shortening is the major contributor to 
overall RV performance, longitudinal strain has been suggested as a surrogate for 
global RV function. Unlike other echo parameters, such as TAPSE and S'Wave 
(section 4.4.2.2.2, pg 151 and section 4.4.2.2.3, pg 152), which measure 
displacement or velocity of only the basal segment, STE allows analysis of the 
entire RV free wall and interventricular septum. The RV can additionally be divided 
in to six segments (three each for the free wall and septum, see Figure 40, pg 
158), allowing true regional assessment of RV function. Unlike echocardiographic 
volumetric assessment, there are no geometric assumptions. 
Strain measurements are independent of global cardiac movement which can 
impact Tricuspid Annular Plane Systolic Excursion (TAPSE) and S'Wave velocity 
at the tricuspid annulus (S'Wave) analysis. As well as the impact of global cardiac 
translation, TAPSE and S'Wave are also angle dependent measures of RV 
function308. Speckle tracked strain is angle independent, meaning there is not a 
reliance on obtaining a low angle of incidence (<20o) as is required for tissue 
Doppler measurements.  
Strain assessment of the RV has previously been suggested as a load 
independent measure of RV contractility and this was the rationale for including it 
in this study151, 309. However, when examined robustly this appears to be incorrect, 
with Missant et al.310 demonstrating in a sheep model (n=6) that maximal strain 
rate was associated with the slope of the preload recruitable stroke work 
relationship (a load independent measure of RV contractility). They also 
demonstrated however, that as afterload increased (from banding of the PA), 
strain rate was reduced while contractility was unchanged. This suggested that 
during inotropy, strain rate tracked changes in contractility, but not when afterload 
was altered suggesting strain rate is not load independent. 
A review article examining RV strain by La Gerche et al. provides worked 
examples of how deformation parameters (such as strain) cannot be load 
independent and explains that reduced RV deformation is not synonymous with 
myocardial dysfunction when afterload changes. In disease states with increased 
afterload they described three situations that may occur149: 
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1. Normal deformation (strain) as a result of normal afterload or increased 
afterload and increased contractility. 
2. Reduced deformation (strain) due to increased afterload but maintained 
contractility. 
3. Reduced deformation (strain) due to increased afterload and/or reduced 
contractility. 
A further clinical example of load dependence is provided by Puwanant et al. who 
demonstrate RV strain is strongly associated with pulmonary artery pressure 
(increasing pressure was associated with reduced strain i.e. poorer RV function) 
when it would be expected that contractility would be increasing in this situation112, 
311. In a swine model of repaired tetralogy of Fallot, Hodzic et al. demonstrated no 
association between conductance catheter determined Emax (the reference method 
for load independent contractility) and strain measurements. Furthermore strain 
was associated with RV end systolic pressure (used as a surrogate of afterload) 
and RV end diastolic volume (used as a surrogate of preload), confirming its load 
dependence312. 
Previous work has highlighted the potential benefit of strain parameters for 
assessment of RV function and has shown them to perform better than 
conventional parameters of RV function when compared to reference methods121, 
122, 150, 313, 314. Focardi et al. demonstrated RV-FWPLS showed excellent predictive 
power for RVEFCMR ≤45% with an AUROCC of 0.92 in a heterogeneous population 
referred for CMR evaluation121. RV-GPLS did not perform as well in this population 
with an AUROCC of 0.78, although both strain parameters outperformed 
conventional echo parameters (AUROCC of 0.66 for TAPSE and 0.78 for FAC). 
Strain has also been shown to be predictive of RV dysfunction in other groups. In 
a population with ischaemic cardiomyopathy, Park et al. showed RV-GPLS had an 
AUROCC of 0.96 for detection of RVEFCMR≤50%
150. No study has attempted to 
validate RV-FWPLS or RV-GPLS in a lung resection cohort. 
This study has demonstrated association between RV-GPLS, RV-FWPLS and 
RVEFCMR on pooled analysis. When taking account of within subject factors, RV-
GPLS showed no association and RV-FWPLS only showed a trend towards 
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association (p=0.054). AUROCC analysis of the pooled results showed that both 
had good predictive power for RV dysfunction with AUROCC of 0.74 for RV-GPLS 
and 0.76 for RV-FWPLS. To assess the ability of the two parameters to predict RV 
dysfunction at each peri-operative stage, an individual analysis was performed at 
each time point which showed that RV-GPLS had predictive power at all time 
points (AUROCC 0.78-0.79) and that RV-FWPLS had predictive power pre-op and 
on POD 2 (AUROCC 0.79-0.86). Trend analysis demonstrated association 
between ΔRVEFCMR and ΔRV-FWPLS, but no association with ΔRV-GPLS. 
Neither variable showed predictive power for a change in RVEFCMR of one 
standard deviation. 
The poorer association between strain and RVEFCMR demonstrated within this 
investigation will also have been impacted by the factors that influence the 
conventional echo parameters described in section 6.4, pg 218. The tighter range 
of RV function in the current study, compared to the wide range of RV function in 
validation studies, mean association will be harder to demonstrate. 
7.5.1 Strengths and limitations 
The robust assessment of a novel echo parameter and its validation against a 
reference method in a representative population is a strength of this investigation. 
This includes dual reporting of anonymised scans with good agreement for dual 
reported images (signified by intraclass correlation coefficients >0.9). 
A limitation of the STE technique is the dependence on image quality to obtain 
values. This was seen in the early period following lung resection when strain 
results were only available in 84.6% of participants on POD 2. The thin RV wall 
means it is difficult to define an accurate region of interest with the problem 
compounded when image quality is poor76, 308. These difficulties may have 
contributed to the discrepancy between observers, with 22.1% of scans requiring 
expert review and some of these yielding additional results. 
The software utilised for strain analysis in this investigation had no specific RV 
tool, requiring use of an LV strain protocol applied to the RV. Software platforms 
specifically for RV strain analysis have now been developed. Additionally, there is 
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significant inter-vendor variability, meaning results may be influenced by the 
software used315-317. 
7.6  Conclusion 
This investigation demonstrates that RV-FWPLS may have utility as a validated 
method for assessment of RV systolic function following lung resection. Strain has 
the potential to overcome some of the difficulties associated with standard 
echocardiographic assessment of the RV. Although not the ideal measure, it 
shows promise and performs better than the conventional methods discussed in 
chapter 6.  
Further work in larger numbers will be required for confirmation of these findings. 
Additionally, investigations using RV specific speckle tracked echocardiography 
platforms may improve the predictive ability of strain for poor RV function in this 
population. 
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Chapter 8  Biomarkers of Myocardial Dysfunction 
8.1  Introduction 
This chapter describes the results of the biomarkers of myocardial dysfunction; B-
type natriuretic peptide (BNP) and high sensitivity troponin T (hsTnT). Firstly it will 
describe changes in the biomarkers over time. Secondly, the association between 
these biomarkers and cardiac function will be assessed. Finally, on an exploratory 
basis, a comparison with post-op outcomes and functional capacity will be made. 
Other than at 2-months post-op, BNP results were available for all 27 study 
participants at all time points. At 2-months, samples were available for 24 patients. 
Of the three participants without samples at 2-months, one declined venepuncture, 
one was unwell in another hospital and was unable to attend follow-up, and the 
third was as a result of administration error. Troponin results were available for 26 
participants from pre-op to POD 2 and for 22 participants at 2-months. The 
reasons for unavailability of samples at 2-months were the same as for BNP, with 
an additional two not available as a result of laboratory administration errorX. The 
troponin results unavailable at the other time points were as a result of laboratory 
administration error.  
Coefficients of variation for BNP and hsTnT were 5.9% (calculated from frozen 
controls as described in section 4.6.2.2, pg 161) and <10% (report from 
biochemistry lab at Golden Jubilee National Hospital) respectively.  
8.2  Changes in biomarkers over time 
BNP increased over time, peaking on POD 2 and returning to baseline levels by 2-
months (Figure 92, pg 244 and Table 47, pg 245). HsTnT showed a small but 
statistically significant post-op rise (Figure 93, pg 244 and Table 47, pg 245).  
 
 
                                            
X BNP analysis was performed by the author and hsTnT analysis was performed by labs at the 
Golden Jubilee National Hospital. 
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Figure 92. Changes in BNP over time 
Box plots represent median, IQR and range. Changes over time assessed with Friedman's test, 
p<0.0005. Post-hoc comparisons with Wilcoxon rank sum test. Pre-op = immediately pre-op, prior 
to induction of anaesthesia, Post-op = immediately post-op, extubated in the recovery area, POD 
= post-op day, BNP = B-type natriuretic peptide. 
 
 
 
Figure 93. Changes in hsTnT over time 
Box plots represent median, IQR and range. Changes over time assessed with Friedman's test, 
p<0.0005. Post-hoc comparisons with Wilcoxon rank sum test. Pre-op = immediately pre-op, prior 
to induction of anaesthesia, Post-op = immediately post-op, extubated in the recovery area, POD 
= post-op day, hsTnT = high sensitivity troponin T. 
  
 
2
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Biomarkers of myocardial dysfunction 
 pre-op post-op POD 1 POD 2 2-months p-value 
 n=27 n=27 n=27 n=27 n=24  
BNP (pg/ml) 
28.0 
(5.0,160.0) 
32.0 
(6.0,170.0) 
71.0 
(5.0, 381.0)† ‡ 
93.0 
(5.0, 304.0)† ‡ 
28.5 
(5.0,199.0)§ll 
<0.0005* 
       
 n=26 n=26 n=26 n=26 n=22  
hsTnT (pg/ml) 
6.8 
(3.0, 27.2) 
6.9 
(3.0, 23.2) 
12.3 
(3.7, 21.9)†‡ 
9.5 
(3, 20.7)†‡ 
9.0 
(3.9, 24.9)†‡ 
<0.0005* 
Table 47. Biomarkers of myocardial function over time 
Data are presented as median (IQR), * = Friedman's Test, † = significant difference from pre-op, ‡ = significant difference from immediate post-op, § = significant 
difference from POD 1, ll = significant difference from POD 2, pre-op = immediately pre-op, prior to induction of anaesthesia, Post-op = immediately post-op, 
extubated in the recovery area, POD = post-op day, BNP = B-type natriuretic peptide, hsTnT = high sensitivity troponin T. 
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8.3  Association of biomarkers with cardiac function by 
cardiovascular magnetic resonance 
Association between the biomarkers and CMR determined cardiac function was 
assessed at each peri-operative time point. A summary is displayed in Table 48, 
pg 247. As evident in Table 48 (pg 247), there is moderate negative association 
between BNPPOD2 and RVEFPOD2 (Figure 94).  
 
Figure 94. Association between RVEFPOD2 and BNPPOD2 
Pearson's correlation coefficient, RVEF = right ventricular ejection fraction, BNP = B-type 
natriuretic peptide, POD = post-op day. 
 
There is also evidence of negative association between both RVEF2months, 
LVEF2months and; hsTnTpreop, hsTnTpostop and hsTnT2months. Visual inspection of 
these plots however, showed an outlier influencing the association (Figure 95).  
 
Figure 95. Association between LVEFCMR at 2-months and hsTnT at peri-op time points 
A) pre-op hsTnT, B) post-op hsTnT, C) 2-months hsTnT. LVEF = Left ventricular ejection fraction, 
hsTnT = high sensitivity troponin T. Black arrows indicate outlier described in section 8.3, pg 
246. 
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Table 48. Association of biomarkers of myocardial dysfunction with RVEFCMR and LVEFCMR 
All associations are Pearson's correlation coefficient. Significant associations are highlighted in 
BOLD. Pre-op = immediately pre-op, prior to induction of anaesthesia, Post-op = immediately 
post-op extubated in the recovery area, POD = post-op day, BNP = B-type natriuretic peptide, 
hsTnT = high sensitivity troponin T. 
  RVEFCMR LVEFCMR 
  pre-op POD 2 2months pre-op POD 2 2months 
BNPpreop 
r 0.15 0.21 0.16 0.21 0.13 -0.20 
p 0.468 0.346 0.465 0.313 0.560 0.357 
n 26 22 24 26 22 24 
  
 
  
 
  
BNPpostop 
r 0.18 0.13 0.07 -0.18 
p 0.42 0.56 0.76 0.41 
n 22 24 22 24 
      
BNPPOD1 
r -0.07 0.09 -0.28 -0.17 
p 0.749 0.693 0.202 0.428 
n 22 24 22 24 
      
BNPPOD2 
r -0.44 -0.04 -0.06 -0.19 
p 0.041 0.867 0.782 0.371 
n 22 24 22 24 
  
 
 
 
 
BNP2months 
r 0.12 -0.06 
p 0.601 0.777 
n 23 23 
        
hsTnTpreop 
r 0.01 -0.02 -0.43 -0.23 -0.59 -0.47 
p 0.973 0.932 0.034 0.280 0.004 0.022 
n 25 22 24 25 22 24 
  
 
  
 
  
hsTnTpostop 
r 0.16 -0.41 -0.44 -0.41 
p 0.480 0.046 0.048 0.044 
n 21 24 21 24 
      
hsTnTPOD1 
r -0.09 -0.20 -0.26 -0.14 
p 0.696 0.349 0.264 0.516 
n 21 24 21 24 
      
hsTnTPOD2 
r -0.08 0.12 -0.36 0.05 
p 0.734 0.601 0.110 0.823 
n 21 23 21 23 
  
 
 
 
 
hsTnT2months 
r -0.49* -0.44 
p 0.025 0.045 
n 21 21 
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This patient has been previously described as an outlier for cardiac function at 2-
months (Footnote P, pg 180). Sensitivity analysis with this patient excluded 
resulted in loss of the linear relationship and no statistical significance (p>0.247 for 
all). This pattern was the same for association between RVEF2months and 
hsTnTpreop, hsTnTpostop and hsTnT2months. Again, sensitivity analysis with this 
patient excluded resulted in loss of the linear relationship and no statistical 
significance (p>0.304 for all, figures not shown). There is also moderate negative 
association between hsTnTpreop, hsTnTpostop and LVEFPOD2 (Table 48, pg 247 and 
Figure 96). This suggests that those patients with higher troponin immediately 
before and immediately after lung resection had poorer LV function on POD 2 
(signified by lower LVEFPOD2). 
 
Figure 96. Association between LVEFCMR on POD 2 and hsTnT at peri-op time points 
A) Immediately pre-op hsTnT, B) Immediately post-op hsTnT, associations are Spearman's 
correlation coefficient, LVEF = left ventricular ejection fraction, hsTnT = high sensitivity 
troponin T, POD = post-op day. 
 
The association between the absolute biomarkers and change in cardiac function 
(ΔRVEFCMR and ΔLVEFCMR) was assessed (Table 49, pg 249). Finally, to fully 
explore the potential role of the biomarkers in assessing post-op cardiac function, 
association between a change in the biomarkers (ΔBNP and ΔhsTnT) was 
compared with absolute cardiac function (Table 50, pg 250).  
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  ΔRVEF ΔLVEF 
  
POD2- 
preop 
2months-
preop 
POD2- 
preop 
2months-
preop 
BNPpreop 
r -0.03 0.06 -0.14 -0.34 
p 0.893 0.788 0.533 0.108 
n 22 23 22 23 
      
BNPPOD2 
r -0.52* -0.06 -0.29 -0.38 
p 0.014 0.803 0.195 0.076 
n 22 23 22 23 
  
 
 
 
 
BNP2months 
r -0.11 -0.35 
p 0.643 0.116 
n 22 22 
      
hsTnTpreop 
r 0.06 -0.43* -0.36 -0.30 
p 0.805 0.039 0.098 0.158 
n 22 23 22 23 
      
hsTnTPOD2 
r -0.27 -0.07 -0.32 0.09 
p 0.234 0.757 0.160 0.707 
n 21 22 21 22 
  
 
 
 
 
hsTnT2months 
r -0.34 -0.31 
p 0.142 0.188 
n 20 20 
Table 49. Association of biomarkers of myocardial dysfunction with ΔRVEFCMR and ΔLVEFCMR 
All associations are Pearson's correlation coefficient. Significant associations are highlighted in 
BOLD. Pre-op = Immediately pre-op prior to induction of anaesthesia, Post-op = Immediately 
post-op extubated in recovery area, POD = post-op day, BNP = B-type natriuretic peptide, hsTnT 
= high sensitivity troponin T. 
 
There was evidence of moderate negative association between BNPPOD2 and 
ΔRVEFPOD2-preop, this suggests that those patients with the highest BNP on POD2 
were those with the largest change in RVEFCMR by the same time point (Table 49 
and Figure 97, pg 250). There was also association between ΔRVEF2months-preop 
and hsTnTpreop; this association was impacted by a single outlier (participant with 
largest drop in RVEFCMR by 2-months as previously described). Sensitivity analysis 
with this patient excluded resulted in loss of any linear association with no 
statistical significance (p=0.505, figure not shown). 
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Figure 97. Association between ΔRVEFPOD2-pre and BNPPOD2 
Associations is Pearson's correlation coefficient with p-value as illustrated, RVEF = right 
ventricular ejection fraction, BNP = B-type natriuretic peptide, POD = post-op day. 
 
A moderate negative association between RV function on POD 2 and change in 
both biomarkers by this time point was demonstrated (ΔBNPPOD2-preop and 
ΔhsTnTPOD2-preop). There was no association between LV function and the change 
in the biomarkers (Table 50 and Figure 98, pg 251). 
   RVEFPOD2 LVEFPOD2 
ΔBNP 
POD2-
preop 
r -0.52 -0.14 
p 0.012 0.535 
n 22 22 
     
ΔhsTnT 
POD2-
preop 
r -0.46 0.07 
p 0.035 0.762 
n 21 21 
Table 50. Association of ΔBNPPOD2-preop and ΔhsTnTPOD2-preop with cardiac function on POD 2 
Associations are Pearson's correlation coefficient. Significant associations are highlighted in 
BOLD. Pre-op = immediately pre-op, prior to induction of anaesthesia, POD = post-op day, BNP = 
B-type natriuretic peptide, hsTnT = high sensitivity troponin T, RVEF = right ventricular ejection 
fraction, LVEF = left ventricular ejection fraction. 
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Figure 98. Association between ΔBNPPOD2-preop , ΔhsTnTPOD2-preop and RVEFPOD2 
Pearson's correlation coefficient. Pre-op = immediately pre-op, prior to induction of anaesthesia, 
POD = post-op day, BNP = B-type natriuretic peptide, hsTnT = high sensitivity troponin T, RVEF = 
right ventricular ejection fraction. 
 
 
8.3.1 Prediction of right ventricular dysfunction 
This study demonstrated moderate negative association between RVEFPOD2 and; 
BNPPOD2, ΔBNPPOD2-preop and ΔhsTnTPOD2-preop. There is also moderate negative 
association between ΔRVEFPOD2-preop and BNPPOD2. The ability of these 
parameters to predict RV dysfunction on POD 2 (defined as RVEFCMR≤45%) were 
assessed. 
 
Figure 99. BNPPOD2, ΔBNPPOD2-preop and ΔhsTnTPOD2-preop versus RVEFPOD2>45% and RVEFPOD2≤45%  
Box plots represent median, IQR and range. All comparisons are Mann-Whitney U-Test, Pre-op = 
immediately pre-op, prior to induction of anaesthesia, POD = post-op day, BNP = B-type 
natriuretic peptide, hsTnT = high sensitivity troponin T, RVEF = right ventricular ejection 
fraction. 
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There was a difference in ΔBNPPOD2-preop between those with RVEF>45% and 
those with RVEF ≤45%. There was no difference in the other parameters between 
the two groups (Figure 99, above). Using area under the receiver operating 
characteristic curve (AUROCC) analysis, the predictive ability of ΔBNPPOD2-preop to 
detect RVEFPOD2 ≤45% was assessed. This demonstrated an AUROCC of 0.78 
(Figure 100 and Table 51). 
 
Figure 100. Receiver operating characteristic identifying RVEFPOD2 ≤45% with ΔBNPPOD2-preop  
Pre-op = Immediately pre-op prior to induction of anaesthesia, POD = post-op day, BNP = B-type 
natriuretic peptide, RVEF = right ventricular ejection fraction. 
 
 
 ΔBNPPOD2-preop 
 RVEFCMR ≤45% 
AUROCC (95%CI) 0.78(0.58, 0.99) 
p 0.026 
Cut-off valueY 58.5 pg/ml 
Sensitivity 72.7% 
Specificity 90.9% 
PPV 88.8% 
NPV 76.9% 
Table 51. Predictive performance of a cut-off of ΔBNPPOD2-preop to detect RVEFPOD2 ≤45% 
AUROCC = Area under the receiver operating characteristic curve, PPV = positive predictive 
value, NPV = negative predictive value, Pre-op = immediately pre-op, prior to induction of 
anaesthesia, POD = post-op day, BNP = B-type natriuretic peptide, RVEF = right ventricular 
ejection fraction. 
                                            
Y Defined by Youden's index (Maximum combination of sensitivity and specificity). 
AUROCC = 0.78 
95% CI (0.58, 0. 99) 
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Given the association between ΔRVEFPOD2-preop and BNPPOD2, the ability of 
BNPPOD2 to predict a change in RVEF by POD 2 was assessed. As no minimal 
clinically important difference for change in RVEF following lung resection exists, 
the standard deviation of ΔRVEFPOD2-preop, 5.43%, was used as the minimal 
change that would be useful to determine and AUROCC analysis was performed. 
 
Figure 101. BNPPOD2 and ΔRVEFPOD2-preop ≥5.43% and ΔRVEFPOD2-preop <5.43%.  
Box plots represent median, IQR and range. A) Mann-Whitney U-Test. B) AUROCC to identify 
ΔRVEFPOD2-preop ≥5.43%. Pre-op = Immediately pre-op prior to induction of anaesthesia, POD = 
post-op day, BNP = B-type natriuretic peptide, RVEF =right ventricular ejection fraction.  
 
As can be seen in Figure 101A there was a difference in BNPPOD2 between 
ΔRVEFPOD2-preop ≥5.43% and ΔRVEFPOD2-preop <5.43%. BNPPOD2 was able to predict 
ΔRVEFPOD2-preop ≥5.43% with an AUROCC of 0.75 (Figure 101B and Table 52). 
 
 BNPPOD2 
 ΔRVEFPOD2-preop ≥5.43% 
AUROCC (95%CI) 0.75(0.54, 0.97) 
p 0.045 
Cut-off valueZ 125.5 pg/ml 
Sensitivity 63.6% 
Specificity 90.9% 
PPV 87.5% 
NPV 71.4% 
Table 52. Predictive performance of a cut-off of BNPPOD2 for ΔRVEFPOD2-preop ≥5.43% 
AUROCC = area under the receiver operating characteristic curve, PPV = positive predictive 
value, NPV = negative predictive value, Pre-op = immediately pre-op, prior to induction of 
anaesthesia, POD = post-op day, BNP = B-type natriuretic peptide, RVEF = right ventricular 
ejection fraction. 
                                            
Z Defined by Youden's index (Maximum combination of sensitivity and specificity). 
AUROCC = 0.75 
95% CI (0.54, 0. 97) 
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8.4  Biomarkers and post-operative outcomes 
As described in chapter 4, only two patients developed AF in the post-op period. 
Those patients were not outliers for BNP or hsTnT level at any time point (not 
shown). The association between the biomarkers and duration of stay (High 
dependency unit [HDU] and hospital) was explored. There was no relationship 
between hospital stay and the biomarkers, however there was a moderate positive 
association between BNPPOD2 and duration of HDU stay (r=0.462, p=0.015, 
Pearson's correlation coefficient, figure not shown) which was strengthened when 
ΔBNPPOD2-preop was compared (Figure 102).  
 
Figure 102. Association between ΔBNPPOD2-preop and HDU length of stay 
Pearson's correlation coefficient. Pre-op = immediately pre-op, prior to induction of anaesthesia, 
POD = post-op day, BNP = B-type natriuretic peptide, HDU = high dependency unit. 
 
8.5  Biomarkers and functional capacity 
The association between the biomarkers and functional capacity was explored. 
There was no evidence of association between BNPpreop or hsTnTpreop and any of 
the measures of functional capacity pre-operatively (p>0.123 for all, Spearman's 
correlation coefficient, not shown). Association was examined between the 
biomarkers and functional capacity at both 2-months and at 1-year (Table 53, pg 
255).  
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  2-months 1 year 
  WHO-PS MRC NYHA WHO-PS MRC NYHA 
BNPpreop 
r 0.21 0.24 0.15 -0.28 -0.02 0.02 
p 0.321 0.248 0.489 0.228 0.929 0.929 
n 25 25 25 20 21 22 
        
BNPpostop 
r 0.30 0.35 0.16 -0.23 -0.11 0.03 
p 0.142 0.086 0.452 0.337 0.648 0.880 
n 25 25 25 20 21 22 
        
BNPPOD1 
r 0.46 0.56 0.22 -0.41 -0.05 0.19 
p 0.020 0.003 0.288 0.074 0.831 0.410 
n 25 25 25 20 21 22 
        
BNPPOD2 
r 0.44 0.33 0.28 -0.32 -0.03 0.07 
p 0.027 0.105 0.178 0.170 0.886 0.757 
n 25 25 25 20 21 22 
        
BNP2months 
r 0.26 0.18 0.06 -0.26 0.15 0.10 
p 0.216 0.401 0.787 0.290 0.535 0.665 
n 24 24 24 18 19 20 
        
hsTnTpreop 
r -0.28 -0.02 0.02 -0.16 -0.27 0.05 
p 0.228 0.929 0.929 0.504 0.251 0.836 
n 20 21 22 19 20 21 
        
hsTnTpostop 
r -0.23 -0.11 0.03 -0.02 -0.19 0.08 
p 0.337 0.648 0.880 0.941 0.431 0.717 
n 20 21 22 19 20 21 
        
hsTnTPOD1 
r -0.41 -0.05 0.19 -0.24 -0.12 0.12 
p 0.074 0.831 0.410 0.331 0.622 0.595 
n 20 21 22 19 20 21 
        
hsTnTPOD2 
r -0.32 -0.03 0.07 -0.30 -0.16 -0.04 
p 0.170 0.886 0.757 0.201 0.500 0.872 
n 20 21 22 20 21 21 
        
hsTnT2months 
r -0.26 0.15 0.10 -0.42 -0.44 -0.20 
p 0.290 0.535 0.665 0.086 0.061 0.409 
n 18 19 20 18 19 20 
Table 53. Association between biomarkers and functional capacity at 2-months and 1 year 
All associations are Spearman's correlation coefficient. Significant associations are highlighted in 
BOLD. WHO-PS = World Health Organisation performance status. MRC = Medical Research Council 
dyspnoea scale. NYHA = New York Heart Association classification, Pre-op = immediately pre-op, 
prior to induction of anaesthesia, Post-op = immediately post-op, extubated in recovery area, 
POD = post-op day, BNP = B-type natriuretic peptide, hsTnT = high sensitivity troponin T. 
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There was moderate positive association between BNPPOD1, BNPPOD2 and World 
Health Organisation performance status (WHO-PS) at 2-months. There was also 
moderate positive association between BNPPOD1 and Medical Research Council 
dyspnoea scale (MRC-DS, Figure 103). There was no association between BNP 
and any of the measures of functional capacity at one year. There was no 
association between hsTnT with any of the measures of functional capacity at 2-
months or one year.  
 
Figure 103. Association between 2-month MRC-DS and BNPPOD1 
Spearman's correlation coefficient. MRC = Medical Research Council, POD = post-op day, BNP = B-
type natriuretic peptide. 
 
The association between the biomarkers and 6 minute walk test (6MWT) 
performance was explored. As can be seen in Figure 104 and Figure 105 (pg 
257), BNPpreop and hsTnTpreop were both higher in those participants who went on 
to have a deterioration in their 6MWT performance at 2-monthsAA. For the hsTnT 
group (Figure 105, pg 257) there was a change over time in the group with a 
deterioration in 6MWT performance (p=0.005, Friedman's test) but not in the group 
with unchanged 6MWT performance (p=0.062, Friedman's test). 
                                            
AA Deterioration defined as a reduction in 6MWT by the minimal clinically important difference of 
28m, see section 4.2.5.3, pg 130. 
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Figure 104. Changes in BNP over time by 6MWT group 
Box plots represent median, IQR and range. Grey = deterioration of ≥28m from pre-op or unable 
to walk, White = deterioration <28m or walked further than pre-op. Changes over time assessed 
with Friedman's test (Grey p=0.020, White p=0.001). Pairwise comparisons between groups using 
Mann-Whitney U-Test, significant p-values as illustrated. Pre-op = immediately pre-op, prior to 
induction of anaesthesia, Post-op = immediately post-op, extubated in recovery area, POD = 
post-op day, BNP = B-type natriuretic peptide. 
 
 
Figure 105. Changes in hsTnT over time by 6MWT group 
Box plots represent median, IQR and range. Grey = deterioration of ≥28m from pre-op or unable 
to walk, White = deterioration <28m or walked further than pre-op. Changes over time assessed 
with Friedman's test (Grey, p=0.005, White p=0.062). Pairwise comparisons between groups using 
Mann-Whitney U-Test, significant p-values as illustrated. Pre-op = immediately pre-op, prior to 
induction of anaesthesia, Post-op = immediately post-op, extubated in recovery area, POD = 
post-op day, hsTnT = high sensitivity troponin T. 
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The ability of BNPpreop and hsTnTpreop to predict a deterioration in 6MWT 
performance at 2-months was assessed using AUROCC analysis (Figure 106 and 
Table 54). 
 
Figure 106. Receiver operating characteristic curve to identify a post-op deterioration in 
6MWT using BNPpreop and hsTnTpreop 
A) BNPpreop, AUROCC = 0.80 (0.62, 0.97) B) hsTnTpreop, AUROCC = 0.75 (0.55, 0.95). AUROCC = 
area under the receiver operating characteristic curve, Pre-op = Immediately pre-op, prior to 
induction of anaesthesia, BNP = B-type natriuretic peptide, hsTnT = high sensitivity troponin T, 
6MWT = 6 minute walk test. 
 
 
 BNPpreop hsTnTpreop 
 6MWT deterioration 
AUROCC (95%CI) 0.80 (0.62, 0.97) 0.75 (0.55, 0.97) 
p 0.013 0.040 
Cut-off valueBB 13pg/ml 8.18pg/ml 
Sensitivity 100% 72.7% 
Specificity 50% 76.9% 
PPV 61.1% 72.7% 
NPV 100% 76.9% 
Table 54. Predictive performance of BNPpreop and hsTnTpreop for a deterioration in post-op 
6MWT performance 
AUROCC = area under the receiver operating characteristic curve, PPV = positive predictive 
value, NPV = negative predictive value, Pre-op = immediately pre-op, prior to induction of 
anaesthesia, BNP = B-type natriuretic peptide, hsTnT = high sensitivity troponin T. 
                                            
BB Defined by Youden's index (Maximum combination of sensitivity and specificity). 
AUROCC = 0.80 
95% CI (0.62, 0.97) 
AUROCC = 0.75 
95% CI (0.55, 0.97) 
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To explore association between the biomarkers and a deterioration in functional 
capacity, a composite endpoint was created. This composite consisted of either an 
increase in MRC dyspnoea scale and/or a deterioration in 6MWT performance. 
Comparison in the biomarkers was made between those participants with a 
deterioration in functional capacity, or those participants with unchanged functional 
capacity (Figure 107 and Figure 108, pg 260).  
 
 
 
Figure 107. Changes in BNP over time by functional capacity group at 2-months 
Box plots represent median, IQR and range. Grey = deterioration MRC and/or 6MWT, White = 
unchanged MRC and 6MWT. Changes over time assessed with Friedman's test (Grey p<0.0005), 
(White p=0.339). Pairwise comparisons between groups using Mann-Whitney U-Test, significant p-
values as illustrated. Pre-op = immediately pre-op, prior to induction of anaesthesia, Post-op = 
immediately post-op, extubated in recovery area, POD = post-op day, BNP = B-type natriuretic 
peptide, MRC = Medical Research Council dyspnoea scale, 6MWT = 6 Minute walk test. 
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Figure 108. Changes in hsTnT over time by functional capacity group at 2-months 
Box plots represent median, IQR and range. Grey = deterioration MRC and/or 6MWT, White = 
unchanged MRC and 6MWT. Changes over time assessed with Friedman's test (Grey p<0.0005), 
(White p=0.711). Pairwise comparisons between groups using Mann-Whitney U-Test revealed no 
significant results. Pre-op = immediately pre-op, prior to induction of anaesthesia, Post-op = 
immediately post-op, extubated in the recovery area, POD = post-op day, hsTnT = high sensitivity 
troponin T, MRC = Medical Research Council dyspnoea scale, 6MWT = 6 Minute walk test. 
 
 
As can be seen in Figure 107 there was an increase in BNP over time for the 
group who had a deterioration in post-op functional capacity (p<0.0005, 
Friedman's test) but not in the group who had unchanged functional capacity 
(p=0.339, Friedman's test). BNP was also higher at every peri-operative time point 
in those patients who went on to have a deterioration in post-op functional 
capacity. For the group with a deterioration in post-op functional capacity, hsTnT 
changed over the duration of the study (p<0.0005, Friedman's test) but not for 
those with unchanged functional capacity (p=0.711, Friedman's test). There was 
no difference between the groups for peri-operative hsTnT at each time point 
(Figure 108). 
To assess the predictive ability of BNPpreop to determine a change in post-op 
functional capacity, AUROCC analysis was performed (Figure 109 and Table 55, 
pg 261). 
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Figure 109. Receiver operating characteristic curve to identify deterioration in functional 
capacity using BNPpreop  
AUROCC = 0.82 (0.65, 0.99). AUROCC = area under the receiver operating characteristic curve, 
Pre-op = immediately pre-op, prior to induction of anaesthesia, POD = post-op day, BNP = B-type 
natriuretic peptide. 
 
 BNPpreop 
 Functional capacity deterioration 
AUROCC (95%CI) 0.82 (0.65, 0.99) 
p 0.011 
Cut-off valueCC 46.5pg/ml 
Sensitivity 58.8% 
Specificity 100% 
PPV 100% 
NPV 53.3% 
Table 55. Predictive performance of BNPpreop for a deterioration in functional capacity 
AUROCC = Area under the receiver operating characteristic curve, PPV = positive predictive 
value, NPV = negative predictive value, Pre-op = immediately pre-op, prior to induction of 
anaesthesia, BNP = B-type natriuretic peptide. 
  
                                            
CC Defined by Youden's index (Maximum combination of sensitivity and specificity). 
AUROCC = 0.82 
95% CI (0.65, 0. 99) 
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8.6  Discussion 
The main findings of this investigation are that BNP and hsTnT are elevated 
following lung resection and that they are associated with both; post-op RVEF and 
functional outcomes. 
Peri-operative changes in BNP have previously been described in patients 
undergoing lung resection and the data in this investigation follows a similar 
pattern318. In the largest study published to date in this cohort, Cagini et al. 
measured BNP in 294 participantsDD; pre-op, on PODs 1, 2, 4 and 7 (Figure 
110)318. They demonstrated BNP peaked on POD 1, was falling by POD 2, but 
was not yet back to base line by POD 7. A smaller study (n=25) showed BNP 
peaked on POD 3 and was still elevated from base line at POD 7278. For the 
pattern of change in BNP following lung resection, the results of the current 
investigation confirm these previous findings.  
 
Figure 110. BNP over time, redrawn from Cagini et al.318. 
Plots represent median, IQR. BNP = B-type natriuretic peptide, POD = post-op day 
 
The peri-operative changes in troponin demonstrated in this investigation have not 
previously been described beyond 24 hours. Muley et al. established troponin 
(TnI) is elevated in the first 24 hours following both lobectomy and 
                                            
DD 178 lobectomy, 68 wedge/segmentectomy, 24 pneumonectomy, 13 bilobectomy and 11 sleeve 
lobectomy in a mixed thoracotomy / VATS population. 
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pneumonectomy, with a larger rise occurring in the pneumonectomy group319. In a 
third group undergoing wedge resection there was no rise. The current study 
demonstrates hsTnT is elevated following lung resection and peaks on POD 1 with 
a median (IQR) concentration of 12.3pg/ml (3.7, 21.9) at that time. Despite a small 
absolute change in values over the duration of the study, there is an increase in 
the proportion with an abnormal value. An upper normal range (99th percentile) for 
hsTnT has been described at 14pg/ml156 and this study demonstrates two patients 
(7.7%) have levels above this pre-operatively, three (11.5%) immediately post-op, 
11 (42.3%) on POD 1, seven (26.9%) on POD 2 and four (18.2%) at 2-months. 
None of the patients had any other criteria for diagnosis of myocardial infarction 
during the study152. 
In other studies of patients undergoing high risk non-thoracic surgery, abnormal 
hsTnT (>14pg/ml) was present in 31% of patients pre-op280. Levels were higher in 
those with advancing age, poorer renal function and higher ASA status. With only 
two patients having a level >14pg/ml in the current cohort, there is no ability to 
perform assessment of the factors associated with raised pre-op troponin. It is 
worth noting that the patient who has been identified as an outlier at a number of 
times in this thesis as a result of his poor cardiac function on CMR at 2-months 
(footnote P, pg 180), was one of only two patients to have hsTnT >14pg/ml at all 
peri-operative time points. This patient had a history of ischaemic heart disease 
(IHD) and the author hypothesises that the elevated hsTnT is a result of sub-
clinical myocardial ischaemia in the context of his lung resection which ultimately 
decompensated by 2-month follow-up. The two patients who developed AF peri-
operatively had abnormal hsTnT on POD 1, POD 2 and at 2-months, making up 
50% of the patients with an abnormal level at long-term follow-up. 
Troponin release is common following non-cardiac surgery281. In an observational 
study of 203 patients undergoing major non-thoracic surgery, Noordzij et al. 
demonstrated an elevated hsTnT (>14pg/ml) in 52.2% of patients between POD 1-
3280. In non cardiac surgery elevated peri-operative troponin has been shown to be 
associated with increased complications (both cardiac and non-cardiac) and 
mortality152, 275, 280, 281, 320. Devereaux et al. measured troponin (TnT) in 15,133 
patients following surgery (282 [1.9%] of which were "major thoracic"), and found a 
positive association between post-op troponin and 30-day mortality282. A similar 
pattern is found in lung resection where peri-operative troponin rise is associated 
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with early mortality279. No patients from the current investigation died within the 
first year following surgery and the small numbers mean any attempt to seek 
association between mortality and hsTnT levels would be meaningless. On an 
exploratory basis there was no association between peri-operative hsTnT and 
duration of hospital or critical care stay. The clinicians involved in patient care 
were blinded to hsTnT results, meaning hsTnT levels would not have impacted 
decision making unless ordered independently as a result of clinical suspicion. 
In a non cardiac surgery cohort, Gibson et al.283 demonstrated pre-op BNP 
predicted those with post-op cardiac complicationsEE. BNP has also been shown to 
predict long-term mortality following non-cardiac surgery321. Following lung 
resection, elevated peri-operative BNP is associated with post-op AF and (both 
respiratory and cardiovascular) complicationsFF (Figure 111)276, 318. In patients 
undergoing lung resection, elevated pre-op BNP has been shown to be associated 
with increased risk of post-op atrial fibrillation and complications275-277. 
 
Figure 111. BNP over time in those with (black) and those without (grey) complications, 
redrawn from Cagini et al.318. 
Plots represent median, IQR. Black bars represent those participants with complications, Grey 
bars represent those without complications. Comparisons between groups using Mann-Whitney U-
Test, significant p-values as illustrated. BNP = B-type natriuretic peptide, POD = post-op day. 
                                            
EE Non-fatal myocardial infarction and cardiac death. 
FF Pulmonary complications were diagnosed when four or more of the following were present: 
radiological evidence of consolidation, temp >38°C, SaO2 <90% on air, abnormal sputum 
production, sputum culture indicating infection, ↑WCC, abnormal examination, physician’s 
diagnosis or administration of antibiotics. Cardiovascular complications included: arrhythmias 
(AF, SVT and VT), angina pectoris, MI, CHF, thromboembolic events, DVT, acute renal failure and 
TIA. 
Chapter 8  265 
 
 
In this investigation, as only two patients developed AF, it is difficult to make any 
meaningful comparisons with BNP. The study has demonstrated an association 
between duration of critical care stay and the magnitude of BNP rise on POD 2. 
There are multiple heterogeneous reasons for prolonged duration of HDU stay but 
this association suggests a role of cardiac dysfunction. As with hsTnT, the 
clinicians involved in the peri-operative care of these patients were blinded to BNP 
results. 
BNP and hsTnT are associated with myocardial injury but are not specific to either 
the LV or RV. In the absence of left sided disease, hsTnT or BNP elevation can 
indicate RV dysfunction158. This investigation demonstrated consistent association 
between BNP and RV function on POD 2. This included BNP and RVEF, ΔBNP 
and RVEF, BNP and ΔRVEF. There was also association between ΔhsTnT and 
RVEF on POD 2. The consistent association between biomarkers and RV function 
on POD 2 is in contrast to that of LV function. There was no change in LVEFCMR 
over the duration of the study and the study was unable to find association 
between any of the biomarkers in the post-op period (or magnitude of change in 
biomarkers) and LVEF. This adds support to the hypothesis that BNP and hsTnT 
are released in response to changes affecting the right ventricular-pulmonary 
vascular unit. 
There was moderate positive association between hsTnTpreop, hsTnTpostop and 
LVEF on POD 2. Other than one outlier who had a hsTnT rise during surgery of 
18.73 pg/ml, hsTnT pre-op is very similar to hsTnT immediately post-op (Pearson's 
correlation coefficient, r=0.867, p<0.0005) meaning it's largely the same patients 
with a higher troponin level. As can be seen from Figure 112 (pg 266), there was a 
tendency for those patients with a pre-op diagnosis of ischaemic heart disease 
(IHD) to have a lower LVEF (57.1% of those with LVEF <55% had a pre-op 
diagnosis of IHD in contrast to 6.7% of those with LVEF >55%). Similarly those 
with IHD were more likely to have higher hsTnT pre-op and the author 
hypothesises the association between hsTnT and LVEF is as a result of this 
relationship. Those patients with IHD are more likely to have elevated troponin and 
are more likely to have lower LVEF. 
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Figure 112. HsTnT and POD 2 LVEF by diagnosis of ischaemic heart disease 
Crosses = pre-op diagnosis of IHD, Circles = no pre-op diagnosis of IHD, LVEF = left ventricular 
ejection fraction, hsTnT = hsTnT = high sensitivity troponin T, IHD = ischaemic heart disease. 
 
Association between biomarkers and RV dysfunction has not been established in 
a lung resection population but has been demonstrated in other clinical conditions. 
In acute pulmonary embolism (hypothetically, a clinical situation analogous to lung 
resection with a sudden increase in RV afterload), BNP271, NT-pro-BNP272 and 
troponin-t272 have all been shown to be predictive of RV dysfunctionGG on 
echocardiography with AUROCC of 0.78, 0.91 and 0.80 respectively. Another 
study by Kline et al. demonstrated BNP and troponin-I levels at the time of 
"submassive" pulmonary embolism was associated with RV hypokinesis (signified 
by AUROCCs of 0.71 for both biomarkers)273. Kline et al. also demonstrated an 
additional association between elevated BNP and mortality at 6-months. In a 
pulmonary hypertension population, NT-pro-BNP has been shown to predict RV 
systolic dysfunction (defined as an RVEF <42%) with 100% sensitivity and 94 
specificity155. 
Following lung resection Tayama et al.278 demonstrated association between BNP 
and extent of resection, with levels higher on POD 3 and POD 7 in 
pneumonectomy patients compared with lobectomy patients. The same authors 
                                            
GG Kruger et al. defined RV dysfunction as one or more of; RV dilation, RV/LV ratio>1, abnormal 
motion of interventricular septum and pulmonary hypertension. Choi et al. defined RV 
dysfunction as RV free wall hypokinesia/akinesia or RV/LV ratio>1 and pulmonary 
hypertension 
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also demonstrated association between BNP and pulmonary vascular resistance 
on POD 3 (n=10, r=0.56, p<0.01), caution must be used when interpreting this 
result though as visual inspection of the scatter plot demonstrates the significant 
impact of an outlier on the correlation coefficient. This association suggests 
biomarkers of myocardial dysfunction may be influenced by changes in the right 
ventricular-pulmonary vascular unit. Consistent with the findings in other 
populations, this study has demonstrated BNP has the ability to predict RV 
dysfunction, with the magnitude of change in BNP between pre-op and POD 2 
(BNPPOD2-preop) predictive of an RVEF≤45% with an AUROCC of 0.78. 
As described above, peri-operative BNP has been shown to be associated with 
post-op complications in the lung resection population. There has been no work 
examining the association of peri-operative BNP and longer term functional 
outcomes following lung resection. BNP at the time of pulmonary embolism is 
associated with exercise intolerance (signified by 6MWT <330m) at 6-months273. 
The current study has shown association between peri-operative BNP and; 6MWT 
performance at 2-months and MRC dyspnoea scale at the same time. To further 
explore this association, these parameters were combined using 6MWT as an 
objective measure of functional capacity and MRC dyspnoea scale as a subjective 
measure. There was association at all peri-operative time points between BNP 
and this composite endpoint. Although there was no difference in hsTnT between 
functional capacity groups, there was evidence of an increase over time in the 
group with a deterioration in functional capacity, but no change in the group with 
unchanged functional capacity.  
Calculation of predicted post-op (PPO) pulmonary function is currently 
recommended as a method to predict those at higher risk of dyspnoea following 
lung resection15, 27, 228. As described in chapter 1, pulmonary function is poorly 
associated with post-op functional outcomes and a post-hoc analysis in this cohort 
demonstrated no association between pulmonary function and the composite 
functional capacity outcome (Figure 113, pg 268). BNP is a quantitative biomarker 
of cardiac function and its association with functional capacity strengthens the 
hypothesis that cardiac function has an impact on post-op functional outcomes.  
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Figure 113. Predicted post-op pulmonary function and functional capacity 
Box plots represent median, IQR and range. A) = PPO percentFEV1, B) = PPO percent TLCO. 
Comparisons between groups using Mann-Whitney U-Test. MRC = Medical Research Council 
dyspnoea scale, 6MWT = 6 Minute walk test. PPO = predicted post-op , FEV1 = forced expiratory 
volume in 1 second, TLCO = transfer factor for carbon monoxide. 
 
The finding that pre-op biomarkers are predictive of post-op functional capacity is 
interesting. As described above, pre-op BNP has been shown to be associated 
with post-op complications following thoracic surgery. In non-cardiac surgery BNP 
has also been shown to be associated with long-term mortality321. The finding that 
it is also predictive of functional capacity suggests pre-op biomarkers may be 
useful in the assessment and pre-op planning of patients undergoing lung 
resection.  
Current guidelines, for assessment of the lung resection candidate, advocate the 
use of PPO lung function as a method to predict those patients at higher risk of 
post-op complications and dyspnoea. Inclusion of biomarkers may improve the 
ability to accurately predict risk (of complications and functional deterioration) and 
would allow improvement of the consent process. Additionally, the ability to identify 
an at risk population would give a group in who interventions could be targeted to 
try and ameliorate post-op complications and dyspnoea. The use of BNP to predict 
post-op outcome in this population would fit with combined guidelines by the 
European Society of Cardiology and the European Association of Anaesthesiology 
(2014) which advocate the use of BNP measurement for obtaining prognostic 
information for peri-operative and late cardiac events in high-risk non-cardiac 
surgery patients322. 
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8.6.1 Strengths and limitations 
Despite being an a-priori secondary endpoint, the study had a modest sample size 
and no power analysis was performed. The results therefore are at high risk of 
type 1 error meaning that the findings should be considered hypothesis generating 
and require validation in larger cohorts. There was a small amount of missing data 
for the biomarker samples. The majority of missing samples were at 2-months and 
there were no relevant significant comparisons at this time, meaning missing data 
probably didn't impact reported results. 
As discussed above, peak BNP following lung resection has been described as 
occurring from POD 1 to POD 3. This peak is for all patients considered together 
however, and in those patients developing complications following lung resection 
there is a suggestion that BNP levels continue to rise peaking later compared to 
those patients that don't develop complications276, 323. The current study measured 
BNP until POD 2 and it cannot be certain that BNP wouldn't continue to rise 
beyond this time. Biomarkers at this later time may have better predictive power 
for poor RV function. Additionally there was no continuous method of assessing 
RV function, meaning comparison was made between biomarkers on POD 1 and 
RVEF on POD 2. Continuous assessment would not have been possible using 
CMR but a validated bedside alternative may allow association with paired 
biomarker results. 
8.7  Conclusion 
BNP and troponin increase following lung resection and return to base line levels 
by 2-months. Association between the biomarkers and RVEF (and not LVEF) 
suggests the cardiac biomarkers are released in response to changes in the right 
heart. BNP shows promise in its ability to predict RV dysfunction following lung 
resection and this needs to be further explored. Given the difficulties of 
echocardiographic assessment of RV function in the post-op period, biomarkers 
(by themselves or in combination with imaging) may have clinical utility. 
Peri-operative changes in BNP and troponin are associated with a decrease in 
functional capacity following lung resection. The lack of any association between 
predicted post-op pulmonary function and changes in functional capacity, supports 
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the hypothesis that cardiac dysfunction has a role in post-op limitation. BNP and 
troponin need to be studied further, but may be incorporated in to future risk 
stratification protocols.  
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Chapter 9  Mechanisms of Right Ventricular 
Dysfunction 
This chapter describes a number of exploratory analyses performed to examine 
potential mechanisms of post-op RV dysfunction. Echocardiographic measures of 
pulmonary heaemodynamics are described followed by changes in a 
cardiovascular magnetic resonance imaging derived surrogate of right ventriculo-
pulmonary artery (RV-PA) coupling. 
9.1  Pulmonary artery acceleration time and pulmonary 
artery systolic pressure 
9.1.1 Reproducibility  
A summary of the inter-observer and intra-observer variability for trans thoracic 
echocardiographic measurement of pulmonary artery systolic pressure (PASP) 
and pulmonary artery acceleration time (PAAT) is provided in Table 56. Both 
measures showed good agreement with intraclass correlation coefficients for 
absolute agreement ≥0.78. 
Inter-Observer Variability 
 
Paired 
Measures 
CV (%) ICC Agreement (95% CI) 
PASP (mmHg) n=32 4.78% 0.96 (0.92, 0.98) p<0.0005 
PAAT (ms) n=72 10.97% 0.78 (0.59, 0.87) p<0.0005 
    
Intra-Observer Variability 
 
Paired 
Measures 
CV (%) ICC Agreement (95% CI) 
PASP (mmHg) n=10 5.27% 0.91 (0.63, 0.98) p<0.0005 
PAAT (ms) n=10 8.78% 0.85 (0.23, 0.97) p<0.0005 
Table 56. Inter and intra-observer variability for PASP and PAAT 
Coefficient of Variation (CV) calculated as per Equation 8, pg 138, intraclass Correlation 
coefficient (ICC) calculated as mixed effect, absolute agreement. PASP = pulmonary artery 
systolic pressure, PAAT = pulmonary artery acceleration time, POD = post-op day. 
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There was no disparity in availabilityHH of PASP and PAAT between the author and 
the echocardiography technicians (ET's). There were however changes in 
availability of PASP and PAAT over the duration of the study. PASP could only be 
determined in 44.% of patients pre-operatively, 53.8% on POD 2 and 25% at 2-
months. PAAT was available in all patients pre-operatively and on 95.8% of 
patients post-operatively (Table 57).  
 Pre-op (n = 27) POD 2 (n = 26) 2-Months (n = 24) 
 ET Author ET Author ET Author 
PASP 
12 
(44.4%) 
12 
(44.4%) 
14 
(53.8%) 
14 
(53.8%) 
6 
(25.0%) 
6 
(25.0%) 
PAAT 
27 
(100%) 
26 
(96.3%) 
23 
(88.5%) 
23 
(88.5%) 
24 
(100%) 
23 
(95.8%) 
Table 57. Availability of PASP and PAAT at each time point 
POD = post-op day, ET = echocardiography technician, PASP = pulmonary artery systolic pressure, 
PAAT = pulmonary artery acceleration time.  
  
                                            
HH Availability in this context refers to the ability to obtain a result from the echocardiographic 
image provided. Availability will have been affected by the quality of the image and by the 
interpretation by the observer. 
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9.1.2 Bland Altman Analysis 
Bland Altman analysis between the author and ETs of the tricuspid regurgitant 
pressure gradient and PAAT showed minimal bias with acceptable limits of 
agreement (Figure 114 and Figure 115). 
 
 
Figure 114. Bland Altman analysis of Tricuspid Regurgitation Pressure Gradient (TRPG*) 
measurements (n = 32) 
Solid line represents mean bias (-0.15mmHg) and dashed lines represent 95% limits of agreement 
(-5.29, 4.99 mmHg). *TRPG used to calculate pulmonary artery systolic pressure (see Equation 
14, pg 154) 
 
 
Figure 115. Bland Altman analysis of PAAT measurements (n = 72) 
Solid line represents mean bias (-7.35ms) and dashed lines represent 95% limits of agreement (-
35.52, 20.82ms). PAAT = pulmonary artery acceleration time. 
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9.1.3 Change over time 
As displayed in Figure 116 and Table 58 there was no significant change in PASP 
or PAAT over the duration of the study (Friedman's test and one-way repeated 
measures ANOVA respectively, p>0.074 for both). 
 
Figure 116. PASP and PAAT over time 
Box plots represent median, IQR and range. Bar (error bars) represent mean (95% CI). PAAT = 
pulmonary artery acceleration time, PASP = pulmonary artery systolic pressure, POD = post-op 
day.  
 
 Pre-op POD 2  2-Months p-value 
PASP (mmHg) 
n=12 n=10 n=5 
0.074† 
30.8 (29.2, 39.8) 42.9 (34.9, 54.0) 37.1 (30.8, 46.0) 
     
PAAT (ms) 
n=26 n=23 n=23 
0.350* 
86.4 (24.9) 72.0 (16.9) 81.0 (22.8) 
Table 58. PASP and PAAT over time 
Values are mean (SD) or Median (IQR). * = one-way repeated measures ANOVA. † = Friedman's 
test. PAAT = pulmonary artery acceleration time, PASP = pulmonary artery systolic pressure, POD 
= post-op day. 
 
9.1.4 Comparison of pulmonary artery systolic pressure and 
pulmonary artery acceleration time with right ventricular 
ejection fraction 
Pooled analysis revealed weak positive association between RVEFCMR and PAAT 
(Figure 117 and Table 59, pg 275). The presence of an outlier appeared to 
influence this association. This outlier has previously been described (footnote P, 
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pg 180). Sensitivity analysis with the outlier excluded revealed a stronger positive 
association (r=0.410, p=0.001). There was no association between PASP and 
RVEFCMR (Figure 117 and Table 59). 
 
Figure 117. Relationship between PASP and PAAT with RVEFCMR 
p-value for pooled association (Pearson's) as illustrated. PAAT = pulmonary artery acceleration 
time, PASP = pulmonary artery systolic pressure, RVEF = right ventricular ejection fraction. Black 
arrow indicates outlier described in section 9.1.4. 
 
Within subject (ANCOVA) analysis was performed and this strengthened the 
positive association between RVEFCMR and PAAT (Table 59). ANCOVA analysis 
confirmed no association between PASP and RVEFCMR.  
Pooled analysis (Pearson's) 
  PASP PAAT 
RVEFCMR 
r -0.259 0.384 
p 0.192 0.001 
    
Within-subject analysis (ANCOVA) 
  PASP PAAT 
RVEFCMR 
r 0.473 0.468 
p 0.198 0.002 
Table 59. Association between PASP, PAAT and RVEFCMR 
PAAT = pulmonary artery acceleration time, PASP = pulmonary artery systolic pressure, RVEF = 
right ventricular ejection fraction. ANCOVA = analysis of covariance. 
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9.2  Right ventricular stroke volume / end systolic volume 
The ratio of RV stroke volume (RVSV) to RV end systolic volume (RVESV) has 
been described as a volumetric surrogate of RV-PA coupling. Inter and intra-
observer variability data for RVSV and RVESV is provided in chapter 5. There was 
a significant change in the median (IQR) RV SV/ESV ratio over time from 1.0 (0.9, 
1,.2) pre-op to 0.8 (0.7, 1.0) on POD 2 and 0.8 (0.1, 1.0) at 2-months (Figure 118, 
p=0.011, Friedman's test). 
 
Figure 118. Change in RVSV / RVESV over time 
Box plots represent median, IQR and range. Pairwise comparisons with Wilcoxon rank sum test. 
RVSV = RV stroke volume, RVESV = RV end systolic volume. 
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9.3  Discussion 
This investigation explored potential mechanisms of RV dysfunction following lung 
resection. The main finding is that increased afterload (lower PAAT) is associated 
with poor RV function (lower RVEF). There is also suggestion of a deterioration in 
RV-PA coupling with the ratio of RV SV/ESV decreasing on POD 2 and remaining 
depressed at 2-months. 
Although widely hypothesised, increased afterload following lung resection has not 
been consistently demonstrated170, 174, 176. Previous studies have utilised PVR as a 
measure of afterload and have been unable to demonstrate sustained changes 
(see section 2.4, pg 104). As described in chapter 2, whilst commonly used in 
clinical practice, PVR measures opposition to mean flow and ignores the pulsatile 
component. Up to half of the hydraulic power in the main pulmonary artery is 
contained in the pulsatile components of flow; comprising resistance, capacitance, 
inertia and pulse wave reflection. The true opposition to pulsatile flow, the RV 
impedance, is a composite of both static and pulsatile components.  
Acceleration time is an indicator of constraint to ejection; 
shortened times have been associated with increased pulmonary 
vascular resistance and pressure. 
Tousignant et al. (2015)324 
PAAT is an index of afterload that does not assume constant flow in the pulmonary 
artery (as PVR does) and can provide insight into the pulsatile nature of pulmonary 
afterload. Despite an apparent trend towards reduced PAAT on POD 2, there was 
no significant change in PAAT in the post-op period (p=0.350, Table 58 and Figure 
116, pg 274). Reduced PAAT has been associated with abnormal wave reflections 
(increased pulsatile afterload) in pulmonary hypertension. In a swine model, 
acceleration time was associated (r=-0.65) with increasing RV impedance (from 
banding of the pulmonary artery)II325. PAAT is also associated with pulmonary 
artery pressures and pulmonary vascular resistance in pulmonary hypertension70, 
139, 140.  
                                            
II PAAT was assessed in 15 pigs (7 open pericardium, 8 closed pericardium). RV impedance was 
not specifically measured and PA banding was used as a method of increased impedance. 
Association was made between PAAT and resistance over the banding. 
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The relationship between PAAT and RVEFCMR in this cohort demonstrates 
association between higher afterload and poorer RV function. On an exploratory 
basis the association between change in RVEF by POD 2 (ΔRVEFPOD-preop) and 
change in PAAT by the same time (ΔPAATPOD2-preop) was assessed and this 
demonstrated a strong positive association (Figure 119). This suggests that 
change in afterload (as measured by PAAT) is associated with deterioration in RV 
function following lung resection. 
 
Figure 119. Changes in PAAT against corresponding changes in RVEFCMR by POD 2 
Pearson's correlation coefficient. RVEF = Right ventricular ejection fraction, PAAT = Pulmonary 
artery acceleration time. 
 
Although there was no significant change in PASP, there was an apparent trend 
towards increased PASP on POD 2 (compared to pre-op, p=0.09, Wilcoxon 
Signed Rank test, Figure 116, pg 274). There was also an increase in the 
proportion of patients who had tricuspid regurgitant jets (TRJ's) visible on POD 2. 
This may suggest that PASP is increasing in some participants (meaning they now 
have visible TRJ's).  
It was not possible to determine PASP in a large proportion of patients in this 
study, with TRJ's measurable in approximately half of patients pre- and post-
operatively and a quarter of patients at 2-months. There was no discrepancy 
between the author and the echocardiography technicians with regards to result 
availability from provided images. Difficulties in obtaining adequate tricuspid 
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regurgitant jets have previously been described following lung resection. Amar et 
al. described a deterioration in the number of patients with available TRJ's 
following lung resection, though they had much better availability than the current 
study198. In their cohort RVSP availability was 88% pre-operatively, 74% on POD 1 
and 82% at POD 2-6. Backlund et al.176 observed TRJ's in 33.3% pre-operatively 
and only 16.7% on POD 1. Six months following lobectomy, Foroulis et al.201 
obtained reliable TRJ's in 58.8% of participants. 
On reviewing the images in this study where TRJ's were not available, there were 
some patients with evidence of trace tricuspid regurgitation. Guidelines on 
echocardiographic assessment of the right heart by Rudski et al. only recommend 
reporting of values in those with "reliable" regurgitant jets128. Qualitative review 
indicated that those patients with trace TRJ tended to have lower velocities 
(<2m/sec, <16mmHg). As the TRJ's had been obtained (although analysed at a 
later date) at the time of echocardiographic imaging, it is not possible to know from 
the current investigation if further interrogation would have provided more (or 
better) images for analysis. The non-invasive assessment of PASP following lung 
resection is therefore not reliable. 
Pulmonary artery pressure is an often used parameter of RV function and provides 
some information on RV afterload. In an oscillatory system (one without constant 
flow), the pressure generated is equal to the product of impedance (opposition to 
flow) and flow itself (Equation 15)324. 
        
Equation 15. Relationship of pulmonary artery pressure, impedance and flow 
P = pulmonary artery pressure, Z = pulmonary artery impedance, Q = pulmonary artery flow 
 
As can be seen from the above equation, PA pressure is dependent on both; the 
opposition to pulmonary artery flow (pulmonary artery impedance or afterload) and 
pulmonary artery flow itself (cardiac output). As afterload increases, if cardiac 
output remains constant, pressure will increase. If cardiac output were to drop in 
response to higher afterload however, there would be a drop in PA pressure. This 
can be observed clinically the later stages of pulmonary hypertension, when PA 
pressures start to fall as the RV has maximally compensated and cannot increase 
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cardiac output in response to increasing afterload. This is illustrated in Figure 
120160. 
 
Figure 120. Relationship of CO, PASP and afterload in progressive pulmonary vascular disease 
Adapted from Haddad et al.160 CO = cardiac output, PASP = pulmonary artery systolic pressure. 
 
Figure 120 shows that PASP can be influenced by both the afterload experienced 
by the RV and by RV function itself. When interpreting PA pressures, it is 
important that RV function is taken in to account. As described in chapter 1, 
effective RV function relies on haemodynamically efficient interaction with the 
pulmonary circulation81. The ideal assessment of RV and pulmonary vasculature 
would incorporate both afterload and RV function along with their matching.  
The changes in RVEF observed in chapter 5 may result from alterations in the 
loading conditions, contractility or a combination. Although RVEF is the most 
commonly used index of function, it is described as highly load dependent and 
doesn't solely reflect RV contractility46. As described in Section 1.2.3.4.2, pg 34, 
maximal ventricular elastance (Emax) is a load-independent parameter for 
assessing RV contractility. Arterial elastance (Ea) is an index of afterload faced by 
the ventricle. The ratio of these two elastances (Emax/Ea) reflects RV-PA coupling 
(coupling) and is a measure of matching between the ventricle and pulmonary 
circulation (Section 1.2.3.7, pg 38).  
The reference method for determining coupling involves simultaneous 
measurement of pressure and volumes. Given common terms within the 
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calculation of Emax/Ea, an estimation of coupling can be made from volume 
measurements using CMR (Equation 16):  
Ees is the elastance at end systole. It is typically calculated as 
described below, where ESP = end systolic pressure, ESV = end 
systolic volume and V0 = the theoretical volume of an unstressed 
or unloaded ventricle: 
                 
A common assumption is that V0 is negligible and can be excluded 
from calculations: 
              
Ea can be represented by the slope of the arterial ESP versus 
stroke volume (SV) relationship: 
          
Coupling is the ratio of Ees/Ea 
   
  
 
         
        
 
Cancelling out ESP: 
   
  
 
  
   
 
Equation 16. Derivation of volume method for assessment of coupling from Sanz et al.83. 
Ees = end systolic elastance, ESP = end systolic pressure, ESV = end systolic volume, V0 = 
theoretical volume of unloaded ventricle, SV = stroke volume. 
 
This surrogate approximation has a number of assumptions, firstly it assumes 
ventricular volume at time zero is negligible and secondly it calculates end-systolic 
elastance and not maximal elastance which is a better measure of RV 
contractility326-328. This measurement contains the same information as required to 
calculate RVEF and they have a non-linear relationship (Figure 121 [pg 282]) 
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meaning there is uncertainty about the additional information that it may provide, 
but there is a suggestion it provides information on RVEF in a "less preload 
dependent manner" 326.  
The SV/ESV estimation of coupling has been shown to be predictive of outcome in 
patients with pulmonary hypertension329 including a group where RVEF was shown 
not to be predictive (but SV/ESV was)330. SV/ESV has been compared to a 
combined pulmonary artery catheter and CMR determined measure of coupling 
with good association (r=0.93, p<0.001)83. As V0 is assumed to be zero, Ees is 
underestimated, meaning the SV/ESV ratio would be expected to underestimate 
invasively determined Ees/Ea
326.  
The non-linear relationship observed in Figure 121 may be responsible for why 
SV/ESV may be a better predictor than RVEF. The range of RVEF is 0.17 to 0.67JJ 
and the range of SV/ESV is 0.2 to 2.2. This results in over a 3 times wider range 
with SV/ESV for the same patients, which may improve the predictive ability of the 
constituent parameters328. 
 
Figure 121. Relationship of RVSV/RVESV and RVEF 
RVSV= RV stroke volume, RVESV = RV end systolic volume, RVEF = right ventricular ejection 
fraction. 
 
                                            
JJ RVEF in this context is reported as an actual fraction. e.g. RVEF of 55% = 0.55 
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Coupling values in awake humans (control patients without pulmonary 
hypertension) using SV/ESV are reported from 1.5-2.083, 113, 331 with values in 
patients with 'early pulmonary hypertension' reported as 1.1113. The patients in the 
current investigation show a ratio of 1.0 which falls following surgery. The majority 
of the patients in this study had underlying health conditions e.g. smoking history, 
older age, pulmonary malignancy etc (Table 17, pg 164). As these conditions can 
impact on both ventricular function and pulmonary afterload, they may partly 
explain the lower baseline value. A study by Wink et al.85 using the conductance 
catheter intra-operatively in patients undergoing lung resection demonstrated a 
similar percentage deterioration in coupling at time of PA clamping, as seen with 
the change in SV/ESV in the current study (a more complete description of the 
Wink et al. study is provided in section 2.3.4, pg 102). The current investigation 
has shown this decrease is still present on POD 2 and more interestingly that it 
persists at 2-months.  
The change in SV/ESV suggests a deterioration in RV-PA coupling. This may be 
as a result of increased afterload (increased Ea), a deterioration in contractility (Ees) 
or a combination. 
9.3.1 Strengths and limitations 
The dual analysis of anonymised images by blinded observers is a strength of this 
investigation. Additionally, the availability of PAAT in the majority of patients 
(93.5%) means this may provide a reliable method for assessing RV afterload in 
this patient population. 
The lack of availability of tricuspid regurgitant jets mean reliable assessment of 
PASP was not possible. This difficulty has been previously reported in similar 
cohorts. 
Full RV assessment, including loading conditions, requires the use of the 
conductance catheter. Although this gold standard technique offers high fidelity 
data and is able to assess rapid changes in RV function, non- invasive modalities 
are favoured in clinical practice76. The SV/ESV volumetric approximation of RV-PA 
coupling has been used in pulmonary hypertension, but has not yet been 
compared to a reference method such as the conductance catheter.  
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9.4  Conclusion 
This study is the first to describe a convincing association between afterload and 
RV function in patients undergoing lung resection. It also demonstrates 
association between an increase in afterload (as measured by PAAT) following 
lung resection and deterioration in RV function. These results provide some 
confirmation for the underlying hypothesis that increased RV afterload results in 
RV dysfunction following lung resection. 
The change in SV/ESV suggests a deterioration in coupling that is still present 2-
months following surgery. Although the changes in PAAT suggest an association 
of increased afterload with RV function, it is not clear from the current results if 
there are also changes in RV contractility.  
Future work fully analysing contractility and the RV input impedance (along with its 
components) is required to fully explore the changes in afterload and RV function 
following lung resection. 
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Chapter 10  Major Findings, Conclusions and 
Future Directions 
This thesis initially provides a review of RV physiology and its assessment. It then 
presents a comprehensive assessment of the RV response to lung resection. A 
summary of each investigations' major findings is presented here. 
10.1  Major findings 
10.1.1  Chapter 2 
The literature review describes the studies to date examining the RV response to 
lung resection. Although there is concern about the methodology used (based on 
the validity of the volumetric pulmonary artery catheter), there appears to be a 
deterioration in RV function, that is associated with post-op morbidity. Although 
widely hypothesised, an elevation in afterload (most commonly measured as 
pulmonary vascular resistance) has not been consistently demonstrated. There 
are consistent changes in RV haemodynamics on exercise. 
10.1.2  Chapter 3  
The results of this investigation demonstrate an unplanned intensive care unit 
admission rate of 2.6% following lung resection. It also shows an incidence of RV 
dysfunction in this cohort of at least 25% and that RV dysfunction is associated 
with high mortality. 
10.1.3  Chapter 4 
Chapter 4 describes the methodology for future studies (Chapters 5-9) and 
provides generic outcome results. Lung resection is associated with decreased 
functional capacity, increased dyspnoea and poorer quality of life. 
10.1.4  Chapter 5 
Using an established reference method, this investigation demonstrated that RV 
function (CMR determined RV ejection fraction - RVEFCMR) deteriorates 
immediately following lung resection and that it continues to be impaired long in to 
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the recovery period. This occurs despite no change in LV function during the same 
time period. 
10.1.5  Chapter 6 
Fractional area change (FAC), Tricuspid Annular Plane Systolic Excursion 
(TAPSE) and S'Wave velocity at the tricuspid annulus (S'Wave) are established 
echocardiographic methods for assessment of RV function. These were compared 
to RVEFCMR and were found not to be useful for assessment of RV function in this 
population. 
10.1.6  Chapter 7 
The novel technique of speckle tracked echo strain was compared to RVEFCMR. 
Although strain does not change over time, RV free wall strain shows promise as 
an echocardiographic measure of RV function following lung resection. 
10.1.7  Chapter 8 
The biomarkers of myocardial dysfunction, Troponin (hsTnT) and B-type natriuretic 
peptide (BNP), increase following lung resection and are both associated with RV 
dysfunction in the immediate post-op period (but not LV function). This 
investigation also demonstrates these biomarkers are associated with functional 
capacity in the post-op period. 
10.1.8  Chapter 9 
This investigation demonstrates an association between increased afterload (as 
measured by echo determined pulmonary artery acceleration time [PAAT]) and RV 
dysfunction following lung resection. It also suggests (using a volumetric 
surrogate) that RV-PA coupling deteriorates in the immediate post-op period and 
that this deterioration is still present at 2-months. 
10.2  Conclusion 
The main finding of this thesis is the confirmation that RV function deteriorates in 
the immediate post-op period following lung resection. It also demonstrates a 
novel finding that RV function is impaired 2-months in to the recovery period. 
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Cardiovascular Magnetic Resonance is a reference method for assessment of RV 
function, but is not suitable for use in the immediate post-op period. Alternative 
non-invasive options include echocardiography or biomarkers. 
Although technically challenging, echocardiography is the most widely utilised 
method for assessment of RV function and could potentially be suitable for use in 
this population. The difficulties with this modality however, are compounded 
following lung resection surgery, with image quality and availability impacting on 
interpretation, especially in the immediate post-op period. Conventional 
echocardiographic methods were found to be inadequate in this population and 
not suitable for prediction of poor RV function. Speckle tracked strain 
echocardiography of the RV, has been shown to overcome some of the difficulties 
associated with these conventional methods in other populations. Although RV 
global strain (RV-GPLS) was unable to provide information on RV function, RV 
free wall strain (RV-FWPLS) showed promise. As can be seen from Table 60, pg 
288, RV-FWPLS performed better than global strain and the conventional methods 
in multiple domains. 
RV-FWPLS was available in the majority of patients on POD 2 (84.6%). This was 
comparable to S'Wave, the parameter that was available in most patients at this 
time point (88.5%). RV-FWPLS performs best on pooled analysis and is the only 
parameter to even approach significance when within subject factors are 
accounted for (p=0.054). Using an area under the receiver operating characteristic 
curve of 0.75 or above as providing "good diagnostic value", only RV-FWPLS 
reaches this level on pooled analysis332. RV-FWPLS was the only variable to 
achieve significance on trend analysis. 
The author considers the immediate post-op period as a time when determination 
of RV dysfunction is perhaps most clinically important. Identification at this time 
would allow management targeted to specific pathology. In future intervention 
studies, accurate identification of RV dysfunction (or its absence) at this time may 
be useful as an end-point. There was moderate negative association between RV-
FWPLS and RVEFCMR on POD 2, with RV-FWPLS demonstrating good diagnostic 
value at this time with an AUROCC of 0.86 (Table 60, pg 288). 
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 Conventional Parameters  Strain 
 FAC TAPSE S'Wave  
RV-
GPLS 
RV-
FWPLS 
Pooled imaging 
availability 
61.0% 93.5% 96.1%  94.8% 94.8% 
Pooled association 
(Pearson's coefficient) 
- 0.34 0.29  -0.41 -0.48 
Pooled prediction 
(AUROCC) 
- 0.65 -  0.74 0.76 
Within subject 
association (ANCOVA) 
- - -  - -0.31* 
Trend association - - -  - -0.32 
Trend prediction - - -  - - 
Time point 
association 
Pre-op - - -  -0.41 -0.53 
POD 2 - - -  -0.54 -0.51 
2-Months - - -  -0.52 -0.55 
Time point 
prediction 
(AUROCC) 
Pre-op - - -  0.79 0.79 
POD 2 - - -  0.78 0.86 
2-Months - - -  0.79 - 
Table 60. Summary of conventional parameters and speckle tracked strain echocardiography 
in comparison to RVEFCMR 
Only statistically significant results are displayed. * = p-value approached significance (p=0.054). 
Results highlighted in bold are considered to be at a level considered clinically useful. AUROCC 
are for prediction of RVEF <45%. RVEF = right ventricular ejection fraction, FAC = fractional area 
change, TAPSE = tricuspid annular plane systolic excursion, S'Wave = S' Wave velocity at the 
tricuspid annulus. ANCOVA = analysis of covariance, RV-GPLS = RV global peak longitudinal strain, 
RV-FWPLS = RV free wall peak longitudinal strain, AUROCC = area under the receiver operating 
characteristic curve. 
 
In other clinical settings the diagnostic accuracy of imaging parameters can be 
complemented by the use of biomarkers. In this investigation the magnitude of 
change in BNP by POD 2 (ΔBNPPOD2-preop) demonstrated good diagnostic value for 
RV dysfunction at this time with an AUROCC of 0.78. The size of the current study 
does not allow robust multivariate analysis with a combination of imaging and 
biomarkers. On an exploratory basis a binary logistic regression model was 
created to ascertain the effect of RV-FWPLS on POD 2 and ΔBNPPOD2-preop on the 
likelihood of having RV dysfunction on POD 2 (RVEF<45%). The model was 
statistically significant (p<0.0005) and explained 88.2% (Nagelkerke R2) of the 
variance, correctly classifying 94.4% of the cases of RV function. The combined 
model corresponded to an AUROCC of 0.98 (95% CI 0.91,1.00 and p=0.001). 
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This is the first investigation to demonstrate a consistent association between RV 
afterload (pulmonary artery acceleration time [PAAT]) and RV function in a cohort 
undergoing lung resection. It has also shown association between an increase in 
afterload and a deterioration in RV function by POD 2. An increase in the RV 
SV/ESV ratio suggests a deterioration in RV-PA coupling with an imbalance in RV 
contractility and afterload. 
In summary, RV function deteriorates following lung resection. Surgery is 
associated with a favourable admission rate to intensive care. Those patients 
admitted to intensive care have a high incidence of RV dysfunction and this is 
associated with higher mortality. Conventional echocardiographic methods for 
assessment of RV function are not suitable in this population but speckle tracked 
RV free wall strain shows promise. Biomarkers of myocardial dysfunction increase 
following lung resection and are associated with functional outcomes and RV 
function, but not LV function. RV dysfunction is associated with an increase in RV 
afterload, with the suggestion of a deterioration in the coupling of RV contractility 
and afterload. 
10.3  Future directions 
Future work building on this thesis needs to further explore the mechanisms of RV 
dysfunction following lung resection, assess the clinical impact of these changes 
and assess the RV on exercise. Improved understanding should lead to targeted 
interventions, trying to reduce post-operative morbidity in this population and 
ultimately benefiting patients. 
10.3.1  Explore mechanisms 
Although an association has been demonstrated between increased PAAT and RV 
dysfunction following lung resection, this only provides some insight in to RV 
afterload. Further exploration of the RV input impedance (comprising pulsatile and 
static afterload) is required to fully explain the relationship between RV function 
and afterload following lung resection.  
Utilising imaging already performed, indices of afterload can be obtained non-
invasively using CMR flow analysis and include; PAAT, pulmonary artery 
distensibility and wave intensity analysis. Pulmonary artery acceleration time is 
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associated with increased wave reflections in pulmonary hypertension333. 
Pulmonary artery distensibility is a measure of the compliance of the pulmonary 
vessels, with reduced levels suggesting increased afterload334, 335. Wave intensity 
analysis combines changes in area and flow through the pulmonary vessels during 
the cardiac cycle in to wave intensity. This wave can be separated into 
compression waves that drive blood away from, or towards the heart. With 
decreased vessel compliance, a forward wave will be partial reflected back 
towards the heart, causing increased afterload333. In preliminary work assessing 
these parameters, Dr Adam Glass (clinical research fellow in anaesthesia) has 
demonstrated an increase in pulsatile afterload following lung resection338. This 
increase results from the operative pulmonary artery and there is also association 
between wave intensity and RV function following lung resection339. 
In pulmonary embolism, a clinical situation analogous to lung resection with an 
acute occlusion (in contrast to clamping in lung resection) of a pulmonary artery, 
there is evidence of RV inflammation with neutrophil infiltration of RV 
myocardium254. CMR T1 mapping (section 1.3.2.1, pg 44) is a method of 
assessing inflammation/fibrosis in the RV myocardium and could provide insight in 
to the role of inflammation in post-op RV dysfunctionKK.  
10.3.2  Further assess the clinical impact 
This thesis demonstrates association between biomarkers of RV dysfunction and 
functional capacity. A larger study would be required to definitively assess the 
impact of post-op RV dysfunction on functional and quality of life outcomes. 
Speckle tracked RV free wall strain and BNP (individually or in combination) could 
be used to identify those with RV dysfunction. 
10.3.3  Assess right ventricular function on exercise 
Previous work examining RV function in this population has demonstrated 
inconsistent results. When function is assessed on exercise there are consistent 
changes in RV and pulmonary vascular parameters (Table 5, pg 82)169, 171, 172, 174, 
177. Although the changes observed in the current investigation are modest, the 
                                            
KK The author is a co-applicant on this successful 2016 ACTACC Project Grant - 'Right ventricular 
inflammation after lung resection'. Recruitment commencing April 2018.  
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author hypothesises that the changes observed at rest would be exacerbated with 
exercise, limiting functional capacity. 
There is growing appreciation of the importance of the right ventricles capacity to 
respond to exercise, with its ability to accommodate termed 'reserve.' Ventricular 
reserve is the "extent of increase or change in ventricular function that occurs 
during exercise336." Decreased reserve means the ventricle is unable to increase 
function at times of increased demand and this parameter has prognostic value in 
pulmonary hypertension337.  
Assessment of the ventricular reserve following lung resection would provide 
insight in to the ability of the RV to cope during exercise and determine if the 
modest changes observed in this population are exacerbated on exerciseLL.  
                                            
LL The author is a co-applicant on the successful 2016 Ernest Leach Research Fund - 'Assessment 
of RV contractile reserve on exercise following lung resection - a pilot study '. Recruitment 
commenced Dec 2017. 
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Right side of heart function after lung resection. 
CRF 1 – Baseline demographics 
 
 
Patient ID number in this study: RV |__|__| 
 
 
1. Sex:      
 
2. Age:  |__|__|__| years 
 
3. Date of birth: |__|__| |__|__| |__|__|__|__| d d m m y y y y 
 
4. Height:   |__|__|__| cm 
 
5. Weight:   |__|__|.|__| kg 
 
 
6. Ever smoked?:      
 
6.2 If yes,   *  -smoker*   
 
6.3 If yes, No. of pack years smoked*:  |__|__| years 
 
*See footnote for definitions 
  
6.4. If current smoker,  No. of cigarettes per day:   |__|__| 
 
6.5. If past smoker,  When stopped: |__|__| |__|__|__|__| [mm/yyyy] 
 
 
7. Ever drink alcohol?:    
 
7.1 Currently Drinking?:     
 
7.2  If yes, Units per week:  |__|__|__| 
 
 
8. Chronic co-morbidity:     no 
 
8.2 If yes, tick all that apply   
    
   
 
 
 
 
 
*See footnote for definitions 
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9. Pulmonary function test results: 
 
9.1 Oxygen saturation on air:  |__|__|__| % 
 
9.2 FEV1: Pre-bronchodilator  |__|.|__|__| L  |__|__|__| % 
predicted  
9.3 FEV1: Post-bronchodilator (if applicable)         
     
      |__|.|__|__| L  |__|__|__| % 
predicted 
  
9.4 FVC:  |__|.|__|__| L  |__|__|__| % predicted 
 
9.5 FEV1/FVC: |__|__| % 
 
9.6 DLCO: |__|__|.|__|__| mmol kPa-1min-1 |__|__|__| % predicted  
 
 
10. Baseline laboratory values: 
 
10.1 Hb:   |__|__|__| g/L  
 
10.2.  Albumin:   |__|__|__|__|__| g/L 
 
10.3. Creatinine:  |__|__|__| μmol/L  
 
10.4 eGFR:  |__|__|__| ml/min 
 
10.5 CRP:   |__|__|__| mg/L 
 
 
11. Pre-operative neo-adjuvent therapy: 
 
11.1 Pre-operative chemo-therapy?       
 
11.2 Pre-operative radio-therapy?      
 
 
12. Medication History: 
 
    
     
  antagonist 
 antagonist 
 
 
 
 
 
 
 
 
 
Appendix 2. Case report form 1  303 
 
 
 
 
Please record all medications (including those above and those purchased over 
the counter): 
Medication Dose Frequency 
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Explanatory notes: 
6. Smoking History 
Past Smoker (stopped > 1 month prior to operation 
Current Smoker should be selected if the patient stopped smoking <1 month prior 
to the surgical procedure. 
 
Pack Years: 
One ‘Pack Year’ is 20 cigarettes smoked/day for one year 
 
No. of cigarettes/day x number of years = No. of pack years 
    20 
 
Loos tobacco: ounces per week x 2/7 x number of years = pack years 
 
Info taken from: “Pack year” smoking histories: what about patients who use loose 
tobacco? doi: 10.1136/tc.2004.009977 
 
8.2 Chronic co-morbidity: 
 
[These co-morbidities are being collected to allow calculation of the 
Thoracoscore (Ref: http://www.sfar.org/scores2/thoracoscore2.php)]. 
 
 
History of cancer Includes cancers treated many years previously. But 
does not include non-melanoma skin cancer or 
premalignant conditions such as cervical dysplasia or 
Barrett’s disease. 
 
 COPD    FEV1/FVC ration <0.7 after bronchodilator therapy 
 
Arterial hypertension Treated, or higher than 140/90 on more than one 
occasion 
 
Heart disease Either ischaemic heart disease (documentation of 
angina, myocardial infarction (MI), CABG, PCI) or 
congestive cardiac failure (documentation of 
symptomatic cardiac failure, asymptomatic low ejection 
fraction does not count), or symptomatic valvular heart 
disease. 
 
Diabetes mellitus Presence and/or history of diabetes mellitus, 
regardless of duration of disease or need for anti-
diabetic agents diagnosed prior to surgical intervention.  
 
Peripheral vascular  Claudication either with exertion or rest; carotid 
Disease   occlusion or > 50% stenosis; previous or planned  
   surgery on abdominal aorta, limb arteries or carotids;  
   documented abdominal (below the diaphragm) aortic  
   aneurysm with or without repair; positive non-invasive 
   or invasive testing documented ankle brachial index ≤ 
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   0.9, angiography, ultrasound, MRI or CT imaging of >  
   50% stenosis in any peripheral artery.  
.  
Obesity   Body mass index ≥ 30. 
 
Alcoholism Current alcohol intake > 14 units/week for Women and 
>21 units/week for men. Previous treatment for alcohol 
dependence.
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Right side of heart function after lung resection. 
CRF 2 – Self-report of functional status / quality of life 
 
 
 
Patient ID number in this study: RV |__|__| 
 
 
 
Pre-op   2 months   1 year   
 
 
 
We would like to ask you some questions about how your health / symptoms effect 
your day to day life. Please read the instructions and tick the appropriate box. 
Though, some of the scoring systems overlap it is important that you answer each 
one individually. This should take no longer than 10 minutes. 
 
Thank you for your time! 
 
 
 
World Health Organization Performance status: 
Please tick the ONE box that best describes you: 
Fully active, able to carry on all pre-disease performance without 
restriction 
 
Restricted in physically strenuous activity but ambulatory (able to walk) 
and able to carry out work of a light or sedentary nature, e.g., light 
house work, office work 
 
Ambulatory (able to walk) and capable of all self-care but unable to 
carry out any work activities. Up and about more than 50% of waking 
hours 
 
Capable of only limited self-care, confined to bed or chair more than 
50% of waking hours 
 
Completely disabled. Cannot carry on any self-care. Totally confined to 
bed or chair 
 
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MRC Breathlessness Scale: 
Please tick the ONE box that best describes you:  
No breathlessness except with strenuous exercise  
Breathless when walking up an incline or hurrying on the level  
Walks slower than most people on the level, or stops after 15 minutes of 
walking on the level 
 
Stops after a few minutes of walking on the level  
Breathless with minimal activity such as getting dressed, to breathless 
to leave the house 
 
 
New York Heart Association classification: 
Please tick the ONE box that best describes you:  
No symptoms and no limitation in ordinary physical activity, e.g. 
shortness of breath when walking, climbing stairs etc. 
 
Mild symptoms (mild shortness of breath and/or angina) and slight 
limitation during ordinary activity. 
 
Marked limitation in activity due to symptoms, even during less-than-
ordinary activity, e.g. walking short distances (20–100 m). 
 
Severe limitations. Experiences symptoms even while at rest. Mostly 
bedbound. 
 
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Quality of Life 
Under each heading, please tick the ONE box that best describes your health 
TODAY  
 
MOBILITY 
I have no problems in walking about       
I have slight problems in walking about       
I have moderate problems in walking about      
I have severe problems in walking about      
I am unable to walk about         
 
SELF-CARE 
I have no problems washing or dressing myself     
I have slight problems washing or dressing myself     
I have moderate problems washing or dressing myself    
I have severe problems washing or dressing myself     
I am unable to wash or dress myself       
 
USUAL ACTIVITIES (e.g. work, study, housework,  
family or leisure activities) 
I have no problems doing my usual activities      
I have slight problems doing my usual activities     
I have moderate problems doing my usual activities     
I have severe problems doing my usual activities     
I am unable to do my usual activities       
 
PAIN / DISCOMFORT 
I have no pain or discomfort        
I have slight pain or discomfort        
I have moderate pain or discomfort       
I have severe pain or discomfort        
I have extreme pain or discomfort       
 
ANXIETY / DEPRESSION 
I am not anxious or depressed        
I am slightly anxious or depressed       
I am moderately anxious or depressed       
I am severely anxious or depressed       
I am extremely anxious or depressed       
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 We would like to know how good or bad your health is  
TODAY. 
 This scale is numbered from 0 to 100. 
 100 means the best health you can imagine. 
0 means the worst health you can imagine. 
 Mark an X on the scale to indicate how your health is 
TODAY.  
 Now, please write the number you marked on the 
scale in the box below.  
      
 
 
 
YOUR HEALTH TODAY = 
 
 
 
 
 
 
 
10 
0 
20 
30 
40 
50 
60 
80 
70 
90 
100 
5 
15 
25 
35 
45 
55 
75 
65 
85 
95 
The best health   
 you can imagine 
 
The worst health   
 you can imagine 
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Pre-op 
  RVEFpreop 
WHO-PS r -0.108 
 p 0.598 
 WHO-PS any* p 0.586 
   
MRC-DS r 0.157 
 p 0.443 
 MRC-DS any* r 0.597 
   
NYHA class r 0.201 
 p 0.326 
 NYHA any* r 0.367 
   
Global Health Score r -0.57 
 p 0.782 
   
EQ5D   
 Mobility r -0.149 
  p 0.468 
 Self care r 0.093 
  p 0.650 
 Usual activities r 0.153 
  p 0.457 
 Pain / discomfort r 0.049 
  p 0.813 
 Anxiety / depression r -0.039 
  p 0.849 
    
Health Utility Score r -0.052 
 p 0.799 
Association between pre-op RV function and pre-op functional and quality of life scores 
All comparisons are Spearman's correlation coefficient. RVEF = right ventricular ejection 
fraction, ΔRVEF = change in right ventricular ejection fraction, WHO-PS = World Health 
Organisation performance status. MRC-DS = Medical Research Council dyspnoea scale. NYHA = 
New York Heart Association, EQ5D = EuroQol 5 domain. 
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2-Months 
  RVEF ΔRVEF 
  POD 2 2months POD2-preop 2months-preop 
WHO-PS r -0.230 -0.162 -0.091 -0.189 
 p 0.329 0.448 0.703 0.387 
 WHO-PS any* p 0.275 0.815 0.311 0.477 
      
MRC-DS r -0.323 0.055 -0.105 -0.109 
 p 0.165 0.799 0.659 0.622 
 MRC-DS any r >0.999 0.673 0.437 0.812 
      
NYHA class r -0.233 -0.145 -0.091 -0.175 
 p 0.323 0.498 0.703 0.423 
 NYHA any r 0.445 0.804 0.349 0.671 
      
Global Health Score r -0.029 0.351 -0.011 .438* 
 p 0.903 0.093 0.962 0.037 
      
EQ5D      
 Mobility r 0.005 -0.151 0.359 -0.144 
  p 0.983 0.481 0.120 0.511 
 Self care r -0.043 -0.339 0.412 -0.225 
  p 0.856 0.105 0.071 0.302 
 Usual activities r -0.427 -0.230 0.137 -0.164 
  p 0.061 0.280 0.563 0.453 
 Pain / discomfort r 0.086 0.220 0.203 0.295 
  p 0.718 0.303 0.391 0.172 
 Anxiety / depression r -0.010 -0.078 -0.112 -0.025 
  p 0.968 0.718 0.638 0.912 
       
Health Utility Score r 0.078 .452* -0.316 0.263 
 p 0.744 0.027 0.175 0.225 
Association between post-op RV function and functional and quality of life scores at 2-
months 
All comparisons are Spearman's correlation coefficient. RVEF = right ventricular ejection 
fraction, ΔRVEF = change in right ventricular ejection fraction, WHO-PS = World Health 
Organisation performance status. MRC-DS = Medical Research Council dyspnoea scale. NYHA = 
New York Heart Association, EQ5D = EuroQol 5 domain. 
  
Appendix 4. Functional outcomes and RV function 312 
 
 
 
 
1 Year 
  RVEF ΔRVEF 
  POD2 2months POD2-preop 2months-preop 
WHO-PS r -0.109 -0.195 0.326 0.075 
 p 0.688 0.438 0.217 0.767 
 WHO-PS any p 0.562 0.536 0.313 0.930 
      
MRC-DS r 0.043 0.083 -0.001 -0.045 
 p 0.869 0.736 0.996 0.856 
 MRC-DS any r <0.999 0.831 0.660 0.966 
      
NYHA class r 0.030 0.126 -0.278 -0.145 
 p 0.907 0.596 0.265 0.542 
 NYHA any r 0.645 0.933 0.505 0.445 
      
Global Health Score r -0.242 -0.033 0.053 0.279 
 p 0.333 0.890 0.835 0.233 
      
EQ5D      
 Mobility r 0.078 0.056 0.078 -0.086 
  p 0.760 0.813 0.760 0.717 
 Self care r 0.204 0.246 0.273 0.132 
  p 0.416 0.296 0.274 0.578 
 Usual activities r 0.129 -0.123 0.184 -0.174 
  p 0.611 0.606 0.465 0.464 
 Pain / discomfort r 0.417 0.322 0.096 0.113 
  p 0.085 0.166 0.705 0.634 
 Anxiety / depression r -0.143 0.012 0.117 -0.097 
  p 0.571 0.960 0.645 0.684 
       
Health Utility Score r -0.335 -0.076 -0.233 0.148 
 p 0.174 0.751 0.352 0.533 
Association of post-op RV function with functional and quality of life scores at 1 year 
All comparisons are Spearman's correlation coefficient. RVEF = right ventricular ejection 
fraction, ΔRVEF = change in right ventricular ejection fraction, WHO-PS = World Health 
Organisation performance status. MRC-DS = Medical Research Council dyspnoea scale. NYHA = 
New York Heart Association, EQ5D = EuroQol 5 domain. 
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